Program and Conference Information

CROI
Conference on Retroviruses and Opportunistic Infections

Seattle
March 4-7, 2019
CONTENTS

CROI FOUNDATION ................................................................. 2
IAS–USA ................................................................................. 2

CROI 2019 PROGRAM COMMITTEE .......................... 3
Scientific Program Committee ........................................... 3
Community Liaison Subcommittee ....................................... 5

EXTERNAL REVIEWERS .......................................................... 6

SCHOLARSHIP AWARDEES .................................................. 8
New Investigator Awardees .................................................... 8
International Investigator Awardees ....................................... 12
Community Educator Awardees ............................................. 12

CONTINUING MEDICAL EDUCATION ............................ 13

GENERAL INFORMATION ...................................................... 15
Overview ............................................................................. 15
Conference Support ............................................................ 15
Americans With Disabilities Act ......................................... 15
Emergency Services ............................................................. 15
Embargo Policies and Social Media ....................................... 16
Welcome Reception ............................................................... 16
Meals ................................................................................. 16
Overflow Accommodations for Session Rooms ...................... 17
Mobile App ........................................................................ 17
Video Upload .................................................................... 18
Website ............................................................................ 18
Webcasts .......................................................................... 18
USB Flashdrive ................................................................. 18
Affiliated and Proximate Activities Policy .............................. 18
Wi-Fi Access at the Conference ........................................ 19
Conference Badges ............................................................. 19
Child Care ....................................................................... 19
Conference Etiquette .......................................................... 19

CROI HOTELS ........................................................................ 20

CONFERENCE SERVICES ..................................................... 22

ABSTRACT PROCESS ............................................................. 24

ORAL SESSIONS ................................................................. 26

POSTER SESSIONS, BY DAY .............................................. 62

POSTER SESSIONS, BY CATEGORY .................................. 158

INDEX OF STUDIES RELATED TO RESEARCH IN WOMEN .... 162

INDEX OF PRESENTING AUTHORS ................................... 169

RECORD OF PARTICIPATION .................................................. INSIDE BACK COVER

CONVENTION CENTER FLOOR PLANS .......................... BACK COVER

Printed in the United States of America.
© Copyright 2019 CROI Foundation/IAS–USA. All rights reserved.
ISBN #978-1-7320053-0-3
CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Program Committee (CROI PC) and the CROI Organizer to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Organizer
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constance A. Benson, MD</td>
<td>University of California San Diego</td>
<td>San Diego, CA, United States</td>
</tr>
<tr>
<td>John M. Coffin, PhD</td>
<td>Tufts University</td>
<td>Boston, MA, United States</td>
</tr>
<tr>
<td>Elaine J. Abrams, MD</td>
<td>ICAP at Columbia University</td>
<td>New York, NY, United States</td>
</tr>
<tr>
<td>Susan P. Buchbinder, MD</td>
<td>San Francisco Department of Public Health</td>
<td>San Francisco, CA, United States</td>
</tr>
<tr>
<td>Judith S. Currier, MD, MSc</td>
<td>University of California Los Angeles</td>
<td>Los Angeles, CA, United States</td>
</tr>
<tr>
<td>Kevin M. De Cock, MD</td>
<td>Centers for Disease Control and Prevention</td>
<td>Nairobi, Kenya</td>
</tr>
<tr>
<td>Scott M. Hammer, MD</td>
<td>Columbia University</td>
<td>New York, NY, United States</td>
</tr>
<tr>
<td>Sharon L. Hillier, PhD</td>
<td>University of Pittsburgh</td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>John W. Mellors, MD</td>
<td>University of Pittsburgh</td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>Robert T. Schooley, MD</td>
<td>University of California San Diego</td>
<td>La Jolla, CA, United States</td>
</tr>
</tbody>
</table>

IAS–USA

The International Antiviral Society–USA is a 501(c)(3) not-for-profit professional education organization. The IAS–USA partners with the CROI PC and Foundation to organize CROI. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Executive Director: Donna M. Jacobsen
Address: 425 California Street, Suite 1450
San Francisco, CA 94104-2120
Phone: 415-544-9400
Website: www.iasusa.org
CROI 2019 PROGRAM COMMITTEE

The Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee

Richard A. Koup, MD  
CROI 2019 Chair  
Vaccine Research Center  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Bethesda, MD, United States

Elaine J. Abrams, MD  
CROI 2019 Vice Chair  
ICAP at Columbia University  
New York, NY, United States

Sharon L. Hillier, PhD  
CROI 2019 Vice Chair  
University of Pittsburgh  
Pittsburgh, PA  
United States

Adaora Adimora, MD  
University of North Carolina at Chapel Hill  
Chapel Hill, NC, United States

Paul Bieniasz, PhD  
The Rockefeller University  
New York, NY, United States

Galit Alter, PhD  
Ragon Institute of MGH, MIT and Harvard  
Cambridge, MA  
United States

Susan P. Buchbinder, MD  
San Francisco Department of Public Health  
San Francisco, CA, USA

Jintanat Ananworanich, MD, PhD  
University of Maryland

Connie L. Celum, MD, MPH  
University of Washington  
Seattle, WA, United States

Katharine J. Bar, MD  
University of Pennsylvania  
Philadelphia, PA,  
United States

Richard E. Chaisson, MD  
The Johns Hopkins University  
Baltimore, MD, United States

Constance A. Benson, MD  
University of California  
San Diego  
San Diego, CA, United States

Nicolas Chomont, PhD  
Université de Montréal  
Montreal, Canada
General Information

John M. Coffin, PhD
Tufts University
Boston, MA, United States

Ilesh V. Jani, MD, PhD
Instituto Nacional de Saude
Maputo, Mozambique

Judith S. Currier, MD, MSc
University of California Los Angeles
Los Angeles, CA
United States

Angela Kashuba, PharmD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

François Dabis, MD, PhD
University of Bordeaux
Bordeaux, France

Frank Kirchhoff, PhD
Ulm University Medical Center
Ulm, Germany

Kevin M. De Cock, MD
Centers for Disease Control and Prevention
Nairobi, Kenya

Dennis L. Kolson, MD, PhD
University of Pennsylvania Philadelphia, PA, United States

Wafaa M. El-Sadr, MD, MPH
ICAP at Columbia University
New York, NY, United States

Hermione Lyall, MD
Imperial College Healthcare National Health Service Trust
London, United Kingdom

Joseph J. Eron, Jr, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

James A. McIntyre, MBChB, FRCOG
Anova Health Institute
Johannesburg, South Africa

Huldrych F. Günthard, MD
University Hospital Zurich
Zurich, Switzerland

John W. Mellors, MD
University of Pittsburgh Pittsburgh, PA, United States

Timothy Hallett, PhD
Imperial College London
London, United Kingdom

Jonathan Mermin, MD, MPH
Centers for Disease Control and Prevention
Atlanta, GA, United States

Diane V. Havlir, MD
University of California San Francisco
San Francisco, CA
United States

Penelope L. Moore, PhD
University of Witwatersrand
Johannesburg, South Africa

James A. Hoxie, MD
University of Pennsylvania Philadelphia, PA
United States

Nelly R. Mugo, MBChB, MPH
Kenya Medical Research Institute
Nairobi, Kenya

Peter W. Hunt, MD
University of California San Francisco
San Francisco, CA
United States

Landon Myer, MD, PhD
University of Cape Town
Cape Town, South Africa
Community Liaison Subcommittee
The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Former Members
The CROI Foundation wishes to thank for their service the following individuals who rotated off the Program Committee in 2018:

Courtney V. Fletcher, PharmD
Scott M. Hammer, MD
Alexandra Trkola, PhD

And thanks to those who rotated off the Community Liaison Subcommittee in 2018:

Mark Hubbard
Jeffrey W. Taylor
EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2019.

Edward P. Acosta, PharmD
University of Alabama at Birmingham

Peter L. Anderson, PharmD
University of Colorado

John M. Blandford, PhD
Centers for Disease Control and Prevention

Marta Boffito, MD, PhD
Chelsea and Westminster NHS Foundation Trust

Jacob Bor, ScD
Boston University

William Borkowsky, MD
New York University

Bruce J. Brew, MD, DSc, MBBS
University of New South Wales

Melanie M. Brinkmann, PhD
Helmholtz Centre for Infection Research

Todd T. Brown, MD, PhD
Johns Hopkins University

David M. Burger, PhD
Radboud University Medical Center

Corey Casper, MD
Infectious Disease Research Institute

Ellen G. Chadwick, MD
Ann & Robert H. Lurie Children’s Hospital of Chicago

David B. Clifford, MD
Washington University in St Louis

Kelly E. Dooley, MD, PhD
Johns Hopkins University

David Evans, PhD
University of Wisconsin—Madison

Paul J. Farrell, PhD
Imperial College London

Courtney V. Fletcher, PharmD
University of Nebraska Medical Center

Charles W. Flexner, MD
Johns Hopkins University

Patricia M. Flynn, MD
St. Jude Children’s Research Hospital

John Frater, MD, PhD
University of Oxford

Jennifer Furin, MD, PhD
Harvard University

Dana H. Gabuzda, MD
Dan–Farber Cancer Institute

Monica Gandhi, MD, MPH
University of California San Francisco

Gerardo Garcia-Lerma, PhD
Centers for Disease Control and Prevention

Elvin H. Geng, MD, MPH
University of California San Francisco

Carlo Giaquinto, MD
University of Padova

Beatriz Grinsztejn, MD
Fiocruz

Beatrice H. Hahn, MD
University of Pennsylvania

James G. Hakim, MD
University of Zimbabwe

Scott M. Hammer, MD
Columbia University

P. Richard Harrigan, PhD
BC Centre for Excellence in HIV/AIDS

Theodora Hatzioannou, PhD
The Rockefeller University

Ya-Chi Ho, MD, PhD
Yale University School of Medicine

Priscilla Y. Hsue, MD
University of California San Francisco

Harold W. Jaffe, MD
Centers for Disease Control and Prevention

Jennifer Jao, MD
Northwestern University

Susan E. Krown, MD
AIDS Malignancy Consortium

Raphael J. Landovitz, MD
University of California Los Angeles

Scott L. Letendre, MD
University of California San Diego

Sharon R. Lewin, MD
University of Melbourne

Annie F. Luetkemeyer, MD
University of California San Francisco

Patrick W.G. Mallon, PhD, MBBS
University College Dublin

Jeanne M. Marrazzo, MD, MPH
University of Alabama at Birmingham

Natasha Martin, PhD
University of California San Diego

Grace A. McComsey, MD
University Hospitals Cleveland Medical Center

Graeme Meintjes, PhD, MBChB
University of Cape Town
CROI is committed to supporting new and early career investigators working in HIV research to help them further their education and to network with other researchers in the field. New Investigator Scholarship awardees are presenting authors on accepted abstracts and have been highly recommended by their mentors. In addition, CROI offers scholarships to international investigators and community educators working in resource-limited countries who would otherwise be unable to attend CROI. Through their applications and letters of recommendation, these awardees have shown that they will greatly benefit from the opportunity to participate in CROI.

### New Investigator Awardees

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Country</th>
<th>Institutional Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hadega Aamer</td>
<td>Seattle Children’s Research Institute</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Andrew Max Abaasa</td>
<td>London School of Hygiene &amp; Tropical Medicine</td>
<td>UK</td>
<td></td>
</tr>
<tr>
<td>Dawit Assefa Arimde</td>
<td>Lund University</td>
<td>Sweden</td>
<td></td>
</tr>
<tr>
<td>Daniele Armenia</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Arinaite Samuel Arnold</td>
<td>Infectious Disease Institute Uganda</td>
<td>Uganda</td>
<td></td>
</tr>
<tr>
<td>Ryan David Assaf</td>
<td>University of California Los Angeles</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Antonio Astorga Gamaza</td>
<td>Vall d’Hebron Research Institute</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Edmond Atindaaana</td>
<td>University of Michigan</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Max Augustin</td>
<td>Cologne University Hospital</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Jose Avendaño-Ortiz</td>
<td>Instituto de Investigación Hospital Universitario La Paz</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Riddhima Banga</td>
<td>Lausanne University Hospital</td>
<td>Switzerland</td>
<td></td>
</tr>
<tr>
<td>Himanshu Batra</td>
<td>The Catholic University of America</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Alejandra E Benitez</td>
<td>University of California Berkeley</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Cherie Blair</td>
<td>University of California Los Angeles</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Seth M. Bloom</td>
<td>Massachusetts General Hospital</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Melissa Jayne Blumenthal</td>
<td>University of Cape Town</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Aaron Bochner</td>
<td>University of Washington</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Pauline Bollen</td>
<td>Radboud University Medical Center</td>
<td>Netherlands</td>
<td></td>
</tr>
<tr>
<td>Alberto Borghetti</td>
<td>Catholic University of Sacred Heart</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Emily Bowman</td>
<td>The Ohio State University</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Ceejay Boyce</td>
<td>University of Washington</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Fazila Sadik Bunglawala</td>
<td>University of Liverpool</td>
<td>Uganda</td>
<td></td>
</tr>
<tr>
<td>Jon Cantero</td>
<td>Vall d’Hebron Research Institute</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Cristina Ceriani</td>
<td>ASST Ovest Milanese</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Lelio Harding Chairson</td>
<td>Johns Hopkins University</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Mathieu Chalouni</td>
<td>INSERM</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Nomathemba Chiwoneso Chandiwana</td>
<td>Wits Reproductive Health and HIV Institute</td>
<td>South Africa</td>
<td></td>
</tr>
<tr>
<td>Jaya Chandna</td>
<td>University of Liverpool</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Kevin Chihow Chang</td>
<td>University of California San Francisco</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Omkar Chaudhary</td>
<td>Yale University</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Glen M. Chew</td>
<td>University of Hawaii at Manoa</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Belinda Varaidzo Chihota</td>
<td>Centre for Infectious Disease Research in Zambia</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Witness Chirinda</td>
<td>South African Medical Research Council</td>
<td>South Africa</td>
<td></td>
</tr>
<tr>
<td>Benedikt Christ</td>
<td>Institute of Social and Preventive Medicine</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Steven J. Clipman</td>
<td>Johns Hopkins University</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Florent Colomb</td>
<td>The Wistar Institute</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Ryan Cook</td>
<td>University of California Los Angeles</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Anaïs Corma-Gómez</td>
<td>Hospital Universitario de Valme</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Perrine Courlet</td>
<td>Centre Hospitalier Universitaire Vaudois</td>
<td>Switzerland</td>
<td></td>
</tr>
<tr>
<td>Elvira Couto Jaime</td>
<td>Institut d’Investigations Biomédiques August Pi i Sunyer</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Sara Cristinelli</td>
<td>Lausanne University Hospital</td>
<td>Switzerland</td>
<td></td>
</tr>
<tr>
<td>Jessica Culhane</td>
<td>University of Washington</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Paul Curley</td>
<td>University of Liverpool</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Subathira Dakshina</td>
<td>Central and North West London NHS Trust</td>
<td>UK</td>
<td></td>
</tr>
<tr>
<td>Gonché Danesh</td>
<td>Université de Montpellier</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Gilles Darcis</td>
<td>Liege University Hospital</td>
<td>Belgium</td>
<td></td>
</tr>
<tr>
<td>Davide De Francesco</td>
<td>University College London</td>
<td>UK</td>
<td></td>
</tr>
<tr>
<td>Tafadzwa G. Dhokotera</td>
<td>National Cancer Registry</td>
<td>Botswana</td>
<td></td>
</tr>
<tr>
<td>Modiegi Diannah Diseko</td>
<td>Botswana Harvard AIDS Institute Partnership</td>
<td>Botswana</td>
<td></td>
</tr>
<tr>
<td>Laura Doepker</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Sara Dominguez Rodríguez</td>
<td>Fundación Investigación Biomédica Hospital 12 Octubre</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Jienchi Dorward</td>
<td>University of Oxford</td>
<td>UK</td>
<td></td>
</tr>
<tr>
<td>Debashis Dutta</td>
<td>University of Nebraska Medical Centre</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Kevin Einkauf</td>
<td>Brigham and Women’s Hospital</td>
<td>USA</td>
<td></td>
</tr>
</tbody>
</table>
International Investigator Awardees

Patricia Aladi Agaba
Jos University Teaching Hospital

Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership

Manuela Bullo
Ramos Mejia Hospital

Bernard Chasekwa
Zvitambo Institute for Maternal and Child Health Research

Lena Géraldine Dietrich
Kantonsspital Baselland

Ameet N. Dravid
Poona Hospital and Research Centre

Kostyantyn Dumchev
Ukrainian Institute on Public Health Policy

Chido Dziva Chikwari
Biomedical Research and Training Institute

Jonathan Euvrard
University of Cape Town

Maria Inés FIGUEROA
Fundación Huelsp

Kamunkhwala Gausi
University of Cape Town

Eduard Grebe
Stellenbosch University

Barbara Labelia Henrique
Universidade de São Paulo

Elizabeth M Irunu
Kenya Medical Research Institute

Joseph Kagaayi
Rakai Health Science Program

Sarah Kanema
Zambart

Samuel Wilson Kogne
Botswana Harvard AIDS Institute Partnership

Marina Kornilova
Alliance for Public Health

Tshepo Botho Leeme
Botswana Harvard AIDS Institute Partnership

Linghua Li
Guangzhou Eighth People's Hospital

Maneno Lupunya
Jhpiego

Philo Wilson Maenettje
The Aurum Institute

Sana Mahtab
University of Cape Town

Gosego Masasa
Botswana Harvard AIDS Institute Partnership

Sithabiso Daphne Masuku
Wits Health Consortium

Gloria Katuta Mayondi
Botswana Harvard AIDS Institute Partnership

Keoleboqile Nicholas Mmusa
Botswana Harvard AIDS Institute Partnership

Sikhulile Moyo
Botswana Harvard AIDS Institute Partnership

Malango T. Msukwa
University of Geneva

Kenneth Nguere
Jomo Kenyatta University of Agriculture and Technology

Robert Ntozini
Zvitambo Institute for Maternal and Child Health Research

Stephen Okoboi
Makerere University

Oluwakemi Okwuegbu
University of California San Diego

Lynda Myra Oluoch
Kenya Medical Research Institute

Carolyne Onyango–Makumbi
Makerere University–Johns Hopkins University Research Collaboration

Shen Chumin
Chinese Academy of Sciences

Kombatende Sikombe
Centre for Infectious Disease Research in Zambia

Nguyen Thi Mai Thu
Oxford University Clinical Research Unit in Vietnam

Peris Lucas Ur USA
National AIDS Control Program

Community Educator Scholarship List

Oluwatobin Alaka
New HIV Vaccine and Microbicide Advocacy Society

Giorgio Barbaresci
European AIDS Treatment Group

Liz Barr
Jhpiego

Jorge Szaz Berges
Javes Postitus

Giulio Maria Corbelli
European AIDS Treatment Group

Florita C. Duruwee
New HIV Vaccine and Microbicides Advocacy Society

Angel L. Fernandez
University of Puerto Rico

Brian Kanyemba
Advocates for HIV Prevention and AIDS

Sandris Klavins
Atbalsta Grupa Inficētajiem ar HIV un AIDS Slimniekiem

Tapiwanaashe Kujinga
Pan-African Treatment Access Movement

Udom Likhitwonnavut
Global Advocacy for HIV Prevention

Imelda I. Mahaka
Pangaea Zimbabwe AIDS Trust

Kennedy Mupeli
Centre for Youth of Hope

Lilian B. Mwakyosy
Tanzania Youth Alliance

Robert E. Newells
AIDS Project of the East Bay

Simon O. Ondiek
Centre for Health Research Advocacy

Julia M. Patterson
AIDS Funding Collaborative

Fernan Pujol Roca
Projecte dels NOMS-HispanoAIDS

Pich Seekaw
Thai Red Cross AIDS Research Centre

Laurie Sylla
defeatHIV

Jeffrey W. Taylor
HIV+ Aging Research Project

Harry C. Tembo
Zambia Community Advisory Platform

Teopista N. Tibaijuka
Mujimu Research Organization
CONTINUING MEDICAL EDUCATION

Accreditation Statement
The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS—USA designates this live activity for a maximum of 17 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives
After participating in CROI 2019, participants will be able to:
• Describe basic science research advances in HIV
• List the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies
• Describe current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public-health program planning; and current advances in biobehavioral prevention

Statement of Need
Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections.

CME Credit Information
Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI. CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, and symposia. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions. For physician attendees certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).
ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

During the conference, links to the daily and final evaluations will be available at a secure web page on the CROI website at www.CROIconference.org/electronic-materials. You will need your e-mail address that you used to register for this conference and your reference number to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, all final evaluations must be completed by April 9, 2019. Once the final evaluation and posttest are submitted, your certificate will be uploaded to your CROI profile in the CROI website or IAS–USA website within 2 to 3 business days.

To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference, including premeeting workshops, opening session lectures, plenary lectures, and symposia. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 3 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended for your certificate.


Disclosure of Financial Relationships

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with commercial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation.

The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount and defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests — unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” The information is intended to make the audience aware of speaker and contributor interests and commitments with commercial interests, enabling the audience members to form their own judgments about such associations.

Each author, contributor, or person in control of content in the CME activity is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information is detailed in the Abstract eBook.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
GENERAL INFORMATION

Overview
CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Conference Support
CROI is largely supported by participant registration fees. CROI registration fees cover all hosted attendee meals (including the Welcome Reception) and travel expenses for invited participants (eg, speakers, leaders, moderators, and CROI PC members), as well as selected meeting materials and other conference expenses.

In addition, CROI seeks grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations. Commercial support is used to cover some of the costs of the convention center, audiovisual services, and other conference services.

CROI 2019 received grant support commitments from the following commercial companies:

PLATINUM SUPPORTERS
- Gilead Sciences
- Merck & Co, Inc.
- ViiV Healthcare, Inc.

SILVER SUPPORTER
- Janssen Therapeutics

Additional support has been provided by
- AbbVie Inc.
- Theratechnologies Inc.

Americans With Disabilities Act
CROI endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site, please visit the Attendee Services booth on the Plaza level during the conference.

Emergency Services
In the event of a medical emergency, please contact Security Control immediately by dialing 5127 from any house phone located in the facility. In addition, there are red “hot line” phones located around the facility that ring directly into the Security Control office.

CROI staff or any uniformed Washington State Convention Center (WSCC) personnel with a 2-way radio can also assist you in an emergency. Contacting Security Control will greatly minimize response time in the event an emergency medical unit needs to report to the WSCC. Security personnel can quickly assess the situation, and bring emergency personnel directly to the individual in need. For this reason, WSCC requests that our clients and guests NOT contact 911 directly.
Embargo Policies and Social Media

The research presented at CROI 2019 is embargoed until the conclusion of the session in which it is presented. For example, if a study is presented from 10:15 AM to 10:30 AM as part of an oral session that ends at 12:00 PM, the embargo on that study lifts at 12:00 PM. Embargoes on poster presentations lift at the beginning of the session in which the poster is presented. If a study to be presented at CROI 2019 is included in an official CROI press conference and that press conference takes place before the official presentation of the study at the conference, the embargo lifts at the conclusion of the press conference in which the study is featured.

CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (e.g., blogs) or social media (e.g., Facebook, Twitter). No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Welcome Reception

All registered CROI attendees are invited to join us for a Welcome Reception immediately following the Opening Session on Monday evening. The reception will be held at the WSCC.

This Welcome Reception will offer attendees the opportunity to network with colleagues. Light hors d'oeuvres will be served. Each attendee will be given 2 drink tickets with their registration materials to be used for alcoholic or nonalcoholic beverages.

Meals

Morning coffee and a light continental breakfast will be available to conference registrants from 7:30 AM to 8:30 AM, Tuesday, Wednesday, and Thursday, in the registration area. An afternoon snack break will be available at 2:30 PM in the Poster Hall. Attendees are on their own for all other meals, including lunch and dinner, each day. Below is a list of food service options located in the WSCC or within a short walking distance.

Food Service at the Convention Center

| Cyber Dogs — Internet Café | 820 Pike Street — Pan Asian Cuisine |
| Unconventional Pizza & Salad | Espresso Caffé Dior |
| Moby’s Restaurant and Lounge | Crêpes Voilá |
| The Juicy Café | Wild Rye Café Bakery |
| Subway Sandwiches | Tully’s Coffee |

Food Service Within 4 Blocks of the Convention Center

| Blueacre Seafood | 1700 7th Ave | 206-659-0737 | blueacreseafood.com |
| Blue C Sushi | 1510 7th Ave | 206-467-4022 | bluesushi.com |
| Café Yumm! | 717 Pine St | 206-624-9866 | cafeyumm.com |
| Daily Grill | 629 Pike St | 206-624-8400 | dailygrill.com |
| Dragonfish Asian Café | 722 Pine St | 206-467-7777 | dragonfishcafe.com |
| FareStart | 700 Virginia St | 206-267-7606 | farestart.org |
| Frolik Kitchen / Cocktails | 1415 5th Avenue | 206-971-8010 | frolik.motifseattle.com |
| GameWorks | 1511 7th Ave | 206-521-0951 | gameworks.com |
| Gordon Biersch Brewery Restaurant | 600 Pine St, Ste 401 | 206-405-2707 | gordonbiersch.com |
| Homegrown Sustainable Sandwich Shop | 1531 Melrose Market | 206-682-0935 | eathomegrown.com |
| Il Fornaio | 600 Pine St, Ste 132 | 206-264-0994 | illfornaio.com |
| Juicy Café | 800 Pike Street | 206-447-6960 | www.thejuicycafe.com |
| L’il Woody’s | 1211 Pine Street | 06-457-4148 | www.lilwoodys.com |
| Loulay Kitchen & Bar | 600 Union Street | 206-402-4588 | thechefinthehat.com |
| Mamnoon | 1508 Melrose Avenue | 206-906-9606 | mamnoonrestaurant.com |
### Restaurants within 4 Blocks of the Convention Center (continued)

<table>
<thead>
<tr>
<th>Restaurant</th>
<th>Address</th>
<th>Phone</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Masala Grill</td>
<td>820 Pine Street</td>
<td>206-467-7272</td>
<td>masalagrillseattle.com</td>
</tr>
<tr>
<td>MOD Superfast Pizza</td>
<td>1302 6th Ave</td>
<td>206-332-0200</td>
<td>modsuperfast.com</td>
</tr>
<tr>
<td>Morton's Steakhouse</td>
<td>1511 6th Ave</td>
<td>206-223-2751</td>
<td>mortons.com</td>
</tr>
<tr>
<td>Nordstrom Flagship Store: Dining</td>
<td>500 Pine Street</td>
<td>206-628-2111</td>
<td><a href="http://www.nordstrom.com">www.nordstrom.com</a></td>
</tr>
<tr>
<td>NYC Hyatt Deli Market</td>
<td>1520 7th Ave</td>
<td>206-682-7011</td>
<td></td>
</tr>
<tr>
<td>Palomino</td>
<td>6th and Union</td>
<td>206-623-1300</td>
<td>r-u-i.com</td>
</tr>
<tr>
<td>Pike Place Chowder Pacific Place</td>
<td>600 Pine St, Ste 404</td>
<td>206-838-5680</td>
<td>pikeplacechowder.com</td>
</tr>
<tr>
<td>Potbelly Sandwich Shop</td>
<td>1429 4th Ave</td>
<td>206-623-0099</td>
<td>potbelly.com</td>
</tr>
<tr>
<td>RN74</td>
<td>1425 4th Ave</td>
<td>206-456-7474</td>
<td>michaelmina.net</td>
</tr>
<tr>
<td>Rock Bottom Restaurant</td>
<td>1333 5th Ave</td>
<td>206-623-3070</td>
<td>rockbottom.com</td>
</tr>
<tr>
<td>Ruth's Chris Steak House</td>
<td>727 Pine St</td>
<td>206-624-8524</td>
<td>ruthschris.com</td>
</tr>
<tr>
<td>Serious Pie on Pike</td>
<td>1124 Pike Street</td>
<td>206-923-8012</td>
<td></td>
</tr>
<tr>
<td>Soup's On!</td>
<td>1420 5th Ave</td>
<td>206-625-9976</td>
<td>soupsonusa.com</td>
</tr>
<tr>
<td>Starbucks Coffee Company</td>
<td>721 Pike Street</td>
<td>206-774-1234</td>
<td><a href="http://www.starbucks.com">www.starbucks.com</a></td>
</tr>
<tr>
<td>Stateside</td>
<td>300 E Pike Street</td>
<td>206-557-7273</td>
<td>statesideseattle.com</td>
</tr>
<tr>
<td>Sullivan's Steakhouse</td>
<td>612 Union St</td>
<td>206-494-4442</td>
<td>sullivansteakhouse.com</td>
</tr>
<tr>
<td>Tango Restaurant &amp; Lounge</td>
<td>1100 Pike St</td>
<td>206-583-0382</td>
<td>tangorestaurant.com</td>
</tr>
<tr>
<td>Tap House Grill</td>
<td>1506 6th Ave</td>
<td>206-816-3314</td>
<td>taphousegrill.com</td>
</tr>
<tr>
<td>Terra Plata</td>
<td>1501 Melrose Ave</td>
<td>206-325-1501</td>
<td>terraplata.com</td>
</tr>
<tr>
<td>Thai Ginger</td>
<td>600 Pine St</td>
<td>206-749-9100</td>
<td>thaijnger.com</td>
</tr>
<tr>
<td>The Capital Grille</td>
<td>1301 4th Ave</td>
<td>206-382-0900</td>
<td>thecapitalgrille.com</td>
</tr>
<tr>
<td>The Cheesecake Factory</td>
<td>700 Pike St</td>
<td>206-652-5400</td>
<td>thecheesecakefactory.com</td>
</tr>
<tr>
<td>The Elephant and Castle Pub &amp; Restaurant</td>
<td>1415 Fifth Ave</td>
<td>206-624-9977</td>
<td><a href="http://www.elephantcastle.com">www.elephantcastle.com</a></td>
</tr>
<tr>
<td>Toss'd Custom Salads</td>
<td>1420 5th Ave</td>
<td>206-682-6700</td>
<td></td>
</tr>
<tr>
<td>Tully's Coffee</td>
<td>800 Pike Street</td>
<td>800-MY-TULLY</td>
<td>tullycoffee.com</td>
</tr>
<tr>
<td>Urbane</td>
<td>1635 8th Ave</td>
<td>206-676-4600</td>
<td>olive8.hyatt.com</td>
</tr>
<tr>
<td>Veggie Grill</td>
<td>1427 4th Ave</td>
<td>206-624-1332</td>
<td>veggiegrill.com</td>
</tr>
<tr>
<td>Wild Rye Café Bakery</td>
<td>806 Pike St</td>
<td>206-694-5049</td>
<td>wildryecafe.com</td>
</tr>
</tbody>
</table>

### Overflow Accommodations for Oral Sessions

There is a simultaneous overflow area located in Room 611-612. There are 6 screens, and each will be live streaming one of the concurrent oral sessions (Oral Abstracts, Themed Discussions, and Symposia). Headsets with an audio switch will be available for easy transitioning between the concurrent sessions.

Overflow monitors for individual session rooms will become available as needed. CROI staff will direct you to these locations.

### Mobile App

To access the CROI Mobile App, use your reference number (on your name badge) and the email address you used to register for CROI.

The CROI 2019 Mobile App has many features to enhance your conference experience, including:

- View abstracts
- Find information about speakers and other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- E-mail session notes
General Information

- Receive the latest changes to the CROI program
- View electronic posters and video descriptions of presentations

The Mobile App is compatible with iOS and Android devices. Search “CROI 2019” in your mobile device App store. Access is restricted to registered attendees. Your log-in information and password are provided with the registration materials.

Video Upload

Poster presenters have the opportunity to upload a video of up to 3 minutes to describe their research findings and conclusions. The video, as well as the electronic version of your poster, will be available to registered CROI attendees on the CROI Mobile App during the conference. In addition, the video and electronic poster will be publicly available on the CROI website after the meeting to serve as important enduring educational resources.

Website

For additional information about the conference and to access electronic materials please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2019 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014, 2015, 2016, 2017, and 2018 are available at www.CROIconference.org/abstracts/search-abstracts/

USB Flash Drive

Any registrant who purchased a USB flash drive with the Abstract eBook preloaded onto it will receive it in their welcome packet at registration. Abstracts can also be found in the Abstract eBook and searchable database on the CROI website after the session in which the abstract is presented.

Webcasts

Plenaries, symposia, oral abstract sessions, and themed discussions are available as webcasts and are available within 24 hours of the end of the relevant session. Webcasts are also available as streaming videos for the Apple iPad and iPhone. Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts.

Affiliated and Proximate Activities Policies

The goal of CROI is to promote meaningful, high-level scientific interchange of ideas and debate in order to find better ways to prevent, treat, and cure HIV/AIDS. In keeping with this goal, organizations (commercial companies and their agents, not-for-profit groups, government agencies, etc) have been approved to host Affiliated Activities occurring outside CROI session times. Affiliated Activities are not sponsored by, endorsed by, or supported by the IAS–USA, the CROI Foundation, or CROI 2019.

If an affiliated activity is found to have violated the Guidelines for Affiliated Activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an Affiliated Activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and damages, and could negatively impact the registration status and attendance of those attending an unapproved affiliated activity.

If you have organized a meeting or activity that includes CROI attendees, as described in the Affiliated Activity guidelines, and have not completed the Affiliated Activity application, please see an IAS–USA staff member in the IAS–USA office (Room 603) for assistance.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel may not have been approved by CROI, please contact an IAS–USA staff member in the IAS–USA office.
WiFi Access at the Conference
Complimentary Wi-Fi access is provided at the WSCC. Network information is as follows:

Network name: CROI2019
The Wi-Fi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will assist in maximizing the internet speeds for those devices actively in use. The password for each day of the conference are listed below, and are case sensitive.

Monday password: monday2019
Tuesday password: tuesday2019
Wednesday password: wednesday2019
Thursday password: thursday2019

If you are having issues with Wi-Fi access, please contact an IAS–USA staff member. Additional Internet hotspots not located in the session rooms are listed in the Convention Center map on the back of the Program.

Conference Badges
Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. The CROI badge must be worn at all times during the conference in order to gain entry to all official meeting activities, including the poster sessions. Attendees will not be admitted into the venue without their CROI badge. THE CROI BADGE MAY ONLY BE USED BY THE PERSON STATED ON THE BADGE AND CANNOT BE TRANSFERRED OR SHARED WITH OTHERS. THE USE OF ANOTHER INDIVIDUAL’S BADGE OR GIVING YOUR BADGE TO SOMEONE ELSE TO GAIN ACCESS TO THE CONFERENCE IS STRICTLY PROHIBITED AND IS A VIOLATION OF CROI POLICIES.

DO NOT LOSE YOUR BADGE. Payment of US $850 will be required to replace a lost badge.

Child Care
Out of respect for the presenters and conference attendees, children are not permitted in meeting rooms, including the poster area. If you require child care services, you may refer to the following resources suggested by local hosts. You may also contact the concierge of your hotel.

Annie's Nannies, Inc.
www.aniseattle.com
Phone: (206) 784-8462

Best Sitters, Inc.
www.bestsittersinc.com
Phone: (206) 682-2556

Poppy
www.meetpoppy.com

Please note, this CROI does not endorse any of these services. List is provided as a courtesy only.

Conference Etiquette
Please ensure all mobile devices are turned off or set on SILENT mode in session rooms. In consideration for the work of the presenters at CROI and the CROI copyright policy, attendees are not allowed to photograph posters, record parts of talks, or post data without the presenter’s consent.
CROI HOTELS

CROI 2019 hotels are listed below. For more detailed housing information, please visit the CROI 2019 conference website: www.CROIconference.org/housing. Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Seattle area (ie, within a 50-mile radius of the Washington State Convention Center) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI housing system.

<table>
<thead>
<tr>
<th>Hotel Name</th>
<th>Address</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crowne Plaza Seattle Downtown</td>
<td>1113 6th Avenue</td>
<td>+1 206 464-1980</td>
</tr>
<tr>
<td>Embassy Suites Pioneer Square</td>
<td>255 S. King Street</td>
<td>+1 206 859-4400</td>
</tr>
<tr>
<td>The Fairmont Olympic Hotel</td>
<td>411 University Street</td>
<td>+1 206 621-1700</td>
</tr>
<tr>
<td>Grand Hyatt Seattle</td>
<td>721 Pine Street</td>
<td>+1 206 774-1234</td>
</tr>
<tr>
<td>Hilton Seattle</td>
<td>1301 6th Avenue</td>
<td>+1 206 624-0500</td>
</tr>
<tr>
<td>*Homewood Suites</td>
<td>1011 Pike Street</td>
<td>+1 206 682-8282</td>
</tr>
<tr>
<td>*Hotel Max</td>
<td>620 Stewart Street</td>
<td>+1 206 728-6299</td>
</tr>
<tr>
<td>*Hotel Monaco</td>
<td>1101 4th Avenue</td>
<td>+1 206 621-1770</td>
</tr>
<tr>
<td>*Hotel Theodore</td>
<td>1531 7th Avenue</td>
<td>+1 206 621-1200</td>
</tr>
<tr>
<td>Mayflower Park Hotel</td>
<td>405 Olive Way</td>
<td>+1 206 623-8700</td>
</tr>
<tr>
<td>Motif Seattle</td>
<td>1415 5th Avenue</td>
<td>+1 206 971-8000</td>
</tr>
<tr>
<td>Hyatt at Olive 8</td>
<td>1635 8th Avenue</td>
<td>+1 206 685-1234</td>
</tr>
<tr>
<td>Renaissance Seattle Hotel</td>
<td>515 Madison Street</td>
<td>+1 206 583-0300</td>
</tr>
<tr>
<td>Sheraton Grand Seattle</td>
<td>1400 6th Avenue</td>
<td>+1 206 621-9000</td>
</tr>
<tr>
<td>W Seattle</td>
<td>1112 4th Avenue</td>
<td>+1 206 264-6000</td>
</tr>
<tr>
<td>*Warwick Seattle</td>
<td>401 Lenora Street</td>
<td>+1 206 443-4300</td>
</tr>
<tr>
<td>The Westin Seattle</td>
<td>1900 5th Avenue</td>
<td>+1 206 728-1000</td>
</tr>
</tbody>
</table>

*Hotels past January 31, 2019 are not reflected in the map on the following page.
### Conference Services

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seattle Visitor Center and Concierge Services</td>
<td>Upper Pike St. Lobby Level 1</td>
<td>Monday to Friday 9:00 AM – 5:00 PM</td>
</tr>
<tr>
<td><strong>Note:</strong> Full-service concierge assistance, including maps, guides, tickets, restaurant reservations, tours, ground transportation, and personal services is available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bag and Coat Check</td>
<td>Hall 4C Level 4</td>
<td>Monday: 8:00 AM – 10:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday: 7:30 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wednesday and Thursday: 7:30 AM – 6:30 PM</td>
</tr>
<tr>
<td><strong>Note:</strong> Bag and coat check are free of charge.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyber Cafe</td>
<td>4D Skybridge Level 4</td>
<td>Sunday: 3:00 PM – 5:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday to Wednesday: 7:30 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thursday: 7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Note:</strong> Computers with Internet access are available for webcasts, abstract searches, and messages.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Media Center</td>
<td>Room 400 Level 4</td>
<td>Monday: 10:00 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday to Thursday: 8:00 AM – 6:30 PM</td>
</tr>
<tr>
<td><strong>Note:</strong> There is no on-site press registration. Registered press can pick up press kits and obtain location for press conferences at this location.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Badge Pickup</td>
<td>Hall 4C</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td>Attendee Services</td>
<td>Level 4</td>
<td>Monday: 7:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Housing Information</td>
<td>Tuesday: 7:00 AM – 6:00 PM</td>
<td></td>
</tr>
<tr>
<td>Scholarship Badge Pickup</td>
<td>Wednesday: 8:00 AM – 6:00 PM</td>
<td></td>
</tr>
<tr>
<td>Media Badge Pickup</td>
<td>Thursday: 8:00 AM – 6:00 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> Badges and conference materials can be picked up at this location.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker Ready Room</td>
<td>Room 620 Level 6</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday to Thursday: 6:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Note:</strong> Oral abstract, invited, and themed discussion session speakers must drop off presentations at least 24 hours before their presentation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal Considerations Room</td>
<td>Room 507 Level 5</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday: 9:00 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday to Thursday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Note:</strong> The Personal Considerations Room is a room set aside for those who require a short-term private space for personal health needs. Use of this room is available on a first-come, first-served basis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Mother’s Room</td>
<td>Room 416 Level 4</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday: 9:00 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday to Thursday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Note:</strong> The New Mother’s Room is a room set aside for nursing mothers who require a short-term private room. Use of this room is available on a first-come, first-served basis.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ABSTRACT PROCESS

Scientific Categories
A. Virology
B. Pathogenesis: Human Studies and Animal Models
C. HIV-Associated Tumor Viruses
D. Host Immune Responses to Infection, Vaccines, and Immunotherapy
E. HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy
F. Neuropathogenesis and Neurologic Complications
G. Clinical Pharmacology
H. Antiretroviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy and Effectiveness Studies
I. HIV Drug Resistance
J. HIV Diagnostics
K. Hepatitis Viruses and Liver Complications
L. AIDS-Related Malignancies
M. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
N. Other Complications of HIV Infection and Antiretroviral Therapy
O. Tuberculosis and Other Opportunistic Infections
P. Maternal and Fetal HIV
Q. Pediatrics and Adolescents
R. Epidemiology
S. Testing
T. Prevention Interventions
U. Contraception, Sexually Transmitted Infections, and Reproductive Health
V. Implementation and Scale-Up of Treatment and Care
W. Population and Cost Modeling

Abstract Content
Author names, institutions, titles, and abstracts in the Abstract eBook and other materials are presented as submitted by the corresponding author.

Abstract Review Process
The PC and a panel of volunteer external reviewers reviewed more than 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise. PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected).

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores were identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls for each scientific category. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (distinct from a late submission).
Common Reasons for Abstract Rejection
• Information is not new enough
• Methodology is inadequate or insufficient to support conclusions
• Background does not summarize the hypothesis
• Submission is poorly written
• Abstract is duplicative of other submissions
• Abstract is not appropriate for CROI
• Controls are absent or inadequate
• Statistical evaluation is inadequate or absent
• Summary of essential results is inadequate or absent
• Data are inadequate or insufficient to support conclusions
• Submission reports clinical trial and data from unplanned analysis or incomplete or ongoing studies
• Format does not follow guidelines (e.g., section[s] missing, more than 1 graphic, table, or figure submitted)

Statistics for Abstracts
General abstract submitted ............................................. 1859
General abstracts accepted ............................................... 992
General oral abstracts ................................................. 92
General poster abstracts .............................................. 900
Late-breaking abstracts submitted ................................. 189
Late-breaking abstracts accepted ...................................... 35
Late-breaking oral abstracts ........................................... 18
Late-breaking poster abstracts ....................................... 17
Total abstracts submitted ............................................. 2048
Total abstract accepted .............................................. 1027

All Representing Authors on Accepted Abstracts
Region N Percent
Africa ......................................................... 97 11
Asia ......................................................... 19 2
Australia ..................................................... 9 1
Europe ....................................................... 193 21
Central and South America .................................. 15 2
North America ............................................. 584 63
Preconference Session - Monday

PRECONFERENCE SESSIONS

MONDAY MARCH 4, 2019

Workshop W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
Room 6AB 9:00 AM – 12:25 PM

Target Audience: This workshop is directed toward new trainees (e.g., undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). However, it is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 3 years.

Objectives: At the completion of the session, participants will be able to:
- Describe the current state of the art of selected areas of HIV basic and clinical research
- List the leading research themes being presented at CROI 2019
- Navigate CROI 2019, maximize the knowledge gained, and interact with research colleagues
- Clarify their individual research interests in relation to the priorities discussed at the workshop and CROI 2019 overall

Conveners

Serena S. Spudich, Yale University, New Haven, CT, USA
John W. Mellors, University of Pittsburgh, Pittsburgh, PA, USA

1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

UPDATE ON HIV VIROLOGY
Paul Bieniasz, The Rockefeller University, New York, NY, USA

UPDATE ON HIV IMMUNOLOGY
Penelope L. Moore, University of the Witwatersrand, Johannesburg, South Africa

UPDATE ON HIV PREVENTION
Sharon L. Hillier, Magee–Womens Hospital of UPMC, Pittsburgh, PA, USA

BREAK

UPDATE ON TUBERCULOSIS TREATMENT AND PREVENTION
Constance A. Benson, University of California San Diego, San Diego, CA, USA

UPDATE ON HIV CURE
Katharine J. Bar, University of Pennsylvania, Philadelphia, PA, USA
Preconference Session

Workshop MD LUNCH AND MARTIN DELANEY PRESENTATION
Room 6AB 12:25 PM - 1:45 PM

Description: The Martin Delaney Presentation is held annually during the workshops for New Investigators, International Investigators, and Community Educator Scholars in honor of pioneering HIV/AIDS activist Martin Delaney (1945–2009). It recognizes the important contributions of community advocacy and engagement in research.

Target Audience: This session is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows), new investigators (both international and domestic) and community educators. Attendance is mandatory for all scholarship recipients and is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 1 year.

2 DISCOVERING THE ART IN SCIENCE (AND MEDICINE):
THE HUMAN CONNECTION

Dawn Averitt, The Well Project, Womens Research Initiative on HIV/AIDS, South Strafford, VT, USA

Workshop W-2 FRONTIERS IN LABORATORY SCIENCE
Room 606-609 2:00 PM - 4:00 PM

Target Audience: This session is directed to students, researchers, and clinicians who are interested in learning the hot new technologies that are influencing HIV research or hold a substantial potential for research.

Level of Knowledge: It is assumed that the participants are familiar with the main technological and data analysis approaches used in HIV research.

Objectives: After attending this session, learners will be able to:
- Envision novel prospects to engineer the latent virome as a path to functional cure
- Visualize the whole body distribution of the virus reservoir
- Describe emerging flow cytometric tools

Conveners
Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Frank Kirchhoff, Ulm University Medical Center, Ulm, Germany

3 ENGINEERING THE LATENT RESERVOIR
Paula Cannon, University of Southern California, Los Angeles, CA, USA

4 NOVEL IMAGING APPROACHES TO CHARACTERIZE AND QUANTIFY VIRAL RESERVOIRS
Jacob D. Estes, Oregon Health and Sciences University, Portland, OR, USA

5 MORE COLORFUL IMMUNOLOGY: TARGETED ISOLATION OF MONOCLONAL ANTIBODIES
Mario Roederer, NIH, Bethesda, MD, USA
Oral Sessions

Workshop W-3 CLINICAL TRIAL DESIGN AND ANALYSIS  
Room 6C  
2:00 PM - 4:00 PM

**Target Audience:** This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

**Level of Knowledge:** It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and with basic HIV epidemiology.

**Objectives:** After attending this session, learners will be able to:
- Describe microbiomic data
- Identify how missing data can be managed
- Appreciate novel methods for evaluating and interpreting HIV prevention trials

**Conveners**

Richard E. Chaisson, Johns Hopkins University, Baltimore, MD, USA
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

6  **FELLOW TRAVELERS: INTERPRETING THE IMPACT OF THE MICROBIOME IN CLINICAL INTERVENTION**
Adam Burgener, Public Health Agency of Canada, Winnipeg, MB, Canada

7  **MISSING U: HANDLING AND AVOIDING MISSING DATA IN CLINICAL TRIALS**
Heather Ribaudo, Harvard T.H. Chan School of Public Health, Boston, MA, USA

8  **DESIGNING & INTERPRETING HIV PREVENTION TRIALS IN THE ERA OF EFFECTIVE INTERVENTIONS**
David Dunn, University College London, London, UK

Workshop W-4 INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS  
Room 6E  
2:00 PM - 4:00 PM

**Target Audience:** This session is directed to persons interested in the management of hepatitis C, D, or E viral infections as well as management of NASH.

**Level of Knowledge:** It is assumed that participants are familiar with the general principles of hepatitis treatment and the medications used as well as the basics of fatty liver disease.

**Objectives:** At the completion of the session, participants will be able to:
- Diagnose and manage liver disease in HIV coinfection including NASH, hepatitis C, D, and E, and taking care of advanced liver disease stages
Conveners
Marion G. Peters, University of California San Francisco, San Francisco, CA, USA
Andri Rauch, University Hospital Bern, Bern, Switzerland

9 INTERACTIVE CASE-BASED WORKSHOP ON LIVER DISEASE

HEPATITIS E: CLINICAL CHALLENGES
Sven Pischke, University Hospital Hamburg–Eppendorf, Hamburg, Germany

HEPATITIS D: CLINICAL CHALLENGES
Jeffrey Glenn, Stanford University, Stanford, CA, USA

NASH IN HIV
Giada Sebastiani, McGill University Health Centre Research Institute, Montreal, QC, Canada

RETREATMENT OF HCV IN ADVANCED LIVER DISEASE
John D. Scott, University of Washington, Seattle, WA, USA
Oral Sessions

05-1 OPENING SESSION
Auditorium - 4AB
5:00 PM - 7:00 PM

Session Hosts

Richard A. Koup
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

Sharon L. Hillier
University of Pittsburgh, Pittsburgh, PA, USA

Elaine J. Abrams
ICAP at Columbia University, New York, NY, USA

SPECIAL PRESENTATION
ENDING THE HIV EPIDEMIC: A PLAN FOR THE UNITED STATES
Anthony S. Fauci, National Institute of Allergy and Infectious Diseases, National Institute of Health, US Department of Health and Human Services, Bethesda, MD, USA

BERNARD FIELDS LECTURE
The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the Opening Session, usually by a basic scientist recognized for his or her important and relevant contributions to the fields of virology and viral pathogenesis.

10 DISCOVERY AND DEVELOPMENT OF HIV BROADLY NEUTRALIZING ANTIBODIES
Michel Nussenzweig, The Rockefeller University, New York, NY, USA

N’GALY-MANN LECTURE
The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research. The Lecture is named in honor of Drs Bosenge N’Galy and Jonathan Mann for their crucial, pioneering work in HIV science in Africa.

11 THAILAND’S ACHIEVEMENTS IN HIV TREATMENT, PREVENTION, AND CURE RESEARCH
Praphan Phanuphak, Thai Red Cross AIDS Research Center, Bangkok, Thailand

The Seattle Men’s Chorus With Artistic Director Paul Caldwell will perform during the opening session at CROI.
TUESDAY MARCH 5, 2019

Plenary PL-1 TUESDAY PLENARY SESSION
Auditorium - 4AB
8:30 AM - 9:30 AM

Session Hosts
Sharon L. Hillier, University of Pittsburgh, Pittsburgh, PA, USA
Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA

12
8:30
DENIAL, DOOM, OR DESTINY? RESURGENT STIs IN HIV CARE & PREVENTION
Jeanne M. Marrazzo, University of Alabama at Birmingham, Birmingham, AL, USA

13
9:00
INFLAMMATION: TAMING THE FLAMES
Irini Sereti, NIAID, Bethesda, MD, USA

Oral Abstract 0-01 AIDS MALIGNANCIES AND KSHV
Room 606-609
10:00 AM - 12:00 PM

Oral Abstract Moderators
Thomas Schulz, Medizinischen Hochschule Hannover, Hannover, Germany
Scott Dryden-Peterson, Brigham and Women’s Hospital, Boston, MA, USA

14
10:00
HPV VACCINE WITH LEEP DID NOT PREVENT RECURRENT CERVICAL HSIL IN HIV-INFECTED WOMEN
Cindy Firnhaber, Avril Swarts, Masangu Mulongo, Bridgette Goeieman, Sophie Williams, Simon Levin, Mark Faesen, Pamela Michelow, Timothy Wilkin

15
10:15
OPTIMAL LUNG CANCER SCREENING CRITERIA AMONG PERSONS LIVING WITH HIV
Subhashini A. Sellers, Andrew Edmonds, Catalina Ramirez, Sushma Cribbs, Igbo Ofotokun, Laurence Huang, Alison Morris, Meredith C. McCormack, Ken M. Kunisaki, Maria P. Rivera, M. Brad Drummond, Adaora Adimora

16
10:30
HIV IS ASSOCIATED WITH DECREASED BREAST CANCER SURVIVAL: A PROSPECTIVE COHORT STUDY
Katrin S. Sadigh, Ryan M. Hodgeman, Neo Tapela, Isaac Nkele, Memory Bvchora-Nsingo, Sebasthi Chiaypo, Tlotti B. Ralefala, Jason A. Efstathiou, Oatise John, Galaletsang Motsweta, Surbhi Grover, Jerry Younger, Mompati O. Mmalane, Shahin Lockman, Scott Dryden-Peterson

17
10:45
LONG-TERM OUTCOMES OF 58 PATIENTS WITH HIV AND KSHV+ MULTICENTRIC CASTLEMAN DISEASE
Ramya Ramaswami, Kathryn Lurain, Priscila H. Gonçalves, Mark Polizotto, Anaïda Widell, Matthew Lindsley, Richard F. Little, Thomas S. Uldrick, Robert Yarchoan

18
11:00
REDUCTION OF KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS LATENCY USING CRISPR-CAS9
For Yue Tso, John T. West, Charles Wood

19
11:15
THE ROLE OF WILMS’ TUMOR 1 IN KAPOSI SARCOMA HERPESVIRUS ONCOGENESIS
Ayana Morales, Ethel Cesarman, Paul Rubinstein, Warren Phipps
Oral Sessions

20 LB  
11:30  
**QUANTIFICATION OF KSHV DNA AS A DIAGNOSTIC TEST FOR KAPOSI SARCOMA IN AFRICA**  
Aggrey Semeere, Andrea Gardner, Megan Wenger, Priscilla Namaganda, Ryan Snodgrass, Varun Kopparthy, Esther Freeman, John Ssali, Mwebesa Bwana, Toby Maurer, Robert Lukande, Miriam Laker-Oketta, David Erickson, Ethel Cesarmar, Jeffrey Martin

21  
11:45  
**SPECIAL PRESENTATION: TWO NOVEL POTENTIAL THERAPEUTIC TARGETS IN THE KSHV LIFE CYCLE**  
Thomas Schulz

Oral Abstract O-02 STRATEGIES FOR HIV CURE  
Room 6E  
10:00 AM - 12:00 PM

Oral Abstract Moderators  
Denise C. Hsu, US Military HIV Research Program, Bangkok, Thailand  
Sarah B. Joseph, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

22  
10:00  
**TARGETING THE NONCANONICAL NF-κB PATHWAY REVERSES SIV LATENCY**  
Maud Mavigner, Richard M. Dunham, Alyssa Brooks, Cristin Galardi, Gavin C. Sampey, Steven E. Bosinger, Thomas Vanderford, David M. Margolis, Guido Silvestri, Ann Chahroudi

23  
10:15  
**NONSUPPRESSIBLE VIREMIA ON ART FROM LARGE CELL CLONES CARRYING INTACT PROVIRUSES**  

24  
10:30  
**EX VIVO AND IN VIVO EDITING OF THE SIV GENOME IN NONHUMAN PRIMATES BY CRISPR-CAS9**  
Tricia H. Burdo, Pietro Mancuso, Rafal Kaminski, Jennifer Gordon, Binhua Ling, Andrew MacLean, Kamel Khalili

25  
10:45  
**DELAYED VIRAL REBOUND DURING ATI AFTER INFUSION OF CCR5 ZFN-TREATED CD4 T CELLS**  
Pablo Tebas, Julie Jadlowsky, Pamela Shaw, Gary Lee, Dale Ando, Sukyung Kim, SoeYu Naing, Simon Lacey, Bruce L. Levine, Don L. Siegel, Carl H. June, James L. Riley

26  
11:00  
**MULTIDOSE IV ROMIDEPSIN: NO INCREASED HIV-1 EXPRESSION IN PERSONS ON ART, ACTG A5315**  

27  
11:15  
**PEMBROLIZUMAB INDUCES HIV LATENCY REVERSAL IN HIV+ INDIVIDUALS ON ART WITH CANCER**  
Thomas S. Uldrick, Steven Fling, Scott V. Adams, Ajantha Solomon, Priscila H. Gonçalves, Nicolas Chomont, Rob Gorelick, Jeffrey D. Lifson, Robert Yarchoan, Martin “Mac” A. Cheever, Frank Maldarelli, Steven G. Deeks, Sharon R. Lewin, for the DARE and CITN-12 Study Teams
Oral Sessions

28 LB 11:30 POTENT ANTIVIRAL ACTIVITY OF TRISPECIFIC BROADLY NEUTRALIZING HIV ANTIBODIES
Amarendra Pegu, Ling Xu, Megan Demouth, Cassandra Almasri, Eun S. Yang, Jason M. Hataye, Mangeaarkarasi Asokan, Wanwisa Promsote, Ronnie R. Wei, Dana M. Lord, Ercole Rao, Jochen Beninga, Zhi-yong Yang, John R. Mascola, Gary Nabel

29 LB 11:45 SUSTAINED HIV-1 REMISSION FOLLOWING HOMOZYGOUS CCR5 DELTA32 ALLOGENIC HSCT
Ravindra K. Gupta, Sultan Abduljawad, Laura McCoy, H P. Mok, Dimitra Peppa, Helen Lee, Eleni Nastouli, Jonathan Lambert, Matthew Pace, John Frater, Andrew Lever, Simon Edwards, Eduardo Olavarria, Ian Gabriel, for the CHERUB and ICISTEM Study Groups

Oral Abstract 0-03 NONCOMMUNICABLE DISEASES IN TREATED HIV Auditorium - 4AB 10:00 AM - 12:00 PM

Oral Abstract Moderators
Janine M. Trevillyan, Monash University, Melbourne, Australia
Anjali Sharma, Albert Einstein College of Medicine, Bronx, NY, USA

30 10:00 BREAKING BONES IS BAD: INCIDENT FRACTURE AND MORTALITY IN THE HIV OUTPATIENT STUDY
Linda Battalora, Carl Armon, Frank J. Palella, Jun Li, Edgar T. Overton, John Hammer, Jack Fuhrer, Richard Novak, John Spear, Kate Buchacz

31 10:15 COPD AND THE RISK FOR MYOCARDIAL INFARCTION BY TYPE IN PEOPLE LIVING WITH HIV
Kristina Crothers, Barbara N. Harding, Bridget M. Whitney, Joseph Delaney, Robin M. Nance, Susan Heckbert, Mathew Budoff, W. C. Mathews, Joseph J. Eron, Richard D. Moore, Michael J. Mugavero, Michael Saag, Marie Kitahata, Heidi M. Crane, for the CNICS Cohort

32 10:30 SUDDEN CARDIAC DEATH AMONG HIV-INFECTED AND -UNINFECTED VETERANS
Matthew Freiberg, Meredith S. Duncan, Suman Kundu, Asri Mumpuni, Emily Epstein, Annie Bedigian, Amy C. Justice, Eric Vittinghoff, Zian H. Tseng, for the Veterans Aging Cohort Study Investigators

33 10:45 HIV POST SCD STUDY: 80% HIGHER RATE OF AUTOPSY-DEFINED SUDDEN ARRHYTHMIC DEATH IN HIV
Zian H. Tseng, Ellen Moffat, Eric Vittinghoff, Annie Bedigian, Joseph K. Wong, Philip Ursell, Andrew Connolly, Jeffrey Olgin, Priscilla Hsue

34 LB 11:00 CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HIV-NEGATIVE INDIVIDUALS: HPTN 077

35 11:15 ASSESSING THE PROBIOTIC EFFECT IN TREATED HIV: RESULTS OF ACTG A5350
Edgar T. Overton, Eunice Yeh, Rachel Presti, Jeffrey Jacobson, Brett Williams, Cara Wilson, Alan Landay, Jason Brenchley, Michael Dube, Carl Fichtenbaum, Netanya S. Utay, Douglas W. Kitch, Adriana Andrade, for the ACTG A5350 Study Team
36 11:30 FACTOR X INHIBITION REDUCES COAGULATION BUT NOT INFLAMMATION IN PERSONS WITH HIV
Jason V. Baker, Julian Wolfson, Tess Peterson, Kelly Garcia-Myers, Jonathan Klapheke, Micah Moolberry, Matthew Gissel, Kathleen Brummel-Ziedins, Irini Sereti, Nigel Key, Russell Tracy

37 LB 11:45 SAFETY, TOLERABILITY AND IMMUNOLOGIC ACTIVITY OF RUXOLITINIB ADDED TO SUPPRESSIVE ART
Vincent C. Marconi, Carlee Moser, Christina Gavegnano, Athi Tsibris, Amy Kantor, Edgar T. Overton, Charles W. Flexner, Peter W. Hunt, Rafick-Pierre Sekaly, Carlos del Río, Michael M. Lederman, Randall Tressler, Steven G. Deeks, Jeffrey J. Lennox, Raymond F. Schinazi

Oral Abstract 0-04 CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH
Room 6C 10:00 AM - 12:00 PM

Oral Abstract Moderators
Sharon Nachman, Stony Brook University, Stony Brook, USA
Bolanle Oyeledun, Centre for Integrated Health Programs, Abuja, Nigeria

39 LB 10:00 RANDOMIZED TRIAL OF RALTEGRAVIR-ART VS EFAVIRENZ-ART WHEN INITIATED DURING PREGNANCY
Mark Mirochnick, David E. Shapiro, Leavitt Morrison, Lisa Frenkel, Nahida Chakhtoura, George K. Sibery, Brookie Best, Maria Leticia S. Cruz, Blandina T. Mmbaga, Jose Henrik S. Pilotto, Avy Virolali, Sinart Prommas, Esau Joao, for the NICHD P1081 Protocol Team

40 LB 10:15 RCT OF DOLUTEGRAVIR VS EFAVIRENZ-BASED THERAPY INITIATED IN LATE PREGNANCY: DOLPHIN-2
Kenneth Kintu, Thoko Malaba, Jscsa Nakibuka, Christiana Papamichael, Angela Colbers, Kay Seden, Victoria Watson, Helen Reynolds, Duolao Wang, Catriona Waitt, Catherine Orrell, Mohammed Lamorde, Landon Myer, Saye Kho, for the DOLPHIN-2 Study Group

41 10:30 MATERNAL HBV VIREMIA IS ASSOCIATED WITH ADVERSE INFANT OUTCOMES IN HIV/HBV WOMEN

42 10:45 IMPACT OF IMPROVED NUTRITION/SANITATION ON NEURODEVELOPMENT OF HIV-EXPOSED CHILDREN
Robert Ntozini, Jaya Chandna, Ceri Evans, Gwendoline Kandawasvika, Bernard Chasekwa, Florence D. Majo, Naume Tavengwa, Kuda Mutasa, Batsirai Mutasa, Lawrence Moulton, Jean Humphrey, Andrew Prendergast, Melissa Gladstone, for the SHINE Trial Team

43 11:00 UNIQUE IMMUNOLOGICAL AND VIROLOGICAL FEATURES OF EARLY TREATED HIV-INFECTED NEWBORNS
Pilar García Broncano, Kevin Einkauf, Ce Gao, Shivaali Maddali, Chenyang Jiang, Kenneth Maswabi, Gbolahan Ajibola, Sikhulile Moyo, Terence Mohammed, Thabani Ncube, Joseph Makhema, Kathleen M. Powis, Daniel R. Kutzkes, Roger L. Shapiro, Mathias Lichterfeld
**Oral Sessions**

**NEONATAL ART < 7 DAYS VS 7-28 DAYS REDUCED TIME TO SUPPRESSION**

Alfredo Tagarro, Sara Domínguez Rodríguez, Thanyawee Puthanakit, Paolo Palma, Caroline Foster, Thidarap Jupimai, Nicola Cotugno, Jintanat Ananworanich, Santiago Jimenez de Ory, Paola Zangari, Maria Luisa Navarro, Paolo Rossi, Eleon Nastuoli, Carlo Giaquinto, Pablo Rojo Conejo, for the EPICAL Consortium

**SAFETY AND PHARMACOKINETICS OF MONOCLONAL ANTIBODY, VRC01 LS, IN HIV-EXPOSED NEWBORNS**

Elizabeth J. McFarland, Coleen K. Cunningham, Edmund V. Capparelli, Petronella Muresan, Elizabeth Smith, Charlotte Perlowski, Leavitt Morrison, Patricia Morgan, Adrian B. McDermott, Rohan Hazra, John R. Mascola, Barney S. Graham, for the IMPAACT P1112 Protocol Team

**BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS**


---

**Oral Abstract O-05 STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING**

**Room 6AB 10:00 AM - 12:00 PM**

**Oral Abstract Moderators**

Peter L. Anderson, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Flavia K. Matovu, Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda

**INCIDENT SYPHILIS RATES AND PREDICTORS IN US WOMEN WITH HIV, 2005-2016**

Jodie Dionne-Odom, Andrew Westfall, Michael J. Mugavero, Sonia Napravnik, Julia C. Dombrowski, Mari Kitahata, Richard D. Moore, Benigno Rodriguez, Maile Y. Karris, Elvin Geng, Kenneth H. Mayer, Jeanne M. Marrazzo

**PREPARING FOR PrEP IN ENGLAND: PREVALENCE AND INCIDENCE OF HIV AND BACTERIAL STIs**

Dana Ogaz, Ada R. Miltz, Sarika Desai, John Saunders, Andre Charlett, Owen N. Gill, Hamish Mohammed

**EXPANDING TESTING STRATEGIES IN PARIS: A FREE POSTAL COMPREHENSIVE STI TEST KIT**

Delphine Rahib, Heloise M. Delagreverie, Iris Bichard, Audrey Gabassi, Nicolas Guigue, Marie-Laure Chaix Baudier, Beatrice Bercot, Constance Delaugerre, Nathalie Lydié

**RANDOMIZED CONTROLLED TRIAL OF INTRAUTERINE DEVICE SAFETY IN WOMEN LIVING WITH HIV**

Catherine S. Todd, Heidi Jones, Nontokozilo Langwenya, Donald R. Hoover, Greg Petro, Landon Myer

**DOUBLE-DOSE LEVONORGESTREL IMPLANT DOES NOT FULLY OVERCOME INTERACTION WITH EFAVIRENZ**

Kimberly K. Scarsi, Lauren Cirrincione, Shadia Nakalema, Kristin Darin, Ian Musinguzi, Isabella Kyohairwe, Pauline Byakika-Kibwika, Andrew Owen, Lee Winchester, Anthony Podany, Susan E. Cohn, David Back, Courtney V. Fletcher, Marco Siccardi, Mohammed Lamorde
52 11:15 PHARMACOGENETICS WORSENS AN ADVERSE ANTIRETROVIRAL-HORMONAL CONTRACEPTIVE INTERACTION
David Haas, Yoninah S. Cramer, Catherine Godfrey, Susan L. Rosenkranz, Francesca Aweeka, Baiba Berzins, Robert Coombs, Kristine Coughlin, Laura E. Moran, David Gingrich, Carmen D. Zorrilla, Paxton Baker, Susan E. Cohn, Kimberly K. Scarsi, for the AIDS Clinical Trials Group A5316 Study Team

53 LB 11:30 POINT-OF-CARE VIRAL LOAD TESTING IMPROVES HIV VIRAL SUPPRESSION AND RETENTION IN CARE

54 LB 11:45 EFFECT OF THE HITS INTERVENTION ON HIV TESTING UPTAKE AMONG MEN IN SOUTH AFRICA
Frank Tanser, Hae-Young Kim, Thulile Mathenjwa, Maryam Shahmanesh, Janet Seeley, Philippa Matthews, Sally Wyke, Nuala McGrath, Benn Sartorius, H. Manisha N. Yapa, Thembilehi Zuma, Anya Zeitlin, Ann Blandford, Adrian Dobra, Till Bärnighausen

Themed Discussion TD-01 KSHV VIROLOGY AND PATHOGENESIS
Room 615-617 1:30 PM - 2:30 PM

Themed Discussion Leader
Blossom Damania, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

270 PRIMARY ROLE OF KSHV IN PATHOGENESIS OF ENDEMIC AND EPIDEMIC KAPOSI SARCOMA
Salum J. Lidenge, For Yue Tso, Andrew V. Kossenkov, Owen Ngalamika, John R. Ngowi, Yasaman Mortazavi, Eun Hee Kwon, Danielle M. Shea, Veenu Minhas, Julius Mwaiselage, Paul M. Lieberman, Charles Wood, John T. West

271 METABOLIC ABNORMALITIES IN CD8 T CELLS FROM HIV+ INDIVIDUALS WITH KAPOSI SARCOMA
Genevieve T. Clutton, Michael McGrath, Toby Maurer

272 SINGLE CELL EVALUATION OF KAPOSI SARCOMA TUMORS REVEALS COMPLEX IMMUNE INFILTRATE
Warren Phipps, David Coffey, Yuexin Xu, James Kafeero, Peter Mooka, Lazarus Okoche, Diana Basemera, Britta Flach, Andrea Towlerton, Edus H. Warren

273 NEW VARIANT OF KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS IN MEN WHO HAVE SEX WITH MEN

269 KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS IN AN HIV-INFECTED COHORT, SOUTH AFRICA
Elizabeth M. Etta, Lufuno G. Mavhandu-Ramarumo, George Gachara, Denise Tebit, Wendell Miley, Vickie Marshall, Denise Whitby, Pascal O. Bessong
Oral Sessions

Themed Discussion TD-02 STRUCTURE AND LOCATION OF PROVIRUSES ON ART
Room 606-609  1:30 PM - 2:30 PM

Themed Discussion Leader
Sarah Palmer, The Westmead Institute for Medical Research, Westmead, NSW, Australia

338  A METHOD TO DETERMINE BOTH THE INTEGRATION SITES AND SEQUENCES OF HIV-1 PROVIRUSES
Sean Patro, Leah D. Brandt, Michael J. Bale, Elias K. Halvas, Michele Sobolewski, Jenna Hasson, Aurelie Niyongobo, Xiaolin Wu, Shuang Guo, Steven G. Deeks, Stephen H. Hughes, John M. Coffin, Jason W. Rausch, John W. Mellors, Mary F. Kearney

339  DISTINCT CHROMOSOMAL POSITIONS OF INTACT HIV-1 PROVIRUSES
Kevin Einkauf, Guinevere Q. Lee, Ce Gao, Radwa Sharaf, Xiaoming Sun, Stephane Hua, Samantha M. Chen, Chenyang Jiang, Xiaodong Lian, Fatema Z. Chowdhury, Eric Rosenberg, Tae-Wook Chun, Jonathan Z. Li, Xu G. Yu, Mathias Lichterfeld

340  RELATIONSHIP BETWEEN INTACT HIV-1 PROVIRUSES AND PLASMA REBOUND VIRUSES
Ching-Lan Lu, Joy A. Pai, Lilian Nogueira, Pilar Mendoza, Marina Caskey, Mila Jankovic, Michel Nussenzweig

341  LANDSCAPE OF HIV-1 INTEGRATION SITES IN LYMPHOID TISSUE FROM ART-TREATED INDIVIDUALS
Vincent H. Wu, Christopher L. Nobles, Leticia Kuri Cervantes, Perla Del Río-Estrada, Gustavo Reyes-Terán, Frederic Bushman, Michael R. Betts

342  RELATIONSHIP BETWEEN INTACT HIV-1 PROVIRUSES AND PLASMA REBOUND VIRUSES
Ching-Lan Lu, Joy A. Pai, Lilian Nogueira, Pilar Mendoza, Marina Caskey, Mila Jankovic, Michel Nussenzweig

Themed Discussion TD-03 LET’S CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE
Room 6C  1:30 PM - 2:30 PM

Themed Discussion Leader
Rodolphe Garraffo, Université de Nice-Sophia-Antipolis, Hôpital Pasteur, CHU de Nice, Nice, France

461  PI DRUG-LEVEL TESTING AS A SCREENING TOOL FOR DRUG RESISTANCE IN 2ND-LINE ART FAILURE
Lucas E. Hermans, Kim Steegen, Rob ter Heine, Rob Schuurman, Hugo Tempelman, Robert Moraba, Erik Maarseveen, Taryn Pillay, Derryn Legg-Esilia, Jonathan M. Schapiro, David M. Burger, Sergio Carmona, Annemarie Wensing

462  PLASMA EFV AND TFV VS DRIED BLOOD SPOT TFV-DP TO PREDICT VIRAL SUPPRESSION IN WOMEN

CROI 2019  37
463  TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS FOLLOWING ESCALATING TAF/FTC DOSING

Jenna Yager, Jose R. Castillo-Mancilla, Mustafa E. Ibrahim, Kristina M. Brooks, Cricket McHugh, Samantha MaWhinney, Mary Morrow, Scott McCallister, Lane R. Bushman, Jennifer J. Kiser, Peter L. Anderson

464  VALIDATION OF A URINE TFV IMMUNOASSAY FOR REAL-TIME PrEP AND ART ADHERENCE TESTING

Monica Gandhi, Peter Bacchetti, Hideaki Okochi, Matthew A. Spinelli, Jared Baeten, Warren Rodrigues, Guohong Wang, Michael Vincent, Rachel W. Kubiak, Yardpirono Tawon, Virat Klinbuaayma, Pra-ornsuda Sukrakanchana, Oraphan Siriprakaisil, Tim R. Cresssey, Paul K. Drain

465  URINE FTC AND TFV CONCENTRATIONS AS POTENTIAL BIOMARKERS FOR ARV ADHERENCE

Richard Haaland, Tamee Livermont, Jeffrey Fountain, Chuong Dinh, Amy Martin, Davis Lupo, LaShonda Hall, Christopher Conway-Washington, Colleen F. Kelley

Themed Discussion TD-04 WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?

Room 6AB 1:30 PM - 2:30 PM

Themed Discussion Leader

Judith Aberg, Icahn School of Medicine at Mount Sinai, New York, NY, USA

518  IMPORTANT SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ART

Catherine Godfrey, Michael D. Hughes, Justin Ritz, Robert Gross, Robert A. Salata, Rosie Mngqibisa, Carole Wallis, M umbi Makanga, Marije Van Schalkwyk, Mitch Matoga, Courtney V. Fletcher, Beatriz Grinsztejn, Ann Collier, for the ACTG 5288 Team

516  DEPRESSION IS A STRONGER PREDICTOR OF EXECUTIVE DYSFUNCTION IN HIV+ WOMEN THAN MEN

Leah H. Rubin, Gayle Springer, Eileen Martin, Eric C. Seaberg, Ned Sacktor, Andrew Levine, Victor Valcour, Mary Young, James T. Becker, Pauline M. Maki

517  GENDER AND COINFECTIONS CONTRIBUTE TO IMMUNE ACTIVATION IN TREATED HIV INFECTION


519  TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS

Melanie Thompson, Indira Brar, Cynthia Brinson, Catherine Creticos, Debbie Hagins, Ellen Koenig, Claudia Martorell, Cristina Mussini, Laura Waters, Susan Guo, Ya-Pei Liu, Lauren L. Temme, Devi SenGupta, Moupali Das

520  EFFECT OF ANTIRETROVIRAL THERAPY AND IMMUNE RECONSTITUTION ON VAGINAL MICROBIOME

Zoe Packman, Cindy M. Liu, David Servwadda, Fred Nalugoda, Malika Aziz, Alison Abraham, Jessica Prodgser, Rupert Kaul, Ronald H. Gray, Aaron Tobian, Thomas C. Quinn, Steven J. Reynolds
Oral Sessions

CROI 2019 39

Oral Sessions

Themed Discussion TD-05 THE MASKED MARVELS YOU DON’T WANT TO MEET: SYphilIS AND LGV
Room 6E 1:30 PM - 2:30 PM

Themed Discussion Leader
Khalil G. Ghanem, Johns Hopkins University, Baltimore, MD, USA

1011 EFFECTIVE TREATMENT OF LYMPHOGRA NULOMA PROCTITIS WITH EXTENDED AZITHROMYCIN REGIMEN
José L. Blanco, Irene Fuertes, Jordi Bosch, Ana González-Cordón, Esteban Martínez, Andrea Vergara, Teresa Estrach, Jose M. Gatell, Alsina Merçè

1012 ADHERENCE OF HEALTH CARE PROVIDERS TO CDC LUMBAR-PUNCTURE CRITERIA AMONG SYphilIS/HIV
Barbara L. Henriques, Vivian I. Avelino-Silva, Marília B. Antonio, Jose E. Vidal

1013 HEARING LOSS IN UNSELECTED INDIVIDUALS WITH SYphilIS
Meena Ramchandani, Jamie Litvack, Clare Maxwell, Lauren Tantalo, Sharon Sahi, Shelia Dunaway, Christina Marra

1014 COGNITIVE IMPAIRMENT IN INDIVIDUALS WITH SYphilIS
Kevin Robertson, Haley Mendoza, Clare Maxwell, Shelia Dunaway, Arielle P. Davis, Sharon Sahi, Lauren Tantalo, Jana Zahlan, Sheryl Storey, Christina Marra

1015 RESPONSE TO SYphilIS TREATMENT: CDC GUIDELINES IN HIV-INFECTED ADULTS ON cART
Melody Ren, Leah Szadkowski, Darrell H. Tan, Sharon Walmsley

Symposium S-1 HIV-ASSOCIATED TUMOR VIRUSES: PARTNERS IN CRIME
Room 6C 4:00 PM - 6:00 PM

Target Audience: This session is directed both to clinicians treating HIV-infected individuals and basic scientists who study viral-host interactions. It is expected that this audience will recognize and have interest in the ongoing problem of HIV-associated cancers, particularly those caused by Kaposi sarcoma-associated herpes virus (KSHV), Epstein-Barr virus (EBV), human papilloma virus (HPV), and hepatitis B (HBV).

Level of Knowledge: It is assumed that the participants will be familiar with the ongoing challenge of HIV-associated cancers, particularly KSHV, cervical and anal cancer, and lymphomas and liver cancer.

Objectives: At the completion of the session, participants will be able to:
• Describe the mechanisms and emerging concepts concerning the links between KSHV, HPV, EBV, and HBV and cancer
• Describe how coinfection of these viruses with HIV is contributing to an ongoing epidemic of cancer in individuals living with HIV
• Appreciate how a basic understanding of tumor viruses is leading to novel interventions to prevent infection or the development of the cancers these viruses cause
Conveners
Thomas Schulz, Medizinischen Hochschule Hannover, Hannover, Germany
Jianxin You, University of Pennsylvania, Philadelphia, PA, USA

55  MODULATION OF HOST INNATE IMMUNITY BY KSHV
   Blossom Damania, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

56  EBV: IMMUNOPATHOGENESIS AND THE PATH TO AN EBV VACCINE
   Jeffrey Cohen, NIAID, Bethesda, MD, USA

57  HPV: NEW INSIGHTS INTO ONCOGENESIS AND OPPORTUNITIES FOR IMMUNE CONTROL
   Denise Galloway, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

58  HBV: FROM VIRAL INTEGRATION TO LIVER CANCER, IMPACT ON CURE STRATEGIES
   Fabien Zoulim, INSERM, Strasbourg, France

Symposium S-2 ART AND REPRODUCTION
Room 6E 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the current state of knowledge regarding the use of antiretroviral therapy in women of reproductive potential and the potential impacts of antiretrovirals on maternal health and pregnancy outcomes.

Level of Knowledge: It is assumed that the participants have familiarity with issues of HIV treatment and prevention of mother-to-child transmission, as well as basic understandings of the processes of conception, gestation and delivery.

Objectives: At the completion of the session, participants will be able to:

- Describe the existing evidence for associations between contemporary ARVs and birth defects in the context of state-of-art HIV treatment
- Elucidate issues facing clinicians, policymakers, and researchers related to this topic

Conveners
Tendayi Westerhof, Pan African Positive Women’s Coalition-Zimbabwe, Kadoma, Mashonaland West Province, Zimbabwe
Meg Doherty, WHO, Geneva, Switzerland

59  UPDATE ON ANTIRETROVIRAL DRUGS AND BIRTH DEFECTS
   Lynne M. Mofenson, Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA

60  ART OPTIONS AND TREATMENT DECISIONS FOR WOMEN OF REPRODUCTIVE POTENTIAL
   Monica Gandhi, University of California San Francisco, San Francisco, CA, USA
61  POLICY AND PROGRAM DECISIONS FOR ART IN WOMEN OF REPRODUCTIVE POTENTIAL
Irene Mukui, Ministry of Health, Nairobi, Kenya

62  CHALLENGES IN ANTIRETROVIRAL RESEARCH IN WOMEN OF REPRODUCTIVE POTENTIAL
Anne D. Lyerly, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Symposium  S-3 ADDING FUEL TO THE FIRE: SUBSTANCE USE AND HIV
Room 6AB  4:00 PM - 6:00 PM

Target Audience: This session is aimed for researchers, clinicians, and program designers and implementers interested in the intersection between substance use and HIV as related to both prevention of HIV acquisition and management of persons living with HIV with challenges related to substance use.

Level of Knowledge: It is assumed that attendees have knowledge of behavioral factors associated with HIV acquisition and how such factors influence access to HIV related testing, prevention, and treatment services.

Objectives: At the completion of the session, participants will be able to:
- Describe epidemiology of substance use in HIV infection
- Describe emerging issues in HIV and substance use with regard to:
  - Increase in HIV risk
  - Impact on adherence with ART
  - Effects on morbidity and mortality

Conveners
Nabila El-Bassel, Columbia University, New York, NY, USA
Dianne M. Rausch, National Institute of Mental Health, Bethesda, MD, USA

63  CHASING THE DRAGON: OPIATES AND HIV
Ricky N. Bluthenthal, University of Southern California, Los Angeles, CA, USA

64  CHEMSEX AND IMPLICATIONS FOR HIV TRANSMISSION AND MANAGEMENT
Mark R. Pakianathan, St. George’s University of London, London, UK

65  HIDDEN IN PLAIN SIGHT: THE ALCOHOL EPIDEMIC
Leickness C. Simbayi, Human Sciences Research Council, Pretoria, South Africa

66  TOBACCO SMOKING: THE SILENT KILLER
Lene Ryom, Centre of Excellence for Health, Immunity and Infections, Copenhagen, Denmark
WEDNESDAY MARCH 6, 2019

Plenary PL-2 WEDNESDAY PLENARY SESSION
Auditorium - 4AB 8:30 AM - 9:30 AM

Session Hosts
Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Jonathan Mermin, Centers for Disease Control and Prevention, Atlanta, GA, USA

67 8:30 RAISING THE WALL IN MATERNAL/FETAL IMMUNITY
Sallie Permar, Duke Human Vaccine Institute, Durham, NC, USA

68 9:00 HUGGING PHYLOGENETIC TREES: USE OF MOLECULAR ANALYSIS FOR PUBLIC HEALTH INTERVENTION
Alexandra M. Oster, CDC, Atlanta, GA, USA

Oral Abstract 0-06 VIRUS-CELL INTERACTION
Room 606-609 10:00 AM - 12:00 PM

Oral Abstract Moderator
Wei-Shau Hu, National Cancer Institute, Frederick, MD, USA
Stefan Sarafianos, Emory University School of Medicine, Atlanta, GA, USA

69 10:00 A VIRUS-PACKAGEABLE CRISPR SCREEN IDENTIFIES HIV RESTRICTION AND DEPENDENCY FACTORS
Molly Ohainle, Louisa Pendergast, Jolien Vermeire, Ferdinand Roesch, Daryl Humes, Julie M. Overbaugh, Michael Emerman

70 10:15 A FUNCTIONAL MAP OF HIV-HOST INTERACTIONS IN PRIMARY HUMAN CD4+ T CELLS
Judd F. Hultquist, Joe Hiatt, Lara Rheinemann, Ryan Leenay, Andrew May, Wesley I. Sundquist, Alexander Marson, Nevan J. Krogan

71 10:30 HIV-1 COMPLEXES TRAFFIC WITH HOST CPSF6 ON MICROTUBULES PRIOR TO NUCLEAR ENTRY
Zhou Zhong, Douglas K. Fischer, Chris Kline, Sooin Jang, Alan N. Engelman, Simon C. Watkins, Zandrea Ambrose

72 10:45 HIV-1 CAPSID DETERMINANTS THAT INFLUENCE NUCLEAR ENVELOPE DOCKING AND NUCLEAR IMPORT
Mohamed Husen M. Munshi, Ryan C. Burdick, Wei-Shau Hu, Vinay K. Pathak

73 11:00 SINGLE HIV-1 VIRUS IMAGING WITH CA-EGFP QUESTIONS A ROLE OF NUCLEAR CA IN INTEGRATION
Irena Zurnic, Lieve Dirix, Veerle Lemmens, Doortje Borrenberghs, Susana Rocha, Johan Hofkens, Frauke Christ, Jelle Hendrix, Zeger Debyser

74 11:15 DISRUPTION OF HIV-1 LTR SEQUENCE BY A NUCLEOCAPSID MUTATION LEADS TO DTG RESISTANCE
Atsuko Hachiya, Karen A. Kirby, Hirotaka Ode, Maritza Puray-Chavez, Mai Kubota, Urara Shigemi, Reiko Okazaki, Masakazu Matsuda, Mayumi Imahashi, Wataru Sugiuira, Yoshiyuki Yokomaku, Yasumasa Iwataani, Stefan Sarafianos
75 11:30 INTEGRASE (IN) TETRAMERS ARE THE AUTHENTIC TARGETS FOR ALLOSTERIC HIV-1 INHIBITORS
Pratibha Chowdary Koneru, Nanjie Deng, Ashley Hoyte, Jared Lindenberg, Stephanie Rebensburg, Ashwanth Francis, Dmitry Lyumkis, Alan N. Engelman, Gregory Melikian, Ronald Levy, Mamuka Kvaratskhelia

76 LB 11:45 TARGETING VIRUS ENV AND CD44 IMPROVES bNAb AVIDITY AND NEUTRALIZATION POTENCY
Djin-Ye Oh, Lihong Liu, Jian Yu, Manoj Nair, Manxue Xia, Sho Iketani, Lili Tsai, Yehuda Z. Cohen, Neal Patde, Yaoxing Huang, David Ho

Oral Abstract 0-07 TB: FROM CONTACT TO CURE AND BEYOND
Room 6AB 10:00 AM - 12:00 PM

Oral Abstract Moderators
Timothy R. Sterling, Vanderbilt University School of Medicine, Nashville, TN, USA
Annie F. Luetkemeyer, University of California San Francisco, San Francisco, CA, USA

77 10:00 IPT AND PREGNANCY OUTCOMES IN HIV-POSITIVE WOMEN, THE TSHEPISO COHORT
Nicole Salazar-Austin, Sanjay Lala, Ziyaad Waja, Silvia Cohn, Jennifer Hoffmann, Fildah Mashabela, Christopher Hoffmann, Kelly E. Dooley, Richard E. Chaisson, Neil A. Martinson, for the TSHEPISO Study Team

78 10:15 POTENTIAL CONCERN FOR TIMING OF DMPA INJECTION AMONG WOMEN TREATED FOR HIV AND TB
Rosie Mngqibisa, Susan E. Cohn, Michelle A. Kendall, Xingye Wu, Kelly E. Dooley, Helen Mcilleron, Jennifer A. Robinson, Cindy Firnhaber, Jhoanna C. Roa, Sharlaad Badal-Faesen, Francis Angira, Mpho S. Raesi, James G. Hakim, Catherine Godfrey, for the A5338 study team

79 10:30 IMPROVING CHILD TUBERCULOSIS CONTACT MANAGEMENT IN LESOTHO
Yael Hirsch-Moverman, Andrea Howard, Limakatso Lebelo, Koen Frederix, Aprielle Wills, Anneke Hesseling, Joanne E. Mantell, Sharon Nachman, Llang Maama-Maime, Wafaa M. El-Sadr

80 LB 10:45 SAFETY & PK OF WEEKLY RIFAPENTINE/ISONIAZID (3HP) IN ADULTS WITH HIV ON DOLUTEGRAVIR
Kelly E. Dooley, Gavin Churchyard, Radojka M. Savic, Akshay Gupte, Mark A. Marzinke, Nan Zhang, Vinodh Edward, Lisa Wolf, Modulakgotla Sebe, Morongwe Likoti, Mark Fyvie, Innocent Shamboro, Trevor Beattie, Richard E. Chaisson, for the DOLPHIN Study Team

81 LB 11:00 PHARMACOKINETICS AND SAFETY OF ADJUSTED DARUNAVIR/ RITONAVIR WITH RIFAMPIN IN PLWH
Ismaeel Ebrahim, Gary Maartens, Wynand Smythe, Catherine Orrell, Lubbe Wiesner, Helen Mcilleron

82 11:15 EARLY BACTERICIDAL ACTIVITY OF HIGH-DOSE ISONIAZID AGAINST MULTIDRUG-RESISTANT TB
Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L. Rosenkranz, Eric Nuermberger, Laura E. Moran, Kathleen Donahue, Susan Swindells, Andreas H. Diacon, for the ACTG A5312 Study Team

83 11:30 LONG-TERM MORTALITY AFTER TUBERCULOSIS CURE IN THE CIPRA HT-001 TRIAL
Yvetot Joseph, Marc Antoine Jean Juste, Serena Koenig, Sean Collins, Zhiwen Yao, Akanksha Dua, Piere Cremieux, Patrice Severe, Daniel Fitzgerald, Jean William Pape
Oral Sessions

84 LB 11:45

**QT EFFECTS OF BEDAQUILINE, DELAMANID OR BOTH IN MDR-TB PATIENTS: THE DELIBERATE TRIAL**

Kelly E. Dooley, Susan L. Rosenkranz, Francesca Conradie, Laura E. Moran, Richard Hafner, Florian von Grote-Biddingmaier, Javier R. Lama, Justin Shenje, Kyla Comins, Joel Morganroth, Andreas H. Diacon, Yoninah S. Cramer, Kathleen M. Donahue, Gary Maartens, for the ACTG A5343 Study Team

Oral Abstract 0-08 HEPATITIS C: NOW YOU SEE ME; SOON YOU WON’T
Room 6C 10:00 AM - 12:00 PM

Oral Abstract Moderators

Jennifer Price, University of California San Francisco, San Francisco, CA, USA
Gilles Wandeler, Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland

85 10:00

**FALL IN HCV INCIDENCE IN HIV+ MSM IN LONDON FOLLOWING WIDER ACCESS TO DAA THERAPY**

Lucy J. Garvey, Colette J. Smith, Christof Stingone, Indrajit Ghosh, Alison Rodger, Lakshmi Jain, Chandni Sood, Tabitha Mahungu, Carolyn Freeman, Subathira Dakshina, Filippo Ferro, Laura Waters, Ashley Brown, Graham S. Cooke, Sanjay Bhagani

86 10:15

**HCV REINFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY**

Jesse R. Carollo, Stephanie H. Factor, Gabriela Rodriguez-Caprio, Asa Radix, Stephen M. Dillon, Rona Vail, Kriszczar J. Bungay, Robert Chavez, José Lares-Guia, Daniel S. Fierer, for the New York Acute Hepatitis C Surveillance Network

87 10:30

**A PHASE 1 STUDY OF LEDIPASVIR/SOFOSBUVIR IN PREGNANT WOMEN WITH HEPATITIS C VIRUS**

Catherine A. Chappell, Elizabeth E. Krans, Katherine Bunge, Ingrid Macio, Debra Bogen, Kimberly K. Scarsi, Leslie A. Meyn, Sharon L. Hillier

88 10:45

**INCIDENT DIABETES AND GLUCOSE CONTROL AFTER HCV TREATMENT WITH DAA s IN ARCHIVES**

Adeel A. Butt, Samia Aslam, Peng Yan, Obaid S. Shaikh, Abdul-Badi Abou-Samra

89 11:00

**INTRAHEPATIC HEPATITIS C KINETICS WITH DIRECT-ACTING ANTIVIRALS IN HIV COINFECTION**

Ashwin Balagopal, Laura M. Smeaton, Vincent Vu, Charles S. Venuto, Gene D. Morse, Beverly Alston-Smith, Daniel E. Cohen, Jorge L. Santana, Donald D. Anthony, Mark Sulkowski, David L. Wyles, Andrew H. Talal, for the ACTG A5335S Substudy Team

90 11:15

**HIV VIREMIA AND LOW CD4+ INCREASE HCC RISK IN THOSE WITHOUT ADVANCED LIVER FIBROSIS**

Jessie Torgersen, Michael J. Kallan, Dena M. Carbonari, Jason A. Roy, Lesley S. Park, Tamar Taddei, Rajni Mehta, Kathyrn D’Addeo, Joseph Lim, Matthew B. Goetz, Janet Tate, Norbert Bräu, Amy C. Justice, Vincent Lo Re

91 LB 11:30

**SINGLE HEPATOCYTE ANALYSIS IN HIV-HBV COINFECTION SHOWS HBV TRANSCRIPTION SILENCING**

Ashwin Balagopal, Hyon S. Hwang, Tanner Grudde, Jeffrey Quinn, Richard K. Sterling, Mark Sulkowski, Chloe Thio
Oral Abstracts

Oral Abstract O-09 TESTING, VIRAL SUPPRESSION, AND IMPACT
Room 6E
10:00 AM - 12:00 PM

92 LB
10:00
IMPACT OF UNIVERSAL TESTING AND TREATMENT IN ZAMBIA AND SOUTH AFRICA: HPTN071(POPART)

Richard J. Hayes, Deborah J. Donnell, Sian Floyd, Nomtha Mndla, Justin Bwalya, Kwame Shanaube, Ayana Moore, Susan H. Esheleman, Christophe Fraser, Wafaa M. El-Sadr, Peter Bock, Nulda Beyers, Helen Ayles, Sarah Fidler, for the HPTN 071 (PopART) Study Team

93
10:15
A RANDOMIZED TRIAL ON INDEX HIV SELF-TESTING FOR PARTNERS OF ART CLIENTS IN MALAWI

Kathryn Dovel, Kelvin Balakasi, Frackson Shaba, Khumbo Phiri, Ogechukwu Offorjebe, Sundeeup Gupta, Vincent Wong, Eric Lungu, Mike Nyirenda, Brooke E. Nichols, Khumbo Ngona, Risa M. Hoffman, for the EQUIP Innovations for Health

94
10:30
VIRAL LOAD SUPPRESSION AND YIELD OF HIV TESTS ARE SPATIALLY CORRELATED, KENYA 2015-17

Anthony Waruru, Joyce Wamicwe, Thomas Achia, Lucy Ng’ang’a, Kenneth Masamaro, Jacques Muthusi, Emily C. ZIELINSKI-GUTIERREZ, James Tobias, Stella Nyuguna, Catherine Mbaire, Kevin M. De Cock, Thorkild Tylløeskård

95
10:45
HIV TESTING, TREATMENT, AND VIRAL SUPPRESSION COVERAGE IN A CLUSTER-RANDOMIZED TRIAL

Kathleen Wirth, Tendani Gaolathe, Molly Pretorius Holme, Mompati O. Mmalane, Etienne Kadima, Kutlo Manyake, Sikhhulile Moyo, Kara Bennett, Jean Leidnin, Refeltswile Lebelonwayne, Pamela J. Bachanas, Joseph Makhema, Max Essex, Shahin Lockman, Eric Tchetgen Tchetgen

96
11:00
FACTORS ASSOCIATED WITH PERSISTENT VIREMIA WITH UNIVERSAL “TEST & TREAT” IN UGANDA

Eshan U. Patel, Kate Grabowski, Aaron Tobian, Gertrude Nakigozi, Victor Ssemipija, Joseph Sekeasanu, Godfrey Kigozi, Fred Nalugoda, Ronald H. Gray, Thomas C. Quinn, David Serwadda, Maria Wawer, Larry W. Chang, Joseph Kagaayi, Steven J. Reynolds

97
11:15
VIROLOGIC FAILURE, LOW-LEVEL VIREMIA, AND VIRAL BLIP AFTER HIV RNA SUPPRESSION


98
11:30
FIFTY PERCENT REDUCTION IN HIV INCIDENCE IN CHOKWE DISTRICT, MOZAMBIQUE, 2014-2017

Duncan A. MacKellar, Robert Nelson, Ricardo Thompson, Isabelle Casavant, Sherri Pals, Ishani Pathmanathan, Judite Cardoso, Dawud Ujamaa, Ernest L. Yufenyuy, Katrina Sleeman, Victor Chivuure, Noela Chicuecue, Keydra Oladapo, Aleny M. Couto, Alfredo Vergara

99
11:45
A MODEL IMPACT ANALYSIS OF PrEP AND TasP IN FSW DEMONSTRATION PROJECT IN BENIN

Lily Geidelberg, Kate M. Mitchell, Marlène Aza-Gndandji, Luc Béhanzin, Fernand A. Guédou, Djimon M. Zannou, Djissou Affolabi, Rene Keke, Flore Gangbo, Moussa Bachabi, Peter Vickerman, Michel Alary, Marie-Claude Boily

Oral Abstract Moderators
Amanda Derryck Castel, The George Washington University, Washington, DC, USA

Nyaradzo Mgodi, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
Oral Abstract O-10 NEW OPTIONS AND OPPORTUNITIES IN PrEP
Auditorium - 4AB 10:00 AM - 12:00 PM

Oral Abstract Moderators
Charlotte-Paige M. Rolle, Orlando Immunology Center, Orlando, Florida, USA
Marc Baum, Oak Crest Institute of Science, Monrovia, CA, USA

Oral Abstract O-10 NEW OPTIONS AND OPPORTUNITIES IN PrEP

100 PROTECTION AGAINST PENILE OR INTRAVENOUS SHIV CHALLENGES BY bnAb 10-1074 OR 3BNC117
10:00
David A. Garber, Debra R. Adams, Patricia Guenther, James Mitchell, Shanon Ellis, Kristen Kelley, Michael S. Seaman, Janet McNicholl, Michel Nussenzweig, Walid Heneine

101 PROTECTION AGAINST VAGINAL SHIV INFECTION WITH AN INSERT CONTAINING TAF AND EVG
10:15
Charles Dobard, M. Melissa Peet, Kenji Nishiura, Onkar N. Singh, Timothy J. McCormick, James Mitchell, Gerardo Garcia-Lerma, Vivek Agrahari, Pardeep Gupta, Sriramakamal Jonnalagadda, Jill Schwartz, Walid Heneine, Gustavo Doncel, Meredith Clark

102 MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES
10:30
Ivana Massud, Mian-er Cong, Susan Ruone, Angela Holder, Kenji Nishiura, George Khalil, Yi Pan, Jonathan T. Lipscomb, James F. Rooney, Darius Babusis, Yeojin Park, Scott McCallister, Christian Callebaut, Walid Heneine, Gerardo Garcia-Lerma

103 LYMPHOID TISSUE PHARMACOKINETICS OF TENOFOVIR-ALAFENAMIDE VS -DISOPROXIL FUMARATE
10:45
Courtney V. Fletcher, Ann Thorkelson, Kayla Campbell, Lee Winchester, Timothy Mykris, Jon Weinhold, Jodi Anderson, Jacob Zulk, Puleng Moshele, Siri Jorstad, Anthony Podany, Jason V. Baker, Timothy Schacker

104 LB THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS
11:00
Charles B. Hare, Josep Coll, Peter Ruane, Jean-Michel Molina, Kenneth H. Mayer, Heiko Jessen, Robert M. Grant, Joss J. De Wet, Melanie Thompson, Edwin DeJesus, Ramin Ebrahimi, Robertoino Mera Giler, Moupali Das, Diana Brainard, Scott McCallister

105 USING EHR DATA TO IDENTIFY POTENTIAL PrEP CANDIDATES IN A LARGE HEALTH CARE SYSTEM
11:15
Julia L. Marcus, Leo Hurley, Stacey Alexeeff, Douglas Krakower, Michael J. Silverberg, Jonathan E. Volk

106 PERSISTENCE WITH HIV PREEXPOSURE PROPHYLAXIS IN THE UNITED STATES, 2012-2016
11:30
Ya-Lin A. Huang, Guoyu Tao, Dawn K. Smith, Karen W. Hoover

107 IMPACT OF PrEP ON DRUG RESISTANCE AND ACUTE HIV INFECTION, NEW YORK CITY, 2015-2017
11:45
Kavita Misra, Jamie Huang, Demetre C. Daskalakis, Chi-Chi Udeagu
Oral Sessions

CROI 2019

1:30 PM - 2:30 PM

Themed Discussion TD-06 EARLY EVENTS
Room 606-609

166  ENTRY KINETICS OF GLOBALLY REPRESENTATIVE AND VERTICALLY TRANSMITTED HIV ENVELOPES
Nicholas E. Webb, Nicole Tobin, Grace M. Aldrovandi

167  CD4-DEPENDENT MODULATION OF HIV-1 ENTRY BY LY6E
Jingyou Yu, Chen Liang, Shan-Lu Liu

168  ELUCIDATING MECHANISMS BY WHICH MUTATIONS IN ENV CONTRIBUTE TO HIV-1 DRUG RESISTANCE
Rachel Van Duyne, Phuong Pham, Jonathan Spindler, Ann Wiegand, Mary F. Kearney, Eric O. Freed

169  NONRANDOM GENERATION OF DELETIONS WITHIN HIV PROVIRAL SEQUENCES IN VIVO
Bonnie Hiener, Bethany A. Horsburgh, Vincent Morcilla, Eunok Lee, Susanne von Stockenstrom, Jeffrey M. Milush, Teri Liegler, Rebecca Hoh, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer, Robert Lanfear

170  HOST FACTORS INFLUENCE SIV AND HIV-1 INFECTION AND SENSITIVITY TO CAPSID INHIBITORS
Rachel Scheck, Augustin P. Twizerimana, Zeli Zhang, Dieter Häussinger, Carsten Münk

1:30 PM - 2:30 PM

Themed Discussion TD-07 INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS
Auditorium - 4AB

389  ANALYTICAL TREATMENT INTERRUPTION (ATI) IN PATIENTS WITH VERY SMALL HIV RESERVOIR
Pieter Pannus, Sofie L. Rutseaert, Stephane de Wit, Sabine Allard, Guido Vanham, Coca Ncssoi, Joeri Aerts, Ward De Spiegeleare, Achilleas Tsoumanis, Marie Couttenye, Natacha Herssens, Linos Vandekerckhove, Eric Florence

390  N-803 INDUCES ROBUST SIV REACTIVATION IN ART-TREATED CD8-DEPLETED MACAQUES

391  REBOUND OF HIV-1 IN CEREBROSPINAL FLUID AFTER TREATMENT INTERRUPTION
Richard W. Price, Maria Bednar, Laura P. Kincer, Rebecca Hoh, Magnus Gisslén, Sarah B. Joseph, Serena S. Spudich, Steven G. Deeks, Ronald Swanstrom

392  COMPARTMENTALIZED HIV REBOUND IN THE MALE GENITAL TRACT AFTER ART INTERRUPTION
Sara Gianella, Antoine Chaillonn, Tae-Wook Chun, Caroline Ignacio, Colin Kovacs, Erika Benko, Sanja Huibner, Rupert Kaul
Oral Sessions

CROI 2019

Oral Sessions

• Wednesday

393  SEEKING SUPPRESSION IN HAVARTI: VIREMIA & T CELLS AFTER VEDOLIZUMAB & ATI IN HIV/ART

Michaeline McGuinty, Jonathan Angel, Ashok Kumar, Richmond Sy, Sanjay Murthy, Donald Kilby, Nancy Tremblay, Elizabeth Lavoie, Stephanie Burke Schinkel, Siddappa N. Byrareddy, D. William Cameron, for the HAVARTI CTNPT031 Study Team

Themed Discussion TD-08 WEIGHT GAIN DURING ART
Room 6AB  1:30 PM - 2:30 PM

Themed Discussion Leader
Jane A. O’Halloran, Washington University in St Louis, St Louis, MO, USA

669  RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR–BASED ART

Jordan E. Lake, Kunling Wu, Kristine M. Erlandson, Sara H. Bares, Paula DeBroy, Catherine Godfrey, John R. Koethe, Grace A. McComsey, Frank J. Palella, Katherine Tassiopoulos

670  GREATER WEIGHT GAIN AMONG TREATMENT-NAIVE PERSONS STARTING INTEGRASE INHIBITORS


671  WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT-EXPERIENCED ADULTS WITH HIV

Grace A. McComsey, Joseph J. Eron, Steven Santiago, Karam Mounzer, Graeme Moyle, Thanes Vanig, Paul E. Sax, Keri N. Althoff, Scott Milligan, Michael Marks, Richard Haubrich, Richard A. Elion

672  INTEGRASE STRAND TRANSFER INHIBITORS ARE ASSOCIATED WITH WEIGHT GAIN IN WOMEN

Anne M. Kerchberger, Anandi N. Sheth, Christine D. Angert, Cyra Christina Mehta, Nathan A. Summers, Igbo Ofotokun, Deborah Gustafson, Sheri Weiser, Seble Kassaye, Deborah Konkle-Parker, Anjali Sharma, Adaora Adimora, Hector Bolivar, Cecile D. Lahiri

673  THE IMPACT OF WEIGHT GAIN AND SEX ON IMMUNE ACTIVATION FOLLOWING INITIATION OF ART

Sara H. Bares, Laura M. Smeaton, Vincent Vu, Beth A. Zavoda-Smith, Sarah E. Scott, Catherine Godfrey, Grace A. McComsey

Themed Discussion TD-09 THE STATE OF THE MIND: GROWING UP WITH HIV
Room 6E  1:30 PM - 2:30 PM

Themed Discussion Leader
Robert Paul, University of Missouri, St. Louis, St. Louis, MO, USA

819  YOUTH PSYCHIATRIC TRAJECTORIES PREDICT PERINATALLY HIV INFECTED YOUNG-ADULT VIREMIA

Oral Sessions

820

**TRAJECTORY ANALYSIS OF COGNITIVE OUTCOMES IN CHILDREN WITH PERINATAL HIV**

Payal Patel, Tanakorn Apornpong, Stephen J. Kerr, Thanyawee Puthanakit, Kulvadee Thongpibul, Pope Kosalaraksa, Pradthana Ounchanum, Suparat Kanjanavanit, Ly Penh Sun, Saphonn Vonthanak, Serena S. Spudich, Jintanat Ananworanich, Robert Paul, for the PREDICT/Resilience Study Group

821

**FOCUSED COGNITIVE FUNCTION TESTING IN YOUNG PEOPLE WITH PERINATAL HIV IN ENGLAND**

Alejandro Arenas-Pinto, Hannah Castro, Diane Melvin, Marthe Le Prevoist, Caroline Foster, Kate Sturgeon, Alan Winston, Lindsay Thompson, Diana Gibb, Ali Judd, for the Adolescents and Adults Living with Perinatal HIV (AALPHI) Steering Committee

822

**SYSTEMIC INFLAMMATION AND STRUCTURAL BRAIN CHANGES IN PERINATALLY HIV+ ADOLESCENTS**

Jackie Hoare, Landon Myer, Sarah Heany, JP Fouche, Nicole Phillips, Heather Zar, Dan Stein

823

**GENOMICS LINKS AUTOPHAGY WITH NEUROCOGNITIVE IMPAIRMENT IN HIV-INFECTED CHILDREN**

Stephen A. Spector, Sean S. Brummel, Kumud K. Singh, Jihoon Kim, Kelly Frazer, Sharon Nichols, Olivier Harismendy, George R. Seage, Paige L. Williams, Russell B. Van Dyke, Rodney Trout

**Themed Discussion TD-10 NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS**

Room 6C 1:30 PM - 2:30 PM

**Themed Discussion Leader**

Frank Tanser, *African Health Research Institute, Durban, South Africa*

856

**INCIDENT INFECTION IN HIGH-PRIORITY HIV MOLECULAR TRANSMISSION CLUSTERS**

Joel O. Wertheim, Nivedha Panneer, Anne Marie France, Neeraja Saduvala, Alexandra M. Oster

857

**MOLECULAR SURVEILLANCE AS A MEANS TO EXPAND AN OUTBREAK INVESTIGATION: MA, 2015-2018**

Betsey John, Nivedha Panneer, Matthew Tumpney, Paul McClung, Erica Dawson, Kate Buchacz, Kathleen Roosevelt, Philip J. Peters, Tracy Stiles, Elsworth M. Campbell, William M. Switzer, Alfred DeMaria, Kevin Cranston, Sheryl Lyss, for the Massachusetts Epi-Aid Investigation Team

876

**HIV MOLECULAR SURVEILLANCE AND PRETREATMENT DRUG RESISTANCE IN MEXICO CITY**


867

**CLUSTER SURVEILLANCE OF FRENCH PRIMARY INFECTIONS: TOWARD A MORE VIRULENT CRF02_AG?**

Benoit Visseaux, Lambert Assoumou, Mary Anne Trabaud, Brigitte Montes, Laurence Bocket, Samira Fafi-Kremer, Marc Wirden, Corinne Amiel, Anne De Monte, Karl Stefic, Camille Tumiotto, Anne Maillard, Diane Descamps, Marie-Laure Chaix Baudier, for the AC43 ANRS Resistance Group
841  LITTLE OR NO OVERLAP OF SEXUAL NETWORKS OF TRANSGENDER WOMEN AND MSM IN LIMA, PERU
Jessica E. Long, Hugo Sanchez, Dania Calderon Garcia, Leyla Huerta Castillo, Javier R. Lama, Ann Duerr

Themed Discussion TD-11 PLACES AND PEOPLE: MODELING THE COSTS AND EFFECT OF INTERVENTIONS ON HIV INCIDENCE
Room 615-617  1:30 PM - 2:30 PM

Themed Discussion Leader
Ruanne V. Barnabas, University of Washington, Seattle, WA, USA

1087  SCALE-UP OF ART AND VMMC EXPLAIN A TWO-FOLD DECLINE IN HIV INCIDENCE IN WESTERN KENYA
Anna Bershteyn, Adam N. Akullian, Daniel J. Klein, Britta Jewell, Kennedy Mutai, Samuel M. Mwalili

1084  EPIDEMIC IMPACT OF SUSTAINED VIREMIA AMONG FEMALE SEX WORKERS IN SOUTHERN AFRICA
Sharmistha Mishra, Huiting Ma, Sheree Schwartz, Deliwe R. Phethlu, Vijayanand Guddera, Nora West, Carly Comins, Harry Hauser, Stefan Baral, for the Siyamphambili Study Team

1085  ESTIMATING HIV INCIDENCE AMONG YOUNG WOMEN IN HPTN 082 USING BASELINE HIV RISK SCORES
James R. Moore, Deborah J. Donnell, Marie-Claude Boily, Kate M. Mitchell, Sinead Delany-Moretlwe, Connie L. Celum, Dobromir Dimitrov

1086  A MATHEMATICAL MODELING ANALYSIS OF COMBINATION HIV PREVENTION IN ANTENATAL CLINICS
Kimberly A. Powers, Kate Orroth, Nora E. Rosenberg, Lauren A. Graybill, Andrew Kumwenda, Tiwonge Mtande, Katie Mollan, Oliver Mweemba, Wilbroad Mutale, Benjamin H. Chi

1083  COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS AMONG ADOLESCENT SEXUAL MINORITY MALES
Li Yan Wang, Deven T. Hamilton, Eli Rosenberg, Patrick S. Sullivan, David A. Katz, Richard Dunville, Lisa C. Barrios, Maria Aslam, Steven M. Goodreau

Symposium S-4 EXPRESS YOURSELF: PROVIRUS
Room 6C  4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the nature and role of the latent reservoir in HIV-1 persistence.

Level of Knowledge: It is assumed that the participants are familiar with basic aspects of HIV-1 replication and the concept that HIV-1 DNA can adopt an integrated, latent state in infected cells.

Objectives: At the completion of the session, participants will be able to:
- Evaluate progress in the field of latency reversing agents
- Describe concepts and mechanisms the underlie stochastic HIV-1 gene expression and its silencing by host proteins
- Describe how HIV-1 proviruses can influence host gene expression
Oral Sessions

Conveners
Vicente Planelles, University of Utah School of Medicine, Salt Lake City, UT, USA
Florence Margottin-Goguet, Institut Cochin, INSERM, Paris, France

108  THE CURRENT STATUS OF LATENCY REVERSING AGENTS
Carine M. Van Lint, Université Libre de Bruxelles, Brussels, Belgium

109  DISCOVERY AND CHARACTERIZATION OF A VIRUS-INTRINSIC HIV LATENCY CIRCUIT
Leor Weinberger, Gladstone Institutes, San Francisco, CA, USA

110  SILENCING OF RETROVIRAL GENE EXPRESSION BY THE HUSH COMPLEX
Stephen P. Goff, Columbia University Medical Center, New York, NY, USA

111  THE POWER OF THE HIV PROMOTER: IMPACT OF HIV-DRIVEN VIRAL AND HOST GENE EXPRESSION
Ya-Chi Ho, Yale University, New Haven, CT, USA

Symposium S-5 COINFECTIONS: TUBERCULOSIS, HEPATITIS B AND C, AND HIV
Room 6E  4:00 PM - 6:00 PM

Target Audience: This session is directed to persons interested in understanding the importance of tuberculosis and hepatitis confections in persons with HIV.

Level of Knowledge: It is assumed that the audience has a broad knowledge of medicine and infectious diseases.

Objectives: After attending this session, learners will be able to:
- Outline the journey to HBV cure
- Describe HCV vaccine development and recent trial results
- Describe recent advances in treating and preventing tuberculosis

Conveners
Lele Rangaka, University College London, London, United Kingdom
Anchalee Avihingsanon, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

112  DYNAMICS OF ACUTE HCV IN WESTERN EUROPE
Jürgen K. Rockstroh, University of Bonn, Bonn, Germany

113  A VACCINE TO PREVENT HCV: ARE WE GETTING THERE?
Andrea L. Cox, Johns Hopkins University, Baltimore, MD, USA

114  CHOICES AND DILEMMAS: PREVENTING TUBERCULOSIS IN PEOPLE WITH HIV INFECTION
Amita Gupta, Johns Hopkins University, Baltimore, MD, USA
**Oral Sessions**

**115**  
**TREATING MULTIDRUG-RESISTANT TUBERCULOSIS IN THE REAL WORLD: NEW DRUGS AND REGIMENS**  
Jennifer Furin, Harvard Medical School, Boston, MA, USA

---

**Symposium S-6 THE STORY OF U: IMPLICATIONS OF UNDETECTABLE VIRAL LOAD ON TRANSMISSION**

Room 6AB  
4:00 PM - 6:00 PM

**Target Audience:** This session is directed at clinicians and scientists who are interested in HIV transmission risk and mitigating factors, data supporting the lack of transmission risk from persons who are fully virally suppressed, clinical challenges in applying U=U, and community perspectives.

**Level of Knowledge:** It is assumed that the participants are familiar with HIV epidemiology and risk factors for HIV transmission.

**Objectives:** After attending this session, learners will be able to describe Undetectable = Untransmittable with regard to:
- Virology and other basic science issues
- Clinical challenges
- Social implications

**Conveners**

Eugene McCray, CDC, Atlanta, GA, USA  
Loice Achieng, University of Nairobi, Nairobi, Kenya

---

116  
**THE STORY OF U=U: SCIENTIFIC UNDERPINNINGS**  
Pietro L. Vernazza, St Gallen Cantonal Hospital, St Gallen, Switzerland

117  
**CARING FOR U: CLINICAL CONUNDRUMS**  
Nneka Nwokolo, Chelsea and Westminster Hospital, London, UK

118  
**ME AND U: COMMUNITY PERSPECTIVES**  
Carrie Foote, Indiana University, Bloomington, IN, USA

119  
**MORE THAN U: MAXIMIZING POPULATION-LEVEL EFFECTS OF U=U**  
Andrew E. Grulich, University of New South Wales, Sydney, NSW, Australia
THURSDAY MAR 07, 2019

Plenary PL-3 THURSDAY PLENARY SESSION
Auditorium - 4AB  8:30 AM - 9:30 AM

Session Hosts
Angela Kashuba, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Dennis L. Kolson, University of Pennsylvania, Philadelphia, PA, USA

THE CHALLENGES OF HIV TREATMENT IN AN ERA OF POLYPHARMACY
8:30
David Back, University of Liverpool, Liverpool, UK

NEUROHIV: WHAT THE VIRUS TELLS US
9:00
Ronald Swanstrom, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract 0-11 SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS
Room 606-609  10:00 AM - 12:00 PM

Oral Abstract Moderators
Kevin Robertson, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Leah H. Rubin, Johns Hopkins University, Baltimore, MD, USA

BRAIN CONNECTIVITY IN NEUROLOGICALLY ASYMPTOMATIC PEOPLE WITH HIV SWITCHING ART
10:00
Jaime H. Vera, Sofia Toniolo, Mara Cerignani, Borja Mora-Peris, Jasmini Alagaratnam, Jonathan Underwood, Marta Boffito, Mark Nelson, Alan Winston

DEEP-LEARNING CEREBRAL BLOOD FLOW FOR COGNITIVE-IMPAIRMENT CLASSIFICATION IN HIV
10:15
Patrick Luckett, Julie Wisch, Sarah A. Cooley, Beau M. Ances

HOST GLYCOMIC DETERMINANTS OF HIV-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT DURING THERAPY
10:30

CSF SCD30 ELEVATION DESPITE SUPPRESSIVE ART SUGGESTS CNS HIV PERSISTENCE
10:45
Michael Peluso, Cassandra Thanh, Louise Hogan, Sophie Stephenson, Steven G. Deeks, Magnus Gisslén, Richard W. Price, Timothy J. Henrich

CSF HIV RNA DETECTED AT <20 COPIES/ML ASSOCIATES WITH BLOOD-BRAIN BARRIER MEASURES
11:00
Shelli Farhadian, Jennifer Chiarella, Rachela Calvi, Hetal Mistry, Tobias Kirchwey, Payal Patel, Michelle Chintanaphol, Marie L. Landry, Serena S. Spudich
127  
11:15  
EFFECT ON PLASMA NFL, A MARKER OF NEURONAL INJURY, AFTER SWITCHING FROM TDF TO TAF  
Linn Hermansson, Richard W. Price, Aylin Yilmaz, Staffan Nilsson, Scott McCallister, Tarito Makadzange, Moupali Das, Henrik Zetterberg, Kaj Blennow, Magnus Gisslen

128  
11:30  
CARDIOVASCULAR RISK SCORES PREDICT LONGITUDINAL COGNITIVE FUNCTION IN OLDER PLHIV  
Felicia C. Chow, Asya Lyass, Joseph Massaro, Virginia Triant, Kunling Wu, Babla Berzins, Kevin Robertson, Ronald J. Ellis, Katherine Tassiopoulos, Babafemi Taiwo, Ralph D’Agostino

129  
11:45  
OBESITY IS INDEPENDENTLY ASSOCIATED WITH NEUROCOGNITIVE DECLINE IN HIV  
Jeremiah Perez, Adriana Andrade, Ronald J. Ellis, Mary Clare Masters, Karl Goodkin, Susan L. Koletar, Kevin Robertson, Ned Sacktor, Katherine Tassiopoulos, Kristine M. Erlandson

Oral Abstract 0-12 HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE  
Room 6E 10:00 AM - 12:00 PM

Oral Abstract Moderators
Michael M. Lederman, Case Western Reserve University, Cleveland, OH, USA  
Gert U. van Zyl, Stellenbosch University, Cape Town, South Africa

130  
10:00  
HIGH HIV VIRAL BURDEN PERSISTS IN CXCR3+ GCTFH DESPITE VERY EARLY ART INITIATION  
Omolara Baiyegunhi, Jaclyn Mann, Adrienne Yanez, Geetha H. Mylvaganam, Krista Dong, Thumbi Ndhlovu, Bruce D. Walker, Zaza Ndhlovu

131  
10:15  
SIROLIMUS REDUCES T-CELL CYCLING AND IMMUNE CHECKPOINT MARKER EXPRESSION, ACTG A5337  
Timothy J. Henrich, Ronald Bosch, Catherine Godfrey, Hanna Mar, Apsara Nair, Elizabeth Hawkins, Carl Fichtenbaum, Michael Keefer, Jonathan Z. Li, Daniel R. Kuritzkes, Michael M. Lederman, Priscilla Hsue, Steven G. Deeks

132  
10:30  
PD-1 AND CTLA-4 BLOCKADE IN MACAQUES INDUCES T-CELL EXPANSION AND SIV REACTIVATION  

133  
10:45  
FTY720 LIMITS T FOLLICULAR HELPER CELL INFECTION IN LYMPHOID SITES OF SIV PERSISTENCE  
Maria Pino, Sara Paganini, Claire Deleage, Kartika Padhan, Justin L. Harper, Colin T. King, Luca Micci, Barbara Cervasi, Joseph Mudd, Sherrie M. Jean, Kirk A. Easley, Jacob D. Estes, Constantinos Petrovas, Michael M. Lederman, Mirko Piaiardini

134  
11:00  
TRANSCRIPTIONAL SIGNATURE OF LYMPH NODE CD8+ T CELLS IN HIV ELITE CONTROLLERS  
Son Nguyen, Claire Deleage, Sam Darko, Amy Ransier, Duc P. Truong, Divyansh Argawal, Alberto Sada Japp, Perla Del Rio-Estrada, Ali Naji, Gustavo Reyes-Terán, Jacob D. Estes, Daniel Douek, Steven G. Deeks, Marcus Buggert, Michael R. Betts
Oral Sessions

135 11:15 CHARACTERIZING THE PROVIRAL LANDSCAPE IN HIV-1 ELITE CONTROLLERS
Chenyang Jiang, Xiaodong Lian, Joshua Chevalier, Samantha M. Chen, Ce Gao, Xiaoming Sun, Kevin Einkauf, Ben S. Rhe, Kaylee Chang, Jane Blackmer, Bruce D. Walker, Mathias Lichterfeld, Xu G. Yu

136 11:30 INTERFERON A2B REDUCES INDUCIBLE CD4-ASSOCIATED HIV IN ART-SUPPRESSED INDIVIDUALS

137 11:45 NEF-STOP REPAIR DYNAMICS, BUT NOT ANTI-A4B7, INFLUENCE POSTTREATMENT VIRAL CONTROL
Michele Di Mascio, Sharat Srinivasula, Paula DeGrange, Brandon F. Keele, Michael Proschan, Jeffrey D. Lifson, H. Clifford Lane

Oral Abstract 0-13 ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE
Room 6AB 10:00 AM - 12:00 PM

Oral Abstract Moderators
Sharon Riddler, University of Pittsburgh, Pittsburgh, PA, USA
Johnstone Kumwenda, College of Medicine-Johns Hopkins Project, Blantyre, Malawi

138 10:00 SEARCH INTERVENTION REDUCES MORTALITY AT A POPULATION LEVEL IN MEN WITH LOW CD4 COUNT
Moses R. Kamya, Maya L. Petersen, Dalsone Kwarisiima, James Ayieko, Norton Sang, Jane Kabami, Tamara D. Clark, Edwin D. Charlebois, Laura B. Balzer, Craig R. Cohen, Vivek Jain, Elizabeth A. Bukusi, Gabriel Chamie, Diane V. Havlir

139 10:15 LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS
Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary J. Richmond, Giuliano Rizzardini, Axel Baumgarten, Maria Del Mar Masia, Gulam Latiff, Vadim Pokrovsky, Joseph M. Mrus, Jenny O. Huang, Krischan J. Hudson, David A. Margolis, Kimberly Smith, Peter E. Williams, William Spreen

140 LB 10:30 LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS

141 10:45 SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR
Jennifer E. Sager, Rebecca Begley, Martin Rhe, Steve K. West, John Ling, Scott D. Schroeder, Winston C. Tse, Anita Mathias

142 11:00 A PHASE IIA STUDY OF NOVEL MATURATION INHIBITOR GSK2838232 IN HIV PATIENTS
Oral Sessions

143  SYSTEMATIC DETERMINATION OF IN VITRO HIV-1 INTEGRASE RESISTANCE FROM CLINICAL SAMPLES


144  DTG VS LPV/R (DAWNING): EFFICACY BY BASELINE NRTI RESISTANCE AND SECOND-LINE NRTI USE

Dannae Brown, Ruolan Wang, Mark Underwood, Judy Hopking, Maria Claudia Nascimento, Michael Aboud, Jörg Sievers

145 LB  THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS

Kathryn E. Stephenson, Boris Julg, Jessica Ansel, Stephen R. Walsh, Chen S. Tan, Lori Maxfield, Peter Abbink, Huub C. Gelderblom, Frances Priddy, Allan C. deCamp, Roberto Arduini, Edwin DeJesus, Georgia Tomaras, Michael S. Seaman, Dan Barouch

Oral Abstract 0-14 PERSISTENT CHALLENGES WITH ANTIRETROVIRAL THERAPY

Room 6C  10:00 AM - 12:00 PM

Oral Moderators

Alan E. Greenberg, George Washington University, Washington, DC, USA
Adebola Adedimeji, Albert Einstein College of Medicine, Bronx, NY, USA

146  MORTALITY REDUCTION IN WESTERN KENYA DURING SCALE-UP OF HIV TREATMENT, 2011-2016

Martien W. Borgdorff, George O. Otieno, Y. O. Whiteside, Thomas Achia, Daniel Kwaro, Sylvia Ojoo, Maquins Sewe, Paul K. Musingila, Victor Akelo, David Obo, Amek Nyaguara, Kevin M. De Cock, Emily C. Zielinski-Gutierrez

147  OPIOID OVERDOSE DEATHS AMONG PERSONS WITH HIV INFECTION, UNITED STATES, 2011-2015

Karin A. Bosh, Nicole Crepaz, Xueyuan Dong, Sheryl Lyss, Maria Mendoza, Andrew J. Mitsch

148  EARLY MORTALITY IN HIV-INFECTED PATIENTS INITIATING ART WITHOUT A PRETHERAPY CD4

Kombatende Sikombe, Ingrid Eshun-Wilson, Aybuke Koyuncu, Sandra Simbeza, Aaloke Mody, Nancy Czaicki, Laura K. Beres, Carolyn Bolton Moore, Nancy Padian, Izukanji Sikazwe, Charles B. Holmes, Elvin Geng

149  UTILITY OF CD4 CELL COUNT MONITORING IN BOTSWANA: ANALYSIS OF ROUTINE LABORATORY DATA

Tshepo B. Leeme, Madisa Mine, Kwana Lechiile, Mosepele Mosepele, Thongbootho Mphoyakgosi, Charles Muthoga, Julia Njidi, Bornaparte Nkomo, Dinah Ramaabaya, Motomi Tau, Mark W. Tenforde, Richard Hayes, Joseph N. Jarvis

150  TRENDS IN CD4 AND VIRAL LOAD TESTING IN SOUTHERN AFRICA: ANALYSIS OF 6 COUNTRIES

Elizabeth Zaniewski, Cam Ha Dao Ostinelli, Nicola Maxwell, Mary-Ann Davies, Jonathan Euvrard, Jannke van Dijk, Samuel Bosomprah, Frank Tanser, Matthew P. Fox, Nathan Ford, Nosisa Sipambo, Josephine Muhairwe, Matthias Egger
Oral Sessions

151 11:15  HIGH LEVELS OF DRUG RESISTANCE AMONG ART-EXPERIENCED HOSPITALIZED PATIENTS
Claire Bossard, Gloria A. Omollo, Patrick Nqimbi Nsuka, Rose Burns, Lakshmi Jain, Gisèle Mucinya, Valarie S. Opollo, Stephen S. Wanjala, Gilles van Cutsen, Elisabeth Szumilin, David Maman, Birgitt Schramm, Elisabeth Poulet

152 11:30  HIV DRUG RESISTANCE IN SOUTH AFRICA: RESULTS FROM A POPULATION-BASED HOUSEHOLD SURVEY
Sizulu Moyo, Gillian Hunt, Zuma Khangelani, Nompumelelo P. Zungu, Edmore Marinda, Musa Mabaso, Karidia Diallo, Cheryl Dietrich, Thomas Rehle

153 11:45  DURATION OF INFECTIOUSNESS AMONG PERSONS WITH HIV DIAGNOSED DURING 2012-2016
Nicole Crepaz, Riuguang Song, Irene Hall

Themed Discussion TD-12 ART: InSTIs AND TOXICITY
Room 606-609  1:30 PM - 2:30 PM

Themed Discussion Leader
Alan Winston, Imperial College London, London, United Kingdom

440  NEUROPSYCHIATRIC OUTCOMES BEFORE AND AFTER SWITCHING TO DOLUTEGRAVIR-BASED THERAPY
Phillip Chan, Orlanda Goh, Eugène Kroon, Donn J. Colby, Carlo Sacdalain, Suteeraporn Pinyakorn, Sompong Tipsuk, Nittaya Phanuphak, Praphan Phanunphak, Jintanat Ananworanich, Victor Valcour, Serena S. Spudich, Robert Paul, for the RV254/SEARCH010

441  NEUROPSYCHOLOGICAL CHANGES IN EFAVIRENZ SWITCH REGIMENS IN MACS

442  MEMORY AND LEARNING DYSFUNCTION WITH INTEGRASE STRAND TRANSFER INHIBITORS USE
Jane A. O’Halloran, Sarah A. Cooley, Jeremy Strain, Robert Paul, Rachel Presti, Beau Ances

443  CEREBRAL FUNCTION PARAMETERS IN PEOPLE LIVING WITH HIV SWITCHING INTEGRASE INHIBITOR
Borja Mora-Peris, Laura Else, Jaime Vera-Rojas, Caire Petersen, Maryam Khan, Sujan Dilly Penchala, Sofia Tonioi, Mara Cercignani, Michael R. Keegan, Saye Khoo, Alan Winston

439  CENTRAL NERVOUS SYSTEM EFFECTS OF THERAPY INITIATION WITH INTEGRASE INHIBITORS
Anna Prats, Ignacio Martinez-Zalacain, Beatriz Mothe, Eugenia Negredo, Maite Garolera, Sira Domenech-Puigcever, Michael Meulbroek, Carmina R. Fumaz, Maria J. Ferrer, Bonaventura Clotet, Carles Soriano-Mas, Jose A. Munoz-Moreno, for the ARBRE Study Group

Themed Discussion TD-13 HBV: RACING HIV FOR THE CURE
Room 6C  1:30 PM - 2:30 PM

Themed Discussion Leader
Debika Bhattacharya, University of California Los Angeles, Los Angeles, CA, USA

624  HEPATITIS B CURE IN HIV PATIENTS IS MORE LIKELY IN HISPANICS AND THOSE WITH AIDS
Mamta K. Jain, Paul Parisot, Gabriella Go, Trung T. Vu, Karen J. Vigil, Barbara S. Taylor
625  **HIGH RATES OF HBV FUNCTIONAL CURE AMONG HIV/HBV-COINFECTED PATIENTS ON ART IN ZAMBIA**

Belinda V. Chihota, Gilles Wandeler, Roma Chilengi, Lloyd Mulenga, Raymond T. Chung, Debika Bhattacharya, Matthias Egger, Michael J. Vinikoor, for the IeDEA Southern Africa

626  **HEPATITIS B VIROLOGIC FAILURE OF TENOFOVIR-BASED THERAPIES IN PATIENTS WITH HIV/HBV**

Helen L. Zhang, Meredith Mock, Lane R. Bushman, Peter L. Anderson, Andrew J. Muir, Jennifer J. Kiser, Susanna Naggie

627  **HIV LATE PRESENTATION AND ITS IMPACT ON HBV SEROCONVERSION IN HBV/HIV**

Christoph Boesecke, Christian Hoffmann, Stefan Mauss, Thomas Lutz, Patrick Ingliz, Christoph D. Spinner, Stefan H. Scholten, Florian Berger, Stephan Schneeweiss, Fabian Busch, Clara Lehmann, Gerd Fätkenheuer, Jürgen K. Rockstroh, for the DZIF HBV HIV Cohort

628  **ABSENCE OF HBV REACTIVATION IN HIV/HCV/HBCAB COINFECTED PATIENTS TREATED WITH DAA**

Maddalena Cerrone, Francesca Ferretti, Ryan Whyte, Mimie Chirwa, Mark Nelson

---

**Themed Discussion TD-14 PrEP IN FITS AND STARTS**

Room 6AB  1:30 PM - 2:30 PM

**Themed Discussion Leader**

James A. McIntyre, Anova Health Institute, Johannesburg, South Africa

960  **CHANGES IN KIDNEY FUNCTION AMONG MSM INITIATING ON-DEMAND TDF/FTC FOR HIV PrEP**

Geoffroy Liegeon, Guillemette Antoni, Gilles Pialoux, Laurent Cotte, Cécile L. Tremblay, Catherine Capitant, Eric Cua, François Raffi, Eric Senneville, Pierre Charbonneau, Soizic Le Mestre, Veronique Dore, Laurence Meyer, Jean-Michel Molina, for the ANRS IPERGAY Study Group

961  **POINT-OF-CARE CREATININE TESTING WITHIN A PROGRAMMATIC PrEP DELIVERY SETTING**

Jillian Pintye, Felix Abuna, John Kinuthia, Harrison Lagat, Kenneth K. Mugwanya, Julia Dettinger, Emily R. Begnel, Marlaine Serede, Joseph Sila, Jared Baeten, Grace John-Stewart, for the PrEP Implementation for Young Women and Adolescents (PriYA) Program

962  **IMMEDIATE PrEP INITIATION AT NEW YORK CITY SEXUAL HEALTH CLINICS**

Tarek Mikati, Kelly Jamison, Demetre C. Daskalakis

963  **PrEP PERSISTENCE AND DISCONTINUATIONS IN A COHORT OF YOUNG BLACK MSM IN ATLANTA, GA**

David P. Serota, Eli Rosenberg, Annie M. Lockard, Carlos del Rio, Nicole Luisi, Scott R. Cutro, Charlotte-Paige M. Rolle, Aaron J. Siegler, Travis Sanchez, Patrick S. Sullivan, Colleen F. Kelley

964  **LOW UPTAKE OF PREEXPOSURE PROPHYLAXIS AMONG KENYAN ADOLESCENT GIRLS AT RISK OF HIV**

Lynda M. Oluch, Nelly R. Mugo, Alison C. Roxby, Anna Wald, Stacy Selke, Amalia Magaret, Kenneth Nguire, Murugi Micheni, Steven Gakuo, Bhavna Chohan, Catherine Kiptinness
Oral Sessions

Themed Discussion TD-15 TREAT ALL: TREAT FAST
Room 6E 1:30 PM - 2:30 PM

Themed Discussion Leader
Mohammed Limbada, Zambia AIDS Related TB Project (Zambart), Lusaka, Lusaka, Zambia

1017 OUTCOMES OF “TEST AND START” AT SCALE WITHIN HAITI’S NATIONAL ART PROGRAM
Nancy Puttkammer, Kesner Francois, Yrvel Desir, Gracia Desforges, Nadji Joseph, Nathaelf Hyppolite, Jean Guy Honore, Jean Solon Valles, Ermane Robin, Patrice Joseph

1018 SAME-DAY ART INITIATION IN THE SLATE TRIAL IN KENYA: PRELIMINARY RESULTS
Alana T. Brennan, Bruce Larson, Isaac Tsikhurstu, Margaret Bii, Matthew P. Fox, Willem D. Venter, Mhairi Maskew, Lungisile Vezi, Sydney Rosen

1019 LB WITHDRAWN/INTENTIONALLY UNASSIGNED
Alana T. Brennan, Bruce Larson, Isaac Tsikhurstu, Margaret Bii, Matthew P. Fox, Willem D. Venter, Mhairi Maskew, Lungisile Vezi, Sydney Rosen

1020 IMPLEMENTING UTT IN AFRICAN CORRECTIONAL FACILITIES: A PROSPECTIVE COHORT STUDY
Michael Herce, Christopher Hoffmann, Katherine Fielding, Steph Topp, Harry Hausler, Helene Smith, Lucy Chimoyi, Candice Chetty-Makan, Rachek Mukora, Mpho Tlali, Abraham Olivier, Monde Muyoyeta, Stewart Reid, Salome Charambous

1024 PATIENT-REPORTED REASONS FOR DECLINING IMMEDIATE ART INITIATION IN LUSAKA, ZAMBIA
Jake Pry, Jenaia Chipungu, Carolyn Bolton Moore, Jacob Mutale, Helene Smith, Theodora Savory, Michael Herce

1022 UPTAKE OF ANTIRETROVIRAL THERAPY IN THE “TREAT ALL” ERA IN RIO DE JANEIRO, BRAZIL
Lelia H. Chaisson, Juliana Domenico, Valeria Saraceni, Richard D. Moore, Jonathan Golub, Betina Durovni

Symposium S-7 NEW CELLS ON THE BLOCK
Room 6C 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the importance of recently described immune cells and novel immune functions at the intersection between innate and adaptive immunity.

Level of Knowledge: It is assumed that the participants are familiar with basic concepts of cellular immunology.

Objectives: At the completion of the session, participants will be able to:
• Identify newly defined immune cells and their role in HIV infection
• Describe newly identified links between innate and adaptive immunity
• Describe the importance of sampling tissues

Conveners
Caroline Tiemessen, National Institute of Communicable Diseases, Johannesburg, South Africa
Johan K. Sandberg, Karolinska Institute, Stockholm, Sweden

154 4:00 TISSUE-RESIDENT MEMORY CD8+ CELLS
Michael R. Betts, University of Pennsylvania, Philadelphia, PA, USA
Oral Sessions

155  
4:30  
MECHANISMS UNDERLYING LOSS OF ILCs IN HIV/SIV-INFECTED INDIVIDUALS  
Jason Brenchley, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

156  
5:00  
MEMORY NK CELLS AS NOVEL EFFECTORS AGAINST HIV AND SIV  
R. Keith Reeves, Harvard Medical School, Boston, MA, USA

157  
5:30  
HIV SUPPRESSION BY CD8+ LYMPHOCYTES  
Deanna Kulpa, Emory University, Atlanta, GA, USA

Symposium S-8 TOUGH QUESTIONS IN ANTIRETROVIRAL THERAPY MANAGEMENT
Room 6AB  4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding current challenges and questions regarding antiretroviral treatment for people living with HIV.

Level of Knowledge: It is assumed that the participants have an understanding of the principles of antiretroviral therapy and the antiretroviral agents that are commonly used to treat HIV infection.

Objectives: At the completion of the session, participants will be able to:
• Describe the trends in obesity and ART and impact on inflammation
• Describe HIV neurocognitive decline, the aging brain, and neurodegenerative disease
• Enumerate HIV diagnostic dilemmas in the setting of PrEP
• Describe 2-drug ART for initial therapy and maintenance

Conveners
Jennifer Hoy, Alfred Hospital and Monash University, Melbourne, Victoria, Australia
Georg Behrens, Medizinische Hochschule Hannover, Hannover, Germany

158  
4:00  
OBESITY: A GROWING PROBLEM IN ANTIRETROVIRAL THERAPY  
John R. Koethe, Vanderbilt University, Nashville, TN, USA

159  
4:30  
I KEEP FORGETTING: HIV, AGING, AND COGNITIVE DISORDERS  
Victor Valcour, University of California San Francisco, San Francisco, CA, USA

160  
5:00  
PrEP FAILURES: DIAGNOSIS, RESISTANCE, AND TREATMENT  
Jean-Michel Molina, Hôpital Saint-Louis, Paris, France

161  
5:30  
CAN TWO DRUGS TANGO: THE ROLE OF DUAL THERAPY  
Laura Waters, Mortimer Market Centre, London, UK
Symposium S-9 GIRLS AND BOYS JUST WANT TO HAVE FUN: MAKING PREVENTION DESIRABLE FOR YOUTH
Room 6E 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians, HIV prevention scientists, counselors, and community members.

Level of Knowledge: It is assumed that the participants are familiar with basic epidemiology of HIV.

Objectives: At the completion of the session, participants will be able to:
• List the issues around and strategies for engaging youth
• Frame prevention, treatment, and community
• Describe barriers that arise from practitioner attitudes about sexuality

Conveners
Kawango Agot, Impact Research and Development Organization, Kisumu City, Kenya
Kwame Shanaube, Zambart, Lusaka, Zambia

162  YOUNG TRANSGENDER INDIVIDUALS
4:00
Asa Radix, Callen–Lorde Community Health Center, New York, NY, USA

163  ENGAGING YOUNG WOMEN IN SUB-SAHARAN AFRICA
4:30
Sinead Delany-Moretwe, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa

164  MAKING PREVENTION WORK FOR YMSM: BRIDGING REAL-WORLD NEEDS THROUGH DIGITAL ENGAGEMENT
5:00
Lisa Hightow-Weidman, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

165  DON’T LEAVE THEM BEHIND: HETEROSEXUAL YOUNG AFRICAN MEN
5:30
Webster Mavhu, Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
Poster Sessions

POSTER SESSIONS BY DAY

TUESDAY MARCH 5, 2019

Poster P-A1 EARLY EVENTS
Poster Hall - 4EF  2:30 PM - 4:00 PM

166  ENTRY KINETICS OF GLOBALLY REPRESENTATIVE AND VERTICALLY TRANSMITTED HIV ENVELOPES
Nicholas E. Webb, Nicole Tobin, Grace M. Aldrovandi

167  CD4-DEPENDENT MODULATION OF HIV-1 ENTRY BY LY6E
Jingyou Yu, Chen Liang, Shan-Lu Liu

168  ELUCIDATING MECHANISMS BY WHICH MUTATIONS IN ENV CONTRIBUTE TO HIV-1 DRUG RESISTANCE
Rachel Van Duyne, Phuong Pham, Jonathan Spindler, Ann Wiegand, Mary F. Kearney, Eric O. Freed

169  NONRANDOM GENERATION OF DELETIONS WITHIN HIV PROVIRAL SEQUENCES IN VIVO
Bonnie Hiener, Bethany A. Horsburgh, Vincent Morcilla, Eunok Lee, Susanne von Stockenstrom, Jeffrey M. Milush, Teri Liegler, Rebecca Hoh, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer, Robert Lanfear

170  HOST FACTORS INFLUENCE SIV AND HIV-1 INFECTION AND SENSITIVITY TO CAPSID INHIBITORS
Rachel Scheck, Augustin P. Twizerimana, Zeli Zhang, Dieter Häussinger, Carsten Münk

Poster P-A2 VIRAL RESTRICTION
Poster Hall - 4EF  2:30 PM - 4:00 PM

171  VPX INDUCES AN IFN-RELATED INNATE IMMUNE RESPONSE DISTINCT FROM SAMHD1 ABROGATION
Maria Pujantell, Eva Riveira-Muñoz, Alba Ruiz, Roger Badia, Bonaventura Clotet, Jose A. Este, Ester Ballana

172  EVOLUTION-GUIDED STUDIES TO UNDERSTAND THE ANTIVIRAL MECHANISM OF IFITM3
Kazi Rahman, Alex A. Compton

173  ERAP2 ADMINISTRATION REDUCES IN VITRO PBMC SUSCEPTIBILITY TO HIV-1-INFECTION
Irma Saulle, Salomè Valentina Ibba, Cecilia Vittori, Claudio Fenizia, Federica Piancone, Davide Minisci, Elisa Maria Lori, Daria Trabattoni, Mario Clerici, Mara Biasin

174  INCREASED SAMHD1 CORRELATES WITH ISGS IN HIV-1-INFECTED PATIENTS
Maura Statzu, Letizia Santinelli, Claudia Pinacchio, Giancarlo Ceccarelli, Ivano Mezzaroma, Ombretta Turriziani, Vincenzo Vullo, Guido Antonelli, Gabriella d’Ettorre, Carolina Scagnolari

175  SCHLAFEN 14 (SLFN14) INHIBITS TRANSCRIPTION OF HIV-1 BY TARGETING P-TEFB
Chen Shumin, Shan Cen
Poster P-B1 HIV AND LYMPH NODES
Poster Hall - 4EF 2:30 PM - 4:00 PM

196 IP-10 PRODUCTION BY THE LYMPH NODES MEDIATES ENTRY OF SIV-SPECIFIC CXCR3+CD8+ T CELLS
Antonio Valentin, Eric Ramirez, Hrishikesh Pandit, Ashli Earl, Kate E. Broderick, Niranjan Sardesai, George N. Pavlakis, Barbara K. Felber

197 LYMPH NODE TREG SUBSETS ARE EXPANDED IN SOME HIV+ PEOPLE ON SUPPRESSIVE ART
Joy M. Folkvord, Lishomwa C. Ndhlolvu, Brooks I. Mitchell, Fredrick Yost, Martin McCarter, Amie Meditz, Cecilia M. Shikuma, Elizabeth Connick

198 DENDRITIC CELLS CROSSTALK WITH FOLLICULAR CD8+ T-CELLS IN HIV-INFECTED LYMPH NODES

199 LONGITUDINAL DYNAMICS OF FOLLICULAR CD4+ T CELLS IN ACUTE SIV INFECTION
Leticia Kuri Cervantes, Claire Deleage, Emily Roberts, Heidi M. Gunzelman, Diane G. Carnathan, Guido Silverstr, Michael R. Betts

200 LB CYTOLYTIC HIV-SPECIFIC CD8+ T CELLS DO NOT RECIRCULATE THROUGH TISSUES
Marcus Buggert, Son Nguyen, Sam Darko, Amy Ransier, Gustavo Reyes-Terán, Daniel Douek, Yoav Dori, Ian Frank, Max G. Itkin, Michael R. Betts

Poster P-B2 INTO AND OUT OF THE GUT
Poster Hall - 4EF 2:30 PM - 4:00 PM

201 MICROBIAL TRANSLLOCATION MEASURED BY CONFOCAL ENDOMICROSCOPY IN HIV-INFECTED PATIENTS
Elvira Couto Jaime, Flor Etcheverry, Constanza Lucero, Yoko Alenyar, Lorna Leal, Irene Fernandez, Yolanda Romero, Mannel E. Bargalló, Martin Goetz, Joseph Bombi, Maria Pellise, Maria Lopez-Ceron, Montserrat Plana, Nuria Climent, Felipe Garcia

202 ISOLATION OF TRANSLATING BACTERIA IN PROGRESSIVE SIV INFECTION OF RHEUS MACAQUES
Jacob Flynn, Alexandra Ortiz, Jason Brenchley

203 SYNERGY BETWEEN TH1 AND TH22 IMPAIRS TH17 CELLS RECRUITMENT TO THE GUT ON ART
Manon Nayrac, Mary Requena, Claire Loiseau, Maud Mavigner, Fatima L’Faqihi, Nicolas Carrere, Bertrand Suc, Jacques Izopet, Pierre Delobel

204 THE ROLE OF CS1 FIBRONECTIN IN HIV-1 INFECTION OF GUT-HOMING T CELLS
David A. Plotnik, Wenjin Guo, Brad Cleveland, Shiu-Lok Hu

205 INFLAMMATION WITHIN THE SMALL INTESTINE IS ASSOCIATED WITH IMMUNE RECONSTITUTION

206 ALTERED GUT IMMUNITY IN IMMUNOLOGICAL NONRESPONDERS PARTLY RESTORED BY PROBIOTICS
Malin H. Meyer-Myliestad, Martin Kummens, Birgitte Stiksrud, Kristian Holm, Anne Ma D. Riese, Dag Kvale, Ingebjørg Seljeflat, Marius Troseid, Johannes R. Hoy, Asle W. Medhus, Dag Henrik Reikvam
207 INCREASED ADENOSINE SIGNALING WITH DIPYRIDAMOLE DECREASES GUT MUCOSAL TREG FREQUENCY

Poster P-B3 IMMUNOPATHOGENESIS
Poster Hall - 4EF 2:30 PM - 4:00 PM

208 PD-1Hi CD4+ T CELLS ARE ASSOCIATED WITH REDUCED HIV-SPECIFIC RESPONSES
Bernard J. Macatangay, Rajesh T. Gandhi, R. Brad Jones, Deborah McMahon, Allison S. Thomas, Christina Lalama, Ronald Bosch, Luann Borowski, Evelyn Hogg, Joseph J. Eron, John W. Mellors, Charles Rinaldo, for the ACTG A5321 Study Team

209 PROPORTION OF SIV-INFECTED MEMORY T HELPER SUBSETS CORRELATED TO SIZE OF POPULATION
Stephen Lai, Jason Brenchley, Joseph Mudd

210 LB NATURAL HOSTS OF SIV EMPLOY UNIQUE DNA METHYLATION PROGRAMS TO SILENCE THE CD4 GENE
Joseph Mudd, Stephen Lai, Jacob Flynn, Molly Perkins, Carly Elizabeth C. Starke, Maarten Leerkes, Vanessa Hirsch, Mark Cameron, Jason Brenchley

211 HIV-1 INFECTION IS ASSOCIATED WITH INCREASED USP18 AND DAMPENED TYPE 1 IFN RESPONSES
Sho Sugawara, Ramy El-Diwany, Joel Blankson, David L. Thomas, Andrea Cox, Ashwin Balagopal

212 SINGLE HOUSING OF MACAQUES INCREASES THE IMMUNE IMPACT OF SIV INFECTION
Selena Guerrero-Martín, Kirstin McGee, Leah H. Rubin, Suzanne E. Queen, Erin Shirk, Ming Li, Brandon Bullock, David Graham, Chistine Zink, Lucio Gama, Robert J. Adams, Janice E. Clements, Joseph Mankowski, Kelly A. Metcalf Pate

213 ORAL CYTOKINE EXPRESSION IS LINKED TO ORAL HIV-1 LEVELS IN ACTG A5254

214 HIV INFECTION AND SMOKING DEFERENTIALLY REGULATE ALVEOLAR MACROPHAGES
Charles P. Neff, Thomas Campbell, Andrew Fontenot, Brent E. Palmer

215 HUMAN INFECTION WITH ZOONOTIC SIMIAN FOAMY VIRUSES: ALTERED CD4 AND CD8 T LYMPHOCYTES
Antoine Gessain, Thomas Montange, Edouard Betsem, Chanceline Bilounga Ndongo, Richard Njouom, Florence Buseyne

216 CHARACTERIZATION OF PLASMA METABOLITE PROFILE IN HIV+ PERSONS WITH OR WITHOUT IRIS
Luxin Pei, Kiyoshi Fukutani, Brian Ingram, John Luster, Andrea Lisco, Maura Manion, Elizabeth Laidlaw, Bruno Andrade, Irini Sereti

217 EXTRACELLULAR VESICLE–ASSOCIATED CYTOKINES IN HIV-INFECTED HUMAN EX Vivo TONSILS
Vincenzo Mercurio, Wendy Fitzgerald, Leonid Margolis
218  MASSIVE RELEASE OF PLATELET-DERIVED EXTRACELLULAR VESICLES DURING HIV INFECTION
Eva Poveda, Andrés Tabernilla, Marta Grandal, Alexandre Pérez, Ángel Salgado, Hortensia Álvarez, Ana Mariño, Nieves Valcarce, Juan González-García, Félix Gutiérrez, Manuel Crespo, Ezequiel Ruiz-Mateos, Michael M. Lederman, Michael L. Freeman, for the ECRIS integrated in the Spanish AIDS Research Network

219  IN VIVO MODEL FOR HBV/HIV COINFECTION STUDIES
Weimin Wang, Raghubendra S. Dagur, Edward Makarov, Yimin Sun, Catherine L. Gebhart, Murali L. Ganesan, Natalia Osna, Larisa Y. Poluektova

220  AN EARLY DECLINE IN HIV ANTIBODY BREATH PREDICTS MORE RAPID DISEASE PROGRESSION
Oliver Laeyendecker, Kai Kammers, Athena Chen, Mariya V. Sivay, Brandon Sie, Tiezheng Yuan, Divya Mohan, Sanjay Kottapalli, Tomasz Kula, Charles S. Morrison, Stephen Elledge, Ron Brookmeyer, Ingo Ruczinski, H. Benjamin Larman, Susan H. Eshleman

268  KSHV-ASSOCIATED MORTALITY IN HIV-INFECTED SOUTH AFRICANS WITH SUSPECTED TUBERCULOSIS
Melissa J. Blumenthal, Charlotte Schutz, David Barr, Vickie Marshall, Denise Whitby, Arieh Katz, Thomas S. Uldrick, Graeme Meintjes, Georgia Schäfer

269  KAPOSI SARCOMA—ASSOCIATED HERPESVIRUS IN AN HIV-INFECTED COHORT, SOUTH AFRICA
Elizabeth M. Etta, Lufuno G. Mavhandu-Ramarumo, George Gachara, Denise Tebit, Wendell Miley, Vickie Marshall, Denise Whitby, Pascal O. Blessong

270  PRIMARY ROLE OF KSHV IN PATHOGENESIS OF ENDEMIC AND EPIDEMIC KAPOSI SARCOMA
Salum J. Lidenge, For Yue Tso, Andrew V. Kossenkov, Owen Ngalamika, John R. Ngowi, Yasaman Mortazavi, Eun Hee Kwon, Danielle M. Shea, Veenu Minhas, Julius Mwaiselage, Paul M. Lieberman, Charles Wood, John T. West

271  METABOLIC ABNORMALITIES IN CD8 T CELLS FROM HIV+ INDIVIDUALS WITH KAPOSI SARCOMA
Genevieve T. Clutton, Michael McGrath, Toby Maurer

272  SINGLE CELL EVALUATION OF KAPOSI SARCOMA TUMORS REVEALS COMPLEX IMMUNE INFILTRATE
Warren Phipps, David Coffey, Yexiu Xu, James Kafeero, Peter Mooka, Lazarus Okoche, Diana Basemera, Britta Flach, Andrea Towlerton, Edus H. Warren

273  NEW VARIANT OF KAPOSI SARCOMA—ASSOCIATED HERPESVIRUS IN MEN WHO HAVE SEX WITH MEN
274 ANTIRETROVIRAL THERAPY AND KAPOSI SARCOMA TRENDS AND OUTCOMES IN LATIN AMERICA

Jessica L. Castilho, Ahra Kim, Cathy Jenkins, Beatriz Grinsztejn, Eduardo Gotuzzo, Valeria I. Fink, Denis Padgett, Pablo F. Belauzanaran-Zamudio, Brenda Crabtree-Ramirez, Juliana Netto, Claudia P. Cortes, Alexandre Grangeiro, Bryan E. Shepherd, Catherine McGowan, for the Caribbean, Central and South America network for HIV epidemiology (CCASAnet)

275 KAPOSI SARCOMA INCIDENCE BETWEEN 2010 AND 2015 IN THE FRENCH DAT’AIDS COHORT

Isabelle Poizot-Martin, Alain Makinson, Camelia Protopopescu, Antoine Chéret, Marc-Antoine Valantin, David Rey, Claudine Duviyer, Christine Jacomet, Tristan Ferry, Clotilde Allavena, Thomas Huleux, Firouze Bani-Sadr, Véronique Obry-Roguet, Patricia Carrieri, for the Dat’AIDS study group

Poster P-D1 PRECLINICAL AND CLINICAL VACCINE TRIALS
Poster Hall - 4EF 2:30 PM - 4:00 PM

293 LONG BOOST INTERVALS OF ALVAC-HIV/ADSVAX B/E INCREASED GENITAL HIV ENV IGG RESPONSES


294 A VACCINE TARGETING HIV MATURATION PROTECTS AGAINST VAGINAL SIVMAC251 ACQUISITION

Hongzhao Li, Qingsheng Li, Eva Rakas, Nancy Schultz-Darken, Maria J. Alonso, James Whitney, Francis Plummer, Ma Luo, for the Dr. Ma Luo’s group

295 SIV- AND HIV-SPECIFIC IMMUNE RESPONSES ELICITED BY PIIV5 PRIME/VLP BOOST VACCINATION

Biao He, Peng Xiao, Krista Dienger-Stambaugh, Michelle Robillard, Karnail Singh, Francois Villinger, Paul Spearman

296 NOVEL ANTIGEN ELICITS BROADLY NEUTRALIZING ANTI-HIV MONOCLONAL ANTIBODIES IN MICE

Jinhua Xiang, James H. McLinden, Qing Chang, Thomas M. Kaufman, Jack T. Stapleton

297 LB TRANSCRIPTOMIC HOST RESPONSES TO RHCMV/SIV VACCINATION IN RHESUS MACAQUES

Connor Driscoll, Richard Green, Monica Rojas-Peña, Fredrik Barrenas, Jean Chang, Elise Smith, Lynn Law, Jan Komorowski, Scott Hansen, Louis J. Picker, Michael Gale

Poster P-D2 NOVEL THERAPEUTIC INTERVENTIONS INCLUDING EARLY ART
Poster Hall - 4EF 2:30 PM - 4:00 PM

298 EARLY ART PARTLY REDUCES HIV-INDUCED MUCOSAL B-CELL HYPERACTIVATION

299 IMPROVED CD4 T CELLS RESPONSES WITH EARLY TREATMENT DURING PRIMARY HIV INFECTION
Camille Lecuroux, Remonie Seng, Asier Saez-Cirion, Veronique Avettand-Fenoel, Jean-Paul Viard, Delphine Lebrasseur, Claudine Duvivier, Alain A. Venet, Christine Rouzioux, Cécile Goujard, Laurence Meyer, Antoine Chéret

300 EFFECT OF TELMISARTAN GIVEN AT ART INITIATION IN AHI ON IMMUNE CELLS IN LYMPH NODES
Supranee Buranapraditkun, Hiroshi Takata, Eugène Kroon, Suthat Chotchanapund, Carlo Saddalan, Somporn Tipsuk, Khunthalee Benjapornpong, Bessara Nuntapinit, Timothy Schacker, Nicolas Chomont, Merlin L. Robb, Jintanat Ananworanich, Serena S. Spudich, Lydie Trautmann, for the on behalf of the SEARCH018/RV408 Study group

301 METFORMIN TREATMENT IN NONDIABETIC HIV-INFECTED INDIVIDUALS ON ART

302 METFORMIN THERAPY WITH IMMUNE CHECKPOINT INHIBITORS IMPACTS ANTI-HIV T-CELL RESPONSES
Glen M. Chew, Dominic Chow, Scott A. Souza, Danielle M. Clements, Michael J. Corley, Alina P. Pang, Alan J. Korman, Mariana Gerschenson, Cecilia M. Shikuma, Lishomwa C. Ndhlouv

303 ZINC SUPPLEMENTATION AND INFLAMMATION IN TREATED HIV
Sahera Dirajal-Fargo, Jia Yu, Manjusha Kulkarni, Abdus Sattar, Nicholas Funderburg, Grace A. McComsey

304 GLYCOMIC DETERMINANTS OF INTERFERON-α MEDIATED REDUCTION OF HIV PERSISTENCE IN VIVO
Leila B. Giron, Florent Colomb, Andrew V. Kossenkov, Karam Mounzer, Sherry Wang, Jay Kostman, Pablo Tebas, Una O’Doherty, Livio Azzoni, Emmanouil Papasavvas, Luis Montaner, Mohamed Abdel-Mohsen

Poster P-E01 CHARACTERIZING HIV RESERVOIRS
Poster Hall - 4EF 2:30 PM - 4:00 PM

326 LIPIDOMIC FINGERPRINTING TO IDENTIFY HIV RESERVOIRS IN VITRO AND IN VIVO
Christina Gavegnano, Yong Jiang, Sjia Tao, Ruby Kleinbard, Anush Arakelyan, Andrea Lisco, Irini Sereti, Leonid Margolis, Raymond F. Schinazi

327 CHARACTERIZING THE HIV DNA RESERVOIRS IN WHOLE-BODY TISSUES IN THE “LAST GIFT” COHORT
Michelli Faria de Oliveira, Benjamin Murrell, Thomas Vollbrecht, Susanna Concha-Garcia, Venkatesh Kumar, Maqali Porrachia, Brianna Scott, Laura Layman, Caroline Ignacio, Sara Gianella, Davey M. Smith

328 CD4 T-CELL SUBSETS RESPOND DIFFERENTLY TO LATENCY REVERSAL AGENTS
Judith Grau-Expósito, Laura Luque-Ballesteros, Adrià Curran, Joaquin Burgos, Esteban Ribera, Ariadna Torrella, Bibiana Planas, Rosa Badia, Vicenç Falcó, María J. Buzón
329 HIV-TRANSCRIPTION INDUCES CD20 EXPRESSION AND RENDERS CELLS SUSCEPTIBLE TO RITUXIMAB
Carla Serra Peinado, Judith Grau-Expósito, Laura Luque-Ballesteros, Antonio Astorga Gamaza, Rein Willekens, Jordi Navarro, Adrià Curran, Joaquin Burgos, Esteban Ribera, Josep Castellvi, Meritxell Genesca, Vicenç Falco, Maria J. Buzón

330 HIV-INFECTED CD4 T-CELL ISOLATION USING A MICROFLUIDIC MAGNETIC LEVITATION SYSTEM
N. Gozde Durmus, Kaushik Sridhar, Erica Gibson, Cassandra Thanh, Rakhil Gupta, Maya Ball-Burack, Steven G. Deeks, Utkan Demirci, Timothy J. Henrich

331 A NEW PUBLIC DATABASE FOR NEAR FULL-LENGTH HIV SINGLE-GENOME SEQUENCES
Wei Shao, Jigui Shan, Wei-Shau Hu, Elias K. Halvas, Brian Luke, John W. Mellors, John M. Coffin, Mary F. Kearney

332 TRANSCRIPTOMIC CORRELATES OF HIV RESERVOIR SIZE DURING ANTIRETROVIRAL THERAPY
Wim Trypsteen, Mohamed Abdel-Mohsen, Xutao Deng, Christopher D. Pilcher, Steven G. Deeks, Linos Vandekerckhove, Satish K. Pillai

333 EX VIVO CD4+ T-CELL DIFFERENTIATION IMPROVES HIV RESERVOIR QUANTIFICATION
Elizabeth R. Wonderlich, Krupa Subramanian, Ann Wiegand, Carol Lackman-Smith, Michael J. Bale, Mars Stone, Peter Bacchetti, Frank Maldarelli, Michael P. Busch, Roger Ptak, Mary F. Kearney, Deanna Kulpa

334 CYTOF CHARACTERIZATION OF THE IN VIVO LATENT HIV RESERVOIR IN BLOOD AND TISSUES
Jason Neidleman, Xiaoyu Luo, Grace Xie, Rebecca Hoh, Peter W. Hunt, Steven G. Deeks, Warner C. Greene, Marielle Cavrois, Nadia R. Roan

335 TREASURE HUNT: HIV DNA IN DISTINCT SUBSETS IN THE BLOOD, TERMINAL ILEUM, AND RECTUM
Max Augustin, Carola Horn, Meryem S. Ercanoglu, Vincent Bondet, Isabelle Suarez, Seung-Hun Chon, Dirk Nierhoff, Elena Knops, Eva Heger, Mark Oette, Florian Klein, Gerd Fätkenheuer, Darragh Duffy, Michaela Müller-Trutwin, Clara Lehmann

336 PROPORTION OF INDUCIBLE AND INTACT HIV-1 IN BLOOD IS REFLECTIVE OF LYMPH NODES
Alyssa R. Martin, Alexandra M. Bender, Kyungyoon J. Kwon, Diane M. Brown, Niraj Desai, Dorry Segev, Thomas C. Quinn, Aaron Tobian, Christine Durand, Andrew D. Redd, Robert Siliciano

337 LB GENUINE HIV-1 RESERVOIRS FORM IN URETHRAL MACROPHAGES OF ART-SUPPRESSED PATIENTS
Yonatan Ganor, Fernando Real, Alexis Sennepin, Charles-Antoine Dutertre, Eliseo Eugenin, Remi Cheynier, Marc Revol, Sarra Cristofari, Anne Hosmalin, Morgane Bomsel

338 A METHOD TO DETERMINE BOTH THE INTEGRATION SITES AND SEQUENCES OF HIV-1 PROVIRUSES
Sean Patro, Leah D. Brandt, Michael J. Bale, Elias K. Halvas, Michele Sobolewski, Jenna Hasson, Aurelie Niyongabo, Xiaolin Wu, Shuang Guo, Steven G. Deeks, Stephen H. Hughes, John M. Coffin, Jason W. Rausch, John W. Mellors, Mary F. Kearney
339 DISTINCT CHROMOSOMAL POSITIONS OF INTACT HIV-1 PROVIRUSES
Kevin Einkauf, Guinevere Q. Lee, Ce Gao, Radwa Sharaf, Xiaoming Sun, Stephane Hua, Samantha M. Chen, Chenyang Jiang, Xiaodong Lian, Fatema Z. Chowdhury, Eric Rosenberg, Tae-Wook Chun, Jonathan Z. Li, Xu G. Yu, Mathias Lichterfeld

340 RELATIONSHIP BETWEEN INTACT HIV-1 PROVIRUSES AND PLASMA REBOUND VIRUSES
Ching-Lan Lu, Joy A. Pai, Lilian Nogueira, Pilar Mendoza, Marina Caskey, Mila Jankovic, Michel Nussenzweig

341 LANDSCAPE OF HIV-1 INTEGRATION SITES IN LYMPHOID TISSUE FROM ART-TREATED INDIVIDUALS
Vincent H. Wu, Christopher L. Nobles, Leticia Kuri Cervantes, Perla Del Rio-Estrada, Gustavo Reyes-Terán, Frederic Bushman, Michael R. Betts

342 GENETIC AND AGE DISTRIBUTION OF LATENT HIV SEQUENCES IN CD4+ T-CELL SUBSETS
Rachel Miller, Bradley R. Jones, Olivia Tsai, Bemuluyigza Baraki, Natalie Kinloch, Hanwei Sudderuddin, Hawley Rigsby, Art Poon, Rémi Fromentin, Nicolas Chomont, Jeffrey Joy, Zabrina Brumme

Poster P-E03 HIV RESERVOIR CELLS, PROVIRAL LANDSCAPE, AND REBOUND VIRUS

Poster Hall - 4EF 2:30 PM - 4:00 PM

343 B CELL – T CELL DOUBLETS IN GALT ARE ENRICHED FOR TFH CELLS BUT NOT FOR HIV DNA
John P. Thornhill, Matthew Pace, Genevieve E. Martin, Carolina Herrera, Jonathan Hoare, Simon Peake, Helen Brown, Nneka Nwokolo, Julie Fox, Sarah Fidler, John Frater, for the CHERUB Investigators’

344 CD38+CXCR3+ TFH CELLS SERVE AS ACTIVE HIV RESERVOIR IN THE TOTAL TFH CELL POPULATION
Alessandra Noto, Madeleine Suffiotti, Francesco Procopio, Khalid Ohmiti, Jean-Marc Corpataux, Matthias Cavassini, Raphael Gottardo, Craig Fenwick, Giuseppe Pantaleo

345 RESIDENT MEMORY T CELLS ARE A CELULAR RESERVOIR FOR HIV IN THE CERVICAL MUCOSA
Jon Cantero, Judith Grau-Expósito, Carla Serra Peinado, Daniela A. Rosero, Laura Luque-Ballesteros, Josep Castellví, Tamara Sanhueza, Julia G Prado, Antoni Tarrats, Carla Lucemberri, Laura Mahalich-Barrachina, Cristina Centeno-Mediavilla, Vicenç Falcó, Maria J. Buzón, Meritxell Genescà

346 CD32+CD4+ T CELLS ARE ENRICHED IN HIV DNA
Gilles Darcis, Neeltje A. Kootstra, Berend Hooibrink, Thijs van Monfort, Kevin Groen, Suzanne Jurriaans, Margreet Bakker, Carine Van Lint, Ben Berkhout, Alexander Pasternak

347 DIFFERENT T-CELL SUBSETS CONTAIN INTACT PROVIRUSES IN BLOOD AND LYMPH NODE DURING ART
Bonnie Hiener, Katie Fisher, Bethany A. Horsburgh, Timothy E. Schlub, Vincent Morcilla, John-Sebastian Eden, Susanne von Stockenstrom, Jeffery Milush, Teri Liegler, Rebecca Hoh, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer
348 PERSISTENT HIV LOW-LEVEL VIREMIA CAN ARISE FROM AN ACTIVE PROVIRAL CLONE
Xin Zhang, Radwa Sharaf, Behzad Etemad, Ce Gao, Kevin Einkauf, Sigal Yawetz, Guinevere Q. Lee, Jackson W. Lau, Zixin Hu, Colline Wong, Alexandra Rosenthal, Daniel R. Kuritzkes, Athe Tsbiris, Mathias Lichterfeld, Jonathan Z. Li

349 PREDICTING HIV REBOUND IN VIVO BASED ON EX VIVO CD4+ T CELL LATENCY DISRUPTION
Jason M. Hataye, Joseph P. Casazza, Alan S. Perelson, Richard A. Koup

350 LB VRC01 EPITOPE MOTIFS PREDICTED REBOUND KINETICS AFTER VRC01/TREATMENT INTERRUPTION
Evan Cale, Meera Bose, Hongjun Bai, Michael Messina, Donn J. Colby, Nittaya Phanuphak, Nelson L. Michael, Merlin L. Robb, Nicole Doria-Rose, Trevor A. Crowell, John R. Mascola, Jintanat Ananworanich, Sodsai Tovanabutra, Morgane Rolland, for the RV397 Study Group

Poster Sessions

Poster P-F1 HAND: BIOMARKERS, RISKS, PREVALENCE
Poster Hall - 4EF 2:30 PM - 4:00 PM

407 EARLY INFLAMMATORY PROFILES IN LONG-TERM VIRALLY SUPPRESSED WOMEN PREDICTS COGNITION

408 LONGITUDINAL PHENOTYPING OF DECLARATIVE MEMORY AMONG WOMEN LIVING WITH HIV
Kathryn Fitzgerald, Pauline M. Maki, Yanxun Xu, Wei Jin, Gayle Springer, Kathryn Anastos, Deborah Gustafson, Seble Kassaye, Victor Valcour, Leah H. Rubin

409 CAPTURING DNA METHYLATION CHANGES IN MONOCYTES WHEN INITIATING ART IN ACUTE HIV
Michael J. Corley, Carlo Sacdalan, Elizabeth Laws, Nitiya Chomchey, Alina P. Pang, Nisakorn Ratanaratorn, Ivo N. SahBandar, Victor Valcour, Eugene Kroon, Robert Paul, Merlin L. Robb, Jintanat Ananworanich, Lishomwa C. Ndhlovu, for the SEARCH010/RV254 and SEARCH013/RV304 study groups

410 PLASMA (1→3)-ß-D-GLUCAN LEVELS CORRELATE WITH NEUROCOGNITIVE PERFORMANCE IN HIV
Martin Hoenigl, Scott L. Letendre, Jennifer Iudicello, Donald Franklin, Magali Porrachia, Milenka Vargas, Ronald J. Ellis, Malcolm Finkelman, Sara Gianella

411 LB NEURON-DERIVED EXOSOMES IDENTIFY COGNITIVE IMPAIRMENT AND GENDER DIFFERENCES IN HIV
Lynn Pulliam, Nicole Fernandes, Bing Sun

412 REDUCED SCYLLO-INOSITOL CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN HIV+ INDIVIDUALS
Kalpana J. Kallianpur, Cecilia M. Shikuma, Anna Wang, Liangjie Lin, Robert Paul, Lindsay Kohorn, Michelle L. D’Antoni, Louie Mar A. Gangcuangco, Peter B. Barker

413 LEGACY EFFECTS ON COGNITIVE FUNCTIONS AMONG HIV-INFECTED MEN
414  CLUSTER ANALYSIS OF COGNITIVE FUNCTIONING IN HIV+ AND HIV-SUBJECTS
Lillian Ham, Joseph Snow, Brian K. Agan, Bryan Smith, Avindra Nath, Seung Hyun Won, Xiuping Chu, Elizabeth F. Horne, Gina Norato, Tracyann Mburu, for the Neuro-HIV Research Consortium

415  ALZHEIMER’S DEMENTIA CEREBROSPINAL FLUID BIOMARKERS IN HIV-POSITIVE PATIENTS ON cART
Mattia Trunfio, Caterina Martini, Lorenzo Mighetto, Daniela Vai, Daniele Imperiale, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno

416  CSF HIV-SPECIFIC T CELLS PERSIST DURING ART AND ASSOCIATE WITH LOWER CNS INFLAMMATION
Caroline Subra, Faria Fatmi, Supranee Buranapraditkun, Phillip Chan, Carlo Sacdalan, Kamonkan Tангнареe, Morgane Rolland, Shelly J. Krebs, Napapon Saileruta, Sodai Tovanabutra, Nelson L. Michael, Jintanat Amaworanih, Serena S. Spudich, Lydie Trautmann

417  CSF HIV-TAT AS A BIOMARKER OF NEUROCOGNITION AND AGING IN HIV-INFECTED PATIENTS

418  NEUROCOGNITION, FRAILTY, AND MORTALITY AMONG PERSONS AGING WITH HIV AND SUBSTANCE USE
Damani A. Piggott, Ola A. Selnes, Jason Creighton, Shruti H. Mehta, Ned W. Sacktor, Gregory D. Kirk

419  ASSOCIATIONS BETWEEN PLASMA NRTI CONCENTRATIONS AND COGNITIVE FUNCTION
Davide De Francesco, Jonathan Underwood, Emmanuel Baqkeris, Daphne S. Babalis, Xinzhu Wang, Laura Dickinson, Saye Khoo, Marta Boffito, Caroline Sabin, Alan Winston, for the POPPY study group

420  VARIABILITY IN COGNITIVE IMPAIRMENT OVER TIME IN PEOPLE WITH HIV AND MATCHED CONTROLS
Davide De Francesco, Caroline Sabin, Jonathan Underwood, Magnus Gissién, Ferdinand Wit, Rosan van Zoest, Judith Schouten, Ben Schmand, Peter Portegies, Peter Reiss, Alan Winston, for the Co-morBidity in Relation to AIDS (COBRA) collaboration

421  ASSOCIATION BETWEEN NEUROFILAMENT LIGHT PROTEIN AND IMPAIRED COGNITION IN TREATED HIV

422  SCD14, SICAM-1, AND SVCAM-1 CORRELATE WITH NEUROCOGNITIVE FUNCTION IN YOUTH WITH HIV
Julie J. Kim-Chang, Matthew S. Loop, Kevin Donovan, Suzi Hong, Bernard Fischer, Guglielmo Venturi, Patricia A. Garvie, Jordan Kahn, H. Jonathon Rendina, Steven P. Woods, Maureen Goodenow, Sharon Nichols, John W. Sleasman, for the Adolescent Medicine Trials Network (ATN) for HIV/ AIDS Interventions

423  METABOLOMIC PROFILING OF HIV PATIENTS WITH AND WITHOUT HIV-ASSOCIATED DEMENTIA
Andrea Mastrangelo, Magnus Gissién, Richard W. Price, Filippo Turrini, Roberta Caccia, Leonid Gorelik, Bestetti Arabella, Adriano Lazzarin, Cinque Paola
**Poster Sessions - Tuesday**

**424 IMPAIRED COGNITION PREDICTS FALLS AMONG HIV+ AND HIV-WOMEN**

Anjali Sharma, David Vance, Donald R. Hoover, Qiuhu Shi, Michael T. Yin, Susan Holman, Michael Plankey, Phyllis Tien, Kathleen M. Weber, Michelle Floris-Moore, Hector Bolivar, Elizabeth T. Golub, Marica M. Holstad, Leah H. Rubin, for the Women's Interagency HIV Study

**425 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER LEADS TO DEATH**

Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Alice Kisakye, Aggrey Anok, Richard Mayanja, James Batte, Kevin Robertson, Ronald H. Gray, Maria Wawer, Ned W. Sacktor

**426 ANEMIA AND NEUROCOGNITIVE IMPAIRMENT: A LONGITUDINAL MULTICOHORT STUDY**

Oluwakemi Okwuegbuna, Asha R. Kallianpur, Jennifer Iudicello, Ajay Bharti, Ronald J. Ellis, Allen McCutchan, Scott L. Letendre

**Utility**

**Poster Sessions**

**Poster P-G1 OBJECTIVE ASSESSMENT OF ADHERENCE FOR PrEP AND ART**

Poster Hall - 4EF 2:30 PM - 4:00 PM

261 PI DRUG-LEVEL TESTING AS A SCREENING TOOL FOR DRUG RESISTANCE IN 2ND-LINE ART FAILURE

Lucas E. Hermans, Kim Steeghen, Rob ter Heine, Rob Schuurman, Hugo Tempelman, Robert Moraba, Erik Maarseven, Taryn Pillay, Derryn Legg-Esilva, Jonathan M. Schapiro, David M. Burger, Sergio Carmona, Annemarie Wensing

**Poster P-H6 WOMEN AND HIV: ARE OUTCOMES DIFFERENT?**

Poster Hall - 4EF 2:30 PM - 4:00 PM

516 DEPRESSION IS A STRONGER PREDICTOR OF EXECUTIVE DYSFUNCTION IN HIV+ WOMEN THAN MEN

Leah H. Rubin, Gayle Springer, Eileen Martin, Eric C. Seaberg, Ned Sacktor, Andrew Levine, Victor Valcour, Mary Young, James T. Becker, Pauline M. Maki
517  GENDER AND COINFECTIONS CONTRIBUTE TO IMMUNE ACTIVATION IN TREATED HIV INFECTION

518  IMPORTANT SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ART
Catherine Godfrey, Michael D. Hughes, Justin Ritz, Robert Gross, Robert A. Salata, Rosie Mngqibisa, Carole Wallis, Mumbi Makanga, Marije Van Schalkwyk, Mitch Matoga, Courtney V. Fletcher, Beatriz Grinsztejn, Ann Collier, for the ACTG 5288 Team

519  TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS
Melanie Thompson, Indira Brar, Cynthia Brinson, Catherine Creticos, Debbie Hagins, Ellen Koenig, Claudia Martorell, Cristina Mussini, Laura Waters, Susan Guo, Ya-Pei Liu, Lauren L. Temme, Devi SenGupta, Moupal Das

520  EFFECT OF ANTIRETROVIRAL THERAPY AND IMMUNE RECONSTITUTION ON VAGINAL MICROBIOME
Zoe Packman, Cindy M. Liu, David Serwadda, Fred Nalugoda, Maliha Aziz, Alison Abraham, Jessica Prodger, Rupert Kaul, Ronald H. Gray, Aaron Tobian, Thomas C. Quinn, Steven J. Reynolds

521  IMMEDIATE ART INITIATION IN ACUTE INFECTION IMPROVES CLINICAL OUTCOMES, SABES STUDY
Javier R. Lama, Rachel A. Bender Ignacio, Jorge A. Gallardo-Cartagena, Jessica Rios, Ricardo Alfaro, Karin S. Sosa-Barbaran, Carolyn Bain, Christopher D. Pilcher, Ann Duerr, for the Sabes Study

522  VIRAL BLIPS AFTER TREATMENT INITIATION DURING ACUTE HIV INFECTION
Trevor A. Crowell, Suteeraporn Pinyakorn, Carlo Sacdalan, Eugène Kroon, Donn J. Colby, Suwanna Pattamasavin, Sasiwimol Ubolyam, Rapee Trichavaraj, Oratai Butterworth, Ellen Turk, Corinne McCullough, Mark de Souza, Nittaya Phanuphak, Jintanat Ananworanich, for the RV254/SEARCH010 Study Group

523  BENEFITS OF InStI-BASED REGIMEN AT THE TIME OF PRIMARY HIV INFECTION
Raphaël Veil, Isabelle Poizot-Martin, Jacques Reyenes, Cécile Goujard, Remonie Seng, Pierre Delobel, Laurent Cotte, Claudine Duvivier, David Rey, Laurent Tran, Laure Surgers, Clotilde Allavена, Caroline Lascoux-Combe, Antoine Chéret, Laurence Meyer

524  RECTAL AND SEMINAL HIV-1 RNA DECAY IN INFECTED MSM INITIATING WITH DTG/ABC/3TC
Marta Fernández, Vanesa Agulló, José A. García, Sergio Padilla, Javier García-Abellán, Victoria Ortiz de la Tabla, Félix Gutiérrez, Maria Del Mar Masia
**Poster P-I1 RESISTANCE SPREAD AND ITS IMPACT ON ART**
*Poster Hall - 4EF 2:30 PM - 4:00 PM*

525 MODELING ANTIRETROVIRAL DRUG RESISTANCE IN SOUTH AFRICA, THE MARISA PROJECT
*Anthony Hauser*, Katharina Kusejko, Leigh F. Johnson, Fardo Goldstein, Julien Riou, Gilles Wandeler, Matthias Egger, Roger Koyos


527 IMPACT OF PRETREATMENT DRUG RESISTANCE ON TREATMENT OUTCOME IN THE ITREMA TRIAL
*Lucas E. Hermans*, Laura Marije Hofstra, Rob Schuurman, Rob ter Heine, Hugo Tempelman, Willem D. Venter, Monique Nijhuis, Annemarie Wensing

528 INTEGRASE GENOTYPIC TESTING AND DRUG RESISTANCE AMONG NEW HIV DIAGNOSES IN NEW YORK

529 HIV-TRANSMITTED DRUG RESISTANCE IN CISGENDER MSM AND TRANSGENDER WOMEN IN LIMA, PERU
*William L. Trebelcock*, Javier R. Lama, Ann Duerr, Hugo Sanchez, Robinson Cabello, Sari Reisner, Kenneth H. Mayer, James Mullins, Rachel A. Bender Ignacio

**Poster P-I2 PREVALENCE AND SPREAD OF RESISTANCE**
*Poster Hall - 4EF 2:30 PM - 4:00 PM*

530 PRE-TREATMENT HIV DRUG RESISTANCE IN BOTSWANA
*Simani Gaseitsiwe*, Sikhulile Moyo, Melissa Zahralban-Steele, Dorcas Maruapula, Tapiwa Nkhisang, Jean Leidner, Onlmatsete Bareng, Molly Pretorius Holme, Kara Bennett, Kathleen Wirth, Tendani Gaolathe, Joseph Makhema, Shahin Lockman, Max Essex, Vlad Novitsky

531 HIV DRUG RESISTANCE IN ADOLESCENTS AND ADULTS ON SECOND-LINE ART IN KWAZULU-NATAL
*Benjamin Chimukangara*, Benn Sartorius, Richard Lessells, Jennifer Giandhari, Kerusha Govender, Nokukhanya Mdlolose, Reshmi Samuel, Kogieleum Naidoo, Tulio de Oliveira, Pravi Moodley, Raveen Parboosing

532 FREQUENT DISCORDANCE BETWEEN ETRAVIRINE PHENOTYPE & GENOTYPE IN SUBTYPE cART FAILURE

533 IN-DEPTH CHARACTERIZATION OF HIV RESISTANCE TO INTEGRASE INHIBITORS IN BRAZIL
*Nazle Veras*, Rosana Elisa G. Pinho, Ana R. Pati Pascom, José Boullosa, Fernanda Rick, Adele Benzaken

534 HIV DRUG RESISTANCE AMONG PWID IN EASTERN EUROPE AND ASIA, HPTN 074
**Poster Sessions**

### Poster Sessions - Tuesday

#### Poster P-K1 HCV THERAPEUTICS: REALITY TESTING

**Poster Hall - 4EF**

**2:30 PM - 4:00 PM**

**535** INI-RESISTANCE DYNAMICS FROM 2007 TO 2017 IN ITALIAN CLINICAL ISOLATES

Daniele Armenia, Caterina Gori, Ada Bertoli, Vanni Borghi, Alessandra Latini, Roberta Gagliardini, Miriam Lichtner, Federica Forbici, Francesco Montella, Cristina Mussini, Massimo Andreoni, Andrea Antinori, Francesca Ceccherini Silberstein, Carlo Federico Perno, Maria M. Santoro

**536** ANTIRETROVIRAL DRUG RESISTANCE IN PATIENTS RECEIVING CARE AT ETHIOPIAN HEALTH CENTERS

Anton Reepalu, Dawit A. Assefa Arimide, Per Bjorkman, Patrik Medstrand

**537** BASELINE HIV DRUG RESISTANCE AMONG TREATMENT-NAIVE PATIENTS IN ESWATINI, MAXART TRIAL

Shaukat Khan, Anita Hettema, Fiona Walsh, Sikhathele Mazibuko, Velephi Okello, Charlotte Lejeune, Jillian Sacks, Michael R. Jordan, John Koo, P. Richard Harrigan, Chanson J. Brumme, Hope R. Lapointe

**538** MODELING THE IMPACT OF DOLUTEGRAVIR INTRODUCTION ON NNRTI RESISTANCE IN SOUTH AFRICA

Anthony Hauser, Katharina Kusejko, Leigh F. Johnson, Huldrych F. Günthard, Julien Riou, Gilles Wandelner, Matthias Egger, Roger Kouryos

---

**560** A REAL-WORLD STUDY OF EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN HCV PATIENTS

Marcello Persico, Andrea Aglitti, Michele Milella, Carmine Coppola, Vincenzo Messina, Ernesto Ciar, Ivan Gentile, Paola Pierr, Lorenzo Antonio Surace, Filomena Morisco, Paolo Tundo, Giuseppina Brancaccio, Nicola Coppola, Annamaria Longo, Mario Masarone

**561** GRAZOPREVIR/ELBASVIR FOR HCV-INFECTED PWID IN REAL-WORLD SETTINGS: THE ZEPALIVE STUDY

Juan Macías, Luis Morano, Francisco Téllez, Maria J. Rios-Villegas, Rafael Granados, Antonio Collado, Carlos Galera, Francisco Vera, Dolores Merino, Ignacio Santos, Oscar Rincón, Juan A. Pineda, for the HEPAVIR and GEHEP study groups. GEHEP-001 project

**562** REAL-WORLD DATA ON ELBASVIR/GRAZOPREVIR FOR HCV INFECTION IN HIV/NON-HIV PATIENTS

Maria Luisa Montes, Juan Berenguer, Ángela Gil-Martín, Adriana Ahumada, Teresa Aldámicz-Echevarria, José L. Calleja, Agustín Albillos, Antonio Oliveira, María Jesús Tellez Molina, Lourdes Dominguez-Dominguez, Conrado Fernández Rodríguez, José Sanz, Inma Jarrín, María J. Calvo, Juan González-García

**563** EFFECTIVENESS OF HEPATITIS C TREATMENT IN HIV/HCV COINFECTED PATIENTS IN MYANMAR

Derek Johnson, Htay Thet Mar, Phone Thit, Tobias Homan, Phyu Ei Mon, Kyi Pyar Soe, Win Le Shwe Sin Ei, Khin Sanda Aung, Thin Thin Thwe, Nyan Lynn Tun, Kyaw Zay Lwin, Aude Nguyen, Anne Loarec

**564** HCV LATE RELAPSE IN PATIENTS WITH DIRECTLY ACTING ANTIVIRAL-RELATED SVR 12

Carmine Minichini, Mariantonietta Pisaturo, Mario Starace, Caroprese Mara, Margherita Macera, Giuseppina Brancaccio, Stefania De Pascalis, Alfonso Galeota Lanza, Rosa Zampino, Evangelista Sagnelli, Giovanni Battista Gaeta, Nicola Coppola, Antonella Santonicola
565 CLINICAL OUTCOMES IN PERSONS COINFECTED WITH HIV AND HCV: IMPACT OF HCV TREATMENT
Lars Peters, Amanda Mocroft, Jens D. Lundgren, Jan Gerstoft, Line D. Rasmussen, Sanjay Bhagani, Inka Aho, Christian Pradier, Johannes Bogner, Jürgen K. Rockstroh, Cristina Mussini, Adriano Lazzarin, Fernando Matze, Montse Laguno, Gilles Wandelger, for the EuroSIDA Study

566 INTERFERON-FREE REGIMENS IMPROVE RENAL FUNCTION IN PATIENTS WITH CHRONIC HEPATITIS C
Nicola Coppola, Federica Portunato, Antonio Riccardo Buonomo, Laura Staiano, Riccardo Scotto, Biagio Pinchera, Stefania De Pascalis, Salvatore Martini, Mariantonietta Pisaturo, Daniela Caterina Amoruso, Guglielmo Borgia, Carmine Coppola, Ivan Gentile

567 PCSK9 LEVELS DECLINE WITH HCV DIRECT-ACTING ANTIVIRAL THERAPY IN HIV/HCV COINFECTION

568 LIVER STIFFNESS AT SVR PREDICTS HEPATIC COMPLICATIONS IN HCV-INFECTED PATIENTS
Anais Corma-Gómez, Maria Iglesias, Francisco Téllez, Luis Morano, Antonio Rivero-Juárez, Maria J. Rios-Villegas, Marta Santos, Francisco Vera, Jesus Santos, Rafael Granados, Dolores Merino, Ignacio d. Santos Gil, Juan Macías, Juan A. Pineda, for the Proyecto GEHEP-011

569 INFLAMMATION, ARTERIAL STIFFNESS, AND DIRECTLY ACTING ANTIVIRALS IN HCV AND HIV/HCV
Sonika Malik, Ruchi Bisen, Melissa Osborn, Sanjay Gandhi, Grace A. McComsey, Corrilynn O. Hileman

570 EFFECT OF LIVER FIBROSIS STAGE AND DAA TREATMENT ON RISK OF CV EVENTS IN ERCHIVES
Adeel A. Butt, Peng Yan, Samia Aslam, Obaid S. Shaikh

571 LIVER FIBROSIS HINDERS T-CELL HOMEOSTASIS RESTORATION AFTER HCV ERADICATION WITH DAs
Beatriz Álvarez, Andrea García, Clara Restrepo, Marcial García, María Ángeles Navarrete, Victoria M. de Santisteban, José Ligos, Alfonso Cabello, Laura Prieto, Sara Nistal, María Montoya, Miguel Górgolas, Norma Rallón, José Miguel Benito

572 IMPACT OF DIRECT-ACTING ANTIVIRALS ON RATES OF HCC IN HCV- AND HIV-INFECTED PATIENTS
Taiwo A. Ajose, Michael Flood

Poster P-K2 HCV THERAPEUTICS: MOVING FROM TREATING THE PERSON TO TREATING THE POPULATION
Poster Hall - 4EF 2:30 PM - 4:00 PM

573 BARRIERS TO INITIATING DAA THERAPY IN HCV/HIV COINFECTED PATIENTS
Taiwo A. Ajose, Austin Chan

574 PROGRESS TOWARDS HCV MICRO-ELIMINATION IN AN URBAN HIV-INFECTED COHORT
Oluwaseun Falade-Nwulia, Catherine Sutcliffe, Shruti H. Mehta, Juhi Moon, Geetaanjali Chander, Jeanne C. Keruly, Jennifer Katzieaner, Richard D. Moore, Mark Sulkowski
575 NETWORK-BASED RECRUITMENT FOR HEPATITIS C THERAPY AMONG PEOPLE WHO INJECT DRUGS
Oluwaseun Falade-Nwulia, Shruti H. Mehta, Kathleen Ward, Stephanie Katz, Geetanjali Chander, Sean McCormick, Carl A. Latkin, Mark Sulkowski

576 CAN’T BUY ME LOVE? OBSTACLES TO MICRO-ELIMINATION OF ACUTE HCV COINFECTION IN EUROPE
Christoph Boesecke, Mark Nelson, Patrick Ingliz, Thomas Lutz, Stefan H. Scholten, Christine Cordes, Maria Martinez-Rebollar, Christoph D. Spinner, Michael Rausch, Sanjay Bhagani, Lars Peters, Thomas Reiberger, Stefan Mauss, Jürgen K. Rockstroh, for the PROBE-C study group

577 HCV REINFECTION RISK FOLLOWING DAA THERAPY IN PEOPLE LIVING WITH HIV IN AUSTRALIA
Samira Hosseini Hooshyar, Marianne Martinello, Sofia Bartlett, Robert Finlayson, David Baker, Mark Bloch, Joseph S. Doyle, David Shaw, Phillip Read, Jasmine Yee, Lanni Lin, Tanya Applegate, Margaret Hellard, Gregory J. Dore, Gail Matthews

578 CARE FACILITATION FOR HIV/HCV COINFECTED INCREASES MOVEMENT ON THE HCV CARE CASCADE

579 HEPATITIS C TESTING OF TRAUMA SURGERY PATIENTS: INCIDENCE, PREVALENCE, & CARE CASCADE
Jenna M. Wick, Josue Oyola-Jimenez, Davone Singleton, Samantha Webster, David M. Fleece, Jill Volgraf, Amy J. Goldberg, Gina M. Simoncini

580 A RANDOMIZED TRIAL OF HIV/HCV NURSE CASE MANAGEMENT FOR LINKAGE TO HCV CARE
Laura Starbird, Hae-Ra Han, Mark Sulkowski, Chakra Budhathoki, Nancy Reynolds, Jason Farley

581 DEMOGRAPHIC TRENDS IN HCV DIAGNOSIS AND LINKAGE TO HCV CARE AMONG JAIL DETAINEES
Ank E. Nijhawan, Jacqueline Sullivan, Merilyne Aguwa, Esmaili Porsa

582 HEPATITIS C CASCADE OF CARE AMONG PEOPLE WHO INJECT DRUGS IN BRITISH COLUMBIA IN 2017
Sofia Bartlett, Stanley Wong, Amanda Yu, Maria Alvarez, Terri Buller-Taylor, Zahid A. Butt, Maryam Darvishian, Carmine Rossi, Margo Pearce, Jason Wong, Mark Gilbert, Mark W. Tyndall, Mel Krajden, Naveed Z. Janjua

583 A COMMUNITY INTERVENTION INCREASED HCV SCREENING AND TREATMENT IN KING COUNTY, WA
John D. Scott, Meaghan Munn, Atar Baer, Sara N. Glick, Elizabeth Barash, Hilary Armstrong, Kris Kowdley, Matthew Messerschmidt, Pallavi Patel, Michael Ninburg, Matthew R. Golden, Jeff Duchin

584 LOW PERFORMANCE OF THE ORAQUICK HCV RAPID ANTIBODY TEST IN HIV/HCV-INFECTED PEOPLE
Serena Vita, Irene Pozzetto, Raffaella Marocco, Ilenia Mastrini, Laura Fondaco, Blerta Kertusha, Valdo Rossi, Pasquale Dolce, Tiziana Tieghi, Claudio M. Mastroianni, Miriam Lichtner

585 UTILITY OF HCV CORE ANTIGEN FOR THE DIAGNOSIS OF ACUTE HCV IN HIGH-RISK INDIVIDUALS
Subathira Dakshina, Diane Reid, Ania Richardson, Chantal Oxenham, Nina Vora, Richard Gilson, Eleni Nastouli, Laura Waters, Sanjay Bhagani, Indrajit Ghosh
586  DIVERSE OBSTETRICIAN HCV-SCREENING PRACTICES IN A LARGE REGIONAL HEALTH CARE SYSTEM
Dawn Fishbein, Ariunzaya Amgalan, Eshetu Tefera, Shari Sawney, Nicole Brown, Emily Paku, Hala Deeb, Stephen Fernandez, Rachel K. Scott

587  TRANSFORMING PRIMARY CARE PRACTICES FOR HEPATITIS C TREATMENT CENTERS
Risha Irvin, Boatemaa Ntiri-Reid, Mary Kleinman, Alexander J. Millman, Lauren Canary, Tracy Agee, Jeffrey Hitt, Onyeka Anaedozie, Hope Cassidy-Stewart, Oluwaseun Falade-Nwulia, Mark Sulkowski, Noele Nelson, David L. Thomas, Michael Melia

588  DECENTRALIZATION AND TASK-SHIFTING FOR HEPATITIS C: SYSTEMATIC REVIEW & META-ANALYSIS
Ena Oru, Steve Kanters, Rohan Shirali, Philippa J. Easterbrook

589  THE COST-EFFECTIVENESS OF HCV SCREENING OF PREGNANT WOMEN IN THE UNITED STATES
Antoine Chaillon, Nancy S. Reau, Elizabeth B. Rand, Natasha Martin

590  COST-EFFECTIVENESS OF HCV TREATMENT AMONG HIV-POSITIVE INDIVIDUALS IN MYANMAR
Lara K. Marquez, Antoine Chaillon, Kyi Pyar Soe, Derek Johnson, Jean-Marc Zosso, Andrea Incerti, Anne Loarec, Aude Nguyen, Josephine Walker, Nyashadzaishe Mafirakureva, Peter Vickerman, Natasha Martin

Poster P-M1 NOVEL MEASURES AND DRIVERS OF INFLAMMATION AND VASCULAR FUNCTION
Poster Hall - 4EF  2:30 PM - 4:00 PM

631  ANTI-INFLAMMATORY IL-10 IS INVERSELY RELATED TO CORONARY ATHEROSCLEROSIS IN HIV
Lindsay T. Fourman, Charles Saylor, Lediya Cheru, Kathleen V. Fitch, Tricia H. Burdo, Sara E. Looby, Udo Hoffmann, Michael T. Lu, Janet Lo

632  IL-32Δ AND TRAIL: NEW CARDIOVASCULAR DISEASE BIOMARKERS IN ART-TREATED HIV INFECTION
Mohamed El-Far, Madeleine Durand, Carl Chartrand-Lefebvre, Etienne Larouche-Anctil, Sarah M. Zaidan, Genevieve Chabot-Roy, Rémi Bunet, Mohamed Sylla, Jean-Guy Baril, Petronela Ancuta, Sylvie Lesage, Nicolas Chomont, Robert C. Kaplan, Alan Landay, Cécile L. Tremblay, for the The Canadian HIV and Aging Cohort Study

633  INFLAMMATION-RELATED GENES ARE ASSOCIATED WITH ACCELERATED AGING IN HIV
Erin Sundermann, Mariam Hussain, David J. Moore, Steven Horvath, Andrew Levine, for the HNRP Group

634  IMPACT OF INFLAMMATION AND GUT IMMUNITY ON CORONARY ARTERNAL WALL COMPOSITION
Robert C. Guerri-Fernández, Netanya S. Utay, Zhong-Min Ma, Surinder Mann, Talia Sainz, Marjorie Pion, Alan Landay, Friedrich Knollmann, David M. Asmuth

635  CONTRIBUTION OF HUMAN HERPESVIRUS 8 AND HERPES SIMPLEX 2 TO PROGRESSION OF IMT IN HIV
Fernando Lidón, Sergio Padilla, José A. García, Marta Fernández, Javier García-Abellán, Victoria Ortiz de la Tabla, Félix Gutiérrez, María Del Mar Masia, for the Elche
636 HIV INFECTION AND RISK OF RECURRENT VENOUS THROMBOEMBOLISM: A NATIONAL COHORT STUDY
Casper Rokx, Jaime Borjas Howard, Colette Smit, Ferdinand Wit, Elise D. Pieterman, Suzanne Cannegievert, Willem Lijsferring, Karina Meijer, Peter Reiss, Wouter Bierman, Vladimír Tichelaar, Bart Rijnders

637 PREDISPOSING FACTORS FOR VENOUS THROMBOEMBOLISM IN HIV-INFECTED PATIENTS

638 SHORTER ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) IN PEOPLE LIVING WITH HIV
Asbjoern Fink, Andreas D. Knudsen, Rebekka F. Thudium, Jakob Hjorth von Stemann, Shoaib Afzal, Jens D. Lundgren, Thomas Benfield, Sisse R. Ostrowski, Borge Nordestgaard, Susanne D. Nielsen

639 DUAL DRUG-MEDIATED MECHANISM FOR NRTI-ASSOCIATED PLATELET HYPERREACTIVITY
Kirk A. Taylor, Erica Smyth, Francesca Rauzi, Maddalena Cerrone, Akif A. Khawaja, Brian Gazzard, Mark Nelson, Marta Boffito, Michael Emerson

640 PLATELET FUNCTION AFTER DOLUTEGRAVIR AND/OR DARUNAVIR/Cobicistat IN HEALTHY SUBJECTS
Kirk A. Taylor, Francesca Ferretti, Maddalena Cerrone, Akif A. Khawaja, Wing Yip, Marta Boffito, Michael Emerson

641 DIRECT ORAL ANTICOAGULANT AND ART USAGE IN PLWH: DATA FROM THE DC COHORT
Safia S. Kuriakose, Jomy M. George, Anne K. Monroe, Qingjiang Hou, Alice K. Pau, Henry Masur, Colleen Hadigan, Amanda D. Castel, Michael A. Horberg, for the DC Cohort Executive Committee

684 ADIPOSE TISSUE CD4+ AND CD8+ T-CELL PROFILES DIFFER BY GLUCOSE TOLERANCE IN HIV

685 FIBROBLAST GROWTH FACTOR 21 (FGF21) IS ELEVATED IN HIV AND AFFECTED BY INFLAMMATION
Allison Ross Eckard, Mary Ann O’Riordan, Danielle Labbato, Julia C. Kosco, Vanessa El Kamari, Grace A. McComsey

686 HAART IS ASSOCIATED WITH REDUCED RISK OF OSTEOPOROSIS-RELATED FRACTURES
José A. Barletta, Monica Ye, Michelle Lu, Mia Kibel, Viviane D. Lima, Oghenowode Eyawo, Julio S. Montaner, Robert S. Hogg, Silvia Guillemi
687  EFFECTS OF ERADICATION OF HCV ON BONE MINERAL DENSITY IN HIV/HCV-COINFECTED PATIENTS
Ana Carrero, Juan Berenguer, Victor Hontanon, Josep M. Guardiola, Jordi Navarro, Miguel A. Von Wichmann, Maria Jesus Tellez Molina, Carmen Quereda, Ignacio Santos, Jose Sanz, Maria J. Galindo, Jose Hernandez-Quero, Juan Carlos Lopez-Blanco, Jose M. Bellon, Juan Gonzalez-Garcia

688  HIV-ASSOCIATED HYPOPARATHYROIDISM: RESULTS FROM A GERMAN HIV COHORT
Sebastian Noe, Celia Oldenbuettel, Silke Heldwein, Carmen Wiese, Ariane von Krosigk, Farhad Schabaz, Rita Pascucci, Hans Jaeger, Eva Wolf, for the ArchIV Study Group

Poster P-N6 RENAL DISEASE IN TREATED HIV
Poster Hall - 4EF 2:30 PM - 4:00 PM

689  IMPACT OF RENAL TUBE FUNCTION ON BONE MINERAL DENSITY IN OLDER PEOPLE WITH HIV
Elena Alvarez-Barco, Lucy Campbell, Keith Burling, Sebastian Noe, Mingjin Yan, Hiba Graham, Martin Rhee, Patrick W. Mallon, Frank Post

690  GENETIC AND CLINICAL RISK FACTORS FOR CHRONIC KIDNEY DISEASE IN HIV

691  LYosomal TOXICITY AS A NOVEL MECHANISM IN TENOFOVIR-ASSOCIATED NEPHROTOXICITY
Metodi Stankov, Ruisi Lin, Ramachandramouli Budida, Diana Panayotova-Dimitrova, Reinhold E. Schmidt, Georg Behrens

692  DYNAMICS OF E-FGR WITH ONE OR MORE ANTIRETROVIRALS THAT INHIBIT CR TUBULAR SECRETION
Maria Jesus P. Elias, M Mar Gutierrez, Manuel Crespo, Ignacio Santos, Esteban Ribera, Maria J. Galindo, Fernando Lozano, Antonio Payeras Cifre, Vicente Boix, Marta Montero, Jose Sanz, Javier De La Torre Lima, Jesus Santos, Sara de la Fuente Moral, Esteban Martinez

693  EVOLUTION AND REVERSIBILITY OF RENAL FUNCTION AFTER SWITCH FROM TDF TO TAF REGIMENS
Robert Agliardini, Patrizia Lorenzini, Alessandro Cozzi-Leprì, Nicola Gianotti, Loredana Sarmati, Stefano Rusconi, Emanuela Messina, Amedeo Capetti, Annalisa Saracino, Giordano Maddeddu, Antonella Arminio Monforte, Andrea Antonini, for the Icona Foundation Study Group

694  GLOMERULAR FILTRATION RATE RECOVERY AFTER A SWITCH FROM TDF TO TAF OR ABC
Rosanne Verwijis, Ingeborg Wijting, Marjo van Kasteren, Jan G. Hollander, den, Inge Derdelinckx, Guido van den Berk, Saskia Vrouwenraets, Mark Claassen, Wouter Bierman, Casper Rokx, Bart Rijnders

695  SUBCLINICAL TUBULAR IMPAIRMENT IS COMMON IN ART-TREATED HIV+ PATIENTS IN UGANDA
Cecilia Costa, Silvia Scabini, Arvind Kaimal, William Kasozi, Jessica Cusato, Olive Mbabazi, John Bosco Kafufu, Erissa S. Mwaka, Giovanni Di Perri, Mohammed Lamorde, Andrea Calcagno, Barbara Castelnuovo
743 **NEURAL-TUBE DEFECTS, HIV, AND ANTIRETROVIRALS: BIRTH-DEFECT SURVEILLANCE IN UGANDA**  
Linda Barlow-Mosha, Daniel M. Mumpe, Dhelia Williamson, Diana Valencia, Robert Serunjogi, Joyce N. Matovu, Philippa Musoke

744 **NO INCREASE IN BIRTH DEFECTS IN INFANTS EXPOSED TO INTEGRASE INHIBITORS AT CONCEPTION**  
Jeanne Sibiude, Jérôme Le Chenadec, Laurent Mandelbrot, Stephane Blanche, Catherine Dolliffs, Nathalie Leelong, Elisa Arezes, Lamya Alt Si Selmi, Sophie Matheron, Christine Rouzioux, Josiane Warszawski, Rolando Tubiana, for the ANRS-EPF-C01/C011 study groups

745 **EVALUATION OF NEURAL-TUBE DEFECTS AFTER EXPOSURE TO RALTEGRAVIR DURING PREGNANCY**  

746 **REPORTS OF NEURALTUBE DEFECTS FOR 8 ARTS, IN FDA, WHO, EMA, AND UK SAFETY DATABASES**  
Andrew Hill, Nikolien S. van de Ven, Anton Pozniak, Jacob A. Levi, Anna Garratt, Christopher Redd, Lynne Mofenson

747 **InSTI EXPOSURE AND NEURAL-TUBE DEFECTS: DATA FROM ANTIRETROVIRAL PREGNANCY REGISTRY**  
Jessica D. Albano, Vani Vannappagari, Angela Scheuerle, Heather Watts, Claire Thorne, Leslie Ng, Veronica V. Urdaneta, Lynne M. Mofenson

748 **UGANDAN CLINIC EXPERIENCE FOLLOWING POTENTIAL TERATOGENICITY ALERT FOR DOLUTEGRAVIR**  
Arinaitwe S. Arnold, Eva A. Laker Ondongpiny, Noela Owarwo, Onzia Annet, Nasasira Benson, Wailagala Abdullah, Ivan Kalule, Anguzu Godwin, Agnes Kiragga, Kay Sedin, Barbara Castelnuovo, Isaac Lwangu, Rachel Musomba, Mohammed Lamorde

749 **SERUM FOLATE AND BIRTH OUTCOMES: DTG VS EFV TRIAL EVIDENCE IN SOUTH AFRICA**  
Nomathemba C. Chandiwana, Andrew Hill, Matthew Chersich, Ellisha Maharaj, Willem D. Venter, Godspower Akpomiemie, Celicia Serenata, Lee Fairlie, Simiso Sokhela, Masebola Masenya, Michelle A. Moorhouse

---

**Poster P-P2 UNDERSTANDING ANTIRETROVIRAL EXPOSURE AND BIRTH OUTCOMES**  
Poster Hall - 4EF  2:30 PM - 4:00 PM

750 **FETAL BIOMETRY SIMILAR WITH DOLUTEGRAVIR OR EFAVIRENZ EXPOSURE**  

751 **SIMILAR BIRTH ANTHROPOMETRICS WITH IN UTERO EXPOSURE TO DOLUTEGRAVIR OR EFAVIRENZ**  
752  ADVERSE BIRTH OUTCOMES AMONG PRENATALLY VS SEXUALLY HIV-INFECTED WOMEN IN BOTSWANA
Christina Fennell, George R. Seage, Rebecca Zash, Kelesitse Phiri, Modiegi D. Diseko, Gloria K. Mayondi, Shahin Lockman, Tumalano Sekoto, Mompati O. Mmalane, Joseph Makhema, Roger L. Shapiro

753  ADVERSE PREGNANCY OUTCOMES IN HIV-POSITIVE PREGNANT WOMEN IN ART IN KENYA
Lisa L. Abuogi, Maricianah A. Onono, Anna Helova, Kevin Owuor, Tobias Odwar, Karen Hampanda, Thomas A. Odeny, Elizabeth A. Bukusi, Janet M. Turan

754  TIMING OF MATERNAL ANTIRETROVIRAL THERAPY INITIATION AND STILLBIRTH IN MALAWI
Malango T. Msukwa, Olivia Keiser, Andreas Jahn, Joep J. van Oosterhout, Andrew Edmonds, Nozgechi S. Phiri, Ronald Manjomo, Mary-Ann Davies, Janne Estill

755  PRETERM BIRTH AMONG WOMEN WITH ULTRASOUND-BASED GESTATIONAL DATING IN PROMISE 1077BF
Kartik K. Venkatesh, Mona Farhad, Terence Fenton, Dhayendre Moodley, Shilpa Naik, Clemensia Nakabbiito, Lee Fairlie, Bonus Makanani, Friday Saidi, Tsungai Chipato, James A. McIntyre, Mary Glenn Fowler, Benjamin H. Chi, Jeffrey S. Stringer, for the PROMISE 1077BF team

756  LOPINAVIR (AN HIV PROTEASE INHIBITOR) IMPAIRS UTERINE REMODELING DURING PREGNANCY
Smriti Kala, Caroline Dunk, Lena Serghides

Poster P-Q4 RESPONSE TO ART IN CHILDREN AND YOUTH
Poster Hall - 4EF 2:30 PM - 4:00 PM

807  POORER CONTROL OF VIRAL LOAD IN PATIENTS INFECTED PERINATALLY VERSUS DURING ADULTHOOD
Jean Joel Bigna, Remonie Seng, Albert Faye, Catherine Dollfus, Pierre Frange, Laura Nailler, Jérôme Le Chenadec, Faroudy Boufassa, Asma Essat, Veronique Avettand-Fenoel, Stephane Blanche, Cécile Goujard, Laurence Meyer, Jean-Paul Viard, Josiane Warszawski

808  SLOW CD4/CD8 RATIO RECOVERY AMONG CHILDREN AND ADOLESCENTS DESPITE VIRAL SUPPRESSION
Win Min Han, Tanakorn Apornpong, Watsamon Jantarabenjakul, Sivaporn Gatechompol, Sasivimol Uboylam, Stephen J. Kerr, Anchalee Avihingsanon, Kiat Ruxrungtham, Praphan Phanunphak, Thanyawee Puthanakit

809  UNDERSTANDING THE IMPACT OF ART INTERRUPTION ON THYMIC OUTPUT AND TCR REPERTOIRE
Katrine S. Sandgaard, Teresa Attenborough, Ben Margets, Stuart Adams, Deena Gibbons, Mette Holm, Athina S. Gkazi, Nigel Klein

Poster P-Q5 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH WITH HIV
Poster Hall - 4EF 2:30 PM - 4:00 PM

810  HIGH CMV DNAEMIA ASSOCIATES WITH STUNTING AND CHRONIC LUNG DISEASE IN HIV+ CHILDREN
Louis-Marie Yindom, Victoria Simms, Edith D. Majonga, Grace McHugh, Ethel Davua, Tsitsi Bandason, Helene Vincon, Jamie Rylance, Shungu Munyati, Rashida Ferrand, Sarah Rowland-Jones
Poster Sessions

811  IMMUNE IMBALANCE IS ASSOCIATED WITH IMPAIRED SPIROMETRY IN PERINATALLY ACQUIRED HIV
Engi F. Attia, Denise Jacobson, Wendy Yu, Elizabeth Maleche Obimbo, Paige L. Williams, Claudia Crowell, Michael H. Chung, Kristina Crothers, William T. Shearer, for the Pediatric HIV/AIDS Cohort Study

812  ENDOTHELIAL DYSFUNCTION IN SOUTH AFRICAN YOUTH WITH PERINATALLY ACQUIRED HIV ON ART
Sana Mahtab, Heather Zar, Susan J. Joubert, Nana Akua Asafu-Agyei, Norme J. Luff, Nomawethu Jele, Liesl Zülke, Landon Myer, Jennifer Jao

813  EARLY CARDIAC DYSFUNCTION IN HIV-INFECTED CHILDREN AND ADOLESCENTS IN WESTERN KENYA
Andrew W. McCrory, Winstone Nyandiko, Ibrahim Daud, Elcy Birgen, Joseph Kisslo, Piers Barker, Nathan Thielman, Gerald Bloomfield

814  WEIGHT IS AN INDEPENDENT RISK FACTOR IN INSULIN RESISTANCE IN HIV+ UGANDAN CHILDREN
Sahera Dirajlal-Fargo, Lukasz Weiner, Lingpeng Shan, Manjusha Kulkarni, Christine Karungi, Abdul Sattar, Nicholas Funderburg, Grace Mirembe, Cissy Kityo, Victor Musilime, Grace A. McComsey

815  GROWTH AND METABOLIC CHANGES AFTER ANTIRETROVIRAL START IN SOUTH AFRICAN CHILDREN

816  LOWER BONE STRENGTH BY PERIPHERAL QUANTITATIVE CT IN CHILDREN LIVING WITH HIV
Stephanie Shiau, Michael T. Yin, Renate Strehlau, Megan Burke, Faeezah Patel, Louise Kuhn, Ashraf Coovadia, Shane Norris, Stephen M. Arpadi, for the CHANGES Bone Study Team

817  HIV AND CANCER RISK IN ADOLESCENTS AND YOUNG ADULTS IN SOUTH AFRICA, 2004-2014
Tafadzwa G. Dhokotera, Julia Bohlius, Adrian Spoerri, Matthias Egger, Jabulani Ncayiyana, Gita Naidu, Victor Olago, Elvira Singh, Mazvita Sengayi

818  CANCER INCIDENCE IN YOUNG PEOPLE WITH HIV: PRIVACY-PRESERVING RECORD-LINKAGE STUDY
Eliane Rohner, Lina Bartels, Victor Olago, Wenlong C. Chen, Elvira Singh, Adrian Spoerri, Matthias Egger, Mazvita Sengayi, Julia Bohlius

Poster P-R1 DESCRIPTIVE EPIDEMIOLOGY AND BEHAVIOR
Poster Hall - 4EF 2:30 PM - 4:00 PM

831  RECENT HIV INFECTION SURVEILLANCE AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN MALAWI
Danielle Payne, Andrew D. Maher, Kathryn Curran, Elfriede Agymang, Evelyn Kim, Franklin Kilelmba, Trudy Dobbs, Innocent Zungu, Bharat S. Parekh, Suzie Welty, Dalitso Midiani, Andrew F. Auld, Rose Nyirenda, George Rutherford, Andrea A. Kim

832  HIV SEROSTATUS CONVERSION AMONG REPEATE-TESTING FEMALE SEX WORKERS IN TANZANIA
Amasha H. Mwanamsangu, Gaspar Mbita, Kelly Curran, Amani Shao, Raymond Bândio, Nelson Jonas, Friedrich Conrad, Peris Drasa, Erick Mlanga, Jeremie Zoungrena, Maligo Katebalila, Marya Plotkin, Albert Komba, Caterina Casalini
833 QUANTIFYING TRANSMISSIONS FROM AGE GROUPS IN SIMULATIONS OF HPTN071 (POPART) TRIAL
William Probert, Rafael Sauter, Michael Pickles, Anne Cori, Justin Bwalya, Sian Floyd, Nombeth Mandela, Kwame Shanaube, Blia Yang, Helen Ayles, Peter Bock, Deborah J. Donnell, Sarah Fidler, Richard Hayes, Christophe Fraser

834 COMMUNITY PREVALENCE OF VIREMIA: A NEW STANDARD FOR BIO-BEHAVIORAL SURVEYS
Sunil S. Solomon, Gregory M. Lucas, Allison M. McFall, Aylur K. Srikrishnan, Oliver Laeyendecker, Muniratnam S. Kumar, Syed Iqbal, Shaminagam Saravanan, Nandagopal Paneerselvam, Pachamuthu Balakrishnan, David D. Celentano, Shruti H. Mehta

835 HIV EPIDEMIC IN A BRIDGE POPULATION IN UKRAINE CALLS FOR NEW PREVENTION STRATEGIES
Marina Kornilova, Yana Sazonova

836 LOW CROSS-SECTIONAL HIV-1 INCIDENCE AT END OF BOTSWANA “YASE” PREVENTION STUDY
Sikhulile Moyo, Simani Gaseitsiwe, Corretah Boleo, Julia Huesa, Kenanao P. Kotokwe, Molly Pretorius Holme, Tendani Gaolathe, Kara Bennett, Jean Leidner, Kathleen Wirth, Janet Moore, Shahin Lockman, Joseph Makhema, Max Essex, Vlad Novitsky

837 BEHAVIORAL AND SEROLOGICAL FINDINGS OF THE KADUNA STATE AIDS INDICATOR SURVEY, 2017
Adebobola T. Bashorun, Aishat B. Usman, Mark Anthony, Taiwo Ibinaiyi, Abisola Oladimeji, Titi Olugbade, Mustapha Jamda, Patrick Nguku

838 CANGO LYEC (HEALING THE ELEPHANT): HIV INCIDENCE IN POSTCONFLICT NORTHERN UGANDA
Samuel S. Malamba, David S. Zamar, D. Martin Ogwang, Anton Friedman, Kate Jongbloed, Herbert Muyinda, ACHILLES KATAMBA, Nelson Sewankambo, Martin T. Schechter, Patricia M. Spittal

839 HIV, COINFECTIONS, AND RISK BURDEN AMONG PRISONERS AND STAFF: UGANDA NATIONAL SURVEY
Lisa A. Mills, Samuel Sendagala, James Kisambu, Rose N. Bosa, Patrick Omiel Okecho, Bruce J. Kirenga, Samuel Wasike, Robert Downing, Brad Bartholow, Mary N. Kaddu, Lisa J. Nelson, Shona Dalal

840 QUANTIFYING DELAY IN HIV PROGRAMME ACCESS AMONG YOUNG FEMALE SEX WORKERS IN KENYA
Huiting Ma, Marissa Becker, Parinita Bhattacharjee, Helgar Musyoki, Peter B. Gichangi, Robert Lorway, Linwei Wang, Shajy Isac, James F. Blanchard, Sharmistha Mishra

841 LITTLE OR NO OVERLAP OF SEXUAL NETWORKS OF TRANSGENDER WOMEN AND MSM IN LIMA, PERU
Jessica E. Long, Hugo Sanchez, Dania Calderon Garcia, Leyla Huerta Castillo, Javier R. Lama, Ann Duerr

842 FACTORS ASSOCIATED WITH HIV SEROPOSITIVITY AMONG HIGH-RISK MEN IN TANZANIA
Maneno Luponya, Caterina Casalini, Ankita Mehta, Peter Nyanda, Yeronimo Mlawa, Neema Makyao, Angela Ramhadani, Erick Malanga, Jason Reed, Maligo Katebalila, Marya Plotkin, Albert Komba, Jeremie Zoungrana, Kelly Curran
843 HIV EPIDEMIC POTENTIAL IN SEXUAL NETWORKS OF MSM IN SAN FRANCISCO AND ATLANTA
Emeli J. Anderson, Kevin M. Weiss, Pragati Prasad, Samuel Jenness

844 TRENDS IN HIV RISK BEHAVIORS OF HISPANIC MEN WHO HAVE SEX WITH MEN IN 19 US CITIES
Lindsay Trujillo, Monica Adams, Amanda Smith, Cyprian Wejnert, for the NHBS Study Group

845 SUBSTANTIAL UNMET NEED FOR PrEP AMONG MSM IN HANOI

846 RISK FACTORS FOR HIV INFECTION AMONG MSM IN THE ANRS IPERGAY PrEP TRIAL
Marine Pillet, Eric Cua, Catherine Capitant, François Raffi, Christian Chidiac, Julie Chas, Cécile Tremblay, Armelle Pasquet, Brigitte Guillot, Bruno Spire, Constance Delaugerre, Laurence Meyer, Guillemette Antoni, Jean-Michel Molina, for the ANRS IPERGAY Study Group

847 IMPROVED DETECTION OF ACUTE HIV IN THE UNITED STATES, 2012-2017
Laurie Linley, Richard M. Selik, Kevin P. Delaney, Alexandra M. Oster

848 DIAGNOSIS OF HIV INFECTION WITHIN 1 YEAR OF ACQUISITION, US, 2010-2016
Alexandra Balaji, Azfar Siddiqi, Anna S. Johnson, Angela L. Hernandez, Baohua Wu, Riuguang Song

849 INCIDENT STIs AMONG PLWH IN WASHINGTON, DC: MEASURING HIV TRANSMISSION RISK
Hana Akselrod, Alessandra Secco, Jose Lucar, Matthew E. Levy, Morgan Byrne, Anne K. Monroe, Michael A. Horberg, Amanda D. Castel, Rupali K. Doshi, Heather Rivasplata, Leah Squires, David Parenti, Debra A. Benator, for the DC Cohort Executive Committee

850 INFLUENCE OF HIV AND PrEP USE ON HIGH STI PREVALENCES IN MSM IN GERMANY, 2018
Klaus Jansen, Gyde Steffen, Ann-Kathrin Ziesenis, Viviane Bremer, Carsten Tiemann, for the MSM Screening Study research group

851 WHY STIs ARE INCREASING IN AT-RISK BOSTON MEN: MORE SCREENING PLUS
Kenneth H. Mayer, Kevin Maloney, Kenneth Levine, Dana King, Chris Grasso, Douglas Krakover, Eli Rosenberg

852 THE BURDEN OF HIV AND OTHER STIs AMONG TRANSGENDER PERSONS IN NAIROBI, KENYA
Adrian D. Smith, Rhoda Kabuti, Erastus Irungu, Chirsop Nyamweya, Elizabeth Fearon, Peter Weatherburn, Adam Bourne, Joshua Kimani

853 NEISSERIA GONORRHEA INCIDENCE AND TESTING IN THE HIV OUTPATIENT STUDY, 2007-2017
Jun Li, Carl Armon, Frank J. Palella, Richard Novak, Douglas Ward, Stacey Purinton, Marcus Durham, Kate Buchacz
Poster Sessions

854  ANTIBIOTIC USE AND VAGINAL DISCHARGE SYNDROME BY HIV STATUS IN PREGNANCY: BOTSWANA
Modiegi D. Diseko, Sonya Davey, Rebecca Zash, Judith Mabuta, Gloria K. Mayondi, Shahin Lockman, Rebecca Luckett, Chelsea Morroni, Mompati O. Mmalane, Joseph Makhma, Goabaone Mogomotsi, Eldah N. Dintwa, Tumalano Sekoto, Ngozana Seonyatseng, Roger L. Shapiro

855  A CASE-CONTROL STUDY OF OCULAR SYPHILIS IN BRITISH COLUMBIA, CANADA, 2010-2018
Hasan Hamze, Venessa Ryan, Emma Cumming, Christine Lukac, Jason Wong, Troy Grennan

Poster P-S1 HIV AND STI TESTING STRATEGIES
Poster Hall - 4EF 2:30 PM - 4:00 PM

922  HIV-1/2 DIFFERENTIATION IN THE US HIV TESTING ALGORITHM: HIGH BURDEN, LOW YIELD
Anne H. Peruski, Laura Woselowski, Kevin P. Delaney, Pollyanna R. Chavez, S. Michele Owen, Timothy Granade, Vickie Sullivan, William M. Switzer, John T. Brooks, M. Patricia Joyce

923  HIV SEROLOGICALLY INDETERMINATE INDIVIDUALS: FUTURE HIV STATUS AND RISK FACTORS
George Mwinnyaa, Mary K. Grabowski, Ronald H. Gray, Maria Wawer, Larry W. Chang, Joseph Ssekananyu, Joseph Kagaayi, Godfrey Kigozi, Sarah Kalibbala, Ronald M. Galiwango, Anthony Nyabinabo, David Serwadda, Thomas C. Quinn, Steven J. Reynolds, Oliver Laeyendecker

924  ROUTINE TESTING OF NONPATIENTS INCREASES HIV DIAGNOSIS IN WESTERN KENYA
Rachael Joseph, Paul K. Musingila, Fredrick Miruka, Stella Wanjohi, Caroline O. Dande, Polycarp Musee, Dickens Onyango, Gordon Okomo, Samuel Omondi, Emily C. Zielsinski-Gutierrez, Lucy Ng’ang’a, Hellen Muttut, Kevin M. De Cock

925  A NEW PREDICTION MODEL FOR CHLAMYDIA AND GONORRHEA SCREENING IN WOMEN WITH HIV
Jodie Dionne-Odom, Dustin M. Long, Andrew Westfall, Barbara Van Der Pol, Michael J. Mugavero, Sonia Napravnik, Heidi M. Crane, Mari Kitahata, Richard D. Moore, Benigno Rodriguez, Maile Y. Karris, Elvin Geng, Kenneth H. Mayer, Jeannine M. Marrazzo

Poster P-S2 STRATEGIES FOR HIV TESTING PARTNERS AND KEY POPULATIONS
Poster Hall - 4EF 2:30 PM - 4:00 PM

926  SELF-TESTS FOR AT-HOME PARTNER TESTING ARE ACCEPTABLE & UTILIZED AMONG PREGNANT WOMEN
Jillian Pintye, John Kinuthia, Felix Abuna, Nancy M. Ngumbau, Salphine A. Wattoy, Mary M. Marwa, Anjuli D. Wagner, Julia C. Dettinger, Laurent Gómez, Ben O. Odhiambo, Jared Baeten, Grace John-Stewart, for the PrEP Implementation for Mothers in Antenatal Care (PrIMA) Study

927  MALE PARTNER LINKAGE TO CLINIC STI-HIV SERVICES AFTER COUPLE EDUCATION & HIV TESTING
Jennifer Mark, Alison C. Roxby, John Kinuthia, Alfred Osoti, Daisy Krakowiak, Monisha Sharma, Quy Ton, Barbra Richardson, Carey Farquhar

928  OUTCOME AND COST OF 3 METHODS FOR INCREASING MALE PARTNER TESTING IN SOUTH AFRICA
Amy M. Medley, Arielle Lasry, Nompumelo Khanyile, Tonica Maphanga, Mothoemang Tlotleng, Carlos Toledo, Cila Kabongo, John Tumbo
929 INDEX CASE FINDING A STRATEGY FOR CLOSING THE GAP FOR HIV DIAGNOSIS IN TANZANIA
Peris L. Urasa, Angela Ramhadani, Neema Makyao, Leonard Subi

930 HIGH ACCEPTABILITY AND HIV YIELD AMONG PARTNERS OF KEY POPULATIONS IN CENTRAL AMERICA
Erickson Noj-Lara, Ricardo Mendizabal-Burastero, Nasim Farach, Carlos Vargas, Mayte Paredes, Rene Gutierrez, Renato Santa-Luce, Sanny Northbrook, for the Central America partner notification group

931 HIV SELF-TEST UPTAKE, YIELD, AND LINKAGE EXPERIENCES AMONG KEY POPULATIONS IN LESOTHO
Betty B. Tukey, Kgotso Maile, Charles Chasela, Chapelo Maotoe, Ian Sanne, Sibongile Zungu, Thembisisle Xulu, for the EQUIP Health

932 HIV TESTING RATES AMONG YOUTH AND ADOLESCENTS IN ZAMBIA: WILL HIV SELF-TESTING HELP?
Zumbe Sibale, Roma Chilengi, Charles Chasela, Lawrence Mwananyanda, Alumwi Lungu, Shida Nyimbiri, Pedro Pisa, Precious Robinson, Crispin Moyo, Ntombi Sigwebela, Ian Sanne, Thembisisle Xulu, for the EQUIP Health

Poster P-S3 HIV TESTING IN MSM
Poster Hall - 4EF 2:30 PM - 4:00 PM

933 SUSTAINED INCREASES IN HIV TESTING IN MSM WITH HIVST: A RANDOMISED CONTROLLED TRIAL
Muhammad S. Jamil, Garrett Prestage, Kirsty Smith, Rebecca J. Guy, for the FORTH Investigator Group

934 EFFECTIVENESS OF DISTRIBUTING HIV SELF-TEST KITS THROUGH MSM PEER NETWORKS IN UGANDA
Stephen Okoboi, Lazarus Oucul, Barbara Castelnuovo, Collins Agaba, Mastula Nanfuka, Andrew Kambugu, Rachel King

935 PREFERENCES FOR HIV SELF-TESTING IN SUBPOPULATIONS OF AUSTRALIAN GAY AND BISEXUAL MEN
Jason Ong, Richard De Abreu Lorenzo, Deborah Street, Muhammad S. Jamil, Kirsty Smith, Fern Terris-Prestholt, Rebecca J. Guy, for the PUSH Study Group

936 WILLINGNESS TO USE HIV SELF-TESTING AMONG MSM FROM BRAZIL, MEXICO, AND PERU
Thiago S. Torres, Kelika A. Konda, E. Hamid Vega-Ramirez, Oliver A. Elorrega-Reyes, Dulce Diaz-Sosa, Cristina Pimenta, Brenda Hoagland, Hugo López-Gatell, Rebeca Robles-García, Steven D. Diaz, Beatrix Grinsztejn, Carlos Carceres, Valdilea Veloso, for the ImPrEP Study Group

937 SEXUAL RISK AND HIV TESTING DISCONNECT IN MSM RECRUITED TO AN HIV SELF-TESTING TRIAL
Alison Rodger, David Dunn, Andrew N. Phillips, Leanne McCabe, Peter Weatherburn, Fiona Lampe, T Charles Witzel, Fiona Burns, Denise Ward, Roger Pebody, Roy Trevelion, Yolanda Collaco-Moraes, Sheena McCormack

Poster P-T1 OUTCOMES AMONG PrEP USERS
Poster Hall - 4EF 2:30 PM - 4:00 PM

944 INCIDENCE OF HIV IN A NATIONAL COHORT RECEIVING PREEXPOSURE PROPHYLAXIS
Puja Van Epps, Brigid M. Wilson, Will Garner, Lauren Beste, Marissa M. Maier, Michael Ohl
945  HIV-1 INCIDENCE AND RISK FACTORS FOR ACQUISITION AMONG KENYAN MSM WITH ACCESS TO PrEP  
Elizabeth Wahome, Susan M. Graham, Alexander N. Thiong’o, Khamisi Mohamed, Tony H. Oduor, Evans Gichuru, John Mwambi, Eduard Sanders

946  DOSE-DEPENDENT DECLINE IN BONE MINERAL DENSITY BY LONG-TERM TFV EXPOSURE IN IPREX-OLE  
Matthew A. Spinelli, David Glidden, Peter L. Anderson, Valdilea Veloso, Vanessa McMah, Susan P. Buchbinder, Robert M. Grant, Monica Gandhi, for the iPrEx OLE Study Team

947  LOW URINE TFV BY A NOVEL IMMUNOASSAY IS ASSOCIATED WITH HIV SEROCONVERSION ON PrEP  
Matthew A. Spinelli, David Glidden, Warren Rodrigues, Guohong Wang, Michael Vincent, Catherine A. Koss, Hideaki Okochi, Karen Kuncze, Megha Mehrrotra, Patricia Defechereux, Susan P. Buchbinder, Robert M. Grant, Monica Gandhi, for the iPrEx OLE Study Team

948  NO EVIDENCE OF SEXUAL RISK COMPENSATION AMONG HIV SERODISCORDANT COUPLES ON PrEP  
Katrina F. Ortblad, Randy Stalter, Elizabeth A. Bukusi, Kenneth Ngure, Andrew Mujugira, Connie L. Celum, Jared Baeten, Renee Heffron

949  Y-CHROMOSOME DETECTION & CONDOMLESS SEX IN SEX WORKERS IN THE SENEGAL PrEP PROJECT  
Geoffrey S. Gottlieb, Stephen E. Hawes, Mame D. Bousso Bao, Anna J. Ndiaye, Daouda Gueye, Dana Raugi, Moustapha Mane, Aminata Mboup, Ousmane Diouf, Carlos Suarez, Fatima Jones, Josie Presley, Coumba Toure Kane, Moussa Sarr, Souleymane Mboup

950  RISK COMPENSATION FOLLOWING PrEP DISCONTINUATION AMONG HIV-SERODISCORDANT COUPLES  
Randy Stalter, Kenneth K. Mugwanya, Jared Baeten, Katherine Thomas, Lara Kidoguchi, Connie L. Celum, Andrew Mujugira, Kenneth Ngure, Elizabeth A. Bukusi, Renee Heffron, for the Partners Demonstration Project Team

951  VOLUNTARY MEDICAL MALE CIRCUMCISION IN SWAZILAND: ACHIEVEMENTS AND GAPS  

952  SHIKAMANA INTERVENTION SIGNIFICANTLY REDUCES HIV INCIDENCE AMONG FSW IN TANZANIA  
Deanna Kerrigan, Jessie Mbwambo, Samuel Likindikoki, Wendy Davis, S.W. Beckham, Andrea Mantsios, Anna M. Leddy, Noya Galai

953  INTERDISCIPLINARY INTERVENTION FOR HOSPITALIZED PWID MAY INCREASE MAT USE  
Ellen F. Eaton, Andrew Westfall, Eddie A. Mathews, Cayce Paddock, Peter Lane, Michael Saag, Michael J. Mugavero, Karen Cropsey, Rachael A. Lee
### Poster Sessions

#### Poster P-U1 HIV AND VAGINAL MICROBIOME

<table>
<thead>
<tr>
<th>Poster P-U1</th>
<th>HIV AND VAGINAL MICROBIOME</th>
<th>2:30 PM - 4:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td>998</td>
<td>IMPACT OF A CONTRACEPTIVE RING ON VAGINAL BACTERIA ASSOCIATED WITH HIV ACQUISITION</td>
<td>Jeanne M. Marrazzo, Sujatha Srinivasan, Elizabeth M. Irungu, Katherine Thomas, Nelly R. Mugo, Peterson Mwaniki, Catherine Kiptinness, Kenneth Ngure, Kate Heller, Meighan Krows, Kristina Garcia, Steven Gakuo, Tina L. Fiedler, David N. Fredricks</td>
</tr>
<tr>
<td>1000</td>
<td>CHANGES IN VAGINAL MICROBIOTA AMONG HIV-INFECTED AFRICAN WOMEN INITIATING DMPA</td>
<td>Bridget M. Whitney, Ken Tapia, Sujatha Srinivasan, Eric M. Muriuki, Bhavna Chohan, Jacqueline Wallis, Congzhou Liu, R. Scott McClelland, Noah G. Hoffman, David N. Fredricks, Alison C. Roxby</td>
</tr>
<tr>
<td>1001</td>
<td>MENOPAUSE IMPACTS THE VAGINAL MICROBIOME AND IMMUNE MEDIATORS IN WOMEN WITH HIV</td>
<td>Kerry Murphy, Marla J. Keller, Kathryn Anastos, Shada Sinclair, J. C. Devlin, Qiuhu Shi, Donald R. Hoover, Brian Starkman, Jaime McGillick, Caroline Mullis, Howard Minkoff, Maria Gloria Dominguez-Bello, Betsy Herold</td>
</tr>
</tbody>
</table>

#### Poster P-U2 FOREVER YOUNG: STI AND HIV COINFECTION

<table>
<thead>
<tr>
<th>Poster P-U2</th>
<th>FOREVER YOUNG: STI AND HIV COINFECTION</th>
<th>2:30 PM - 4:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1002</td>
<td>PREVALENCE OF CHLAMYDIA AND GONORRHEA IN HIV-POSITIVE ADOLESCENTS IN ESWATINI</td>
<td>Caitlyn L. Jasumback, Sarah Perry, Martha Matsenjwa, Zandile T. Masangane, Mpumelelo Mavimbela, Anna Mandalakas, Alexander Kay</td>
</tr>
<tr>
<td>1003</td>
<td>PREVALENCE AND DETERMINANTS OF STI IN HIV+ AND HIV-PREGNANT SOUTH AFRICAN WOMEN</td>
<td>Dvora Joseph Davey, Dorothy Nyemba, David DiTullio, Yolanda Gomba, Jeffrey D. Klausner, Landon Myer</td>
</tr>
<tr>
<td>1004</td>
<td>INCIDENCE OF HSV-2 AND HIV IN A COHORT OF KENYAN ADOLESCENT GIRLS</td>
<td>Alison C. Roxby, Amalia Magaret, Stacy Selke, Murugi Micheni, Lynda M. Oluoch, Tiffany Yuh, Bhavna Chohan, Catherine Kiptinness, Kenneth Ngure, Nelly R. Mugo, Anna Wald</td>
</tr>
<tr>
<td>1005</td>
<td>PARTNER NOTIFICATION: INCREASING EFFECTIVENESS WITH MODERN COMMUNICATION TECHNOLOGY</td>
<td>Amelia S. Oliveira, Julia Bilinska, Hamish Mohammed, Jay Jarman, John Were, Anatole Menon-Johansson, Lisa Hamzah</td>
</tr>
</tbody>
</table>

#### Poster P-U3 SOMETHING’S MISSING; CONTRACEPTION AND HIV

<table>
<thead>
<tr>
<th>Poster P-U3</th>
<th>SOMETHING’S MISSING; CONTRACEPTION AND HIV</th>
<th>2:30 PM - 4:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1006</td>
<td>INCIDENCE AND CORRELATES OF UNINTENDED PREGNANCY IN HIV-POSITIVE KENYAN SEX WORKERS</td>
<td>Erica Lokken, Barbra A. Richardson, George Wanjie, Katherine Wilson, Walter Jaoko, John Kinuthia, R. Scott McClelland</td>
</tr>
</tbody>
</table>
1007  DRIVERS OF UNPLANNED PREGNANCY AND UNMET NEED FOR CONTRACEPTION IN SOUTH AFRICA
Witness Chirinda, Debra Jackson, Vundli Ramokolo, Yages Singh, Trisha Ramraj, Duduzile Nsibande, Kondwani Ng’oma, Sanjana Bhardwaj, Mireille Cheyip, Mary Magashoa, Carl Lombard, Ameena Goga

1008  UPTAKE OF POSTPARTUM CONTRACEPTION IN BOTSWANA, A HIGH BURDEN HIV SETTING
Kathleen M. Powis, Shan Sun, Keolebogile N. Mmasa, Gosego Masasa, Samuel W. Kgole, Justine Legbedze, Joseph Makhema, Lesego Mokgany, Elaine J. Abrams, Lynn M. Yee, Lisa B. Haddad, Rebecca Lucket, Jennifer Jao

1009  IMPACT OF INTEGRATION OF FAMILY PLANNING INTO HIV TREATMENT PROGRAMS IN CAMEROON

1010  PHARMACOKINETIC AND PHARMACOGENETIC ASSESSMENT OF ART AND CONTRACEPTIVE IMPLANTS
Randy Stalter, Jared Baeten, Kimberly K. Scarsi, Bani Tamraz, Katherine Thomas, David Erikson, Jairam Lingappa, Kavita Nanda, Athena Kourtis, Rena Patel, for the Partners PrEP Study Team

Poster Sessions
Poster Hall - 4EF 2:30 PM - 4:00 PM

1026  ACCESS TO HIV CARE CORRELATES WITH DEPRESSION SEVERITY AND RATES OF VIRAL SUPPRESSION
Ann K. Avery, Mallika Lavakumar, Allison R. Webel, James Alsop, Doug Gunzler, Diana Gurley, Steven Lewis

1027  FACILITATED LINKAGE TO CARE FOLLOWING HOME-BASED HIV TESTING IN RURAL SOUTH AFRICA
Kathy Baisley, Janet Seeley, Mark J. Siedner, Olivier Koole, Philippa Matthews, Till Bärnighausen, Theresa Smit, Dickman Garea, Sphephelo Dlamini, Kobjis Herbst, H. Manisha N. Yapa, Collins C. Iwuju, Hae-Young Kim, Deenan Pillay, Maryam Shahnanes

1028  PROJECT CORECT: PRELIMINARY RESULTS OF DATA TO CARE WITH CT DPH AND HIV CLINICS
Merceditas Villanueva, Janet Miceli, Constance Carroll, Suzanne Speers, Lisa Nichols, Frederick Altice, Heidi Jenkins

1029  DEVELOPMENT OF AN EMR-BASED ALGORITHM TO IDENTIFY PATIENTS LOST TO HIV CARE
Jason Zucker, Jacek Slowikowski, Kenneth Rupert, Peter Gordon

1030  ARE THEY REALLY LOST? MULTI-CENTER TRACING STUDY IN ART PROGRAMS IN SOUTHERN AFRICA
Benedikt Christ, Kathrin Zürcher, Frédérique Chammartin, Josephine Muhairwe, Laura Jefferys, Janneke van Dijk, Kombatende Sikombe, Monique van Lettow, Cleophas Chimbetete, Sam J. Phiri, Matthias Egger, Marie Ballif

1031  HEALTH DEPARTMENT RANDOMIZED TRIAL TO RE-ENGAGE OUT-OF-CARE HIV INFECTED PERSONS
Robyn N. Fanfair, George Khalil, Nasima Camp, Kathleen Brady, Alfred DeMaria, Merceditas Villanueva, Lisa Randall, Heidi Jenkins, Crystal Lucas, Frederick Altice, Anthony Gerard, Nina Kishore, Tiffany Williams, Taraz Samandari, Paul J. Weidle
1032 PATTERNS AND PREDICTORS OF RETURN TO CARE AMONG DISENGAGED HIV PATIENTS IN ZAMBIA
Laura K. Beres, Ingrid Eshun-Wilson, Sandra Simbeza, Sheree Schwartz, Aaloke Mody, Kombatende Sikombe, Jake Pry, Paul Somwe, Carolyn Bolton Moore, Njekwa Mukamba, Steph Topp, Nancy Padian, Izukanji Sikazwe, Charles B. Holmes, Elvin Geng

1033 LONG-TERM OUTCOME IN HIV-1 INFECTED ADULTS WITH ADVANCED IMMUNODEFICIENCY
Guoqing Zhang, Kouakou Adade Aka Digbo Micheline, Peter A. Minchella, Kouadio Leonard Ya, Andre Tehe, Mireille Kalou, Karidia Diallo, Judith Hedje, Heather Alexander, Clement Zeh, G. Laissa Ouedraogo, Christiane Adje-Toure

Poster P-V5 COMORBID CONDITIONS
Poster Hall - 4EF  2:30 PM - 4:00 PM

1062 COMORBID CONDITIONS, VIRAL TRAJECTORIES, AND COORDINATED CARE IN LOS ANGELES COUNTY
Michael J. Li, Erica Su, Wendy H. Garland, Sona Oksuzyan, Robert E. Weiss, Uyen Kao, Sung-Jae Lee, Raphael J. Landovitz, Steven Shoptaw

1063 HIGH NCDs INCIDENCE AMONG PLHIV IN KENYA: LONGITUDINAL ANALYSIS OF TREATMENT OUTCOMES
Dunstan Achwoka, Anthony Waruru, Tai Ho Chen, Kenneth Masamaro, Evelyne Ngugi, Irene Mukui, Abraham Katana, Thomas Achia, Lucy Ng’ang’a, Kevin M. De Cock

1064 NONCOMMUNICABLE DISEASES AS REASONS FOR ADMISSION AMONG HIV-INFECTED ADULTS IN ZAMBIA
Belinda V. Chihota, Michael J. Vinikoor, Nyakulira Kandiwo, Lottie Hachaambwa, Elvin Geng, Charles B. Holmes, Edford Sinkala, Monika Roy

1065 PROJECTED GROWTH AND NEEDS OF AGING PLWH IN HRSA’S RYAN WHITE HIV/AIDS PROGRAM
Stacy Cohen, Pamela W. Klein, Marlene M. Matosky, Robert Mills, R. Chris Redwood, Laura W. Cheever

1066 CASCADES TO EVALUATE THE CERVICAL CANCER SCREENING PROGRAM IN A ZIMBABWEAN ART CLINIC
Katayoun Taghavi, Ardelle Mandiriri, Eliane Rohner, Tinei Shamu, Cleophas Chimbetete, Tsitsi M. Magure, Serra Asangbeh, Matthias Egger, Margaret Pascoe, Julia Bohlius

1067 EARLIER AGE OF ONSET AND HIGHER PREVALENCE OF COMORBIDITIES IN PEOPLE LIVING WITH HIV
Ni Gusti Ayu Nanditha, Martin St-Jean, Hiwot M. Tafessu, Michelle Lu, Kate Salters, Julio S. Montaner, Silvia Guillemin, Robert S. Hogg, Viviane D. Lima

1068 POOR DIABETES CONTROL IN HIV+ AND HIV- WOMEN: OPPORTUNITIES FOR INTERVENTION
Karla I. Galaviz, Jonathan Colasanti, Cyra Christina Mehta, Phyllis Tien, Adaora Adimora, Maria L. Alcaide, Marj de H. Cohen, Deborah Gustafson, Roksana Karim, Deborah Konkle-Parker, Daniel Merenstein, Anjali Sharma, Michael F. Schneider, Gina Wingood, Igho Ofotokun

1069 TOTAL AND CENTRAL OBESITY PREDICT COGNITIVE DECLINE: MULTICENTER AIDS COHORT STUDY
1070  EFFECT OF OBSTRUCTIVE LUNG DISEASE ON MORTALITY AMONG HIV+ PERSONS WHO INJECT DRUGS
Mariah M. Kalmin, M. Brad Drummond, Gregory D. Kirk, Shruti H. Mehta, Daniel Westreich

1071  SYNDemics AND RETENTION IN CARE AMONG WOMEN LIVING WITH HIV IN RIO DE JANEIRO, BRAZIL
Christine M. Zachek, Lara Coelho, Raquel B. De Boni, Jesse L. Clark, Rosa M. Domingues, Paula M. Luz, Ruth K. Friedman, Angela C. Vasconcelos de Andrade, Valdilea Veloso, Jordan E. Lake, Beatriz Grinsztejn

1072  PROSTATE CANCER SCREENING AND INCIDENCE IN AGING VETERANS INFECTED WITH HIV
Michael S. Leapman, Lesley S. Park, Kimberly Stone, Cynthia L. Gibert, Matthew B. Goetz, Roger Bedimo, Roxanne Wadia, Maria Rodriguez-Barradas, Fatma Shebl, Amy C. Justice, Sheldon T. Brown, Kristina Crothers, Keith M. Sigel
**Poster P-A3 MECHANISTIC VIROLOGY**
**Poster Hall - 4EF**
**2:30 PM - 4:00 PM**

176 **FLOW VIROMETRY REVEALS PATIENT VARIATIONS IN HIV PROTEASE THAT CORRELATE WITH FITNESS**
Michał Bonar, Caroline Tabler, John Tilton

177 **THE HIV-1 ANTISENSE PROTEIN ASP IS A NOVEL STRUCTURAL PROTEIN OF THE VIRAL ENVELOPE**
Yvonne Affram, Juan C. Zapata, Marzena Pazgier, Maria Iglesias-Ussel, Krishanu Ray, Olga Latinovic, Fabio Romerio

178 **UNPAIRED GUANOSINES IN THE HIV LEADER RNA DIRECT HIV GENOMIC RNA PACKAGING**
Chijioke Umunnakwe, Sheikh A. Rahman, Alice Duchon, Yang Liu, Olga A. Nikolaitchik, Jianbo Chen, Wei-Shau Hu, Vinay K. Pathak

179 **DETECTION AND SEQUENCING OF ASP TRANSCRIPTS DURING EARLY HIV-1 INFECTION**
Antonio Mancarella, Brian T. Foley, Giampietro Corradin, Giuseppe Pantaleo, Cecilia Graziosi

180 **IDENTIFICATION OF HIV-1 ENV MUTATIONS THAT ENHANCE ENTRY INTO MACAQUE CELLS**
Jeremy I. Roop, Noah R. Cassidy, Jesse Bloom, Julie M. Overbaugh

**Poster P-A4 HOST-VIRUS INTERACTIONS**
**Poster Hall - 4EF**
**2:30 PM - 4:00 PM**

183 **HIV PROVIRAL TRANSCRIPTION RAPIDLY UPREGULATES BCL3, BIRC2, AND BIRC3 TRANSCRIPTION**
Joseph P. Casazza, Quang N. Nguyen, David R. Ambrozak, Christine Grech, Jianfei Hu, Sam Darko, Amy Ransier, Farida Laboune, Daniel Douek, Richard A. Koup

184 **CHARACTERIZATION OF THE EPITRANSCRIPTOMIC LANDSCAPE OF HIV-INFECTED CELLS**
Sara Cristinelli, Angela Ciuffi

185 LB **AN HIV E-MAP REVEALS GENETIC INTERACTIONS MEDIATING HIV INFECTION**
David E. Gordon, Ariane Watson, Assen Roguey, Nevan J. Krogan

186 **ELUCIDATING THE ROLE OF THE PPIP MOTIF IN HIV-1 CAPSID IN POSTENTRY EVENTS**

187 **SINGLE-CELL ANALYSIS REVEALS P2X-DEPENDENT HIV-STIMULATED CALCIUM SIGNALING**
221  HIV INFECTION ALTERS DYNAMIC MACROPHAGE: T-CELL INTERACTIONS TO PROMOTE VIRAL SPREAD
Paul Gabriel C. Lopez, Wan Koh, Ryan Hnatiuk, Thomas Murooka

222  THE ROLE OF MIGRATORY DENDRITIC CELLS IN ESTABLISHING HIV DISSEMINATION
Wan Koh, Paul Gabriel C. Lopez, Ryan Hnatiuk, Umar P. Mohammed, Ajibola Oluwaseun, Thomas Murooka

223  CHARACTERIZATION OF SHIV IMMUNOPATHOGENESIS IN RHESUS MACAQUES
Jennifer A. Manuzak, Ernesto Coronado, Tiffany Hensley-McBain, Charlene Miller, Courtney Broedlow, George Shaw, Katharine J. Bar, Nichole Klett

224  PLASMA CXCL13 AS A MARKER OF HIV DISEASE PROGRESSION AND SYSTEMIC IMMUNE ACTIVATION
Rayoun Ramendra, Vikram Mehraj, Stéphane Isnard, Bertrand Lebouc'h, Cecilia Costiniuk, Rejane Thomas, Jason Szabo, Jean-Guy Baril, Benoit Trottier, Pierre Coté, Roger LeBlanc, Cécile Tremblay, Jean-Pierre Routy, for the Montreal Primary HIV-infection Study Group and Canadian HIV and aging cohort

225  MODULATION AND PATHOGENESIS OF HIV-1 X4 EVOLUTION IN DISEASE PROGRESSION
Li Yin, Wilton B. Williams, Amanda C. Lowe, Kai-Fen Chang, John W. Sleasman, Maureen Goodenow

226  HIV+ TO HIV+ KIDNEY TRANSPLANT: TRACKING DONOR VIRUS IN RECIPIENT URINE AND BLOOD
Maria Blasi, Hannah Stadtler, Jerry Chang, Marion Hemmersbach Miller, Feng Gao, Cameron R. Wolfe, Mary Klotman

227  GUT MICROBES DRIVE EXPANSION AND PREFERENTIAL HIV INFECTION OF GUT CD4 CTL EX VIVO
Stephanie Dillon, Sabrina Nesladek, Allison J. Christians, Christine Purba, Kejun Guo, Martin McCarter, Mario Santiago, Cara Wilson

228  MODULATION OF GUT MICROBIOTA IMPROVES MUCOSAL PERMEABILITY IN HIV+ PATIENTS
Claudia Pinacchio, Luca Laghi, Giacomo Rossi, Eugenio Nelson Cavallari, Letizia Santinelli, Giuseppe P. Innocenti, Paolo Vassalini, Giancarlo Ceccarelli, Carolina Scagnolari, Gabriella d’Ettore, Vincenzo Vullo

229  RECTAL MICROBIOME ALTERATIONS ASSOCIATED WITH TDF/FTC FOR PREEXPOSURE PROPHYLAXIS
Jennifer A. Fulcher, Fan Li, Ryan Cook, Sarah Zabih, Cora Woodward, Alexander Louie, Hideaki Okochi, Nicole Tobin, Monica Gandhi, Steven Shoptaw, Pamina Gorbach, Grace M. Aldrovandi

230  JOINT EFFECTS OF HIV AND OBESITY ON THE MICROBIOME OF YOUNG MEN WHO HAVE SEX WITH MEN
Ryan Cook, Jennifer A. Fulcher, Nicole Tobin, Fan Li, David Lee, Marjan Javanbakht, Ron Brookmeyer, Steven Shoptaw, Robert Bolan, Cora Woodward, Sarah Zabih, Grace M. Aldrovandi, Pamina Gorbach
231 EFFECTS OF LACTOFERRIN ON IMMUNE ACTIVATION AND MICROBIOME AMONG HIV+ INDIVIDUALS
Ornella Sortino, Katherine Huppler HullsieK, Elizabeth Richards, Adam Rupert, Andrea Schminke, Namo Tetekpor, Mariam Quinones, Rachel Prosser, Timothy Schacker, Irini Sereti, Jason V. Baker

232 COTRIMOXAZOLE MODULATES IMMUNE CELL ACTIVATION & THE GUT MICROBIOTA IN HIV INFECTION

233 DARUNAVIR/RTONAVIR THERAPY CONTRIBUTES TO INTESTINAL DYSFUNCTION IN HEALTHY MACAQUES
Alexandra Ortiz, Jacob Flynn, Sarah DiNapoli, Jason Brenchley

Poster P-B6 HIV AND THE REPRODUCTIVE TRACT
Poster Hall - 4EF 2:30 PM - 4:00 PM

234 THE MICROBIOME MAY MODIFY HIV INFECTION RISK ASSOCIATED WITH HORMONAL CONTRACEPTIVES
Laura Noël-Romas, Michelle Perner, Ralfiwe Molatlhegi, Sarah Mutch, Kenzie Birse, Renee Heffron, Lyle McKinnon, Adam Burgener

235 ROLE OF FREM1 IN PRO-INFLAMMATORY RESPONSES DURING VAGINAL HIV/SIV INFECTION
Robert W. Omange, Annelie Tjernlund, Ma Luo, Joshua Kimani, Makobu Kimani, Kristina Brolden, Qingsheng Li, Francis Plummer, Zhe Yuan, Xin Y. Yuan, Mohammad Kashem, Hongzhao Li, Guobin Kang, Lewis R. Liu, Ben Liang

236 CERVICOVAGINAL MICROBIAL STRAINS ARE ASSOCIATED WITH DISTINCT IMMUNOPHENOTYPES
Matthew R. Hayward, Seth M. Bloom, Nomfuneko A. Mafunda, Jiawu Xu, Brittany A. Bowman, Christina Gosmann, Bjorn Corleis, Mara Farcasanu, Justin K. Rice, Curtis Huttenhower, Caroline Mitchell, Douglas Kwon

237 GENITAL AND SYSTEMIC INFLAMMATION ASSOCIATED WITH FACTORS THAT MAY ALTER HIV RISK

238 CHLAMYDIA AND CERVICOVAGINAL MICROBIOTA MODULATE GENITAL-TRACT CD4+ T-CELL SUBSETS
Seth M. Bloom, Nondumiso N. Xulu, Nomfuneko A. Mafunda, Mara Farcasanu, Matthew R. Hayward, Kendall R. Jackson, Douglas Kwon

239 PENILE BACTERIAL SPECIES ASSOCIATED WITH INCREASED HIV RISK IN HETEROSEXUAL MEN

240 FORESKIN HIV TARGET CELLS AND PENILE ANAEROBES ASSOCIATED WITH HIV SEROCONVERSION
241 HIV-SUPPRESSED PATIENTS’ PLASMA AND SEMEN EXOSOMES CONTAIN PROTECTIVE LEVELS OF ART
Jennifer L. Welch, Jack T. Stapleton, Hussein Kaddour, Lee Winchester, Courtney V. Fletcher, Chioma M. Okeoma

242 BLOOD MICROBIOTA CORRELATES WITH INFLAMMATION AND ART-MEDIATED IMMUNE RESTORATION
Sergio Serrano-Villar, Mariano Matarranz, Jose I. Bernardino, Alejandro Vallejo, Carolina Gutiérrez, Otilia Bisbal, Maria Lagarde, Nadia Madrid, Rafael Rubio, Cristina Gomez-Ayerbe, Maria J. Vivancos-Gallego, Alfonso Cabello, Matilde Sanchez-Conde, Vicente Estrada, Santiago Moreno

Poster P-C2 AIDS MALIGNANCES: CERVICAL AND ANAL CANCER
Poster Hall - 4EF 2:30 PM - 4:00 PM

276 EXPLORING THE MICROBIOTA FOR THE DIAGNOSIS OF ANAL PRECANCEROUS LESIONS IN MSM
Sergio Serrano-Villar, Alfonso Cabello, María José Gosalbes, Matilde Sanchez-Conde, Beogna Monge, Jorge Diaz, Talia Sainz, Patricia Roiz, Maria J. Vivancos-Gallego, Maria Jesus P. Elias, Jose L. Casado, Ana Moreno, Santiago Moreno, José A. Pérez-Molina

277 TRANSCRIPTOME ANALYSIS IN HPV+/HIV+ TISSUE REVEALS MARKERS OF HPV-DEPENDENT DYSPLASIA
Eva Riveira-Muñoz, Ivan Galvan-Fermenia, Rafael de Cid, Antoni Tarrats, Marta Piñol, Francesc Garcia-Cuyás, Jose A. Este, Roger Badia, Guillem Sirera, Ester Ballana

278 HPV CLEARANCE AND REINFECTION IN 2 YEARS AFTER RANDOMIZATION TO CRYOTHERAPY OR LEEP
Christine J. McGrath, Anthony Cagle, Hugo De Vuyst, Troy Querec, Elizabeth Unger, Sharon A. Greene, Sameh Sakr, Marleen Temmerman, Nelly R. Mugo, Michael H. Chung

279 HPV DNA TESTS FOR CERVICAL CANCER SCREENING OF HIV-INFECTED WOMEN
Louise Kuhn, Rakiya Saidu, Ana I. Tergas, Rosalind Boa, Jennifer Moodley, Cecilia Svanholm-Barrie, David Persing, Scott Campbell, Thomas C. Wright, Lynette Denny

280 RELATION OF CIN2 PROGRESSION WITH SERIAL CERVICOVAGINAL CYTOKINE/CHEMOKINE LEVELS
Kate G. Michel, Christine Colie, L. Stewart Massad, Cuiwei Wang, Allison G. Doyle, Gypsyamber D’Souza, Lisa Rahangdale, Lisa Flowers, Joel Milam, Joel Palefsky, Howard Minkoff, Howard D. Strickler, Seble Kassaye

281 IMMUNE GENE EXPRESSION IN ANAL DYSPLASTIC LESIONS BY HIV STATUS AND ABLATION OUTCOMES
Nikhil Shampant, Yuxin Liu, Michael Gaisa, Russell McBride, Keith M. Sigel

282 HPV GENOTYPING IN 1,088 ANAL HSIL CASES: EXPECTED AND UNEXPECTED RESULTS
Michael Gaisa, Keith M. Sigel, Yuxin Liu

283 PRIMARY HPV SCREENING IN WOMEN LIVING WITH HIV
Howard D. Strickler, Nancy A. Hessol, Isam-Eldin Eltoum, Mark Einstein, Philip E. Castle, L. Stewart Massad, Lisa Flowers, Lisa Rahangdale, Adaora Adimora, Igbo Ofotokun, Meghan Huchko, Gypsyamber D’Souza, Joel Palefsky, Robert Burk, for the WIHS HPV Screening Study
284 LB REDUCED COVERAGE OF HPV VACCINE TYPES IN CERVICAL PRECANCER IN HIV INFECTION
Christina Carlander, Camilla Lagheden, Carina Eklund, Sara Nordqvist Kleppe, Philippe Wagner, Aylin Yilmaz, Kristina Elfgren, Anders Sönnerborg, Pär Sparén, Joakim Dillner

Poster Sessions

Poster P-D3 STUDIES OF ANTIBODIES AND B CELLS
Poster Hall - 4EF
2:30 PM - 4:00 PM

305 SUSCEPTIBILITY TO bNabs IS CONCORDANT IN PRE-ART PLASMA AND ON-ART PBMCs: ACTG NW413
Jacqueline Reeves, Yu Zheng, Maxine Olefsky, Yolanda Lie, Leah Burke, Babafemi Taiwo, Christos Petropoulos, Pablo Tebas, Marina Caskey, Katharine J. Bar

306 HIGH-THROUGHPUT ASSAY TO ASSESS ADCC ACTIVITY AGAINST CLINICAL ISOLATES OF HIV-1
Allison S. Thomas, Melissa Ghulam-Smith, Manish Sagar

307 IMPACT OF ATI ON B-CELL REGULATION BY IGG3 IN CHRONICALLY HIV-INFECTED INDIVIDUALS
Valerie Melson, Lela Kardava, Christine Youn, Jesse Justement, Victoria Shi, Catherine Seamon, Michael Sneller, Tae-Wook Chun, Susan Moir

308 PTEN OVEREXPRESSION IN ANTIGEN-SPECIFIC B CELLS FROM HIV-INFECTED INDIVIDUALS ON ART
Lesley R. de Armas, Suresh Pallikkuth, Li Pan, Stefano Rinaldi, Nicola Cotugno, Sarah F. Andrews, Rajendra Pahwa, Adrian B. McDermott, Paolo Palma, Savita Pahwa

309 AUTOLOGOUS NEUTRALIZING ANTIBODIES DRIVE VIRUS EVOLUTION DURING REBOUND AFTER ATI
D. B. Salantes, Felicity Mampe, Anya Bauer, Emily Lindemuth, Emmanuelou Papasavvas, Luis Montaner, Katharine J. Bar

310 A NOVEL PHAGE-DISPLAY APPROACH MAPS LINEAR EPITOPES OF GP41-SPECIFIC MABs
Meghan E. Garrett, Katherine L. Williams, Theodore Gobillot, Ryan Basom, Megan M. Stumpf, Katharine Dusenbury, Julie M. Overbaugh

311 RAPID DEVELOPMENT OF AN INFANT-DERIVED HIV-1 BROADLY NEUTRALIZING ANTIBODY
Laura Doepker, Cassandra Simonich, Duncan Ralph, James A. Williams, Amrit Dhar, Christopher T. Small, Brian Oliver, Vladimir Vigdorovich, Vidya Mangala Prasad, Ruth Nduati, D. N. Sather, Kelly K. Lee, Frederick Matsen, Julie M. Overbaugh

312 PROFILING ANTIBODY CROSS-REACTIVITY AMONG SIV ISOLATES USING A PEPTIDE MICROARRAY
Anna S. Heffron, David Baker, Adam Bailey, Eric Peterson, Amelia K. Haj, Mariel S. Mohns, Connor Buechler, Adam Ericson, Dawn M. Dudley, John C. Tan, David H. O’Connor

Poster Sessions • Wednesday

Poster P-E06 HIV CURATIVE APPROACHES: IN VITRO
Poster Hall - 4EF
2:30 PM - 4:00 PM

361 BCL-2 INHIBITOR ABT-199 REDUCES RESISTANCE OF HIV RESERVOIRS TO CD8+ T-CELL KILLING
Szuhan Huang, Shabnum Patel, Yanqin Ren, Ronald Truong, Dean Magat, Chase McCann, Shuntai Zhou, Sabrina Clark, Elizabeth A. Zale, Amanda Macedo, Talia Mota, Ronald Swanstrom, Alberto Bosque, Catherine M. Bollard, R. Brad Jones
362 **BCL-2/XL ANTAGONISTS REDUCE HIV RESERVOIRS FROM IN VITRO MODELS NOT EX VIVO CD4 CELLS**  
Yanqin Ren, Amanda Macedo, Szuhan Huang, Dora Chan, Ronald Truong, Thomas Rohwetter, Talia Mota, Colin Kivacs, Erika Benko, Alberto Bosque, R. Brad Jones

363 **IN VIVO ANTIVIRAL EFFECT OF DASATINIB IN HUMANIZED MICE INFECTED WITH HIV-1**  
Maria Salgado, Javier Martínez-Picado, Cristina Gálvez, Sara Rodriguez-Mora, Victor Urrea, Elena Mateos, José Alcami Pertejo, Mayte Coiras

364 **A BACTERIOPHAGE T4 NANO PARTICLE PLATFORM FOR TARGETED CURATIVE THERAPY AGAINST HIV-1**  
Himanshu Batra, Jingen Zhu, Swati Jain, Neeti Ananthswamy, Marthandan Mahalingam, Pan Tao, Mary F. Kearney, Frank Maldarelli, Veniglia Rao

365 **DISTINCT VULNERABILITY OF VIRAL RESERVOIR CELLS TO NK CELL-MEDIATED IMMUNE EFFECTS**  
Stephane Hua, Hsiao-Hsuan Kuo, Shivaali Maddali, Kevin Einkauf, Chenyang Jiang, Xiaodong Lian, Mathias Lichterfeld, Xu G. Yu

367 **WITHDRAWN/INTENTIONALLY UNASSIGNED**

368 **WITHDRAWN/INTENTIONALLY UNASSIGNED**

**Poster P-E08 MECHANISMS OF LATENCY**  
**Poster Hall - 4EF**  
**2:30 PM - 4:00 PM**

374 **VPU CONTROLS HIV-1 LATENCY THROUGH MODULATION OF THE NF-κB PATHWAY**  

375 **FORMATION OF THE REPLICATION-COMPETENT HIV-1 RESERVOIR COINCIDES WITH ART INITIATION**  

376 **TCR-ACTIVATED CD8+ T CELLS PROMOTE THE ESTABLISHMENT OF HIV LATENCY IN CD4+ T CELLS**  
Michelle Zanoni, David J. Palesch, Claudia Pinacchio, Deanna Kulpa, Guido Silvestri

377 **METHYLATION PROFILES OF HIV-1 PROVIRAL DNA IN ART-SUPPRESSED INDIVIDUALS**  
Valerie F. Boltz, Cristina Ceriani, Wei Shao, Michael J. Bale, Leslie Lipkey, Laura Newman, Brandon F. Keele, Jonathan Spindler, Rebecca Hod, Jeffery Milush, Steven G. Deeks, Frank Maldarelli, Mary F. Kearney, John M. Coffin

378 **THE HIV ANTI SENSE TRANSCRIPT AST INDUCES VIRAL LATENCY VIA SEVERAL SILENCING PATHWAYS**  
Wei Zhou, Kaveh Daneshvar, Michelle Pleet, Francesca Benedetti, Gideon Wolf, Davide Zella, Fatih Kashanchi, Balasubrahmanyam Addepalli, Alan Mullen, Fabio Romero

379 **TARGETING SPHINGOSINE-1-PHOSPHATE TO PREVENT LATENT HIV INFECTION**  
Rachel Resop, Rémi Fromentin, Amanda Macedo, Hawley Riggsby, Nicolas Chomont, Alberto Bosque
389  ANALYTICAL TREATMENT INTERRUPTION (ATI) IN PATIENTS WITH VERY SMALL HIV RESERVOIR
Pieter Pannus, Sofie L. Rutseaert, Stephane de Wit, Sabine Allard, Guido Vanham, Coca Necozi, Joeri Aerts, Ward De Spiegeleere, Achilleas Tsoumanis, Marie Coutteneye, Natacha Herssens, Linos Vandekerckhove, Eric Florence

390  N-803 INDUCES ROBUST SIV REACTIVATION IN ART-TREATED CD8-DEPLETED MACAQUES

391  REBOUND OF HIV-1 IN CEREBROSPINAL FLUID AFTER TREATMENT INTERRUPTION
Richard W. Price, Maria Bednar, Laura P. Kincer, Rebecca Hoh, Magnus Gisslén, Sarah B. Joseph, Serena S. Spudich, Steven G. Deeks, Ronald Swanstrom

392  COMPARTMENTALIZED HIV REBOUND IN THE MALE GENITAL TRACT AFTER ART INTERRUPTION
Sara Gianella, Antoine Chaillon, Tae-Wook Chun, Caroline Ignacio, Colin Kovacs, Erika Benko, Sanja Huibner, Rupert Kaul

393  SEEKING SUPPRESSION IN HAV ARTI: VIREMIA & T CELLS AFTER VEDOLIZUMAB & ATI IN HIV/ART
Michaeline McGuinty, Jonathan Angel, Ashok Kumar, Richmond Sy, Sanjay Murthy, Donald Kilby, Nancy Trembland, Elizabeth Lavoie, Stephanie Burke Schinkel, Siddappa N. Byrareddy, D. William Cameron, for the HAV ARTI CTNPT031 study team

394 LB  ANALYTICAL TREATMENT INTERRUPTION (ATI) AFTER ALLOGENEIC CCR5-D32 HSCT FOR AML IN 2013
Björn-Erik O. Jensen, Elena Knops, Nadine Lübke, Annemarie Wensing, Javier Martinez-Picado, Rolf Kaiser, Monique Nijhuis, Maria Salgado, Thomas Harrer, Eva Heger, Johanna M. Eberhard, Ilona Hauber, Carsten Münk, Dieter Häussinger, Guido Kobbe

Poster P-E11 HUMAN STUDIES OF CURATIVE STRATEGIES AND ATI
Poster Hall - 4EF 2:30 PM - 4:00 PM

395  TELMISARTAN DECREASES HIV-1 RNA IN LYMPH NODES IN TREATED HIV INFECTION
Netanya S. Utay, Jordan E. Lake, Claire Deleage, Douglas W. Kitch, Eunice Yeh, Karin L. Klingman, Michael M. Lederman, Carl Fichtenbaum, Daniel Douek, Judith S. Currier, Jacob D. Estes, for the A5317 Team

396  DEPLETION OF BLOOD PD-1+ CD4 T CELLS BY A-PD-1 ADC SUPPRESSES HIV INFECTION IN VITRO
Patricia Jacquier, Craig Fenwick, Song Ding, Giuseppe Pantaleo

397  CHARACTERIZATION OF HIV-1 TRANSCRIPTION PROFILE AFTER ROMIDEPSIN THERAPY IN VIVO
Sara Moron-Lopez, Peggy Kim, Ole S. Søgaard, Martin Tolstrup, Joseph K. Wong, Steven A. Yukl
398 THE IMPACT OF VORINOSTAT AND THERAPEUTIC VACCINE ON GUT HIV DNA: THE RIVER GUT STUDY

John P. Thornhill, Carolina Herrera, Jonathan Hoare, Simon Peake, Helen Brown, Nneka Nwokolo, Julie Fox, Tomas Hanke, John Frater, Sarah Fidler, for the the RIVER trial investigators

399 RANDOMIZED TRIAL OF IMPACT OF MULTIPLE INTERVENTIONS ON HIV RESERVOIR: SPARC-7 TRIAL

Ricardo S. Diaz, Leila B. Giron, James Hunter, Juliana Galinskas, Danilo A. Dias, Sadia Samer, Muhammad S. Arif, Juliana T. Maricato, Maria A. Juliano, Maria Cecilia Arripe Secupira, Luis M. Janini, Andrea Savarino, Luiz Rodolfo R. Travassos, for the SPARC WORKING GROUP

400 IMPACT OF EVEROLIMUS THERAPY ON HIV PERSISTENCE, IMMUNE FUNCTION, AND GENE EXPRESSION

Corinna N. Schreiner, Cheryl A. Cameron, Louise Hogan, Rachel L. Rutishauser, Simon Chu, Brian Richardson, Rodney Rogers, Cassandra Thanb, Sonia Bakkour, Michael P. Busch, Jeffrey M. Milush, Rafick-Pierre Sekaly, Peter Stock, Steven G. Deeks, Timothy J. Henrich

401 NEUROTOXICITY WITH HIGH-DOSE DISULFIRAM AND VORINOSTAT USED FOR LATENCY REVERSAL


402 ANOGENITAL HIV DETECTED DURING ANALYTIC TREATMENT INTERRUPTION IN REMISSION TRIALS

Donn J. Colby, Rapee Trichavaroj, Suteearporn Pinyakorn, Siriwat Akapirat, Trevor A. Crowell, Eugène Kroon, Khunthalee Benjaronpong, Somporn Tipsuk, Carlo Sacedale, Praphan Phanuphak, Merlin L. Robb, Nittaya Phanuphak, Mark de Souza, Jintanat Ananworanich, for the RV254/SEARCH010 Study Team

403 IMPACT OF ATI ON HIV RESERVOIRS AND IMMUNE PARAMETERS IN EARLY TREATED INDIVIDUALS

Erin Huiting, Jana Blazkoa, Jesse Justement, Victoria Shi, Kathleen Gittens, Susan Moir, Michael Sneller, Anthony S. Fauci, Tae-Wook Chun

404 DETECTION OF CELL-ASSOCIATED HIV-1 NUCLEIC ACID IN BLOOD AFTER EARLY ART

Linda Jagodzinski, Mark M. Manak, Holly R. Hack, Jennifer Malia, Nittaya Phanuphak, Mark de Souza, Eugene Kroon, Donn J. Colby, Nitiya Chomchey, Merlin L. Robb, Nelson L. Michael, Jintanat Ananworanich, Sheila A. Peel, for the RV254/SEARCH010 study group

405 ALTRUISM IN END OF LIFE HIV RESEARCH: INSIGHTS FROM LAST GIFT STUDY

Karine Dube, Anshula Nathan, Kushagra Mathur, Susanna Concha-Garcia, Hursch Patel, Andy Kaytes, Jeff Taylor, Davey M. Smith, Sara Gianella

406 WITHDRAWN/INTENTIONALLY UNASSIGNED

Poster P-F2 NEUROPATHOGENESIS AND MODELING: HIV AND SIV

Poster Hall - 4EF

2:30 PM - 4:00 PM

427 SHIV GENE EXPRESSION IN CSF CD4 T CELLS DURING ACUTE INFECTION OF RHEUS MACAQUES

Vishakha Sharma, Matthew Creggan, Sandhya Vasan, Michael A. Eller, Diane Bolton
428 IN VIVO REPLICATION AND NEUROPATHOGENESIS OF T/F CLADE C SHIVs
Debashis Dutta, Srijayaprakash Uppada, Olwenyi A. Omalla, Lindsey A. Knight, Kabita A. Pandey, Samuel A. Johnson, Celia C. Lebranche, David C. Montefiori, Siddappa N. Byrareddy

429 EVOLVING SIV REGIONAL BRAIN INJURY AND RECOVERY ARE LINKED TO ANTIOXIDANT EXPRESSION
Yoelvis Garcia-Mesa, Brandon L. Bastien, Rolando Garza, Analise Gruenewald, Michael R. Betts, Guido Silvestri, Dennis L. Kolson

430 DOLUTEGRAVIR ACCUMULATES IN THE FETAL BRAIN FOLLOWING IN UTERO EXPOSURE
Aditya N. Bade, Benson Edagwa, JoEllyn McMillan, Gary E. Siuzdak, Howard E. Gendelman

431 HIV BASAL-GANGLIA INJURY CORRELATES WITH ANTIOXIDANT & ENDOTHELIAL ADHESION MARKERS
Analise Gruenewald, Rolando Garza, Yoelvis Garcia-Mesa, Patricia J. Vance, Benjamin B. Gelman, Dennis L. Kolson

432 PLATELET-ENDOTHELIAL INTERACTIONS MAY PROTECT AGAINST VIRAL ENTRY IN THE BRAIN
Claire E. Lyons, Hannah Schneider, Elizabeth L. Engle, Kevin M. Najarro, Suzanne E. Queen, Craig N. Morrell, Joseph Mankowski, Kelly A. Metcalf Pate

433 HIV-1 INDUCED NEUROPATHOLOGY OF A HUMANIZED MICROGLIAL MOUSE
Saumi Mathews, Edward Makarov, Howard E. Gendelman, Larisa Y. Poluekhtova, Santhi Gorantla

434 MTDNA HAPLOGROUP B IS ASSOCIATED WITH EXECUTIVE FUNCTION AND RECALL IN HISPANIC PLWH
Karen E. Volpe, Todd Hulgan, David C. Samuels, Asha R. Kallianpur, Ronald J. Ellis, Donald Franklin, Scott L. Letendre, Robert K. Heaton

435 MECHANISMS OF WHITE-MATTER LOSS DUE TO HIV INFECTION AND ANTIRETROVIRAL THERAPY
Kelly L. Jordan-Sciutto, Lindsay M. Roth, Bassam N. Zidane, Micah Romer, Cagla Akay-Espinoza, Judith B. Grinspan

436 SWITCHING TO FTC/TAF FROM ABC/3TC OR FTC/TDF DOES NOT AFFECT CNS HIV-1 INFECTION
Aylin Yilmaz, Lars Hagberg, Åsa Mellgren, Dietmar Fuchs, Staffan Nilsson, Kaj Blennow, Henrik Zetterberg, Magnus Gisslén

437 POLYPHARMACY IS ASSOCIATED WITH WORSE NEUROCOGNITIVE PERFORMANCE IN AGING ADULTS
Qing Ma, Ronald J. Ellis, Leah H. Rubin, Norman J. Haughey, Donald Franklin, Anne Bang, Rowan Saloner, Mariana Cherner, David J. Moore, Scott L. Letendre

438 CENTRAL NERVOUS SYSTEM SAFETY OF A KICK-AND-KILL STRATEGY WITH ROMIDEPSIN
Sara Carrillo-Molina, Ignacio Martínez-Zalacaín, Beatriz Mothe, José Moltó, Christian Manzano, Jose M. Miro, Josep Coll, Michael Meulbroek, Anna Prats, Maite Garorla, Tomas Hanke, Christian Brander, Carles Soriano-Mas, Jose A. Muñoz-Moreno, for the BCN02-Neuro Substudy Group
439  CENTRAL NERVOUS SYSTEM EFFECTS OF THERAPY INITIATION WITH INTEGRASE INHIBITORS
Anna Prats, Ignacio Martínez-Zalacaín, Beatriz Mothe, Eugènia Negredo, Maite Garolera, Sira Domènech-Puigcerver, Michael Meulbroek, Carmina R.Fumaz, Maria J. Ferrer, Bonaventura Clotet, Carles Soriano-Mas, Jose A. Muñoz- Moreno, for the ARBRE Study Group

440  NEUROPSYCHIATRIC OUTCOMES BEFORE AND AFTER SWITCHING TO DOLUTEGRAVIR-BASED THERAPY
Phillip Chan, Orlanda Goh, Eugène Kroon, Donn J. Colby, Carlo Sacdalan, Suteearporn Pinyakorn, Somporn Tipsuk, Nittaya Phanuphak, Praphan Phanuphak, Jintanat Ananworanich, Victor Valcour, Serena S. Spudich, Robert Paul, for the RV254/SEARCH010

441  NEUROPSYCHOLOGICAL CHANGES IN EFAVIRENZ SWITCH REGIMENS IN MACS

442  MEMORY AND LEARNING DYSFUNCTION WITH INTEGRASE STRAND TRANSFER INHIBITORS USE
Jane A. O’Halloran, Sarah A. Cooley, Jeremy Strain, Robert Paul, Rachel Presti, Beau Ances

443  CEREBRAL FUNCTION PARAMETERS IN PEOPLE LIVING WITH HIV SWITCHING INTEGRASE INHIBITOR
Borja Mora-Peris, Laura Else, Jaime Vera-Rojas, Caire Petersen, Maryam Khan, Sujan Dilly Penchala, Sofia Toniolo, Mara Cercignani, Michael R. Keegan, Saye Khoo, Alan Winston

444  EARLY ART IN ACUTE HIV LIMITS DETRIMENTAL CX3CR1 MONOCYTES LINKED TO CNS DYSFUNCTION
Michelle L. D’Antoni, Phillip Chan, Danielle M. Clements, Yotin Chinvrunch, Vedbar S. Khadka, Somporn Tipsuk, Robert Paul, Nitiya Chomchey, Donn J. Colby, Jintanat Ananworanich, Robert Gramzinski, Serena S. Spudich, Lishomwa C. Ndhlovu, for the RV254/SEARCH010; SEARCH013 and SEARCH011 study groups

445  ART IN EARLY INFECTION IMPROVES NEUROCOGNITION REGARDLESS OF INFECTION DURATION
Kevin Robertson, Javier R. Lama, Peter Brandes, Eduardo Ruiz, Cecilia Correa, Eline Appelmans, Siavash Pasalar, Lindsay Haselden, Rachel A. Bender Ignacio, Serena S. Spudich, Christopher D. Pilcher, Ann Duerr, for the SABES team

---

Poster Sessions - Wednesday

Poster P-G2 ARV AND ANTIHEPATITIS PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS
Poster Hall - 4EF 2:30 PM - 4:00 PM

466  POLYPHARMACY, INAPPROPRIATE DRUGS, AND DRUG-DRUG INTERACTIONS IN HIV-INFECTED ELDERLY
Perrine Courlet, Catia Marzolini, Matthias Cavassini, Manuel Battegay, Susana Alves Saldanha, Deolinda Alves, Vreneli Waelti Da Costa, Chantal Csajka, Laurent A. Decosterd

467  DRUG-INTERACTION MAGNITUDES IN YOUNG VS ELDERLY: EXAMPLE OF RIVAROXABAN–DARUNAVIR/R
Felix Stader, Marco Siccardi, Hannah Kinvig, Manuel Battegay, Melissa A. Penny, Catia Marzolini
468 THE ROLE OF OATP1B1 IN GRAZOPREVIR DRUG-DRUG INTERACTIONS AND THE ELDERLY
Hannah Kinvig, Felix Stader, Owain Roberts, Andrew Owen, Catia Marzolini, Marco Siccardi

469 INTRACELLULAR SOFOSBUVIR (SOF) CONCENTRATIONS IN PERSONS WITH HCV AND COCAINE USE
Kristina M. Brooks, Jose R. Castillo-Mancilla, Mary Morrow, Samantha MalWhinney, Ryan T. Huntley, Joshua Blum, David L. Wyles, Lane R. Bushman, Peter L. Anderson, Jennifer J. Kiser

470 PREDICTION OF RENAL OAT1 AND OAT3 INHIBITION BY CABOTEGRAVIR USING PBPK MODELLING

471 influence of UGT1A1*28 ON RALTEGRAVIR PK/PD IN THE NEAT001/ANRS143 STUDY
Rohan M. Gurjar, Laura Dickinson, Daniel F. Carr, Wolfgang Stohr, Stefano Bonora, Andrew Owen, Antonio D’Avolio, Adam Cursley, Jean-Michel Molina, Gerd Fätkenhueger, Giovanni Di Perri, Anton Pozniak, Laura Richert, François Raffi, Marta Boffito

472 PHARMACOGENETICS OF WEIGHT GAIN AFTER SWITCH FROM EFAVIRENZ TO INTEGRASE INHIBITORS

473 HORMONAL CONTRACEPTIVES DO NOT ALTER CABOTEGRAVIR PK IN HIV-UNINFECTED WOMEN HPTN 077
Cherie Blair, Sue Li, Gordon Chau, Leslie Cottle, Paul Richardson, Mark A. Marzinke, Susan H. Eshleman, Adeola Adeyeye, David Burns, Alex Rinehart, David A. Margolis, Marybeth McCauley, Craig W. Hendrix, Raphael J. Landovitz, for the HPTN 077 Study Team

495 DISCONTINUATIONS & VIROLOGIC RESPONSE IN LATE PRESENTERS WITH InSTI- OR PI-BASED ART
Gundolf Schuettfort, Lena Boekenkamp, Alfonso Cabello, Aoife G. Cotter, Marta Del Palacio Tamarit, Miguel Gòrgolas, Lisa Hamzah, Eva Herrmann, Pavel Khaykin, Patrick W. Mallon, Álvaro Mena, Caroline Sabin, Timo Wolf, Christoph Stephan, Annette E. Haberl

496 QUALITY OF LIFE AND ADHERENCE AS PREDICTORS OF SECOND-LINE ART VIROLOGICAL FAILURE
Thiago S. Torres, Linda J. Harrison, Alberto M. La Rosa, Lu Zheng, Ann Collier, Michael D. Hughes, for the AIDS Clinical Trials Group (ACTG) A5273 Study Group

497 LOW LEVEL VIREMIA AND VIROLOGIC FAILURE IN PERSONS WITH HIV TREATED WITH ART
Julia Fleming, Kelly Gebo, Richard Rutstein, W. C. Mathews, Judith Aberg, Charurut Somboonwit, Laura W. Cheever, Richard D. Moore, for the HIV Research Network

498 SECOND-LINE ANTIRETROVIRAL THERAPY (ART) AFTER FIRST VIRAL FAILURE ON ART, 2008-2016
Thibaut Davy-Mendez, Sonia Napravnik, Oksana Zakharova, Joseph J. Eron

Poster P-H3 VIROLOGIC FAILURES: TO SECOND LINE AND BEYOND
Poster Hall - 4EF
2:30 PM - 4:00 PM
499 PREDICTORS OF VIROLOGIC OUTCOME WHILE CONTINUING A PI-BASED ART REGIMEN IN ACTG A5288

Robert A. Salata, Beatriz Grinsztejn, Justin Ritz, Ann Collier, Peter Mugyenyi, Evelyn Hogg, Linda Wielaw, Robert Gross, Catherine Godfrey, Nagalingeswaran Kumarasamy, Cecilia Kanyama, John W. Mellors, Carole Wallis, Michael D. Hughes

500 WEEK 96 SUBGROUP ANALYSES OF D/C/F/TAF IN HIV-1 TREATMENT-NAIVE & SUPPRESSED ADULTS

Gregory D. Huhn, Edwin DeJesus, Pierre-Marie Girard, Cheryl McDonald, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Romana Petrovic, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, for the AMBER/EMERALD Study Groups

501 INTEGRATED EFFICACY ANALYSIS OF DORAVIRINE IN HIV-1-INFECTED TREATMENT-NAIVE ADULTS

Chloe Orkin, Jean-Michel Molina, Johan Lombaard, Wing-Wai Wong, Edwin DeJesus, Anthony Rodgers, Xia Xu, Sushma Kumar, Elizabeth Martin, George H. Hanna, Carey Hwang

502 96 WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT-NAÏVE ADULTS AND ADULTS ≥50 YRS


503 CD4+ RECOVERY AFTER ART INITIATION: A COMPARISON BETWEEN DOLUTEGRAVIR AND EFAVIRENZ

Mariana V. Meireles, Ana R. Pati Pascom, Adele Benzaken

504 VIROLOGIC AND IMMUNOLOGIC OUTCOMES OF INTEGRASE INHIBITORS (InSTIs) IN RESPOND

Bastian Neesgaard, for the International Cohort Consortium of Infectious Diseases: RESPOND

505 LB 12 MONTH OUTCOMES ON DOLUTEGRAVIR-BASED REGIMENS IN BOTSWANA: THE BEAT COHORT STUDY

Ava Avalos, Tendani Gaolathe, Dannae Brown, Vani Vannapaggari, Heston Phillips, Pinkie Melamu, Dinah Ramaabaya, Bornaparte Nkomo, Kabo Mathlo, Kaelo Seatla, Joseph N. Jarvis, Sikuette Moyo, Mogomotsi Matshaba, Simani Gaseitsiwe, for the Botswana Epidemiological ART Treatment Cohort Study Team

506 PREDICTORS OF SWITCHING FROM TDF TO TAF: REAL-WORLD DATA FROM A NATIONWIDE STUDY

Bernard Surial, Matthias Cavassinni, Alexandra Calmy, Jan S. Fehr, Marcel Stoeckle, Enos Bernasconi, Pietro L. Vernazza, Christoph A. Fux, Helen Kovari, Hansjakob Furrer, Andri Rauch, Gilles Wandelje, for the Swiss HIV Cohort Study

507 SEVEN-YEAR TREATMENT RESPONSES IN SUBTYPE A1 VS D HIV-1 INFECTIONS IN MBARARA, UGANDA

Guinevere Q. Lee, Nicholas Musinguzi, David B. Gootenberg, Suzanne McCluskey, Yap Boum, Bosc M. Bwana, Conrad Muzoora, Simone Kigozi, Peter W. Hunt, Jeffrey N. Martin, David R. Bangsberg, Jessica E. Haberer, Mark J. Siedner, P. Richard Harrigan, Musie Ghebremichael
508  HIV CONTROLLERS MAINTAIN VIRAL SUPPRESSION DESPITE WANING T-CELL RESPONSES ON ART
Nikolaus Jilg, Pilar Garcia-Broncano, Michael Peluso, Florencia Pereyra, Ronald Bosch, Carla Roberts-Toler, Cornelius N. Van Dam, Michael Keefer, Daniel R. Kuritzkes, Alan Landay, Steven G. Deeks, Xu G. Yu, Paul E. Sax, Jonathan Z. Li

509  RESTRICTED MEAN SURVIVAL TIME AS A TREATMENT MEASURE IN HIV/AIDS CLINICAL TRIALS
Xian Abulizi, Philippe Flandre, Heather Ribaudo

510  HOME VS SELF-INITIATED ART REFILL: CLINICAL, IMMUNOLOGICAL, AND VIROLOGIC OUTCOMES
Rory F. Leisegang, Jane Ball, Mark Cotton, David Dowdy, Keri Calkins, Susan Cleary, Gary Maartens, Jean B. Nachega

511  EFFECTIVENESS OF SINGLE- VS MULTIPLE-TABLET REGIMENS AS 1ST-LINE ART IN ICONA COHORT
Annalisa Mondi, Patrizia Lorenzini, Alessandro Tavelli, Alessandro Cozzi-Lepri, Franco Maggiolo, Nicola Gianotti, Daniela Francischi, Chiara Carcieri, Andrea De Vito, Antonio Di Biagio, Antonella D'Arminio Monforte, Andrea Antinori, for the Icona Foundation Study Group

512  BETTER VIROLOGICAL OUTCOMES WHEN INITIATING EARLY ART IN THE HPTN 071 (POPART) TRIAL
Geoffrey Fatti, Ashraf Grimwood, Jean B. Nachega, Jenna Nelson, Kelsea LaSorda, Gert U. van Zyl, Nelis Grobbelaar, Helen Ayles, Richard Hayes, Nulda Beyers, Sarah Fidler, Peter Bock

513  RCT OF INDIVIDUALIZED COMMUNICATION STRATEGY AMONG HIV-INFECTED PERSONS STARTING ART
Marcelo H. Losso, Marisa Fuentes, Valentina Losso, Martha Michaan, Lea Pastore, Lorena Puente, Amalia Vazquez, Manuela Bullo

514  PROJECT RHAE: A PILOT STUDY OF RAPID ART START AND RESTART IN BALTIMORE CITY

515  HIGH RATES OF VIROLOGICAL SUPPRESSION AFTER RAPID ART START IN A SAFETY-NET CLINIC
Susa Coffey, Peter Bacchetti, Darpun Sachdev, Oliver Bacon, Clarissa Osrina-Norvell, Sandra Torres, Elizabeth Lynch, Sulggi Lee, Katerina A. Christopoulos, Christopher D. Pilcher, Jing Hsu, Chengshini Jin, Susan Scheer, Diane V. Havlir, Monica Gandhi

539  A COMPARATIVE EVALUATION OF HIV-1 CAPSID INHIBITOR SUSCEPTIBILITY
Alicia Newton, Charity Ting, Lan Trinh, Christos Petropoulos, Wei Huang

540  IDENTIFICATION OF ARV-RESISTANCE MUTATIONS OUTSIDE OF THE DRUG-TARGET GENE
Phuong Pham, Rachel Van Duyne, Eric O. Freed
541  EMERGENCE OF GAG MUTATION, A364V, IDENTIFIED AS THE KEY IN VITRO RESISTANCE MUTATION
Charlene McDanal, Pauline Schipper, Monique Nijhuis, Jerry Jeffrey, Brian A. Johns

542  COMPARISON OF NEXT-GENERATION SEQUENCING ANALYSIS PIPELINES FOR HIV-1 DRUG RESISTANCE

543  HIV RESISTANCE–ASSOCIATED MUTATIONS OBSERVED IN CELL-ASSOCIATED DNA SEQUENCING ASSAY
Dongmei Yang, Johnny Lai, Suqin Cai, Jonathan Toma, Yuping Tan, Christos Petropoulos, Charles Walworth, Jeannette Whitcomb

544  DETECTION OF ARCHIVED MUTATIONS IN PATIENTS INFECTED WITH MULTICLASS RESISTANT HIV-1
Martin Daeumer, Eva Wolf, Markus Bickel, Albrecht Stoehr, Silke Heldwein, Heribert Knechten, Patrick Braun, Stefan Esser, Ivanka Krznaric, Christoph Wyen, Markus Müller, Jürgen Brust, Jan–Christian Wasmuth, Alexander Thielen, Christian Hoffmann

545  LTR TRANSLOCATION MUTATIONS UNDER HIGH-LEVEL CABOTEGRAVIR MAINTAIN HIV REPLICATION
Xierong Wei, Jonathan T. Lipscomb, Ariana P. Santos, Mian-er Cong, Susan Ruone, Gerardo Garcia-Lerma, Jeffrey A. Johnson

546  ANTIVIRAL ACTIVITY OF TENOFOVIR ALAFENAMIDE AGAINST HIV-1 HARBORING K65R
Stephanie W. Cox, Nicolas A. Margot, Renee R. Ram, Christian Callebaut

547  GSS OF NRTI-BACKBONE PREDICTS TIME TO VIROLOGICAL FAILURE OF INI-BASED REGIMENS
Alberto Borghetti, Arturo Ciccullo, Francesca Lombardi, Giammara Baldin, Simone Belmonti, Mattia Prosperi, Francesca Incardona, Eva Heger, Vanni Borghi, Anders Sonnerborg, Simona Di Giambenedetto, for the INTEGRATE – EuResist Group

548  GENOTYPIC AND PHENOTYPIC SUSCEPTIBILITY TO FOSTEMSARIV IN MULTIDRUG-RESISTANT HIV-1
Francesco Saladini, Alessia Giannini, Franco Maggiolo, Francesca Vichi, Giulio M. Corbelli, Andrea Galli, Alba Bigoloni, Maria M. Santoro, Maurizio Zazzi, Antonella Castagna, for the PRESTIGIO Study Group

549  IN VITRO ACTIVITY OF DTG/BIC/E/CAB ON FIRST-GENERATION InStI-RESISTANT HIV-1
Francesco Saladini, Alessia Giannini, Adele Boccuto, Filippo Dragoni, Alice Appendino, Edoardo Albanesi, Ilaria Vicenti, Maurizio Zazzi

550  SUSCEPTIBILITY TO BICTEGRAVIR IN HIGHLY ARV-EXPERIENCED PATIENTS AFTER InStI FAILURE
Maria M. Santoro, Chiara Fornabaio, Marina Malena, Laura Galli, Andrea Poli, Simone Marrotulli, Marianna Menozzi, Maurizio Zazzi, Kirsten L. White, Antonella Castagna, for the PRESTIGIO Study Group
551 HIGH LEVEL OF PREEXISTING NRTI RESISTANCE PRIOR TO SWITCHING TO B/F/TAF: STUDY 4030
Rima K. Acosta, Madeleine Willkom, Kristen Andreatta, Hui Liu, Ross Martin, Silvia Chang, Hal Martin, Sean Collins, Kirsten L. White

552 LONG-TERM B/F/TAF SWITCH EFFICACY IN PATIENTS WITH ARCHIVED PREEXISTING RESISTANCE
Kristen Andreatta, Madeleine Willkom, Ross Martin, Silvia Chang, Hui Liu, Ya-Pei Liu, Hiba Graham, Hal Martin, Kirsten L. White

553 ACTIVITY OF BICTEGRAVIR AGAINST HIV-2 ISOLATES AND INI-RESISTANT HIV-2 MUTANTS
Robert A. Smith, Dana Raugi, Vincent H. Wu, Christopher Zavala, Jennifer Song, Moussa Syedi, Geoffrey S. Gottlieb, for the University of Washington-Dakar HIV-2 Study Group

Poster P-K3 HCV TRANSMISSION: THE (MOLECULAR) WEBS WE WEAVE
Poster Hall - 4EF 2:30 PM - 4:00 PM

591 TEMPORAL PATTERNS IN HCV PHYLOGENETIC CLUSTERING AMONG PWID IN BALTIMORE, MD

592 COMPLEX PHYLOWODYNAMICS OF HCV AMONG PWID: IMPACT OF TRANSMISSION NETWORKS
Rebecca Rose, Christopher W. Rodriguez, James J. Dollar, Susanna Lamers, Guido Massacci, William Osburn, Stuart C. Ray, David L. Thomas, Andrea Cox, Oliver Laeyendecker

593 PHYLOGENETIC EVIDENCE FOR INTERCITY HCV CLUSTERS OF PEOPLE WHO INJECT DRUGS IN INDIA
Steven J. Clipman, Mary A. Rodgers, Shanmugam Saravanan, Priya Duggal, Shruti H. Mehta, Aylur K. Srikrishnan, Muniratnam S. Kumar, Allison M. McFall, Gregory M. Lucas, Thomas C. Quinn, Gavin Cloherty, Sunil S. Solomon

594 PHYLOWODYNAMICS OF ACUTE HCV INFECTION IN MEN HAVING SEX WITH MEN
Gonché Danesh, Victor Virlogeux, Christophe Ramiere, Caroline Charre, Samuel Alizon, Laurent Cotte

595 VALIDATION OF A GENOTYPE-INDEPENDENT HEPATITIS C WHOLE-GENOME SEQUENCING ASSAY

596 HPTN 078: HIGH PREVALENCE OF HCV ANTIBODIES AMONG MEN WHO HAVE SEX WITH MEN
Risha Irvin, Theresa Gamble, Jowanna Malone, Zhe Wang, Ethan A. Wilson, James P. Hughes, Jason Farley, Kenneth H. Mayer, Carlos del Rio, D. Scott Batey, Susan H. Eshleman, Robert H. Remien, Chris Beyrer, Chloe Thio, for the HPTN 078 Research Group

597 EPIDEMIC HISTORY OF HEPATITIS C VIRUS AMONG MSM IN AMSTERDAM, THE NETHERLANDS
Jelle Koopsen, Thijis J. Van de Laar, Colin Russell, Maria Prins, Elske Hoornenborg, Alvin Han, Edyth Parker, Marc van der Valk, Janke Schinkel
Poster Sessions

598 RISK FACTORS AND PATTERNS OF HCV TRANSMISSION IN MEN WHO HAVE SEX WITH MEN IN ENGLAND
Daniel Bradshaw, Tetyana Vasylyeva, Chris Davis, Oliver Pybus, Julien Theze, Emma Thomson, Marianne Martinello, Gail Matthews, Ruth Burholt, Yvonne Gilleece, Graham S. Cooke, Emma E. Page, Laura Waters, Mark Nelson

599 SURGE IN HEPATITIS C INCIDENCE ASSOCIATED WITH SYPHILIS INFECTION AMONG THAI MSM
Win Min Han, Tanakorn Apornpong, Stephen J. Kerr, Sasiwimol Ubolyam, Sivaporn Gatechompol, Tanyaporn Wansom, Gail Matthews, Pisit Tangkijvanich, Kiat Ruxrungtham, Praphan Planunphak, Anchalee Avihingsan

600 HCV-GT1A SPATIOTEMPORAL DISTRIBUTION, EPIDEMIC HISTORY, AND NS5A RESISTANCE IN SPAIN
Claudia Palladino, Ifeanyi J. Ezeonwumelu, Pedro Borrego, Irene Mate-Cano, Paula Martinez-Román, Sonia Arca-Lafuente, Salvador Resino, Nuno Taveira, Verónica Briz, for the Multidisciplinary Group of viral coinfection HIV/Hepatitis (COVIHEP)

601 HCV ANTIBODY AVIDITY–BASED METHOD TO ESTIMATE POPULATION-LEVEL INCIDENCE
Denali Boon, Veronica Bruce, Eshan U. Patel, Jeffrey Quinn, Aylur K. Srikrishnan, Shanmugam Saravanan, Syed Iqbal, Pachamuthu Balakrishnan, David L. Thomas, Thomas C. Quinn, Kimberly Page, Sunil S. Solomon, Shruti H. Mehta, Oliver Laeyendecker

Poster P-K4 HCV AND HIV: CANCER INFLAMMATION AND FIBROSIS
Poster Hall - 4EF  2:30 PM - 4:00 PM

602 HIGH KYNURENINE:TRYPTOPHAN RATIO IS ASSOCIATED WITH LIVER FIBROSIS IN HIV INFECTION
Ani Kardashian, Yifei Ma, Michael T. Yin, Rebecca Scherzer, Olivia Nolan, Francesca Aweeka, Phyllis Tien, Jennifer Price

603 MORTALITY AFTER DIALYSIS INITIATION AMONG PATIENTS WITH CHRONIC HEPATITIS C INFECTION
Carmine Rossi, Zahid A. Butt, Maryam Darvishian, Geoff W. McKee, Jane Buxton, Hasina Samji, Mawuena Binka, Stanley Wong, Amanda Yu, Maria Alvarez, Mel Krajden, Naveed Z. Janjua

604 SYNDENMIC HIV AND HEPATITIS VIRAL COINFECTIONS AND INCIDENT END-STAGE RENAL DISEASE
Carmine Rossi, Zahid A. Butt, Maryam Darvishian, Jason Wong, Jane Buxton, Stanley Wong, Amanda Yu, Maria Alvarez, Mel Krajden, Naveed Z. Janjua

605 PREVALENCE OF HIV AND PATTERNS OF ART USE AMONG US LIVER-TRANSPLANT CANDIDATES
Ashton A. Shaffer, Alvin G. Thomas, Dorry Segev

606 CHANGES IN LIVER STIFFNESS MEASUREMENT IN HIV AND HIV/ HBV COINFECTED NIGERIANS
Patricia A. Agaba, Adovich Rivera, Placid Ugoagwu, Mohammad Muazu, Jonathan Otokorkwu, Samuel Akpa, Stephen McHenry, Godwin Imade, Oche Agbaji, Chloe Thio, Robert Murphy, Claudia Hawkins
607 IMPACT OF HBCAB+ ON ADVANCED LIVER FIBROSIS DEVELOPMENT IN HIV-HBV INFECTED PATIENTS
Vincenzo Malagnino, Alessandro Cozzi-Lepri, Loredana Sarmati, Antonella Cingolani, Carlotta Cerva, Francesca Ceccherini Silberstein, Alessandra Vergori, Gianluca Cuomo, Carlo Federico Perno, Massimo Puoti, Massimo Andreoni, Antonella D’Arminio Monforte, for the ICONA Foundation Study Group

608 IMPACT OF HIV ON THE SURVIVAL OF HEPATOCELLULAR CARCINOMA IN HCV-INFECTED PATIENTS
Nicolás Merchante, Miguel Rodríguez Fernández, Blanca Figueruela López, Francisco Rodríguez-Arrondo, Boris Revollo, Sofía Ibarra, Esperanza Merino, María J. Galindo, Marta Montero, Francisco Téllez, Antonio Rivero-Juárez, Miguel García-Deltoro, Ignacio Santos, Juan A. Pineda, for the Grupo para el Estudio de las Hepatitis Viricas (GEHEP)

609 LOW PERFORMANCE OF ULTRASOUND SURVEILLANCE FOR THE DIAGNOSIS OF LIVER CANCER IN HIV
Miguel Rodríguez Fernández, Nicolás Merchante, Maria J. Rios-Villegas, Koldo Aguirrebengoa, Maria A. García-Gonzalo, Joseba Portu, Francisco Vera, Marina Villalobos, Carlos Mínguez, Miguel Ángel López Ruz, Mohamed Omar, Carlos Galera, Blanca Figueruela López, Juan A. Pineda, for the Grupo para el Estudio de las Hepatitis Viricas (GEHEP)

610 INTRAHEPATIC HIV IS ASSOCIATED WITH ADVERSE LIVER OUTCOMES IN HIV-HBV COINFECTION
Jennifer M. Zerbato, Kasha P. Singh, Ajantha Solomon, Ashanti Dantanarayana, Surekha Tennakoon, Megan Crane, David Price, Sabine Braat, Hugh Mason, Peter Revill, Jennifer Audsley, Anachelle Avihingsanon, Sharon R. Lewin

611 COMPARTMENTALIZATION OF NS3 AND NSSA RASS IN HIV/HCV GT 1A OR 4D INFECTED PATIENTS
Riccardo Vercesi, Giulia Morsica, Hamid Hasson, Emanuela Messina, Caterina Uberti-Foppa, Sabrina Bagaglio

612 SECOND HITS PROMOTE HEPATOCYTE DEATH AND LIVER INJURY IN HIV INFECTION
Murali Ganesan, Raghubendra S. Dagur, Edward Makarov, Srivatsan Kidambi, Larisa Y. Poluektova, Natalia Osna

613 INFLAMMATORY CHEMOKINES LINKED TO HIV GENETIC DIVERSITY DURING HIV/HBV COINFECTION

614 INFLUENCE OF HCV INFECTION ON HIV-1 SPLICING IN CHRONICALLY COINFECTED PATIENTS
Paula Martínez-Román, Mª Rosa López-Huertas, Claudia Palladino, Marta Sánchez-Carrillo, Luz Martín-Carbonero, Lourdes Domínguez-Dominguez, Pablo Ryan, Ignacio Santos, Sara de la Fuente Moral, José Alcamí Pertejo, Salvador Resino, Amanda Fernández-Rodríguez, Mayte Coiras, Verónica Briz, for the COVIHEP

615 PREVALENCE OF FATTY LIVER DISEASE IN INDIVIDUALS WITH AND WITHOUT HIV INFECTION
Ditte M. Kirkegaard-Klitbo, Flemming Bendtsen, Stefan Stender, Klaus F. Kofoed, Borge Nordestgaard, Jens D. Lundgren, Susanne D. Nielsen, Thomas Benfield
**Poster Sessions**

616  **LIVER INFLAMMATION IS COMMON AND LINKED TO METABOLIC DERANGEMENTS IN TREATED HIV**

Kara W. Chew, Katherine Tassiopoulos, Frank J. Palella, Kunling Wu, Susanna Naggie, Netanya S. Utay, Edgar T. Overton, Mark Sulkowski

617  **FENTANYL USE AND LIVER DISEASE IN THE MIAMI ADULT STUDIES ON HIV (MASH) COHORT**

Marianna K. Baum, Kenneth E. Sherman, Qingyun Liu, Gustavo G. Zarini, Sabrina S. Martinez, Leslie Seminario, Jupshy Jasmin, Jacqueline Hernandez, Colby Teeman, Javier Tamargo, Nathalie Jaspar, Priscilla K. Clayton, Pedro J. Greer, Jag H. Khalsa, Adriana Campa

618  **THE SYNTHETIC OPIOID FENTANYL ENHANCES VIRAL REPLICATION IN VITRO**

Jason T. Blackard, Susan D. Rouster, Mohamed Tarek M. Shata, Kenneth E. Sherman, Ling Kong

---

**Poster P-M3 BEYOND TRADITIONAL RISK FACTORS: MECHANISMS OF VASCULAR DISEASE IN HIV**

Poster Hall - 4EF  2:30 PM - 4:00 PM

---

642  **VIRAL PERSISTENCE IS INDEPENDENTLY PREDICTIVE OF Atherosclerosis IN TREATED HIV**

Megan McLaughlin, Yifei Ma, Rebecca Scherzer, Smruti Rahalkar, Teri Liegler, Jeffrey N. Martin, Claire Mills, Steven G. Deeks, Priscilla Hsue

643  **VAGANCLOVIR REDUCES STNF–R2 AND VASCULAR DYSFUNCTION MARKERS IN TREATED HIV**

Gabriele Beck-Engeser, Frank Maldarelli, Vanessa A. York, Steven G. Deeks, Jeffrey N. Martin, Elizabeth Sinclair, Priscilla Hsue, Russell Tracy, Yong Huang, Peter W. Hunt

644  **PLASMA TISSUE FACTOR AND MCP–1 PREDICTS CIMT PROGRESSION IN TREATED HIV**

Denise C. Hsu, Yifei Ma, Danny Li, Meghan Williams, Adam Rupert, Rebecca Scherzer, Steven G. Deeks, Irini Sereti, Priscilla Hsue

645  **Socioeconomic Status Associates with Arterial Inflammation in HIV**

Lili Zhang, Amrit Narwan, Nicki Naddaf, Smruti Rahalkar, Tomas Patrich, Michael Osborne, Steven G. Deeks, Ahmed Tawakol, Priscilla Hsue

646  **INFLAMMATORY PHENOTYPES PREDICT PULSE WAVE VELOCITY CHANGE ON ART IN MALAWIAN ADULTS**

Christine Kelly, Willard Tinago, Alejandro A. Garcia, Patricia Hunter, Dagmar Alber, Natasha Luckhurst, Jake Connolly, Francesca I. Arrigoni, Raphael Kang’ona, Patrick W. Mallon, Henry Mwandumba, Sarah Walker, Saye Khoo, Nigel Klein, for the REALITY study team

---

**Poster P-M4 ALL THINGS LIPIDS**

Poster Hall - 4EF  2:30 PM - 4:00 PM

---

647  **TOCLIZUMAB ALTERS LIPIDS IN HIV+ INDIVIDUALS IN A RANDOMIZED, DOUBLE-BLIND STUDY**

Emily Bowman, Morgan Cichon, Kenneth Riedl, Jane Baum, Michael L. Freeman, Michael M. Lederman, Benigno Rodriguez, Nicholas Funderburg

648  **HDL CHOLESTEROL EFFLUX CAPACITY AND INCIDENT ASCVD IN HIV: IMPACT OF HAART**

Roger Bedimo, Colby Ayers, Jason Gillman, Amneris Luque, Ayea El-Ghazali, Constance A. Benson, Edgar T. Overton, Pablo TEBAS, ANAND Rohatgi
649  EVIDENCE FOR PLEIOTROPIC EFFECTS OF LIPID-LOWERING DRUGS DURING SUPPRESSIVE HAART
Henning J. Drechsler, Colby Ayers, James Cutrell, Pablo Tebas, Roger Bedimo, for the University of Texas Southwestern School of Medicine

650  PCSK9 AND HIV INFECTION: CORRELATION WITH DYSLIPIDEMIA, INFLAMMATION, AND HAART
Elisabetta Schiaroli, Salvatore Cardaci, Vanessa Bianconi, Massimo R. Mannarino, Matteo Pirro, Daniela Francisci, Franco Baldelli

651  LIPID CHANGES ASSOCIATED WITH TAF ARE REVERSIBLE BY SWITCHING BACK TO TDF
Ana Milinkovic, Florian Berger, Alejandro Arenas-Pinto, Stefan Mauss

652  CHANGES IN LIPIDS AFTER A DIRECT SWITCH FROM TDF TO TAF
Patrick W. Mallon, Laurence Brunet, Jennifer S. Fusco, Girish Prajapati, Andrew Beyer, Gregory Fusco, Michael Wohlfeiler

Poster P-M5 ENDOTHELIAL DYSFUNCTIONS: THE VIRUS, ART, AND OTHER FACTORS
Poster Hall - 4EF  2:30 PM - 4:00 PM

653  HIV-1 GP120 AND TAT-INDUCED MICROPARTICLES IMPAIR ENDOTHELIAL CELL FUNCTION
Jamie Hijmans, Kelly Stockelman, Ma’ayan Levy, L, Madden Brewster, Tyler Bammert, Jared Greiner, Elizabeth Connick, Christopher DeSouza

654  HIV-1, CIRCULATING MICROPARTICLES, AND ENDOTHELIAL CELL DYSFUNCTION
Jamie Hijmans, Kelly Stockelman, Ma’ayan Levy, L, Madden Brewster, Tyler Bammert, Jared Greiner, Brian Stauffer, Elizabeth Connick, Christopher DeSouza

655  ENDOTHELIAL DYSFUNCTION IS COMMON IN EARLY HIV INFECTION AND IS REVERSIBLE WITH ART
Kelvin Bush, Julie Teel, James Watts, Gadiel Alvarado, Rosco Gore, Jason Okulicz

656  ADVANCED GLYCATION END PRODUCTS, INFLAMMATION, AND ENDOTHELIAL DYSFUNCTION IN HIV
Vanessa El Kamari, Alicia Thomas, Abdus Sattar, Grace A. McComsey

657  CUMULATIVE ART EXPOSURE IS ASSOCIATED WITH ENDOTHELIAL AND IMMUNE ACTIVATION IN HIV
Jose R. Castillo-Mancilla, Samantha MalWhinney, Ryan P. Coyle, James Morrison, Eric Poeschla, Rick Rapaport, Thomas Campbell, Lucas Ellison, Jia-Hua Zheng, Lane R. Bushman, Jennifer J. Kiser, Peter L. Anderson, Jonathan Z. Li

Poster P-N1 WEIGHT GAIN DURING ART
Poster Hall - 4EF  2:30 PM - 4:00 PM

669  RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR–BASED ART
Jordan E. Lake, Kunling Wu, Kristine M. Erlandson, Sara H. Bares, Paula Debroy, Catherine Godfrey, John R. Koethe, Grace A. McComsey, Frank J. Palella, Katherine Tassiopoulos
670  GREATER WEIGHT GAIN AMONG TREATMENT-NAIVE PERSONS STARTING INTEGRASE INHIBITORS

671  WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT-EXPERIENCED ADULTS WITH HIV
Grace A. McComsey, Joseph J. Eron, Steven Santiago, Karam Mounzer, Graeme Moyle, Thanes Vanig, Paul E. Sax, Keri N. Althoff, Scott Milligan, Michael Marks, Richard Haubrich, Richard A. Elion

672  INTEGRASE STRAND TRANSFER INHIBITORS ARE ASSOCIATED WITH WEIGHT GAIN IN WOMEN
Anne M. Kerchberger, Anandi N. Sheth, Christine D. Angert, Cyra Christina Mehta, Nathan A. Summers, Igbo Ofotokun, Deborah Gustafson, Sheri Weiser, Seble Kassaye, Deborah Konkle-Parker, Anjali Sharma, Adaora Adimora, Hector Bolivar, Cecile D. Lahiri

673  THE IMPACT OF WEIGHT GAIN AND SEX ON IMMUNE ACTIVATION FOLLOWING INITIATION OF ART
Sara H. Bares, Laura M. Smeaton, Vincent Vu, Beth A. Zavoda-Smith, Sarah E. Scott, Catherine Godfrey, Grace A. McComsey

674  WEIGHT GAIN AMONG VIRALLY SUPPRESSED PERSONS WHO SWITCH TO InSTI-BASED ART
Frank J. Palella, Nabil Rayeed, Jun Li, Douglas Ward, Jack Fuhrer, Stacey Purinton, Ellen Tedaldi, Richard Novak, Kate Buchacz

675  DIFFERENTIAL BMI CHANGES FOLLOWING PI- AND InSTI-BASED ART INITIATION BY SEX AND RACE
Roger Bedimo, Xilong Li, Beverley Adams-Huet, Jordan E. Lake, Barbara S. Taylor, Deborah Kim, Pablo Tebas, Amneris Luque

676  LONG-LASTING ALTERATIONS IN FAT DISTRIBUTION IN PLWH EXPOSED TO THYMIDINE ANALOGUES
Marco Gelpi, Shoaib Afzal, Andreas Fuchs, Jens D. Lundgren, Andreas D. Knudsen, Ninna Drivsholm, Anne-Mette Lebech, Birgitte Lindegaard, Jørgen T. Kuhl, Per E. Sigvardsen, Lars Køber, Børge Nordestgaard, Klaus F. Kofod, Susanne D. Nielsen

677  HIGH PREVALENCE OF CENTRAL OBESITY IN HIV-INFECTED & HIV-UNINFECTED ADULTS, BOTSWANA
Mosepele Mosepele, Pinkie Melamu, Kara Bennett, Tendani Gaolathe, Joseph Makhema, Mompati O. Mmalane, Molly Pretorius Holme, Refeleletswe Lebelonyane, Kathleen M. Powis, Jean Leidner, Joseph N. Jarvis, Neo Tapela, Lucky Mokgatathe, Kathleen Wirth, Shahin Lockman

678  SLEEVE GASTRECTOMY VS ROUX-EN-Y BYPASS ON WEIGHT AND METABOLIC COMPLICATIONS IN HIV
Vanessa El Kamari, Julia C. Kosco, Corrilynn O. Hileman, Grace A. McComsey

Poster P-N2 INTEGRASE INHIBITORS: CARDIOMETABOLIC OUTCOMES
Poster Hall - 4EF 2:30 PM - 4:00 PM

679  DOLUTEGRAVIR AND INSULIN RESISTANCE
Janet Lo, James Oyee, Melissa Crawford, Richard Grove, Ralph DeMasi, Lloyd Curtis, Anna Fettiplace, Vani Vannappagari, Nassrin Payvandi, Michael Aboud, Jean van Wyk
680 LOWER CARDIOVASCULAR DISEASE RISK ASSOCIATED WITH INTEGRASE INHIBITORS
Jane A. O’Halloran, John Sahrmann, Anne M. Butler, Margaret A. Olsen, William Powderly

Poster P-O1 CRYPTOCOCCAL MENINGITIS SCREENING, PREEMPTIVE THERAPY, AND OUTCOMES
Poster Hall - 4EF 2:30 PM - 4:00 PM

705 SCREENING AND PREEMPTIVE ANTIFUNGAL THERAPY FOR SUBCLINICAL CRYPTOCOCCAL DISEASE
Admire Hlupeni, Rhoderick Macheke, Kathryn F. Boyd, Takudzwa Chagumaira, Primrose Nyamanyo, Chiratidzo E. Ndhlovu, Azure T. Makadzange

706 SCREENING FOR TALAROMYCES AND CRYPTOCOCCAL ANTIGENEMIA IN AIDS PATIENTS IN GUANGDONG
Linghua Li, Liya Li, Yao He, Haodi Wang, Kaiyin He, Xiaoping Tang, Thuy Le, Weiping Cai

707 THE COST-EFFECTIVENESS OF AMBISOME FOR ASYMPTOMATIC CRYPTOCOCCAL INFECTION
Radha Rajasingham, David Mey, Elizabeth Nalintya, Bruce Larson, David R. Boulware

708 CRYPTOCOCCAL ANTIGENEMIA IN HIV PATIENTS WITH VIROLOGIC FAILURE IN UGANDA
Edward Mpoza, David Mey, Maria S. Nabaggala, Lillian Tugume, Kenneth Ssebambulidde, Joshua Rhein, David R. Boulware, Radha Rajasingham

709 CYTOMEGALOVIRUS VIREMIA ASSOCIATED WITH MORTALITY IN CRYPTOCOCCAL MENINGITIS
Caleb P. Skipper, Mark R. Schleiss, Jason C. Zabel, Nelmary Hernandez-Alvarado, Sarah Lofgren, Henry Nabeta, Kabanda Taseera, Abdu Musubire, Charlotte Schutz, Ananta Bangdive, Katherine Huppler Hullsiek, Conrad Muzoora, David Mey, Graeme Meintjes, David R. Boulware, for the COAT Trial Team

Poster P-O2 WHAT'S APP WITH OTHER OIs?
Poster Hall - 4EF 2:30 PM - 4:00 PM

710 ASYMPTOMATIC TALAROMYCES MARNEFFEANTIGENEMIA AND MORTALITY IN ADVANCED HIV DISEASE
Nguyen T. Thu, Vu Quoc Dat, Jasper F. Chan, Hien T. Ha, Dung T. Nguyen, Anh T. Ho, Patrick C. Woo, Kwok-Yung Yuen, Sheryl Lyss, Moses Bateganya, Kinh V. Nguyen, Thuy Le

711 PREDICTIVE MODELING OF MORTALITY IN INVASIVE TALAROMYCOSIS IN HIV PATIENTS
Shengxin Tu, Cliburn Chan, Thuy Le

712 WITHHOLDING PCP PROPHYLAXIS IN VIRALLY SUPPRESSED HIV PATIENTS FROM COHERE
Andrew Atkinson, for the Opportunistic Infections Project Team of COHERE
713  PNEUMOCOCCAL VACCINATION IN HIV+ ADULT PATIENTS ON SUPPRESSIVE ART, 2010-2017

María J. Vivancos-Gallego, Alfonso Muriel, Ana Moreno, María Jesus Perez-Elias, Jose L. Casado, Carmen Quereda, Matilde Sanchez-Conde, Santos Del Campo, Fernando Dronda, Sergio Serrano-Villar, Ana Sanchez, Jose Valencia, Santiago Moreno, for the Instituto Ramon y Cajal de Investigacion Sanitaria

Poster P-O3 NOVEL DIAGNOSTICS FOR LATENT AND ACTIVE TB
Poster Hall - 4EF 2:30 PM - 4:00 PM

714  DIGITAL CHEST RADIOGRAPHY OPTIMISES TB SCREENING OF SOUTH AFRICAN CLINIC ATTENDEES

Nishila Moodley, Amashnee Saimen, Noor Zakhura, David Motau, Candice Chetty-Makan, Kavindhran Velen, Gavin Churchyard, Salome Charalambous

715  DIAGNOSIS OF LATENT TUBERCULOSIS AMONG US-BORN PEOPLE LIVING WITH HIV

April Pettit, Jason Stout, Robert Belknap, Constance A. Benson, Marie Nancy Seraphin, Michael Lauzardo, David Horne, Richard S. Garfein, Fernanda Maruri, Dolly Katz, Christine Ho, for the Tuberculosis Epidemiologic Studies Consortium (TBESC)

716  QUANTIFICATION OF CD64: A PREDICTIVE BIOMARKER FOR PROGRESSION TO ACTIVE TUBERCULOSIS

Cristina Ceriani, Arianna Gatti, Massimo Villa, Maria Teresa Manco, Massimo De Paschale, Ilaria Caramma, Bruno Brando, Pierangelo Clerici

717  ORAL SWAB ANALYSIS (TB-OSA) FOR NON–SPUTUM-BASED TB DIAGNOSIS IN KENYA

Sylvia LaCourse, Rachel Wood, Evans Seko, Gregory S. Ouma, Barbra A. Richardson, Grace John-Stewart, Gerard Cangelosi

718  QUANTIFICATION OF CIRCULATING ANTIGENS ENABLES A RAPID BLOOD TB TEST

Tony Hu

719 LB  BD MAX™ MDR-TB ASSAY FOR DETECTION OF TUBERCULOSIS AND DRUG RESISTANCE

Maunank Shah, Josh Betz, Sonia Paradis, Natalie Beylis, Mark Nicol, Lydia Nakiyinyi, Moses L. Joloba, Renu Bharadwaj, Neeta N. Pradhan, Vidya Mave, Tatiana Caceres, Eduardo Gotuzzo, Charles Cooper, Susan E. Dorman, Yukari C. Manabe

Poster P-O4 TB SCREENING AND PREVENTIVE THERAPY
Poster Hall - 4EF 2:30 PM - 4:00 PM

720  THE EFFECTIVENESS OF VARIOUS SYMPTOM-BASED ALGORITHMS FOR TB SCREENING AT HIV TESTING

Vanessa Rivera, Marc Antoine Jean Juste, Jeanwilkens Sainristil, Dani Archange, Samantha Gluck, Harrison Reeder, Oksana Ocheretina, Tahera Doctor, Eleonore Fuqua, Sarah Centanni, Pierre Cremieux, Daniel Fitzgerald, Serena Koenig, Jean William Pape

721  OPTIMIZING DIAGNOSTIC ALGORITHMS FOR ACTIVE PULMONARY TUBERCULOSIS IN HIV CLINICS

Haylea A. Hannah, Bradley G. Wagner, Stewart T. Chang, Paul K. Drain
722 RURAL AND URBAN DIFFERENCES IN THE IMPACT OF THE XPERT MTB/RIF TEST ON TB CARE
Simon Walusimbi, Stella Zawedde-Muyanja, Julius Sendiwala, Abudnoor Nyombi, Stavia Turyahabwe, Andrew Kambugu, Barbara Castelnuovo, Yukari C. Manabe

723 TB PREVENTIVE THERAPY UPTAKE IS HIGH WITH COMMUNITY ART DELIVERY IN SOUTH AFRICA
Adrienne E. Shapiro, Alastair van Heerden, Heidi van Rooyen, Torin T. Schaafisma, Olivier Koole, Deenan Pillay, Jared Baeten, Connie L. Celum, Ruanne V. Barnabas, for the DO ART Study Team

724 EVALUATION OF PULMONARY TUBERCULOSIS FOLLOWING IPT IN KENYAN ADULTS LIVING WITH HIV
Jill K. Gersh, Daniel Matemo, John Kinuthia, Zachary Feldman, Sylvia LaCourse, Alex J. Warr, Ruanne V. Barnabas, Maureen Kamene, David Horne

725 THE IMPACT OF HIV-COINFECTION ON THE EVOLUTION OF MYCOBACTERIUM TUBERCULOSIS
Chloé Loiseau, Marie Ballif, Daniela Brites, Lukas Fenner, Miriam Reinhard, Alash’le Abimiku, Marcel Yotebieng, Helen Cox, E. Jane Carter, Joachim Gnikoro, Jimena Collantes, Anchalee Avihingsan, Nicola M. Zetola, Matthias Egger, Sebastien Gagneux

726 MYCOBACTERIUM TUBERCULOSIS COINFECTION INCREASES HIV RESERVOIR SIZE
Jingna Xun, Hongzhou Lu, Jun Chen, Tangkai Qi, Yongjia Ji, Renfang Zhang, Li Liu, Yinzhong Shen, Wei Song, Yang Tang, Qi Tang, Zhenyan Wang

727 FUNDAMENTAL SHIFTS IN HIV POPULATION STRUCTURE AFTER TB-IRIS
Camille Lange, Maura Manion, Rob Gorelick, Natalie Lindo, Christian Gonsalves, James Virga, Virginia Sheikh, Gregg Roby, Joseph Adelsberger, Frank Maldarelli, Irini Sereti

728 TB-SPECIFIC CD4+ T CELLS ARE ASSOCIATED WITH PULMONARY INFLAMMATION ON ART IN HIV/TB
Pholo W. Maenetje, Shruthi Ravimohan, Itai T. Ncube, Sara C. Auld, Nelly Ratsela, Mandla Mlotshwa, Modulakgotla Sebe, Jonathan Smith, Mboyo-Di-Tamba Vangu, Hardy Kornfeld, Drew Weissman, Gavin Churchyard, Gregory Bisson

729 HIV TEST YIELD AND REASONS FOR UNKNOWN HIV STATUS AMONG TB PATIENTS: THE KOPANYO STUDY
Xiao Jun Wen, Othusitse Fane, Matsiri Ogopotse, Mbathzi Dima, Eleanor Click, Patrick Moonan, John Oeltmann, Rosanna Boyd, Chawangwa Modongo, Christopher Serumola, James Tobias, Alyssa Finlay, Nicola M. Zetola

730 TIMING AND INCIDENCE OF HIV-ASSOCIATED TUBERCULOSIS: A 4-COUNTRY STUDY
Enrico Girardi, Yanink Caro-Vega, Jospeh Musaazi, Gabriela Carriquiry, Alessandro Cozzi-Leprì, Barbara Castelnuovo, Andrea Gori, Yukari C. Manabe, Eduardo Gotuzzo, Antonella D’Arminio Monforte, Brenda Crabtree-Ramirez, Cristina Mussini, for the ICOA , IMT AvH, INNSZ and IDI Cohorts
731 HIGH INCIDENCE OF TUBERCULOSIS AMONG HIV+ PATIENTS TREATED WITH HAART IN ZAMBIA
Simon Mutembo, Jane N. Mutanga, Vincent C. Marconi, Christopher Whalen

732 COMMUNITY ART REFILL GROUPS AND TUBERCULOSIS RATES IN ZIMBABWE
Aaron Bochner, Claudios Muserere, Blessing Wazara, Batsirai Makunike, Gloria Gonese, Elizabeth Meacham, Frances Petracca, Ponesai Nyika, Shiriish Balachandra, Ruth Levine, Ann Downer, Stefan Z. Wiktor

733 INCIDENCE OF TUBERCULOSIS IN THE BOTSWANA NATIONAL ARV PROGRAMME
Lucy Mupfumi, Sikhulile Moyo, Qiao G. Michan, Sanghyuk S. Shin, Judith Nawa, Botshelo T. Kgwaadira, Tony Chebani, Thato Iketlenq, Tuelo Mogashoa, Rosemary Musonda, Ishmael Kasvosve, Nicola M. Zetola, Simani Gasetiwi

734 HIGH RATES OF TB IN THE FIRST 6 MONTHS OF DOLUTEGRAVIR-BASED ART IN BOTSWANA
Lucy Mupfumi, Sikhulile Moyo, Ava Avalos, Lesedi Bewlay, Kaelo Seatla, Sanghyuk S. Shin, Ishmael Kasvosve, Nicola M. Zetola, Simani Gasetiwi, for the BEAT Cohort Study Team

735 KIDNEY DISEASE IN AFRICANS WITH HIV AND TUBERCULOSIS
Nicola Wearne, Rachel Hung, Raphaella Bohmer, Ruan Spies, Aadil Omar, Samantha Ash, Fowzia Ibrahim, Robert Miller, John Booth, Sebastian Lucas, Frank Post

736 MORTALITY AFTER PRESUMED TB TREATMENT COMPLETION IN PERSONS WITH HIV IN LATIN AMERICA
Serena Koenig, Ahra Kim, Bryan E. Shepherd, Carina Cesar, Valdilea Veloso, Claudia P. Cortes, Denis Padgett, Brenda Crabtree-Ramírez, Eduardo Gotuzzo, Catherine McGowan, Timothy R. Sterling, Jean William Pape, for the The Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)

737 LB WITHDRAWN/INTENTIONALLY UNASSIGNED

Poster P-O6 DRUG-RESISTANT TB
Poster Hall - 4EF 2:30 PM - 4:00 PM

738 RIFAMPIN-RESISTANT TUBERCULOSIS IN THE UNITED STATES, 1998–2014
Lisa Sharling, Suzanne Marks, Terence Chorba, Sundari Mase

739 GLOBAL DISPARITIES IN PRICES OF KEY MEDICINES FOR MULTIDRUG-RESISTANT TUBERCULOSIS
Andrew Hill, Dzintars Gotham

740 DEVELOPMENT AND VALIDATION OF A PREDICTIVE MODEL FOR AMINOGLYCOSIDE OTOTOXICITY
Hyejeong Hong, David Dowdy, Kelly E. Dooley, Chakra Budhathoki, Hae-Ra Han, Jason Farley

741 RIFAMPICIN RESISTANCE ACCURATELY IDENTIFIED BY CLUSTERING ULTRA MELTING TEMPERATURES
Gabriel D. Eisenberg, Lesley Scott, Puleng S. Marokane, Pedro da Silva, Kyle Fyvie, Wendy Stevens

742 THE COST AND IMPACT OF MDR-TB TREATMENT GUIDELINE CHANGES IN SOUTH AFRICA
Sithabiso D. Masuku, Ribka Berhanu, Craig Van Rensburg, Ndebele Ndjeka, Sydney Rosen, Lawrence Long, Denise Evans, Brooke E. Nichols
**Poster Sessions**

**CROI 2019**

**Poster P-P5**  **DRILLING DOWN ON VERTICAL TRANSMISSION**

**Poster Hall - 4EF**  
2:30 PM - 4:00 PM

**768 TOWARDS EMTCT IN ZIMBABWE: SERVICE UPTAKE AND IMPACT OF OPTION B+ ON MTCT, 2012-2018**

Mi-Suk Kang Dufour, Sandra I. McCoy, Aybuke Koyuncu, Angela Mushavi, Agnes Mahomva, Nancy Padian, Frances Cowan

**769 HIV DRUG RESISTANCE AT PERINATAL TRANSMISSION AND ACCUMULATION DURING BREASTFEEDING**


**770 GP41 ECTODOMAIN-SPECIFIC IGG IS ASSOCIATED WITH INCREASED VERTICAL HIV-1 TRANSMISSION**

Nicole Naiman, Jennifer Slyker, Ruth Nduati, Julie M. Overbaugh

**771 EPITOPE TARGETS OF ADCC-MEDIATING ANTIBODIES AND THEIR RELATION TO MTCT OF HIV-1**

Nicole Naiman, Jennifer Slyker, Barbra A. Richardson, Ruth Nduati, Julie M. Overbaugh

**772 ABUNDANT EXPRESSION OF CCR5 ON EARLY HOFBAUER CELLS MAY INCREASE HIV-1 SUSCEPTIBILITY**

Dominika Swieboda, Erica L. Johnson, Ioanna Skountzou, Rana Chakraborty

**Poster P-P6**  **PREVENTING HIV ACQUISITION IN PREGNANCY AND BREASTFEEDING**

**Poster Hall - 4EF**  
2:30 PM - 4:00 PM

**773 INCIDENT HIV INFECTION AMONG PREGNANT WOMEN IN BOTSWANA**

Gloria K. Mayondi, Modiegi D. Diseko, Judith Mabuta, Sonya Davey, Arielle Isaacson, Sikhulile Moyo, Chelsea Morroni, Mompati O. Mmalane, Joseph Makhema, Tumalano Sekoto, Goabaone Mogomotsi, Shahn Lockman, Roger L. Shapiro, Rebecca Zash

**774 HETEROGENEITY OF HIV RETESTING DURING PREGNANCY AND POSTPARTUM IN KENYA**

Monalisa Penumetsa, Shiza Farid, Daniel Matemo, Barbra A. Richardson, Grace John-Stewart, John Kinuthia, Alison L. Drake

**775 PRIMARY HIV PREVENTION IN PREGNANT AND LACTATING UGANDAN WOMEN: A RANDOMIZED TRIAL**

Jacio Homsy, Rachel King, Femeke Bannink, Zikulah Namukwaya, Eric Vittinghoff, Alexander Amone, Francis Ojok, Gordon Rukundo, Sharon Amama, Lawrence Ojom, Pamela Atim, Josaphat Byamugisha, George Rutherford, Elly T. Katabira, Mary G. Fowler

**776 MODELING THE IMPACT OF PrEP FOR PREGNANT AND BREASTFEEDING WOMEN IN SOUTH AFRICA**

Dvora Joseph Davey, Linda-Gail Bekker, Yolanda Gomba, Landon Myer, Thomas J. Coates, Leigh F. Johnson

**777 PREFERENCES FOR HOME Vs CLINIC AND BLOOD Vs SALIVA HIV RETESTING IN PREGNANCY**

Anjuli D. Wagner, Jill Neary, David A. Katz, Grace John-Stewart, Daniel Matemo, John Kinuthia, Alison L. Drake
778 CHALLENGES OF POTENTIALLY FALSE-POSITIVE HIV TESTS IN PREGNANT WOMEN IN THE PrEP ERA

Anjuli D. Wagner, John Kinuthia, Julia C. Detttinger, Nancy M. Ngumbau, Laurèn Gómez, Salphine A. Wattouy, Alison L. Drake, Felix Abuna, Jillian Pintye, Ben O. Odhiambo, Grace John-Stewart, Jared Baeten

Poster P-P7 HIV TESTING OF INFANTS AND CHILDREN
Poster Hall - 4EF
2:30 PM - 4:00 PM

779 PILOTING POINT-OF-CARE HIV TESTING AT BIRTH AND 6 WKS POSTNATAL IN 4 KENYAN HOSPITALS

Catherine Wexler, Melinda Brown, Matthew Sandbulte, May Maloba, Brad Gautney, Kathy Goggin, Thomas A. Odeny, Shadrack Babu, Elizabeth Muchoki, Maosa Nick, Sarah Finocchiaro Kessler

780 ROUTINE POINT-OF-CARE HIV TESTING AT BIRTH: RESULTS FROM A 1-YEAR PILOT IN ESWATINI

Emma Sacks, Caspian Chouraya, Bonisile Nhlabatsi, Philiwiwe Khumalo, Thembie Masuku, Tandzile Zikalala, Gcinile Nyoni, Nobuhle Mthetwa, Flavia Bianchi, Jennifer Cohn

781 EARLY INFANT DIAGNOSIS OF HIV USING DNA PCR CT VALUE AND REPEAT TESTING ALGORITHM


782 DIAGNOSTIC ACCURACY OF HIV ORAL RAPID TESTS VS BLOOD-BASED RAPID TESTS AMONG CHILDREN

Chido Dziva Chikwari, Irene Njuguna, Crissi Rainer, Belinda V. Chihota, Jill Neary, Jennifer Slyker, David A. Katz, Dalton Wamalwa, Laura Oyiengo, Grace McHugh, Ethel Dauya, Grace John-Stewart, Rashida Ferrand, Anjuli D. Wagner

783 FINDING THE MISSING CHILDREN WITH HIV: INDEX-LINKED TESTING IN CLINICS & COMMUNITIES

Chido Dziva Chikwari, Tsitsi Bandason, Victoria Simms, Stefanie Dringus, Ethel Dauya, Grace McHugh, Edwin Sibanda, Rudo Chikodzore, Miriam N. Mutseta, Getrude Ncube, Sara Page-Mtongwiza, Elizabeth L. Corbett, Helen A. Weiss, Rashida Ferrand

Poster P-Q1 BRAINS, BONE, AND GENOMES IN HIV-EXPOSED CHILDREN
Poster Hall - 4EF
2:30 PM - 4:00 PM

784 EARLY CHILD DEVELOPMENT OF HIV-EXPOSED UNINFECTED CHILDREN IN RURAL ZIMBABWE

Jaya Chandna, Ceri Evans, Bernard Chasweka, Gwendoline Kandawasvika, Naume Taevengwa, Batsirai Mutasa, Florence D. Majo, Kuda Mutasa, Lawrence Moulton, Robert Ntozini, Andrew Prendergast, Jean Humphrey, Melissa Gladstone, for the SHINE Trial Team

785 NEURODEVELOPMENT IN INFANTS OF WOMEN WITH PERINATALLY VS NONPERINATALLY ACQUIRED HIV

Jennifer Jao, Deborah Kacanek, Wendy Yu, Paige L. Williams, Kunjal Patel, Sandra Burchett, Gwen Scott, Elaine J. Abrams, Rhoda Sperling, Russell B. Van Dyke, Renee Smith, Kathleen Malee, for the Pediatric HIV/AIDS Cohort Study
786 **NEURODEVELOPMENTAL OUTCOMES FOLLOWING IN UTERO EFAVIRENZ EXPOSURE AMONG HEU CHILDREN**

Adam R. Cassidy, Paige L. Williams, Jean Leidner, Gloria K. Mayondi, Gbolahan Ajibola, Judith Mabuta, Joseph Makhema, Kathleen M. Powis, Roger L. Shapiro, Betsy Kammerer, **Shahin Lockman**

787 **HIV-EXPOSED UNINFECTED INFANT GUT MICROBIOME EVOLUTION IN THE FIRST YEAR OF LIFE**


788 **DIFFERENCES IN GUT MICROBIOME IN HIV-INFECTED VERSUS HIV-EXPOSED, UNINFECTED INFANTS**

Wei Li A. Koay, Hyunwook Koh, Mutsa Bwakura-Dangarembizi, Myron Levin, Adriana Weinberg, Ni Zhao, Deborah Persaud

789 **COMPLETE MITOCHONDRIAL GENOME IN HIV-INFECTED CHILDREN AND MOTHER-CHILD PAIRS**

Claudia Fortuny, Constanza Moren, Lidia Carreño, Elena Garcia-Arumí, Emilia Sanchez, Glòria Garrabou, Ingrid Gonzalez-Casacuberta, Ester Tobias, Antoni Noguera-Julian

796 **DETECTION HIV DNA BY DDPCR BEFORE VIREMIA IN INTRAPARTUM & AT BIRTH IN IU INFANTS**

Yvonne Bryson, Ruth Cortado, Dimitrios Vataxis, Irene J. Kim, Jerome Zack, Ting-Ting Wu, Karin Nielsen-Saines, Deborah Persaud, for the HPTN/NICHDD040

797 **MATERNAL HIV RNA AFTER DELIVERY IS CORRELATED WITH INFANT PRETREATMENT HIV RNA**

Maureen Sakol-Mosethi, Gbolahan Ajibola, Kara Bennett, Sikhulile Moyo, Kenneth Maswabi, Oganne Batlang, Joseph Makhema, Kathleen M. Powis, Shahin Lockman, Daniel R. Kuritzkes, Michael D. Hughes, Roger L. Shapiro, Mathias Lichterfeld

798 **EARLY ART START IN CHILDREN IS ASSOCIATED WITH MORE RAPID DECAY OF HIV-1 DNA**

Kirsten A. Veldsman, Anita Janse van Rensburg, Shahieda Isaacs, Shalena Naidoo, Barbara Laughton, Carl Lombard, Mark Cotton, John W. Mellors, Gert U. van Zyl

799 LB **VIROLOGIC RESPONSE TO VERY EARLY ART IN NEONATES WITH IN UTERO HIV: IMPAACT P1115**

Deborah Persaud, Ellen G. Chadwick, Camlin Tierney, Bryan Nelson, Mark Cotton, Anne Coletti, Theodore Ruel, Mutsa Bwakura-Dangarembizi, Macpherson Mallewa, Kimesh L. Naidoo, Christina Reding, Rohan Hazra, Patrick Jean-Philippe, Yvonne Bryson, for the IMPAACT P1115 Study Team

800 **SHIV CHS05 T/F RESERVOIR AND REBOUND IN INFANT AND ADULT RHESUS MACAQUES**

Ria Goswami, Ashley N. Nelson, Joshua J. Tu, Maria Dennis, Riley J. Mangan, Cameron Mattingly, Amit Kumar, Maud Mavigner, Ann Chahroudi, George Shaw, Katharine J. Bar, Kristina De Paris, Koen Van Rompay, Sallie Permam
801 HIV-SPECIFIC ANTIBODY LEVELS CORRELATE WITH TFH MATURATION IN EARLY TREATED INFANTS

Julie Mitchell, Thanyawee Puthanakit, Kenneth Dietze, Marta Massanella, Pope Kosalaraeka, Thitiporn Borkird, Suparat Kanjanavant, Piyarat Sunantaratiwong, Thidarut Jupimai, Panadda Sawangsinth, Mark de Souza, Nicolas Chromont, Jintanat Ananworanich, Lydie Trautmann, for the HIVNAT209 Study group

802 OUTCOMES OF NEONATES WITH RAPID HIV TREATMENT IN US: TREATING INFANTS EARLY STUDY


803 HIV PERSISTS IN DIFFERENTIATED MEMORY CD4 T CELLS IN ART-SUPPRESSED CHILDREN

Marta Massanella, Jintanat Ananworanich, Louise Leyre, Thidarut Jupimai, Julie Mitchell, Panadda Sawangsinth, Mark de Souza, Piyarat Sunantaratiwong, Kulkanya Chokephaibulkit, Lydie Trautmann, Thanyawee Puthanakit, Nicolas Chromont, for the HIVNAT209 and HIVNAT194 study groups

804 IMMUNO-VIROLOGICAL IMPACT OF EARLY VS LATE ART INITIATION IN CHILDREN AND ADOLESCENTS

Pierre Frange, Veronique Avettand-Fenoel, Jérôme Le Chenadec, Catherine Dollfus, Thomas Montange, Stephane Blanche, Albert Faye, Martine Levine, Valérie Marcou, Damien Batalie, Marine Fillion, Laura Nailer, Josiane Warszawski, Florence Buseyne, for the ANRS-EP59-CLEAC Study Group

805 LONG-TERM PERSISTENCE OF HIV-INFECTED CELL CLONES IN CHILDREN TREATED EARLY


806 INTACT HIV PROVIRUSES ARE DETECTABLE 7-9 YEARS LATER WHEN ART STARTS AFTER 3 MONTHS

Mary Grace K. Katusiime, Michael J. Bale, Imogen Wright, Wei Shao, Wei-Shau Hu, Mark Cotton, John W. Mellors, Mary F. Kearney, Gert U. van Zyl

Poster P-R3 PHYLOGENETICS, MAPPING, AND OUTBREAKS

Poster Hall - 4EF 2:30 PM - 4:00 PM

856 INCIDENT INFECTION IN HIGH-PRIORITY HIV MOLECULAR TRANSMISSION CLUSTERS

Joel O. Wertheim, Nivedha Panneer, Anne Marie France, Neeraja Saduvala, Alexandria M. Oster

857 MOLECULAR SURVEILLANCE AS A MEANS TO EXPAND AN OUTBREAK INVESTIGATION: MA, 2015-2018

Betsey John, Nivedha Panneer, Matthew Tumpney, Paul McClung, Erica Dawson, Kate Buchacz, Kathleen Roosevelt, Philip J. Peters, Tracy Stiles, Ellsworth M. Campbell, William M. Switzer, Alfred DeMaria, Kevin Cranston, Sheryl Lyss, for the Massachusetts Epi-Aid Investigation Team

858 WITHDRAWN/INTENTIONALLY UNASSIGNED

859 WITHDRAWN/INTENTIONALLY UNASSIGNED
860 USING NEAR REAL-TIME MOLECULAR SURVEILLANCE TO INFORM DATA-TO-CARE IN NEW YORK CITY
Lucia V. Torian, Chi-Chi N. Udéagu, Lisa A. Forgione, Qiang Xia, Joel O. Wertheim, Kavita Misra, Jamie Huang, Jennifer Rakeman-Cagno, Susan Blank, Michael A. Castro, Sarah L. Braunstein

861 MAPPING GROWTH OF LARGE TRANSMISSION NETWORKS USING DIFFERENT CLUSTERING ALGORITHMS
Nathan Osman, Antoine Chaillon, Ruxandra-Ilinca Ibanescu, Isabelle Hardy, Irene Vrbik, Bonnie Spira, Luc Villandré, David Stephens, Michel Roger, Bluma G. Brenner

862 EPIDEMIOLOGIC CORRELATES OF HIV LINEAGE LEVEL DIVERSIFICATION RATE
Angela McLaughlin, P. Richard Harrigan, Tetyana Kalnyayk, Jinny Choi, Jeffrey Joy

863 GEOSPATIAL DISPERSAL OF HIV-1 TRANSMISSION IN 6 MAJOR CITIES IN GERMANY
Melanie Stecher, Antoine Chaillon, Philipp De Leuw, Johannes Bogner, Anna M. Eis-Hübinger, Clara Lehmann, Georg Behrens, Olaf Degen, Christoph D. Spinner, Christoph Stephan, Joerg Janne Vehrshcild, Sanjay R. Mehta, Martin Hoenigl, for the Translational Platform HIV (TP-HIV) Molecular Epidemiology Team

864 PRETREATMENT HIV DRUG RESISTANCE SPREAD IN 6 GERMAN METROPOLITAN REGIONS
Melanie Stecher, Martin Hoenigl, Philipp De Leuw, Josef Eberle, Jan-Christian Wasmuth, Georg Behrens, Guido Schäfer, Christoph D. Spinner, Christoph Stephan, Elena Knops, Sanjay R. Mehta, Joerg Janne Vehrshcild, Antoine Chaillon, for the Translational Platform HIV (TP-HIV) Molecular Epidemiology Team

865 HIV DYNAMICS IN THE MOST AFFECTED AREA OF EUROPE: A TALE OF 2 COUNTRIES
Lise Marty, Liis Lemsalu, Dominique Costagliola, Kaire Vals, Ruta Kaupe, Indra Linina, Inga Upmace, Kristi Rüütel, Anda Ķīvīte, Virginie Supervie, for the HERMETIC study group

866 WITHDRAWN/INTENTIONALLY UNASSIGNED

867 CLUSTER SURVEILLANCE OF FRENCH PRIMARY INFECTIONS: TOWARD A MORE VIRULENT CRF02_AG?
Benoit Visseaux, Lambert Assoumou, Mary Anne Trabaud, Brigitte Montes, Laurence Bocket, Samira Fafi-Kremer, Marc Wirden, Corinne Amiel, Anne De Monte, Karl Stefic, Camille Tumiotto, Anne Maillard, Diane Descamps, Marie-Laure Chaix Baudier, for the AC43 ANRS Resistance Group

868 WITHDRAWN/INTENTIONALLY UNASSIGNED

869 NEW GENOMES FROM THE CONGO BASIN EXPAND HISTORY OF CRF01_AE ORIGIN AND DISSEMINATION
Eduan Wilkinson, Ana Vallari, Dennis Maletich Junqueira, Carole McArthur, Lazare Kaptue, Dora Mbanya, Gavin Cloherty, Tulio de Oliveira, Mary A. Rodgers

870 PERSISTENT OUTBREAK OF THE HIV-1 CRF19_CPX VARIANT IN TREATMENT-NAIVE MSM PATIENTS
Isabel Viciana, Carmen M. González Domenech, Cristina Gomez-Ayerbe, Marisa Mayorga, Javier De La Torre Lima, Manuel Casteño, Rosario Palacios, Jesus Santos
871  PHYLOGENETIC ANALYSIS OF HIV FROM PWID IN EASTERN EUROPE AND ASIA: HPTN074
Mariya V. Sivay, Philip J. Palumbo, Yinfeng Zhang, Kate Grabowski, Estelle Piwowar-Manning, Xu Guo, Erica Hamilton, Vivian Go, Kostyantyn Dumchev, Zubairi Djoerban, Brett Hanscom, Irving Hoffman, William C. Miller, Susan H. Eshleman, for the HPTN 074 Study Team

872  COMBINING OBSERVATIONAL AND PUBLIC HEALTH PHYLOGENETIC DATA TO IMPROVE HIV PREVENTION
Ethan Morgan, Stephanie Schuette, Nanette Benbow, Richard D’Aquila, Brian Mustanski

873  MOBILITY PATTERNS CREATE DYNAMIC WIDELY DISPERSED RISK NETWORKS IN NAMIBIA
Eugenio Valdano, Justin Okano, Vittoria Colizza, Sally Blower

874  SPATIAL ANALYSIS TO IDENTIFY EMERGING HOT SPOTS OF MTCT IN ZIMBABWE, 2012-2018
Carolyn A. Fahey, Sandra I. McCoy, Aybuke Koyuncu, Mi-Suk Kang Dufour, Angela Mushavi, Agnes Mahomva, Nancy Padian, Frances Cowan

875  MAPPING OF HIV-1C TRANSMISSION NETWORKS IN BOTSWANA
Vlad Novitsky, Melissa Zahralban-Steele, Sikhulile Moyo, Tapiwa Nkhisang, Dorcas Maruapula, Mary F. McLane, Jane Leidner, Kara Bennett, Tendani Gaolathe, Etienne Kadima, Shahin Lockman, Joseph Mahkema, Simani Gaseitsiwe, Victor De Gruttola, Max Essex

876  HIV MOLECULAR SURVEILLANCE AND PRETREATMENT DRUG RESISTANCE IN MEXICO CITY

877  DETERMINANTS OF HIV DIFFUSION ACROSS MEXICO IDENTIFIED THROUGH SPATIAL EPIDEMIOLOGY

878  WITHDRAWN/INTENTIONALLY UNASSIGNED

879  LOCAL HUMAN MOBILITY AND TRANSMISSION ROUTES OF HIV CRF01_AE ACROSS CHINA
Simon Dellicour, Bin Zhao, Xiaoxu Han, Minghui An, Hong Shang, Jin Zhao, Ping Zhong, Davey M. Smith, Bram Vrancken, Antoine Chaillon

Poster P-R4 SUBSTANCE USE AND HIV
Poster Hall - 4EF  2:30 PM - 4:00 PM

880  SUBSTANCE USE DISORDERS ASSOCIATED WITH MORTALITY AMONG HIV+ IN WASHINGTON, DC
Rupali K. Doshi, Morgan Byrne, Matthew E. Levy, Leah Varga, Irene Kuo, Michael A. Horberg, Amanda D. Castel, Anne K. Monroe, for the DC Cohort Executive Committee

881  ACCIDENTAL OVERDOSE DEATHS AMONG HIV+ INDIVIDUALS IN WASHINGTON, DC, 2013-2016
Kerri Dorsey, Jenevieve Opoku, Rupali K. Doshi
882  RELEASED TO DIE: ELEVATED MORTALITY IN PEOPLE WITH HIV AFTER INCARCERATION

883  HIV AND OVERDOSE AMONG PEOPLE WHO INJECT DRUGS IN A COMMUNITY-BASED COHORT
Becky L. Genberg, Jacquie Astemborski, Jing Sun, Gregory D. Kirk, Shruti H. Mehta

884  ATTRIBUTABLE RISK OF METHAMPHETAMINE USE ON VIRAL SUPPRESSION AMONG MSM ON ART
Jennifer A. Fulcher, Marjan Javanbakht, Chelsea L. Shover, Amy Ragsdale, Ron Brookmeyer, Steven Shoptaw, Pamina Gorbach

885  METHAMPHETAMINE DOSE, CLINICAL OUTCOMES, AND HIV STATUS LINKS AMONG DIVERSE MSM IN LA
Steven Shoptaw, Marjan Javanbakht, Amy Ragsdale, Risa Flynn, Robert Bolan, Raul Mandler, Pamina M. Gorbach

886  HIV DIAGNOSES AMONG PEOPLE WHO INJECT DRUGS BY URBAN-RURAL CLASSIFICATION, 2014-2016
Sheryl Lyss, Tianchi Zhang, Alexandra M. Oster

887  INJECTION AND SEXUAL BEHAVIORS AMONG PERSONS WITH DIAGNOSED HIV WHO INJECT DRUGS
Sharoda Dasgupta, Yunfeng Tie, Ansley Lemons, Kathleen Wu, Janet C. Burnett, R. L. Shouse, Linda Beer

888  HIV PHYLODYNAMIC ANALYSIS CORRELATES WITH TRENDS IN ILLICIT OPIOID TRADE IN PAKISTAN
Francois Cholette, Jeffrey Joy, Yann Pelcat, Laura Thompson, Richard Pilon, John Ho, Rupert Capina, Chris Archibald, James F. Blanchard, Faran Emmanuel, Tahira Reza, John Kim, Paul Sandstrom

889  IMPROVING CHRONIC OPIOID THERAPY AMONG PEOPLE LIVING WITH HIV: A CLINICAL RCT

890  HIV CARE OUTCOMES AMONG SUBSTANCE USERS IN PUERTO RICO FOLLOWING HURRICANE MARIA

891  AN OUTBREAK OF HIV IN HOMELESS HETEROSEXUALS WHO INJECT DRUGS IN NORTH SEATTLE, WA
Matthew R. Golden, Richard Lechtenberg, Sara N. Glick, Julia C. Dombrowski, Jeff Duchin, Jennifer R. Reuer, Shireesha Dhanireddy, Santiago Neme, Susan E. Buskin

892  ASSISTED PARTNER SERVICES AMONG PEOPLE WHO INJECT DRUGS IN NAIROBI, KENYA
Aliza Monroe-Wise, Brandon Guthrie, Loice Mbogo, Bill Sinkele, David Bukusi, Matthew Dunbar, Paul Macharia, Esther Gitau, Betsy Sambai, Helgar Musyoki, Sarah Masyuko, Joshua T. Herbeck, Carey Farquhar
893  SUICIDE RATES AMONG US ADULTS LIVING WITH HIV, 2000-2015  
Keri N. Althoff, Paul S. Nestadt, Jennifer S. Lee, Stephen J. Gange, Peter F. Rebeiro, Michael A. Horberg, Michael J. Silverberg, Elizabeth Humes, Amy C. Justice, Angel M. Mayor, Charles Rabkin, Frank J. Palella, Anita Rachlis, Richard D. Moore, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

954  LINKAGE TO CARE IN THE PARTNER SERVICES PRE-EXPOSURE PROPHYLAXIS (PS-PrEP) STUDY  
Daniel S. Teixeira da Silva, Alida Bouris, Olivia Blocker, Billy Davis, James Harris, Ramona Bhatia, John A. Schneider

955  PILOT TEST OF A PrEP TELEMEDICINE SYSTEM FOR YOUNG BLACK MSM IN THE RURAL US SOUTH  
Aaron J. Siegler, James B. Brock, Colleen F. Kelley, Lauren A. Ahlschlager, Charlotte-Paige M. Rolle, Saiya Sheth, Gretchen Wilde, Karen Dominguez, Shanita Greer, Leandro A. Mená

956  RAPID PrEP UPTAKE IN A PUBLICLY FUNDED POPULATION-BASED PROGRAM IN BRITISH COLUMBIA  
K. Junine Toy, Jason Trigg, Wendy Zhang, Paul Sereda, Viviane D. Lima, Katherine Lepik, Mark Hull, Raquel M. Espinoza, Silvia Guillemi, David Hall, David M. Moore, Rolando Barrios, Julio S. Montaner

957  RISK FACTORS ASSOCIATED WITH NONPRESCRIPTION USE OF HIV PREEXPOSURE PROPHYLAXIS  
Uwe Koppe, Ulrich Marcus, Stefan Albrecht, Klaus Jansen, Heiko Jessen, Barbara Gunsenheimer-Bartmeyer, Viviane Bremer

958  PREFERENCES FOR PrEP DELIVERY AMONG FSW IN MALAWI USING A DISCRETE CHOICE EXPERIMENT  
Kathryn E. Lancaster, Thandie Lungu, Agatha Bula, Abigail Shoben, Mina C. Hosseinpour, Raquel E. Kohler, Irving Hoffman, Vivian Go, Carol E. Golín, Stephanie Wheeler, William C. Miller

959  PREEXPOSURE PROPHYLAXIS FOR KEY POPULATIONS IN UGANDA: EARLY SCALE-UP LESSONS  
Joseph Lubwama, Stella Alamo, Caroline Ajulong, Enos Sande, Lisa A. Mills, Donna Kabatesi, Lisa J. Nelson

960  CHANGES IN KIDNEY FUNCTION AMONG MSM INITIATING ON-DEMAND TDF/FTC FOR HIV PrEP  
Geoffroy Liegeon, Guillemette Antoni, Gilles Pialoux, Laurent Cotte, Cécile L. Tremblay, Catherine Capitant, Éric Cua, François Raffi, Éric Senneville, Pierre Charbonneau, Soizic Le Mestre, Veronique Dore, Laurence Meyer, Jean-Michel Molina, for the ANRS IPERGAY Study Group

961  POINT-OF-CARE CREATININE TESTING WITHIN A PROGRAMMATIC PrEP DELIVERY SETTING  
Jillian Pintye, Felix Abuna, John Kinuthia, Harrison Lagat, Kenneth K. Mugwanya, Julia Dettinger, Emily R. Begnel, Marlène Serede, Joseph Sila, Jared Baeten, Grace John-Stewart, for the PrEP Implementation for Young Women and Adolescents (PriYA) Program

962  IMMEDIATE PrEP INITIATION AT NEW YORK CITY SEXUAL HEALTH CLINICS  
Tarek Mikati, Kelly Jamison, Demetre C. Daskalakis
963  **PrEP PERSISTENCE AND DISCONTINUATIONS IN A COHORT OF YOUNG BLACK MSM IN ATLANTA, GA**

David P. Serota, Eli Rosenberg, Annie M. Lockard, Carlos del Rio, Nicole Luisi, Scott R. Cutro, Charlotte-Paige M. Rolle, Aaron J. Siegler, Travis Sanchez, Patrick S. Sullivan, Colleen F. Kelley

964  **LOW UPTAKE OF PREEXPOSURE PROPHYLAXIS AMONG KENYAN ADOLESCENT GIRLS AT RISK OF HIV**

Lynda M. Oluoch, Nelly R. Mugo, Alison C. Roxby, Anna Wald, Stacy Selke, Amalia Magaret, Kenneth Ngure, Murugi Micheni, Steven Gakuwo, Bhavna Chohan, Catherine Kiptinness

**Poster P-T5 STIs IN PEOPLE AND MONKEYS USING PrEP**

Poster Hall - 4EF 2:30 PM - 4:00 PM

965  **HIGH CURABLE STI PREVALENCE AND INCIDENCE AMONG YOUNG AFRICAN WOMEN IN HPTN 082**

Sinead Delany-Moretliwe, Nyaradzo Mgozi, Linda-Gail Bekker, Jared Baeten, Subash Pathak, Deborah J. Donnell, Denni Lennon, Scott M. Rose, Keolopile Makgamathe, Sheetal Kassim, Shorai Mukaka, Heather Noble, Adeola Adeyeye, Connie L. Celum

966  **HIGH PREVALENCE AND ANTIBIOTIC RESISTANCE OF M GENITALIUM INFECTIONS IN MSM ON PrEP**


967  **ASSOCIATION OF PrEP USE AND PAST AND CURRENT STIs AMONG MSM IN WASHINGTON, DC, 2017**

Laura M. Torres, Anya Agopian, Anthony Rawls, Jenevieve Opoku, Manya Magnus, Matthew E. Levy, Michael Kharfen, Irene Kuo

968  **DETECTED EXTRAGENITAL STI AMONG US MSM BY PrEP STATUS**

Johanna Chapin-Bardales, Michelle L. Johnson Jones, Robert D. Kirkcaldy, Kyle T. Bernstein, Christi Phillips, John R. Papp, Henry F. Raymond, Jenevieve Opoku, Sarah L. Braunstein, Emma C. Spencer, Salma Khuwaja, Cyprian Wejnert, for the NHBS Study Group

969  **STI COINFECTIONS DO NOT REDUCE THE PROPHYLACTIC EFFICACY OF CAB LA IN MACAQUES**

Roopa Luthra, Chunxia Zhao, William Spreen, Chuong Dinh, James Mitchell, Frank Deyounks, Kenneth Sutton, Walid Heneine, Gerardo Garcia-Lerma, Janet McNicholl, Sundaram Ajay Vishwanathan

970  **ANTI-A4B7 ANTIBODY REDUCES MACAQUE VIREMIA BUT NOT RISK OF RECTAL SHIV ACQUISITION**

Chunxia Zhao, Roopa Luthra, Michele Daly, Dawn Little, Gerardo Garcia-Lerma, Debra R. Adams, Jining Zhang, Aftab A. Ansari, Siddappa N. Byrareddy, Janet McNicholl, Sundaram A. Vishwanathan

**Poster P-U4 THE MASKED MARVELS YOU DON’T WANT TO MEET: SYPHILIS AND LGV**

Poster Hall - 4EF 2:30 PM - 4:00 PM

1011  **EFFECTIVE TREATMENT OF LYMPHOGRANULOMA PROCTITIS WITH EXTENDED AZITHROMYCIN REGIMEN**

José L. Blanco, Irene Fuertes, Jordi Bosch, Ana González-Cordón, Esteban Martinez, Andrea Vergara, Teresa Estrach, Jose M. Gatell, Alsina Merce
1012  ADHERENCE OF HEALTH CARE PROVIDERS TO CDC LUMBAR-PUNCTURE CRITERIA AMONG SYPHILIS/HIV  
Barbara L. Henriques, Vivian I. Avelino-Silva, Marilia B. Antonio, Jose E. Vidal

1013  HEARING LOSS IN UNSELECTED INDIVIDUALS WITH SYPHILIS  
Meena Ramchandani, Jamie Litvack, Clare Maxwell, Lauren Tantalo, Sharon Sahi, Shelia Dunaway, Christina Marra

1014  COGNITIVE IMPAIRMENT IN INDIVIDUALS WITH SYPHILIS  
Kevin Robertson, Haley Mendoza, Clare Maxwell, Shelia Dunaway, Arielle P. Davis, Sharon Sahi, Lauren Tantalo, Jana Zahlan, Sheryl Storey, Christina Marra

1015  RESPONSE TO SYPHILIS TREATMENT: CDC GUIDELINES IN HIV-INFECTED ADULTS ON ART  
Melody Ren, Leah Szadkowski, Darrell H. Tan, Sharon Walmsley

1034  PREVALENCE AND CORRELATES OF NONENROLLMENT IN HIV CARE, CHÓKWÈ DISTRICT, MOZAMBIQUE  
Kristen Heitzinger, Anne F. McIntyre, Isabelle Casavant, Noela Chicuecue, Victor Chivurre, Aleny Couto, Keydra Oladapo

1035  HIV TREATMENT CASCADE AMONG MEN WHO HAVE SEX WITH MEN IN KIGALI, RWANDA  
Jean Olivier Twahirwa Rwema, Benjamin Liestman, Julien Nyombayire, Sosthenes Ketende, Amelia Mazzei, Carrie E. Lyons, Oluwasolape M. Olawore, Mugwaneza Placidie, Stefan Baral, Patrick S. Sullivan, Susan Allen, Etienne Karita

1036  LONGITUDINAL HIV CARE TRAJECTORIES IN THE CNICS COHORT: A RETROSPECTIVE COHORT STUDY  

1037  CALL FOR LIFE UGANDA TM: AN RCT USING INTERACTIVE VOICE RESPONSE FOR PLHIV ON ART  
Rosalind M. Parkes-Ratanshi, Maria S. Nabaggala, Agnes N. Bwanika, Mohammed Lomorde, Rachel King, Noela Owariwo, Eva A. Laker Odongpinny, Richard Orama, Barbara Castelnuovo, Agnes Kiragga

1038  HIV CARE CONTINUUM CHANGES AMONG PWID AND MSM IN INDIA: A TALE OF 2 KEY POPULATIONS  

1039  HIV OUTCOMES AMONG TRANSGENDER MEN IN HRSA’S RYAN WHITE HIV/AIDS PROGRAM, 2010-2016  
Stacy Cohen, Demetrios A. Psiphopaidas, Antigone Dempsey, Laura W. Cheever

1040  ENGAGEMENT IN CARE OF HIGH-RISK PATIENTS AT AN URBAN HIV PRIMARY CARE CENTER  
Raaka Kumbhakar, Mila Gonzalez Davila, Randi Scott, Noga Shalev, Susan Olender

1041  PRAISE MESSAGES TO INCREASE ART ADHERENCE AND RETENTION IN CARE FOR FSW IN ETHIOPIA  
Nicholas Wilson, Kristen Little, Aderaw Anteneh, Woldemariam Girma, Kelly Bidwell
1042 REPEAT NONADHERENCE TO CLINIC APPOINTMENTS AMONG HIV-INFECTED ADULTS ON ART IN KENYA
Jacques Muthusi, Tai Ho Chen, Kenneth Masamaro, Peter W. Young, Emily C. Zielinski-Gutierrez

1043 ATTRITION ALONG THE CARE CASCADE IN SOUTH AFRICAN EMERGENCY DEPARTMENTS
Bhakti Hansoti, Aditi Rao, George Mwinnyaa, John Black, Reinaldo Fernandez, Elizabeth Hahn, Oliver Laeyendecker, Roshen Maharaj, Pamela Mda, Jernelle Miller, Andrew D. Redd, Steven J. Reynolds, David Stead, Thomas C. Quinn, for the WISE research group

1044 SMOKING AND UNHEALTHY DRINKING AND THE HIV CARE CONTINUUM
Derek Satre, Tory Levine-Hall, Amy C. Justice, Margaret May, Jonathan Sterne, Matthias Cavassini, Jennifer O. Lam, Stacey Åleexeeff, Stacy Sterling, Kendall J. Bryant, Paul Volberding, Constance Weisner, Michael A. Horberg, Michael J. Silverberg

Poster Sessions
Poster Hall - 4EF 2:30 PM - 4:00 PM

1073 SOCIOECONOMIC IMPACTS OF UNIVERSAL ANTIRETROVIRAL THERAPY IN THE SEARCH TRIAL
Harsha Thirumurthy, Aleksandra Jakubowski, Yan He, Jane Kabami, Dalsone Kwarisima, Norton Sang, Laura B. Balzer, Tamara D. Clark, Edwin D. Charlebois, Gabriel Chamie, Craig R. Cohen, Elizabeth A. Bukusi, Moses R. Kamya, Maya L. Petersen, Diane V. Havlir

1074 CONDOM USE AND PRICES IN TRANSACTIONAL SEX ENCOUNTERS AMONG HIGH-RISK WOMEN IN KENYA
Harsha Thirumurthy, Yan He, Perez Ochwal, Noora Marcus, Sue Napierala, Suzanne Maman, Kawango Agot

1075 SABES: A COST-EFFECTIVE TasP INTERVENTION TO IDENTIFY AND TREAT RECENT HIV INFECTIONS

1076 COST-EFFECTIVENESS OF LONG-ACTING ART FOR ADOLESCENTS AND YOUNG ADULTS IN KENYA
Jessica Culhane, Monisha Sharma, Katherine Wilson, Allen Roberts, Cyrus Mugo, Dalton Wamalwa, Irene Inwani, Ruanne V. Barnabas, Pamela K. Kohler

1077 COST-EFFECTIVENESS OF LONG-ACTING MULTIPURPOSE PREVENTION TECHNOLOGY IN SOUTH AFRICA
Marjolein M. van Vliet, Cheryl J. Hendrickson, Brooke E. Nichols, Charles Boucher, Remco P. Peters, David van de Vijver

1078 NONADHERENCE DUE TO PRESCRIPTION DRUG COSTS AMONG US ADULTS WITH HIV, 2015-2016
Linda Beer, Yunfeng Tie, John Weiser, Christine Agnew-Brune, R. L. Shouse, for the Medical Monitoring Project

1079 HEALTH CARE UTILIZATION AND COSTS OF ACCESSING HEALTH CARE IN SOUTH AFRICA AND ZAMBIA
Sarah Kanema, Ranjeeta Thomas, Lawrence Mwenge, Justin Bwalya, Nomtha Mandla, Helen Ayles, Peter Bock, Sarah Fidler, Richard Hayes, Katharina Hauck, for the HPTN071-PopART

Poster P-W1 MODELING AND MONEY
Poster Hall - 4EF 2:30 PM - 4:00 PM

CROI 2019 127
1080  **COST AND IMPACT OF COMMUNITY-BASED, ASSISTED HIV SELF-TESTING AMONGST YOUTH IN ZAMBIA**

Brooke E. Nichols, **Refiloe Cele**, Charles Chasela, Zumbe Siwale, Alimwi S. Lungu, Lawrence Long, Crispin Moyo, Sydney Rosen, Roma Chilengi, for the EQUIP Health team

1081  **COST-EFFECTIVENESS AND NATIONAL IMPACT OF INDEX HIV SELF-TESTING IN MALAWI**

Ogechukwu Offorjebe, Kathryn Dovel, Frackson Shaba, Kelvin Balakasi, Risa M. Hoffman, Sydney Rosen, **Brooke E. Nichols**, for the EQUIP Health team

1082  **THE COST OF PrEP DELIVERY IN KENYAN ANTENATAL, POSTNATAL, AND FAMILY PLANNING CLINICS**

Allen Roberts, Ruanne V. Barnabas, Felix Abuna, Harrison Lagat, John Kinuthia, Jillian Pintye, Aaron Bochner, Jared Baeten, Grace John-Stewart, Carol Levine

1083  **COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS AMONG ADOLESCENT SEXUAL MINORITY MALES**

Li Yan Wang, Deven T. Hamilton, Eli Rosenberg, Patrick S. Sullivan, David A. Katz, Richard Dunville, Lisa C. Barrios, Maria Aslam, Steven M. Goodreau
THURSDAY MARCH 7, 2019

POSTER SESSIONS

THURSDAY MARCH 7, 2019

POSTER P-A5 HIV NEF
Poster Hall - 4EF 2:30 PM - 4:00 PM

188 HOMODIMERIZATION IS REQUIRED FOR HIV-1 NEF FUNCTION IN HUMANIZED MICE
Sherry Shu, Li Chen, Tom E. Smithgall

189 RESTING HIV-INFECTED CD4 T CELLS EXPRESS NEF AND VPU, WHICH DOWNREGULATE MHC AND BST2
Rodrigo Matus-Nicodemos, Daniel Douek, Richard A. Koup

190 IMPAIRED NEF’S ABILITY TO COUNTERACT SERINC5 BY IMMUNE-DRIVEN MUTATIONS
Mako Toyoda, Doreen Kamori, Jonathan Carlson, Ai Kawana-Tachikawa, Hiroyuki Gatanaga, Shinichi Oka, Takamasa Ueno

191 SYNTHESIS AND EVALUATION OF TIGHT-BINDING HYDROXYPYRAZOLE INHIBITORS OF HIV-1 NEF
Haibin Shi, Colin Tice, Lori A. Emert-Sedlak, Li Chen, Wing Fai Li, Jay E. Wrobel, Allen B. Reitz, Thomas E. Smithgall

192 ACTIVATION OF TEC KINASES BY HIV-1 NEF AT THE CELL MEMBRANE REQUIRES DIMER FORMATION
Wing Fai Li, Sherry Shu, Tom E. Smithgall

193 ACTIVATION OF TEC-FAMILY KINASES ITK AND BTK BY HIV-1 AND SIV NEF PROTEINS IN VITRO
Manish Aryal, Kindra Whitlatch, Tom E. Smithgall

194 NEF DIMERIZATION REGULATES HIV-1 INFECTIVITY AND SERINC5 INCORPORATION
Ryan Staudt, Thomas E. Smithgall

195 LIPID BINDING DOMAIN IMPACT ON HIV-1 NEF AND SRC-FAMILY KINASE HCK U-SH3-SH2 COMPLEX
John Alvarado, Haibin Shi, Thomas E. Smithgall

POSTER P-B7 LONG-TERM EFFECTS OF HIV AND ART
Poster Hall - 4EF 2:30 PM - 4:00 PM

243 GLUTAMINOLYSIS AND LIPOPROTEINS KEY FACTORS IN HIV LATE IMMUNE RECOVERY
Anna Rull, Isaac Rosado-Sánchez, Esther Rodríguez-Gallego, Joaquim Peraire, Consuelo Viladés, Sergi Veloso, Maria Peñaranda, Félix Gutiérrez, Jesus Santos, Enrique Bernal, Ricardo Pelazas, Manuel Leal, Francesc Vidal, Yolanda M. Pacheco

244 EXPANSION OF MYELOID-DERIVED SUPPRESSOR CELLS IN ART-SUPPRESSED HIV-INFECTED PATIENTS
Carla Serra Peinado, Laura Luque-Ballesteros, Rein Willekens, Jordi Navarro, Adrià Curran, Joaquim Burgos, Esteban Ribera, Ariadna Torrella, Bibiana Planas, Rosa Badia, Josep Castellví, Vicenç Falcó, María J. Buzón

245 CIRCULATING B-D-GLUCAN AND INDUCTION OF IMMUNE ACTIVATION
Stéphane Isnard, Rayoun Ramendra, Franck P. Dupuy, Vikram Mehraj, Rosalie Ponte, Jun Chen, Cecilia Costiniuk, Réjean Thomas, Jean-Guy Baril, Madeleine Durand, Cécile Tremblay, Petronela Ancuta, Nicole Bernard, Don C. Sheppard, Jean-Pierre Routy
Poster Sessions

246 MINING FOR CD4 CELL RECOVERY PHENOTYPE REVEALS DISTINCT PATTERN FOR BLACK ETHNICITY

Teja Turk, Christian Thorball, Jacques Fellay, Alexandra Trkola, Peter Rusert, Karin Metzner, Dominique L. Braun, Jürg Böni, Sabine Verly, Vincent Aubert, Thomas Klimkait, Huldrych F. Günthard, Roger Kouvos, for the Swiss HIV Cohort Study

247 SPD-L1: A POTENTIAL NOVEL IMMUNE MARKER FOR HIV-1 INFECTION AND VIROLOGIC FAILURE

Jose Avendaño-Ortiz, Marina Rubio Garrido, Emilio Llanos-González, Jorge Romero, Santiago Moreno, Carmen Rodriguez, Eduardo López-Collazo, Africa Holguin

248 IMPACT OF HIV INFECTION AND ANTIRETROVIRAL THERAPY ON IMMUNE CELLULAR FUNCTIONS

Marek Korencak, Enrico Richter, Bruce T. Schultz, Patrick Juszcza, Buena D. Reyes, Sandra Winning, Joachim Fandrey, Stefan Esser, Hendrik Streeck

249 HIV-1 DIVERSITY IN GUT IS ASSOCIATED WITH RESIDUAL MUCOSAL VIRUS PRODUCTION ON ART

Manon Nayrac, Mary Requena, Nicolas Jeanne, Maud Mavigner, Claire Loiseau, Romain Carcenac, Michelle Cazabat, Jacques Izopet, Pierre Delobel

250 ASSOCIATION BETWEEN HIV ANTIBODIES AND D-DIMER: ROLE OF “DEFECTIVE” PROVIRUSES

Hiromi Imamichi, Tracey D. Zhai, Nicole E. Winchester, Francesca Scrimieri, Mindy Smith, Thomas Buerkert, Ivery Davis, Adam Rupert, Robin L. Dewar, Joseph A. Kovacs, H. Clifford Lane

251 ANTI-CD4 AUTOANTIBODIES ARE ASSOCIATED WITH DISCORDANT IMMUNOLOGICAL RESPONSES TO ART

Andrea Lisco, Charalampos Mystakelis, Chun-Shu Wong, Gregg Roby, Virginia Sheikh, Peter Burbelo, Irini Sereti

252 SEX DIFFERENCES IN CMV REPLICATION AND HIV PERSISTENCE DURING SUPPRESSIVE ART

Sara Gianella, Sarah McDonald Tran, Milenka Vargas, Gemma Caballero, Michelli Faria de Oliveira, Steven Lada, Mitchell Zhao, Jyoti S. Mathad, Timothy Wilkin

253 EBV AND CMV LEVELS IN BLOOD ARE ASSOCIATED WITH NON-AIDS EVENTS DURING ART

Sara Gianella, Carlee Moser, Andrej Vitomirov, Ashley McKhann, Laura Layman, Brianna Scott, Steven Lada, Ronald Bosch, Martin Hoenigl, Nell Lurain, Alan Landay, Michael M. Lederman, Peter W. Hunt, Davey M. Smith

254 GAMMA DELTA T-CELL IR SIGNATURES REVEAL DIVERGENCE OF HEALTHY AND AVIREMIC HIV+ AGING

Anna C. Belkina, Alina Starchenko, Katherine Drake, Elizabeth Proctor, Riley Pihl, Alex J. Olson, Douglas Lauffenburger, Nina Lin, Jennifer Snyder-Cappione

255 SENESCECNE & EXHAUSTION OF T-CELL MEMORY SUBSETS INCREASED IN AGING PERSONS WITH HIV


256 CLONAL HEMATOPOIESIS AMONG OLDER TREATED HIV+ PERSONS ENROLLED IN COCOMO

Álvaro H. Borges, Christian H. Eskelund, Rebekka F. Thudium, Yanan Zhao, Andreas D. Knudsen, Marco Gelpi, Cavan Reilly, James Pankow, Mark Polizzato, Francesco Favero, Sisse R. Östrowski, Klaus F. Kofoed, Joachim Weischenfeldt, Kirsten Grønbæk, Susanne D. Nielsen, for the COCOMO
257 IMMUNOSENESCENCE IN HIV IS ASSOCIATED WITH CMV STATUS AND LOWER CD4:CD8 RATIO

258 TELOMERE LENGTH, TELOMERASE ACTIVITY, AND AGE-RELATED DISEASE: ACTG NWCS 422
Chad J. Achenbach, Drew Nannini, Isabelle Clerc, Hannah Hudson, Brian Joyce, Kunling Wu, Katherine Tassiopoulos, Peter W. Hunt, Babafemi Taiwo, Richard D’Aquila, Sudhir Penugonda, Lifang Hou, Frank J. Palella

259 MOVED TO POSTER SESSION P-E04

260 RNAPOL III CONNECTS RIG-1 AND CGAS HIV-SENSING PATHWAYS IN DC FROM ELITE CONTROLLERS
Enrique Martin-Gayo, Ce Gao, Zhengyu Ouyang, Bruce D. Walker, Mathias Lichterfeld, Xu G. Yu

261 PROTEOMIC PROFILE ASSOCIATED WITH LOSS OF SPONTANEOUS HIV-1 ELITE CONTROL
Laura Tarancon-Diez, Esther Rodriguez-Gallego, Felipe Garcia, Verónica Alba, Jorge Romero, José Miguel Benito, Pol Herrero, Anna Rull, Beatriz Dominguez-Molina, Joaquim Peraire, Consuelo Viladés, Manuel Leal, Francesc Vidal, Ezequiel Ruiz-Mateos, for the ECRIS integrated in the Spanish AIDS Research Network

262 ANTI-GP120 ANTIBODY TITRES CORRELATE WITH AB-DEPENDENT FUNCTIONS IN HIV CONTROLLERS
Sanket Kant, Franck P. Dupuy, Chris Leeks, Alexandre Barbe, Ningyu Zhang, Cindy X. Zhang, Jean-Pierre Routy, Petronela Ancuta, Cécile L. Tremblay, Nicole Bernard

263 RAPID DECLINE OF IMMUNE ACTIVATION WITH ART IN HIV CONTROLLERS WITH LOW CD4 COUNTS
Abena Kwa, Eileen P. Scully, Joel Blankson

264 ELITE CONTROL OF HIV-1 INFECTION IS ASSOCIATED WITH REDUCED TRAILSHORT EXPRESSION
Ana Catarina De Oliveira Virgens Paim, Sekar Natesampillai, Nathan Cummins, Enrique Garcia-Rivera, Nicole Kogan, Ujjwal Neogi, Gary D. Bren, Stacey Rizza, Steven G. Deeks, Eric C. Polley, Andrew Badley

265 HIV-DNA CONTENT IN PTFH CELLS IS ASSOCIATED WITH RESIDUAL VIREMIA IN ELITE CONTROLLERS
Marcial García, Vincent Morcilla, María Ángeles Navarrete, Katie Fisher, Alfonso Cabello, Juan Carlos López-Bernaldo, Francisco Javier De La Hera, Carlos Barros, Manuel Fernández, Vicente Estrada, Miguel Górgolas, Sarah Palmer, José Miguel Benito, Norma Rallón

266 CXCR3+ FOLLICULAR HELPER TC ARE ASSOCIATED WITH HIV CONTROL DURING CHRONIC INFECTION
Gonzalo Salgado-Montes de Oca, Perla Del Río-Estrada, Yuria Ablanedo Terrazas, Amaranta Y. Rivero-Arrieta, Gustavo Reyes-Terán
285  **CD4/CDC ratio as a predictor of HIV-associated cancers in CNICS**


286  **Causes of death after cancer diagnosis among PLHIV on ART: Cohort collaboration**

Adam Trickey, Michael John Gill, Dominique Costagliola, Sophie Grabar, Amy C. Justice, Suzanne Ingle, Julia Del Amo, Antonella D’Arminio Monforte, Fabrice Bonnet, Joerg Janne Vehreschild, Ferdinand Wit, Katharina Grabmeier-Pfistershammer, Leah Shepherd, Ramon Teira, Jonathan Sterne

287  **AIDS progression and non-AIDS death in people with HIV following cancer treatment**

Keri Calkins, Geetanjali Chander, Corinne Joshu, Kala Visvanathan, Anthony T. Fojo, Catherine R. Lesko, Richard D. Moore, Bryan Lau

288  **VACS index better predictor of mortality after cancer in HIV+ and HIV- than Charlson**

Keith M. Sigel, Lesley S. Park, Kimberly Stone, Cynthia L. Gibert, Matthew B. Goetz, Roger Bedimo, Roxanne Wadia, Maria Rodriguez-Barradas, Fatma Shebl, Janet Tate, Amy C. Justice, Sheldon T. Brown, Kristina Crothers

289  **AIDS- and non-AIDS-defining cancer incidence, 2010-2015, in the DAT’AIDS cohort**

Camelia Protopopescu, Antoine Chéret, Alain Makinson, David Rey, Claudine Duuvivier, Clotilde Allavena, Pascal Puglièse, Tristan Ferry, Thomas Huleux, Pierre Delobel, André Cabié, Isabelle Lamy, Patricia Carrié, Isabelle Poizot-Martin, for the Dat’AIDS study group

290  **Cancer incidence among a cohort of persons receiving HIV care in Washington, DC**

Amanda B. Spence, Matthew E. Levy, Anne K. Monroe, Joseph Timpone, Amanda D. Castel, Michael A. Horberg, Princy Kumar, for the DC Cohort Executive Committee

291  **High CD20 levels in lung cancer tissue from PLWH associated with improved survival**

Ramsey Yusuf, Franz Villarroel, Kristen Hysell, Fangyong Li, Kurt Schalper, Brinda Emu

292  **Burkitt lymphoma in the ART era: stable incidence and poor survival**

Eva Clark, Kathryn E. Royse, Elaine Chang, Suchismita Raychaudhury, Jennifer R. Kramer, Donna L. White, Elizabeth Chiao
313  REGULATION OF HIV-SPECIFIC CD8+ T-CELL FUNCTIONAL CAPACITY
Rachel L. Rutishauser, Christian Deo T. Deguit, Hossam Abdelsamed, Ashish Sharma, Susan P. Ribeiro, Rebecca Hoh, Melissa Krone, Frederick M. Hecht, Christopher D. Pilcher, Jeffrey N. Martin, Benjamin A. Youngblood, Raffick-Pierre Sekaly, Steven G. Deeks, Joseph M. McCune, Peter W. Hunt

314  PRESERVED TELOMERE ACTIVITY AND TELOMERE LENGTH IN CD28- CD8 T CELLS IN TREATED HIV
Jue Lin, Jeffery Milush, Norman G. Jones, Alexander Carvidi, Heather Hartig, Steven G. Deeks, Jeffrey N. Martin, Sulggi Lee, Elizabeth Blackburn, Peter W. Hunt

315  IMPACT OF INTEGRASE INHIBITORS ON CD8 T-CELL FUNCTION AND ACTIVITY
Enrico Richter, Marek Korencak, Lea Bornemann, Marc Schuster, Matthias Gunzer, Stefan Esser, Hendrik Streeck

316  CD8 T-CELL INHIBITORY RECEPTOR EXPRESSION IS ASSOCIATED WITH CANCER AMONG PLWH ON ART
Omkar Chaudhary, Diane Trotta, Xiuping Chu, Chip Bradley, Xun Wang, Jason Okulicz, Ryan Maves, Karl Kronmann, Christina Schofield, Brian K. Agan, Anuradha Ganesan, Brinda Emu

317  IMPACT OF ART ON T-CELL REPETOIRES OF HIV-INFECTED ADULTS WITH AND WITHOUT CANCER
Abrahams Omoding, Andrea Towlerton, David Coffey, Warren Phipps, Edus H. Warren

318  FINDING THE CELLS AMIDST THE DATA
Boris P. Hejblum, Daniel Commenges, Chariff Alkhassim, Raphael Gottardo, François Caron, Rodolphe Thiebaut

319  MACHINE LEARNING REVEALS T-CELL ACTIVATION PATHWAYS INDUCED BY INFLUENZA VACCINE

320  COMPARATIVE ANALYSIS OF THE MAGNITUDE AND QUALITY OF VACCINE-ELICITED T-CELL RESPONSE

321  REGULATORY T CELLS IN HIV-INFECTED PREGNANT WOMEN
Katelyn J. Rittenhouse, Humphrey Mwape, John Mwale, Gabriel Chipli, Joan T. Price, Bellington Vwalika, Kristina De Paris, Elizabeth M. Stringer, Jeffrey S. Stringer

322  THE IMPACT OF HIV EXPOSURE ON PLACENTAL PATHOLOGY AND TREG CELLS
Nadia M. Ikumi, Nonzwakazi Bangani, Michelle Barbourie, Berenice Alinde, Bryan Gascon, Lizette Fick, Komala Pillay, Landon Myer, Thoko Malaba, Mohamed Lamorde, Saye Khoo, Heather Jaspan, Clive M. Gray

323  HIV RESERVOIR SIZE IS CORRELATED TO NK-MEDIATED KILLING OF EFFECTOR MEMORY CD4 CELLS
Antonio Astorga Gamaza, Judith Grau-Expósito, Laura Luque-Ballesteros, Ariadna Torrella, Bibiana Planas, Rosa Badía, Esteban Ribera, Joaquin Burgos, Jordi Navarro, Adrià Curran, Vicenç Falcó, María J. Buzón
324 LIGATION OF KIR3DS1 BY HLA-F ON ICD4 ACTIVATES PRIMARY NK CELLS FOR ANTI-HIV ACTIVITY
Zahra Kiani, Julie Bruneau, Daniel E. Geraghty, Nicole Bernard

325 IMPACT OF A NOVEL NATURAL KILLER CELL SUBSET ON IMMUNE RECONSTITUTION

351 TRIFUNCTIONAL T-CELL ENGAGERS TARGETING PD-1 AND TIGIT IN CHRONIC HIV/SHIV INFECTIONS
Wanwisa Promsote, David R. Ambrozak, Catherine Liu, Megan Demouth, Cassandra Almasri, Michelle Cully, Jason M. Hataye, Amarendra Pegu, John R. Mascola, Richard A. Koup

352 IMPACT OF RAPAMYCIN ON SIV PERSISTENCE IN RHESUS MACAQUES ON ANTIRETROVIRAL THERAPY

353 COMBINATION OF CRISPR AND LASER ART PREVENTS HIV REBOUND IN HUMANIZED MICE
Kamel Khalili, Howard E. Gendelman

354 A HUMANIZED MOUSE MODEL FOR EVALUATION OF AUTOLOGOUS HIV-SPECIFIC T-CELL THERAPIES
Chase McCann, Elizabeth A. Zale, Adam R. Ward, Shabnum Patel, Catherine M. Bollard, R. Brad Jones

355 DIFFERENTIAL EFFECTS OF IL-15 TREATMENT DELIVERED BY DIFFERENT ROUTES IN MACAQUES
Antonio Valentin, Dionysios C. Watson, Hirshikesh Pandit, Cristina Bergamaschi, Santhi Devasundaram, Sotirios Fortis, Barbara K. Felber, George N. Pavlakis

259 HEU HAVE INCREASED PROPORTIONS OF TREG ASSOCIATED WITH DECREASED T-CELL FUNCTIONALITY
Emilie Jalbert, Kayla M. Williamson, Miranda Kroehl, Michael J. Johnson, Marta Nunes, Clare Cutland, Shabir A. Madhi, Adriana Weinberg

356 GS-9722: FIRST-IN-CLASS EFFECTOR-ENHANCED BROADLY NEUTRALIZING ANTIBODY FOR HIV CURE
Nathan D. Thomsen, Mini Balakrishnan, Craig S. Pace, Xue Zhang, Magdeleine Hung, Mark R. Nagel, Brian A. Carr, Eric Hu, Helen Yu, George Stepan, Joshua Goldsmith, Bing Xia, Debi Jin, John A. Corbin, Romas Geleziunas

357 PASSIVE INFUSION OF FC-MODIFIED NAB DOES NOT AFFECT DYNAMICS OF PLASMA VIRUS DECAY
Mangaiarkarasi Asokan, Anna Maximova, Joana Dias, Andrew Crowley, Amarendra Pegu, Krisha McKee, Wei Shi, John-Paul Todd, Margaret Ackerman, Lucio Gama, Brandon F. Keele, Jeffrey Lifson, Alan S. Perelson, John R. Mascola, Richard A. Koup
358 RELATIONSHIPS BETWEEN NEUTRALIZATION, BINDING AND ADCC OF bNabs AGAINST RESERVOIR HIV
Yanqin Ren, Maria Korom, Ronald Truong, Dora Chan, Szuhan Huang, Colin Kovacs, Erika Benko, Jeffrey T. Safrit, John H. Lee, Hermes Garbán, Rebecca Lynch, R. Brad Jones

359 MULTISPECIFIC ANTI-HIV DUOCAR-T CELLS POTENTLY ELIMINATE bNAB-RESISTANT HIV IN VIVO
Kim Anthony-Gonda, Ariola Bardi, Dimiter S. Dimitrov, Weizao Chen, Christina Ochsenbauer, John C. Kappes, Nina C. Flerin, Winfried Krueger, Dina Schneider, Rimas Orentas, Harris Goldstein, Boro Dropulic

360 LIMITATIONS OF HIV SPECIFIC CAR-T CELLS TO LYSE CELLS BEARING HIV IMMUNE COMPLEXES
Matthew T. Ollerton, Edward Berger, Gregory F. Burton, Elizabeth Connick

Poster P-E07 HIV LATENCY REVERSAL
Poster Hall - 4EF  2:30 PM - 4:00 PM

368 INDUCIBILITY OF LATENT HIV-1 IN RESTING CD4+ MEMORY T-CELL SUBSETS
Kyungyoon J. Kwon, Andrew Timmons, Srona Sengupta, Francesco R. Simonetti, Hao Zhang, Rebecca Hoh, Steven G. Deeks, Rafick-Pierre Sekaly, Janet Siliciano, Robert Siliciano

369 PKC AGONIST EXPOSURE SUFFICIENT TO ACTIVATE T CELLS IN VIVO ALSO CAUSES COAGULOPATHY
Chelsea Snyder, Alivelu Irrinki, Ryan McFadden, Jasmine Kaur, Bally Randhawa, Hoa Truong, Daniel Soohoo, Chad Greco, Dymtro Kornyeyev, Eric Hu, Helen Yu, Bernard Murray, Leigh Ann Burns-Naas, Tomas Cihlar, Jeffrey Murry

370 ACTIVATION OF HIV-SPECIFIC CD8+ T CELLS FROM HIV+ DONORS BY VESATOLIMOD
Renee R. Ram, Tiffany Barnes, Paul Duatschek, Michael E. Abram, Romas Gelezunas, Joseph Hesselgesser, Christian Callebaut

371 DEBIO 1143 IS AN ATTRACTIVE HIV-1 LATENCY REVERSAL CANDIDATE
Michael Babordt, Udayan Chatterji, Sumit Chanda, Susan J. Little, Norbert Wiedemann, Gregoire Vuagniaux, Philippe Gallay

372 HIV-1 PROVIRAL CLONE-SPECIFIC DIFFERENCES IN RESPONSE TO LATENCY REVERSING AGENTS
Edmond Atindaana, Erin T. Larragoite, Sarah Emery, Kalyani Pyaram, Cleo Burnett, Cheong-Hee Chang, Vicente Pianelles, Jeffrey Kidd, Alice Telesnitsky

373 HIV-2 DYNAMICS DURING LATENCY REVERSAL
Fernanda Ferreira, Athi Tsibris, Daniel R. Kuritzkes

Poster P-E09 MECHANISMS OF PERSISTENCE
Poster Hall - 4EF  2:30 PM - 4:00 PM

380 RESIDUAL VIREMIA IS DOMINATED BY MONOTYPIC VIRUS RESULTING IN INFECTIONPLASMA VIRUS
Hadega Aamer, Jan McClure, Sherry McLaughlin, Sheila Styrchak, Daisy Ko, Janine Maenza, Ann Collier, James Mullins, Lisa Frenkel
381 PD-1/PD-L1 INTERACTION REGULATES HIV TRANSCRIPTION IN LYMPH NODES OF TREATED SUBJECTS
Riddhima Banga, Caterina Rebecchini, Francesco Procopio, Alessandra Noto, Olivia M. Monje, Craig Fenwick, Matthias Cavassini, Jean-Marc Corpataux, Laurence de Leval, Giuseppe Pantaleo, Matthieu Perreau

382 CELLULAR PROLIFERATION MAINTAINS GENETICALLY INTACT AND DEFECTIVE HIV-1 OVER TIME
Bethany A. Horsburgh, Bonnie Hiener, John-Sebastian Eden, Eunok Lee, Timothy E. Schlub, Susanne von Stockenstrom, Lina Odevall, Jeffery Milush, Teri Liegler, Rebecca Hoh, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer

383 INCREASED NUMBERS OF INTACT HIV SEQUENCES IN A4B7 T CELLS DURING ACUTE SEROCONVERSION
Sofie L. Rutsaert, Pilar Garcia Broncano, Marie-angélifique D. De Scheerder, Basile Cole, Mathias Lichterfeld, Linos Vandenkerckhove

384 SEX AND OBESITY ARE ASSOCIATED WITH RESIDUAL VIREMIA IN ART-SUPPRESSED INDIVIDUALS
Joshua C. Cyktor, Hanna Mar, Ann Collier, Evelyn Hogg, Catherine Godfrey, Joseph J. Eron, Ronald Bosch, Deborah McMahon, John W. Mellors, Rajesh T. Gandhi, for the A5321 Team

385 CD4+ T-CELL-SURFACE FUCOSYLATION DEFINES PERSISTENT HIV TRANSCRIPTION IN VIVO
Florent Colomb, Leila B. Giron, Andrew V. Kossenkov, Emilie Battivelli, Emmanouil Papasavvas, Luis Montaner, Eric Verdin, Clovis S. Palmer, Mohamed Abdel-Mohsen

386 GALECTIN-9 MEDIATES HIV TRANSCRIPTION BY INDUCING TCR-DEPENDENT ERK SIGNALING
Florent Colomb, Leila B. Giron, Thomas Premeaux, Toshiro Niki, Emmanouil Papasavvas, Luis Montaner, Lishomwa C. Ndhlouvu, Mohamed Abdel-Mohsen

387 TNF SURFACE RECEPTORS RELATE TO SURVIVAL PATHWAY ACTIVATION IN HIV RESERVOIR CELLS
Hsiao-Hsuan Kuo, Stephane Hua, Ce Gao, Shivaali Maddali, Xu G. Yu, Mathias Lichterfeld

388 HIV PROVIRAL DNA METHYLATION IN SEROCONVERTERS, CONTROLLERS, AND ART-TREATED PATIENTS
Sam Kint, Sabine Kinloch-de Loes, Wim Van Criekeinge, Linos Vandenkerckhove

Poster P-F4 CNS RESERVOIRS, ESCAPE, AND IMMUNOLOGY
Poster Hall - 4EF 2:30 PM - 4:00 PM

446 NEUROSYMPTOMATIC HIV CSF ESCAPE CAN BE PRODUCED BY REPLICATION IN T CELLS IN THE CNS
Laura P. Kincer, Magnus Gisslén, Serena S. Spudich, Mattia Trunfio, Andrea Calcagno, Cinque Paola, Ronald Swanstrom, Richard W. Price, Sarah B. Joseph

447 RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED cART REGIMEN CHANGES
Francesca Ferretti, Valentina De Zan, Filippo Turrini, Enzo Boeri, Simonetta Gerevini, Nicola Gianotti, Hamid Hasson, Adriano Lazzarin, Cinque Paola
448 CNS ESCAPE OF DRUG-RESISTANT HIV IN PML-IRIS AND CONSEQUENT PERIPHERAL DISSEMINATION
Andrea Lisco, Camille Lange, Bryan Smith, Maura Manion, Natalie Lindo, Dima A. Hammoud, Catherine A. Rehm, Alice K. Pau, Safia S. Kuriakose, Megan Anderson, Pawel Muransky, Craig Sykes, Frank Maldarelli, Irini Sereti

449 DEEP SEQUENCING REVEALS EXTENSIVE CSF COMPARTMENTALIZATION IN HIV+ PEOPLE IN UGANDA
Sarah B. Joseph, Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Kevin Robertson, Ronald H. Gray, Maria Wawer, Ronald Swanstrom, Ned Sacktor

450 MINIMAL INCIDENCE OF CSF ESCAPE AFTER INITIATION OF ART IN ACUTE HIV INFECTION
Ryan C. Handoko, Phillip Chan, Linda Jagodzinski, Suteeraporn Pinyakorn, Nittaya Phanuphak, Carlo Sacdalan, Eugène Kroon, Chutharat Munkong, Netsiri Dumrongpisutikul, Robert J. O’Connell, Robert Gramzinski, Victor Valcour, Jintanat Ananworanich, Serena S. Spudich, for the SEARCH 010/RV254 Study Team

451 TREATMENT REGIMENS FOR MANAGING SYMPTOMATIC CSF HIV ESCAPE IN PUNE, INDIA
Ameet N. Dravid, Raviraj Gawali, Mahenderkumar Medisetty, Kartik Natarajan, Chinmay Saraf, Milind Kulkarni, Sachin Kore, Niranjan Rathod, Umakant Mahajan, Andrea Calcagno

452 PRESENCE OF INTACT HIV DNA VARIANTS IN THE BRAIN AND LYMPHOID TISSUES DURING ART
Michelli Faria de Oliveira, Benjamin Murrell, Andrej Vitomirov, Thomas Vollbrecht, Venkatesh Kumar, Nikesh Kumar, Ben Gouaux, David J. Moore, Alan F. Jarmusch, Fernando Vargas, Pieter Dorrestein, Ronald J. Ellis, Davey M. Smith, Sara Gianella

Poster P-F5 NEUROIMAGING AND ASSOCIATED BIOMARKERS
Poster Hall - 4EF 2:30 PM - 4:00 PM

453 ASSOCIATION OF CEREBRAL SMALL VESSEL DISEASE WITH THE BRAIN IN HIV INDIVIDUALS
Ryan Sanford, Jeremy Strain, Mahsa Dadar, Josefnia Maranzano, Nancy Mayo, Susan Scott, Lesley K. Fellows, Beau Ances, Louis Collins

454 1H MRS IDENTIFIES SUBCLINICAL NEURONAL INJURY DESPITE CHRONIC VIRAL SUPPRESSION
Lucette A. Cysique, Thomas Gates, Lauriane Juge, Gemma Howdle, Tony Johnson, Avindra Nath, Caroline Rae, Bruce J. Brew, for the CHIEF group

455 INFLAMMATORY PLASMA BIOMARKERS CORRELATE WITH DIFFUSION TENSOR IMAGING IN CHRONIC HIV
Kevin C. Chang, Thomas Premeaux, Yann Cobigo, Benedetta Milanini, Joanna Hellmuth, Shireen Javandel, Lishowma C. Ndhlouo, Robert Paul, Victor Valcour

456 WHITE MATTER HYPERINTENSITIES INCREASE AS A FUNCTION OF CVD RISK AND HIV DISEASE
Minjie Wu, Shaolin Yang, Hoby Hetherington, Tae Kim, Jeffry Alger, Peter B. Barker, Todd B. Parrish, Andrew Levine, Eileen Martin, Cynthia Munro, Ann B. Ragin, Ned W. Sacktor, Eric C. Seaberg, James T. Becker, for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study
**457** RESTING-STATE CONNECTIVITY ASSOCIATES WITH DEPRESSION SYMPTOMS IN ACUTE HIV
Carissa L. Philipp, Leah Reyna, Phillip Chan, Nittaya Phanuphak, Nisakorn Ratnaratorn, Joanna Hellmuth, Khunthalee Benjamponpong, Netsiri Dumrongpisutikul, Mantana Pothisiri, Jintanat Ananworanich, Serena S. Spudich, Victor Valcour, Robert Paul, for the SEARCH 010/RV254 and RV304/SEARCH 013 study teams

**458** LOWER FRONTAL GREY-MATTER BRAIN VOLUMES AND BASAL-GANGLIA ENLARGEMENT IN PERINATAL HIV
Beatriz Ruiz-Saez, Manuela Martín-Bejarano, Ana Martinez de Aragon, Pablo Rojo Conejo, Tália Sainz, Alberto Alvarez, José Tomás Ramos, Sara Guillen, Dolores Falcón, Mario Gil-Correa, Pilar Fernández, Santiago Jimenez de Ory, María Luisa Navarro, María Isabel González-Tomé, for the NeuroCorISpe

**459** BENEFICIAL EFFECTS OF CANNABIS ON BLOOD-BRAIN BARRIER AND INFLAMMATION IN HIV
Ronald J. Ellis, Jennifer Iudicello, Erin Morgan, Brook Henry, Rachel Schrier, Mariana Cherney, Martin Hoenigl, Scott L. Letendre, for the Translational Methamphetamine Research Center

**460** PBR-PET IMAGING OF NEUROINFLAMMATION NOT ELEVATED IN HIV+ PARTICIPANTS
Anna Boerwinkle, Jeremy Strain, John Doyle, Sarah A. Cooley, Jon Christensen, Yi Su, Julie Wisch, Beau Ances

---

**Poster P-G3 ARV PHARMACOLOGY IN COMPARTMENTS AND RESERVOIRS**
Poster Hall - 4EF 2:30 PM - 4:00 PM

**474** BICTEGRAVIR CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF HIV-INFECTED PATIENTS
Juan M. Tiraboschi, Arkaitz Imaz, Saye Khoo, Jordi Niubo, Paula Prieto, Maria Saumoy, Sujan Dilly Penchala, Benito Garcia, Cristina Padilla, Daniel Podzamczer

**475** WHICH PRECLINICAL SPECIES MIMICS TISSUE PENETRATION OF ARV DRUGS IN HUMANS?

**476** ANTIRETROVIRALS CONCENTRATIONS IN THE OLFACTORY MUCOSA OF HIV-POSITIVE PATIENTS
Andrea Calcagno, Amedeo De Nicolò, Mattia Trunfio, Tiziano Allice, Daniele Imperiale, Claudia Bartoli, Valeria Ghisetti, Maria Enrica Amasio, Antonio D’Avolio, Giovanni Di Perri, Stefano Bonora

**477** INFLUENCE OF TENOFOVIR-MONOESTER AND TENOFOVIR ON INTRACELLULAR TENOFOVIR-DIPHOSPHATE
Kristina M. Brooks, Mustafa E. Ibrahim, Jose R. Castillo-Mancilla, Samantha MaWhinney, Cricket McHugh, Lane R. Bushman, Jennifer J. Kiser, Sybil Hosek, Gregory D. Huhn, Peter L. Anderson

**478** DEPO-MEDROXYPROGESTERONE EFFECTS ON TENOFOVIR-DP AND LAMIVUDINE-TP IN CERVICAL TISSUE
Melanie Nicol, Prosperity Eneh, Rita Nakalega, Samuel Kabwigu, Esther Isingel, Noah Kiwanuka, Maqs Beksinska, Craig Sykes, Mary G. Fowler, Todd T. Brown, Flavia K. Matovu
479 A QUANTITATIVE APPROACH TO EVALUATE ARV PROXIMITY TO VIRUS AND CELLS IN LYMPH NODES
Elias Rosen, Claire Deleage, Yuri Fedoriw, Jacob D. Estes, Angela Kashuba

480 GS-6207, A POTENT AND SELECTIVE FIRST-IN-CLASS LONG-ACTING HIV-1 CAPSID INHIBITOR

481 MK-8591 POTENCY AND PK PROVIDE HIGH INHIBITORY QUOTIENTS AT LOW DOSES QD AND QW
Jay Grobler, Kerry Fillgrove, Daria Hazuda, Qian Huang, Ming-Tain Lai, Randolph P. Matthews, Deanne J. Rudd, Ryan Vargo

482 FAVOURABLE OUTCOME OF IN VITRO SELECTIONS WITH NOVEL NRTI PRODRUG GS-9131
Ruxandra-Ilinca Ibanescu, Maureen Oliveira, Bonnie Spira, Jean-Pierre Routy, Bluma G. Brenner, for the Montreal Primary HIV (PHI) Cohort Study Group

483 LONG-TERM SAFETY & EFFICACY OF FOSTEMSAVIR IN TREATMENT-EXPERIENCED HIV PARTICIPANTS
Melanie Thompson, Fernando Mendo Urbina, Gulam Latiff, Sandra Trevino Perez, Edwin DeJesus, Natalia Zakharova, Marcelo Martins, Johannes Bogner, Li Yi, Amy Pierce, Shiven Chabria, Peter Ackerman, Cyril Llamoso, Max Lataillade, for the 205889 Investigative Study Team

484 ACTIVITY OF ECD4-IG AGAINST CCR5 ANTAGONIST-RESISTANT HIV-1
Zixin Hu, Phillip Tomezsko, Matthew Gardner, Michael Farzan, Athe Tsibris, Daniel R. Kuritzkes

485 IBALIZUMAB: WEEK 96 DATA
Brinda Emu, Jay Lalezari, Princy Kumar, Steven Weinheimer, Stanley Lewis, Brandon Cash, Zvi Cohen

486 PRO 140 SC: LONG-ACTING, SINGLE-AGENT MAINTENANCE THERAPY FOR HIV-1 INFECTION
Kush Dhody, Kazem Kazempour, Nader Pourhashian, Paul J. Maddon

487 IN SILICO SIMULATION OF LONG-ACTING TENOFOVIR ALAFENAMIDE SUBCUTANEOUS IMPLANT
Rajith Kumar Reddy Rajoli, Zach Demkovich, Ariane van der Straten, Charles W. Flexner, Andrew Owen, Marco Siccardi

488 LONG-ACTING EMTRICITABINE PRODRUGS PROVIDE PROTECTION FROM HIV INFECTION IN VIVO
Paul Curley, James J. Hobson, Neill Liptrott, Amer Al-Khouja, David Meyers, Caren Freel Meyers, Charles W. Flexner, Marco Siccardi, Steve Rannard, Larisa Y. Poluektova, Andrew Owen

489 PRODRUGS EXTEND THE HALF LIFE AND POTENCY OF CABOTEGRAVIR
Tanmay A. Kulkarni, Aditya N. Bade, Brady J. Sillman, Bhagya Dyavar Shetty, Melinda Wojtkiewicz, JoEllyn McMillan, Benson Edagwa, Howard E. Gendelman
490  HIV REPLICATION AT <40C/ML FOR DTG+3TC VS DTG+TDF/FTC IN THE GEMINI 1 & 2 STUDIES
Mark Underwood, Rimgaile Urbaitye, Choy Man, Jörg Sievers, Ruolan Wang, Brian Wynne, Allan-Raymond Tenorio, Alexander Currie, Keith Pappa, Justin Koteff, Martin Garthian, Michael Aboud

491  RESIDUAL HIV-1 RNA, HIV-1 DNA, AND PLASMA CMIN IN DUAL DTG+3TC, ANRS 167 LAMIDOL
Charlotte Charpentier, Gilles Peytavin, Charles Burdet, Roland Landman, Minh Le, Christine Katlamia, Gilles Collin, Aida Benalycherif, André Cabié, France Mentré, Yazdan Yazdanpanah, Diane Descamps, Veronique Joly, for the LAMIDOL study group

492  IMPACT OF DUAL THERAPY ON THE CD4/CD8 RATIO IS SIMILAR TO TRIPLE THERAPY AT 48 WEEKS
María I. Figueroa, Antonio Camiro-Zuñiga, Juan Sierra Madero, Jaime Andrade Villanueva, Jose R. Arribas, Javier R. Lama, Diego M. Cecchini, Gustavo Lopardo, Brenda Crabtree-Ramirez, Pablo F. Belaunzarán-Zamudio, Patricia Patterson, Valeria I. Fink, Omar G. Sued, Pedro Cahn, for the GARDEL-ANDES study group

493  FACTORS ASSOCIATED WITH THERAPEUTIC FAILURE OF 2-DRUG REGIMENS, DAT’AIDS COHORT
Clotilde Allavena, Colin Deschanvres, Gilles Peytavin, David Rey, Marc-Antoine Valantin, Fiiroze Bani-Sadr, Olivier Robineau, Claudine Duvivier, André Cabié, Laurent Hoque, Lise Cuzin, Veronique Joly, Antoine Chéret, Jacques Neynes, for the Dat’AIDS

494  EFFECTS OF ART SIMPLIFICATION IN THE SPANISH AIDS RESEARCH NETWORK, CORIS
Sergio Serrano-Villar, Inma Jarrin, Pompeyo Viciana, Federico Pulido, Francesc Vidal, Enrique Bernal, Carlos Galera, Santiago Moreno, for the CoRIS

554  SPECIFICITY OF 4 POINT-OF-CARE RAPID HIV TESTS IN A SETTING WITH HIGH PrEP USE
Pollyanna R. Chavez, Laura Wesolowski, Lauren Violette, Lisa Niemann, Vanessa M. McMahan, Andy M. Cornelius-Hudson, David A. Katz, Steven Ethridge, Joanne Stekler, Kevin P. Delaney

555  PERFORMANCE OF HIV DIAGNOSTIC ALGORITHMS IN THE PRESENCE OF VACCINE-INDUCED IMMUNITY
Frank Msafiri, Alice Manjate, Sarah Lindroth, Said Aboud, Eligius Lyamuya, Sören Andersson, Charlotte Nilsson

556  DIFFERENTIATION CAPABILITY OF THE GEENIUS ASSAY FOR HIV-2 AND HIV-1/2 DUAL INFECTIONS
Ming Chang, Eugene Deng, Jose Ortega, Dana Raugi, Babacar Faya, Fatou Kine Simal, Samba Cisse, Khadim Faye, Robert A. Smith, Moussa Seydi, Geoffrey S. Gottlieb, Robert Coombs

557  HIV-1 RNA DETECTION BY ABBOTT M2000 CORRELATES WITH INTEGRASE SINGLE-COPY ASSAY
Melissa A. Tosiano, Hanna Mar, Joshua C. Cytor, Dianna L. Koontz, Joseph J. Eron, Rajesh T. Gandhi, Deborah McMahon, Ronald Bosch, John W. Mellors, for the ACTG A5321 Team
558 **REPLICATE APTIMA ASSAY FOR QUANTIFYING RESIDUAL PLASMA VIREMIA IN INDIVIDUALS ON ART**

Sonia Bakkour, Xutao Deng, Peter Bacchetti, Mars Stone, Andrew Worlock, Scott Hauenstein, Steven G. Deeks, Michael P. Busch, for the RAVEN Program

559 **THE USE OF EXTERNAL QUALITY-ASSURANCE DATA TO COMPARE HIV-1 RNA ASSAY PERFORMANCE**

Cheryl Jennings, Daniel J. Zaccaro, Amy Couzens, Salvatore R. Scianca, Donald J. Brambilla, James W. Bremer

---

**Poster P-K5 HIV AND HBV INFECTION**

**Poster Hall - 4EF 2:30 PM - 4:00 PM**

619 **A DECISION-TREE ANALYSIS FOR HEPATITIS A IMMUNITY AMONG HIV-INFECTED MSM IN TOKYO**

Tomohiko Koibuchi, Michiko Koga, Tadashi Kikuchi, Lay Ahyoun Lim, Hidenori Sato, Eisuke Adachi, Takeya Tsutsumi, Hiroshi Yotsuyanagi

620 **LOW IMMUNE RESPONSE RATE OF HIV-POSITIVE PATIENTS TO SINGLE INJECTION OF HAV VACCINE**

Lucie Noel, Marc-Antoine Valentin, Marc Wirden, Sophie Sayon, Christine Blanc, Roland Tubiana, Christine Katlama, Anne-Geneviève Marcelin, Vincent Calvez, Eve Todesco

621 **LOSS OF HEPATITIS A VIRUS SEROPROTECTION IN PERSONS LIVING WITH HIV**

Rishi Chanderraj, Mark Cichocki, Tejal Gandhi, James Riddell

622 **HBV REVACCINATION AMONG HIV-POSITIVE MSM RECEIVING HAART: A RANDOMIZED CLINICAL TRIAL**

Yi-Chia Huang, Wen-Chun Liu, Yi-Ching Su, Hsin-Yun Sun, Sui-Yuan Chang, Chien-Ching Hung

623 **THE GLOBAL DISTRIBUTION OF HEPATITIS B VIRUS VACCINE ESCAPE MUTATIONS**

Mahad T. Raheel, Wonderful T. Choga, Jason T. Blackard

---

**Poster P-K6 HIV AND HBV: BAD (LIVER) BEDFELLOWS**

**Poster Hall - 4EF 2:30 PM - 4:00 PM**

624 **HEPATITIS B CURE IN HIV PATIENTS IS MORE LIKELY IN HISPANICS AND THOSE WITH AIDS**

Mamta K. Jain, Paul Parisot, Gabriella Go, Trung T. Vu, Karen J. Vigil, Barbara S. Taylor

625 **HIGH RATES OF HBV FUNCTIONAL CURE AMONG HIV/HBV-COINFECTED PATIENTS ON ART IN ZAMBIA**

Belinda V. Chihota, Gilles Wandeler, Roma Chilengi, Lloyd Mulenga, Raymond T. Chung, Debika Bhattacharya, Matthias Egger, Michael J. Vinikoor, for the IeDEA Southern Africa

626 **HEPATITIS B VIROLOGIC FAILURE OF TENOFOVIR-BASED THERAPIES IN PATIENTS WITH HIV/HEV**

Helen L. Zhang, Meredith Mock, Lane R. Bushman, Peter L. Anderson, Andrew J. Muir, Jennifer J. Kiser, Susanna Naggie

627 **HIV LATE PRESENTATION AND ITS IMPACT ON HBV SEROCONVERSION IN HBV/HIV**

Christoph Boesecke, Christian Hoffmann, Stefan Mauss, Thomas Lutz, Patrick Ingiliz, Christoph D. Spinner, Stefan H. Scholten, Florian Berger, Stephan Schneeweiss, Fabian Busch, Clara Lehmann, Gerd Fätkenheuer, Jürgen K. Rockstroh, for the DZIF HBV HIV Cohort
628  ABSENCE OF HBV REACTIVATION IN HIV/HCV/HBCAB COINFECTED PATIENTS TREATED WITH DAA
Maddalena Cerrone, Francesca Ferretti, Ryan Whyte, Mimie Chirwa, Mark Nelson

629  HEPATITIS B VIRUS DNA LEVEL CHANGES IN HBEAG+ PREGNANT WOMEN RECEIVING TDF FOR PMTCT
Nicole Ngo-Giang-Huong, Nicolas Salvadori, Woottichai Khamduang, Tim R. Cressey, Linda J. Harrison, Luc Decke, Camlin Tierney, Jullapong Acharapong, Trudy V. Murphy, Noele Nelson, George K. Siberry, Raymond T. Chung, Stanislas Pol, Gonzaque Jourdain, for the iTAP study group

630  A LONG-ACTING 3TC NANOFORMULATION SUPPRESSES HBV REPLICATION IN HUMANIZED MICE
Nathan Smith, Weimin Wang, Edward Makarov, Yimin Sun, Catherine L. Gebhart, JoEllyn McMillan, Howard E. Gendelman, Larisa Y. Poluektova, Benson Edagwa

Poster P-M6 HEART FAILURE AND PULMONARY DISEASE
Poster Hall - 4EF  2:30 PM - 4:00 PM

658  TRANSCRIPTOMIC BIOMARKERS OF HEART FAILURE IN PEOPLE LIVING WITH HIV
Cheryl Cameron, Chris T. Longenecker, Brian Richardson, Michael Fang, Jonathan Bugey, Sadeer Al-Kindi, Michael Cartwright, Carmen Nichols, Pearline Cartwright, Jackelyn Golden, Mark Cameron

659  HIV/HCV-SPECIFIC MARKERS AND ECHOCARDIOGRAPHIC PULMONARY ARTERY SYSTOLIC PRESSURE
Courtney Zola, Meredith S. Duncan, Kaku So-Armah, Kristina Crothers, Adeel A. Butt, Cynthia L. Gibert, Joon W. Kim, Joseph Lim, Vincent Lo Re, Hilary A. Tindle, Matthew Freiberg, Evan L. Brittain

660  EVIDENCE OF PRECLINICAL MYOCARDIAL FIBROSIS IN ART-TREATED PLWH IN SOUTH AFRICA
Lye-Yeng Wong, Tess Peterson, Julian Wolfson, Justin A. Lumbamba, Stephen Jersmy, Hadil Saad, Scott Shuldiner, Muki Shey, Graeme Meintjes, Ntobeko Ntusi, Mpiko Ntsekhe, Jason V. Baker

661  HIV IS ASSOCIATED WITH LUNG-FUNCTION IMPAIRMENT IN THE MULTICENTER AIDS COHORT STUDY
Ken M. Kunisaki, Seyed M. Nourae, Robert Jensen, Dong Chang, Gypsyamber D’Souza, Megan E. Fitzpatrick, Meredith C. McCormack, Valentina Stosor, Alison Morris, for the MACS Pulmonary Substudy Group

662 LB HIV IS NOT ASSOCIATED WITH SLEEP-DISORDERED BREATHING
Ken M. Kunisaki, Davide De Francesco, Caroline Sabin, Alan Winston, Patrick W. Mallon, Jane Anderson, Marta Boffito, Lewis Haddow, Frank Post, Jaime H. Vera, Wajahat Khalil, Susan Redline, for the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study Group

Poster P-M7 CARDIOVASCULAR DISEASE: MORTALITY, RISK FACTORS, AND MANAGEMENT STRATEGIES
Poster Hall - 4EF  2:30 PM - 4:00 PM

663  SEX-SPECIFIC PATTERNS IN HIV-ASSOCIATED CARDIOVASCULAR MORTALITY IN NEW YORK CITY
David B. Hanna, Chitra Ramaswamy, Robert C. Kaplan, Jorge R. Kizer, Demetre C. Daskalakis, Kathryn Anastos, Sarah L. Braunstein
664 DIFFERENCES IN TYPES OF MYOCARDIAL INFARCTIONS AMONG PATIENTS AGING WITH HIV

665 ALCOHOL USE AND RISK OF MYOCARDIAL INFARCTION (MI): DOES MI TYPE MATTER?

666 CARDIOVASCULAR RISK MANAGEMENT AMONG PLWH: DOES PROVIDER SPECIALTY MATTER?
Nwora L. Okeke, Katherine R. Schafer, Jan Ostermann, Ansal D. Shah, Susanna Naggie, Hayden B. Bosworth

667 INCREASED PREVALENCE OF PROLONGED QTC IN PERSONS LIVING WITH HIV COMPARED TO CONTROLS
Andreas D. Knudsen, Jonas B. Nielsen, Marco Gelpi, Jens D. Lundgren, Per E. Sigvardsen, Amanda Mocroft, Jørgen T. Kuhl, Andreas Fuchs, Børge Nordestgaard, Claus Graff, Lars Kober, Thomas Benfield, Klaus F. Kofoed, Susanne D. Nielsen, for the COCOMO study group

668 HYPERTENSION CONTROL IN INTEGRATED HIV/NCD CLINICS IN THE SEARCH STUDY

Poster P-N3 ADIPOSE TISSUE DENSITY AND BIOLOGY
Poster Hall - 4EF 2:30 PM - 4:00 PM

681 CHANGES IN FAT DENSITY AFTER ART INITIATION
Jordan E. Lake, Carlee Moser, Maxine Olefsky, Kristine M. Erlandson, Ann Scherzinger, James H. Stein, Judith S. Currier, Todd T. Brown, Grace A. McComsey

682 DUAL-ENERGY X-RAY ABSORPTIOEMTRY (DXA) POORLY APPROXIMATES VISCERAL FAT IN HIV
Lindsay T. Fourman, Emma M. Kileel, Jane Hubbard, Tara Holmes, Ellen Anderson, Sara E. Looby, Kathleen V. Fitch, Meghan Feldpausch, Martin Torriani, Janet Lo, Takara L. Stanley, Steven K. Grinspoon

683 UNIQUE MIRNA SIGNATURE IN HIV LIPODYSTROPHY WITH REDUCED ADIPOSE DICER EXPRESSION
Suman Srinivasa, Ruben Garcia, Martin Torriani, Kathleen V. Fitch, Patrick Maehler, Meghan Feldpausch, Aaron M. Cypress, C. Ronald Kahn, Steven K. Grinspoon

Poster P-N7 BAD THINGS HAPPEN: HIV COMORBIDITIES
Poster Hall - 4EF 2:30 PM - 4:00 PM

696 ALOPECIA AFTER SWITCH TO TENOFOVIR ALAFENAMIDE IN 5 AFRICAN AMERICAN WOMEN
Said El Zein, Jennifer Veltman
697 IMPACT AND DETERMINANTS OF COMORBIDITY CLUSTERS IN PEOPLE LIVING WITH HIV
Davide De Francesco, Sebastiaan Verboeket, Jonathan Underwood, Ferdinand Wit, Emmanuel Bagkeris, Patrick W. Mallon, Alan Winston, Peter Reiss, Caroline Sabin, for the POPPY study group

698 WIDESPREAD PAIN AND ASSOCIATIONS WITH HIV-RELATED FACTORS IN PEOPLE WITH HIV
Caroline Sabin, Kennedy Nkhoma, Richard Harding, Adam Geressu, Emmanuel Bagkeris, Patrick W. Mallon, Frank Post, Memory Sachikonye, Marta Boffito, Jane Anderson, Jaime Vera-Rojas, Margaret Johnson, Ian Williams, Alan Winston, for the POPPY Study

699 MOOD DISORDERS & INCREASED RISK OF NONCOMMUNICABLE DISEASES IN ADULTS AGING WITH HIV
Jessica L. Castilho, Peter F. Rebeiro, Bryan E. Shepherd, Cathy Jenkins, Robertson Nash, Rodney S. Adams, Megan M. Turner, Sally S. Furukawa, Todd Hulgan, John R. Koethe, Timothy R. Sterling

700 TREATMENT OF PSYCHIATRIC DISORDERS AND TIME WITH HIV VIRAL LOAD ≥200 COPIES/ML
Matthew E. Levy, Anne K. Monroe, Michael A. Horberg, Debra A. Benator, Sherry Molock, Rupali K. Doshi, Lindsey Powers Happ, Amanda D. Castel, for the DC Cohort Executive Committee

701 BLUNTED MUSCLE MITOCHONDRIAL RESPONSES TO EXERCISE TRAINING IN OLDER ADULTS WITH HIV
Catherine M. Jankowski, Melissa P. Wilson, Samantha MaWhinney, Jane Reusch, Leslie Knaub, Kristine M. Erlandson

702 WEAK GRIP AND FRAILTY ARE ASSOCIATED WITH MTDNA HAPLOGROUP IN ADULTS WITH HIV
Kristine M. Erlandson, Yuki Bradford, David C. Samuels, Todd T. Brown, Jing Sun, Kunling Wu, Katherine Tassiopoulois, Marylyn D. Ritchie, David Haas, Todd Hulgan, for the AIDS Clinical Trials Group

703 GLYCEMIC CONTROL AND COGNITION ARE INDEPENDENTLY ASSOCIATED WITH GAIT SPEED DECLINE
Mary Clare Masters, Jeremiah Perez, Katherine Tassiopoulois, Adriana Andrade, Ronald J. Ellis, Jingyan Yang, Todd T. Brown, Frank J. Palella, Kristine M. Erlandson

704 SERIOUS INJURY AFTER A FALL: ARE THOSE WITH HIV AT GREATER RISK THAN UNINFECTED?
Julie A. Womack, Christine Ramsey, Terrence E. Murphy, Harini Bathulapalli, Alexandra C. Smith, Cynthia L. Gibert, Maria Rodriguez-Barradas, Phyllis Tien, Michael T. Yin, Thomas M. Gill, Gary Friedlaender, Cynthia A. Brandt, Amy C. Justice

757 POPULATION PK OF DOLUTEGRAVIR IN PLASMA, CORD, AND BREASTMILK: RESULTS FROM DOLPHIN-1
Laura Dickinson, Kenneth Kiito, Julie Anne Coombs, Alieu Amara, Christie Heiberg, Stephen I. Walimbwa, Yashna Singh, Shadia Nakalema, Laura Else, Landon Myer, Catriona Waitt, Mohammed Lamorde, Catherine Orrell, Saye Khoo, for the DolPHIN-1 Study Team
758  **DOLUTEGRAVIR PHARMACOKINETICS DURING PREGNANCY AND POSTPARTUM**

Angela Colbers, Pauline Bollen, Jolien Freriksen, Deborah Konopnicki, Katharina Weizsäcker, Carmen Hidalgo Tenorio, José Moltó, Graham P. Taylor, Irene Alba Alejandre, Reinout van Crevel, David M. Burger, for the PANNA

759  **PREGNANCY ASSOCIATED WITH DECREASED SERUM ISONIAZID LEVELS IN WOMEN LIVING WITH HIV**

Kamunkhwala Gausi, Paolo Denti, Lubbe Wiesner, Carole Wallis, Carolyne Onyango-Makumbi, Tsungai Chipato, Gerhard Theron, Sarah Bradford, Diane Costello, Renee Browning, Nahida Chakhtoura, Adriana Weinberg, Grace Montepiedra, Amita Gupta, for the IMPAACT P1078 (TB APPRISE) Study Group Team

---

### Poster P-P4 MATERNAL VIRAL SUPPRESSION AND TREATMENT OUTCOMES

**Poster Hall - 4EF**  
**2:30 PM - 4:00 PM**

760  **VIROLOGICAL RESPONSE OF RAL-BASED REGIMEN AMONG HIV-INFECTED PREGNANT WOMEN IN BRAZIL**

Ana R. Pati Pascom, Mariana V. Meireles, Fernanda Rick, Filipe d. Perini, Fernanda F. Fonseca, Adele Benzaken

761  **SEARCH INTERVENTION INCREASES VIRAL SUPPRESSION AMONG PREGNANT & POSTPARTUM WOMEN**

Jane Kabami, Hachem Saddik Saddiki, James Ayieko, Dalsone Kwariisima, Atukunda Mucunguzi, Edwin D. Charlebois, Tamara D. Clark, Elizabeth A. Bukusi, Craig R. Cohen, Philippa Musoke, Maya L. Petersen, Diane V. Havlíř, Moses R. Kamya, Laura B. Balzer, Gabriel Chamie

762  **IDENTIFYING WOMEN LIVING WITH PERINATAL HIV INFECTION AT RISK OF POSTPARTUM VIREMIA**

Brad Karalius, Claire Berman, Deborah Kacanek, Anna-Barbara Moscicki, Mary Paul, Kathleen M. Powis, Katherine Tassiopoulos, Kunjal Patel

763  **LONG-TERM OUTCOMES OF AN INTEGRATED MATERNAL AND CHILD HIV CARE TRIAL IN SOUTH AFRICA**


764  **EVALUATION OF GUIDELINES FOR VL MONITORING IN PREGNANCY & BREASTFEEDING: A SIMULATION**

Maia Lesosky, Janet M. Raboud, Tracy Glass, Sean S. Brummel, Andrea L. Ciaramello, Judith S. Currier, Shaffiq Essajee, Diane V. Havlir, Catherine A. Koss, Anthony Ogwu, Roger L. Shapiro, Elaine J. Abrams, Landon Myer

765  **MOBILITY AND THE 1-YEAR POSTPARTUM MATERNAL MORTALITY IN HIV-POSITIVE PREGNANT WOMEN**

Hae-Young Kim, Adrian Dobra, Frank Tanser

766  **TENOFOVIR HAIR LEVELS RISE OVER THE POSTPARTUM PERIOD AND HIGHLY PREDICT VIRAL LOADS**

Pamela M. Murnane, Peter Bacchetti, Judith S. Currier, Sean Brummel, Hideaki Okochi, Nhi Phung, Karen Kuncze, Risa M. Hoffman, Teacler Nematadzira, Dean Soko, Maxensia Owor, Friday Saidi, Patricia M. Flynn, Mary Glenn Fowler, Monica Gandhi
767 POSTPARTUM DEPRESSIVE SYMPTOMS IN WOMEN LIVING WITH HIV IN BOTSWANA

Poster P-Q2 GROWING UP WITH HIV AND ARV EXPOSURES
Poster Hall - 4EF 2:30 PM - 4:00 PM

790 SURVIVING AND THRIVING? OUTCOMES OF HIV-EXPOSED CHILDREN IN RURAL ZIMBABWE
Ceri Evans, Bernard Chasekwa, Robert Ntozini, Florence D. Majo, Kuda Mutasa, Naume Tavengwa, Batsirai Mutasa, Mduduzi Mbuya, Rebecca J. Stoltzfus, Lawrence Moulton, Jean Humphrey, Andrew Prendergast, for the SHINE Trial Team

791 IMPACT OF IMPROVED NUTRITION/SANITATION ON STUNTING AND ANEMIA IN HIV-EXPOSED INFANTS
Bernard Chasekwa, Andrew Prendergast, Ceri Evans, Kuda Mutasa, Mduduzi Mbuya, Rebecca J. Stoltzfus, Laura Smith, Florence D. Majo, Naume Tavengwa, Batsirai Mutasa, Lawrence Moulton, Robert Ntozini, Jean Humphrey, for the SHINE Trial Team

792 EXTENDED PROPHYLAXIS WITH NEVIRAPINE DOES NOT AFFECT GROWTH IN HIV-EXPOSED INFANTS
Carolyne Onyango-Makumbi, Ramadhani Mwiru, Arthur Owora, Anthony Mwatha, Alicja Young, Dhayendre Moodley, Hoosen Coovadia, Lynda Stranix-Chibanda, Karim P. Manji, Yvonne Maldonado, Paul Richardson, Philip Andrew, Kathleen George, Wafaie Fawzi, Mary G. Fowler

793 GROWTH PATTERNS IN CHILDREN OF WOMEN WITH PERINATALLY VS NON-PERINATALLY ACQUIRED HIV
Wendy Yu, Denise Jacobson, Paige L. Williams, Kunjal Patel, Russell B. Van Dyke, Linda A. DiMeglio, Mitchell Geffner, Deborah Kacanek, Jennifer Jao, for the Pediatric HIV/AIDS Cohort Study (PHACS)

794 POSTNATAL GROWTH IN CHILDREN EXPOSED OR UNEXPOSED TO HIV: A NATIONWIDE COHORT STUDY
Ellen Moseholm, Marie Helleberg, Terese L. Katzenstein, Merete Storgaard, Gitte Pedersen, Isik S. Johansen, Håkon Sandholdt, Nina Weis

795 IN UTERO HIV EXPOSURE IS LINKED TO OBESITY AND REACTIVE AIRWAY DISEASE IN ADOLESCENCE
Lindsay T. Fourman, Marisa E. Gerard, Chelsea S. Pan, Virginia Triant, Takara L. Stanley, Steven K. Grinspoon

Poster P-Q6 THE STATE OF THE MIND: GROWING UP WITH HIV
Poster Hall - 4EF 2:30 PM - 4:00 PM

819 YOUTH PSYCHIATRIC TRAJECTORIES PREDICT PERINATALLY HIV INFECTED YOUNG-ADULT VIREMIA

820 TRAJECTORY ANALYSIS OF COGNITIVE OUTCOMES IN CHILDREN WITH PERINATAL HIV
Payal Patel, Tanakorn Apornpong, Stephen J. Kerr, Thanyawee Puthanakit, Kulvadee Thongpibul, Pope Kosalaraksa, Pradthana Ounchanum, Suparat Kanjanavanit, Ly Pensun, Saphonn Vonthanak, Serena S. Spudich, Jintanat Ananworanich, Robert Paul, for the PREDICT/Resilience Study Group
821  FOCUSED COGNITIVE FUNCTION TESTING IN YOUNG PEOPLE WITH PERINATAL HIV IN ENGLAND
Alejandro Arenas-Pinto, Hannah Castro, Diane Melvin, Marthe Le Prevost, Caroline Foster, Kate Sturgeon, Alan Winston, Lindsay Thompson, Diana Gibb, Ali Judd, for the Adolescents and Adults Living with Perinatal HIV (AALPHI) Steering Committee

822  SYSTEMIC INFLAMMATION AND STRUCTURAL BRAIN CHANGES IN PERINATALLY HIV+ ADOLESCENTS
Jackie Hoare, Landon Myer, Sarah Heany, JP Fouche, Nicole Phillips, Heather Zar, Dan Stein

823  GENOMICS LINKS AUTOPHAGY WITH NEUROCOGNITIVE IMPAIRMENT IN HIV-INFECTED CHILDREN
Stephen A. Spector, Sean S. Brummel, Kumud K. Singh, Jihoon Kim, Kelly Frazer, Sharon Nichols, Olivier Harismendy, George R. Seage, Paige L. Williams, Russell B. Van Dyke, Rodney Trout

Poster P-Q7 ANTIRETROVIRAL PHARMACOKINETICS, SAFETY, AND EFFICACY IN CHILDREN AND YOUTH
Poster Hall - 4EF 2:30 PM - 4:00 PM

824  HIGH PRESCRIPTION ERROR RATES AMONG CHILDREN ON ANTIRETROVIRAL THERAPY IN KENYA
Irene Mukui, Samuel M. Mwalili, Barbra A. Richardson, Elizabeth A. Bukusi, Carey Farquhar

825  EFFECT OF ANTITUBERCULOSIS THERAPY ON NEVIRAPINE PHARMACOKINETICS IN YOUNG CHILDREN

826  SAFETY AND EFFICACY OF STARTING ANTIRETROVIRAL THERAPY IN THE FIRST WEEK OF LIFE
Roger L. Shapiro, Kara Bennett, Michael D. Hughes, Kenneth Maswabi, Gbolahan Ajibola, Sibhulile Moyo, Patrick Jean-Philippe, Edmund V. Capparelli, Terence Mohammed, Oganne Batlang, Shahin Lockman, Max Essex, Joseph Makheima, Mathias Lichterfeld, Daniel R. Kuritzkes

827  IN SILICO PREDICTION OF DOLUTEGRAVIR PHARMACOKINETICS & DOSE OPTIMISATION IN NEONATES
Fazila S. Bunglawala, Rajith Kumar Reddy Rajoli, Andrew Owen, Marco Siccardi

828  SIMILAR EFFICACY AND SAFETY OF DOLUTEGRAVIR BETWEEN AGE GROUPS OF PEDIATRIC PATIENTS
Pierre Frange, Veronique Avettand-Fenoel, Florence Veber, Stephane Blanche

829 LB  PK AND 4-WEEK OUTCOMES OF DOLUTEGRAVIR DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN
Theodore Ruel, Edward P. Acosta, Rajendra P. Singh, Carmelita Alvero, Kathleen George, Stephanie Popson, Mattie Bartlett, Ann Buchanan, Cindy Brothers, Lucy Koech, Tichaona Vhembo, Rohan Hazra, Ellen Townley, Andrew Wiznia, for the IMPAACT P1093 Team

830 LB  ADULT DOLUTEGRAVIR 50MG TABLETS IN CHILDREN LIVING WITH HIV WEIGHING 20 TO <25KG
Pauline Bollen, Anna Turkova, Hilda Mujuru, Elizabeth Kaudha, Abbas Lugemwa, Pauline Amuge, Angela Colbers, Cecilia Moore, Anna Parker, Victor Musiime, James G. Hakim, Deborah Ford, Diana Gibb, David M. Burger, for the ODYSSEY trial team
Poster Sessions

894 SUCCESSFUL cART NORMALIZES SURVIVAL FOR HIV-HTLV COINFECTED PATIENTS
Fernanda Miranda, Estela Luz, Eduardo M. Netto, Carlos Brites

895 RACIAL DISPARITIES IN BASELINE GENOTYPING IN THE ERA OF “ART FOR ALL”
Sasinya Scott, Lisa A. Forgione, Lucia V. Torian

896 YIELD OF HIV TESTING AND RE-ENGAGEMENT OF KEY POPULATIONS IN UGANDA AND KENYA
Gabriel Chamie, Norton Sang, Dalsone Kwarisiima, Jane Kabami, Kevin Kadede, Irene Bagala, Atukunda Mucunguzi, Tamara D. Clark, Laura B. Balzer, Edwin D. Charlebois, Craig R. Cohen, Elizabeth A. Bukusi, Maya L. Petersen, Diane V. Havlir, Moses R. Kamya

897 ED VISITS AND HOSPITALIZATIONS AS OPPORTUNITIES TO IMPROVE HIV CARE ENGAGEMENT
Tigran Avoundjian, Matthew R. Golden, Meena Ramchandani, Julia C. Dombrowski

898 POVERTY STIGMA AND HIV TREATMENT OUTCOMES AMONG WOMEN LIVING WITH HIV IN THE US
Anna M. Leddy, Janet M. Turan, Mallory Johnson, Torsten B. Neilands, Mirjam- Colette Kempf, Deborah Konkle- Parker, Gina Wingood, Phyllis Tien, Tracey Wilson, Carmen H. Logie, Sheri Weiser, Bulet Turan

899 RISK FACTORS FOR INCREASED HOSPITAL LENGTH OF STAY AMONG PWH, 2014-2015
Julia Fleming, Stephen Berry, W. C. Mathews, Judith Aberg, Laura W. Cheever, Richard D. Moore, Kelly Gebo, for the HIV Research Network

900 FIB-4 SCORE PREDICTS OVERALL MORTALITY IN HIV MONOINFECTED: A PROSPECTIVE STUDY
Hugo Perazzo, Antonio G. Pacheco, Sandra W. Cardoso, Carolyn Yanavich, Ricardo Santos, Ursula B. Chaves, Mario Sergio Pereira, Ronaldo I. Moreira, Estevao P. Nunes, Valdilea Veloso, Beatriz Grinsztejn, for the GPC-HEPATOL

901 LONG-TERM EFFECTIVENESS OF HIV TREATMENT IN ZAMBIA
Elvin Geng, Ingrid Eshun- Wilson, Kombatende Sikombe, Carolyn Bolton Moore, Sandra Simbeza, Paul Somwe, Nancy Padian, David Glidden, Izukanji Sikazwe, Charles B. Holmes

902 PREDICTORS OF LOSS OF VIRAL LOAD SUPPRESSION AMONG MSM IN ATLANTA
Jeb Jones, Jennifer Taussig, Jodie L. Guest, Colleen F. Kelley, Patrick S. Sullivan

903 IMPACT OF HIV TEST-AND-TREAT INITIATIVE IN MIAMI-DADE COUNTY, FLORIDA
Karalee Poschman, Emma C. Spencer, David Goldberg, Kira Villamizar, Tiffany Adams, Jeffrey Beal

904 ANTIRETROVIRAL REGIMEN DURABILITY IS NOT DRIVEN BY VIRAL FAILURE IN AN AFRICAN COHORT
**Poster Sessions**

**Poster Sessions**

**Thursday**

905  **RESUPPRESSION IN 1ST-LINE ART PATIENTS KENYA: DOES ART LONGEVITY AFFECT RESUPPRESSION?**
Christabel Orera Bodo, Kariithi Edward, Osiero Dennis, Crandall Bud, Kinyua Eunice, Elizabeth Mgamb, Jack Magara, Eliza Owino, Abel Omao, Millicent Ongidi, Richard Onkware, Diana Odhiambo, Dominic Mutai, Catherine Bonde, Nick Odiyo

906  **SIX YEARS OF INTEGRASE INHIBITOR USE IN A METROPOLITAN CITY**
B. Sharmila Mohanraj, Qingjiang Hou, Anne K. Monroe, Princy Kumar, Seble Kassaye, for the DC Cohort Executive Committee

907  **ANTIRETROVIRAL ADHERENCE AND HIV-1 DRUG RESISTANCE IN THE US**
Carmela Benson, Laura Mesana, Keith J. Dunn, Xiaotian Wu, Nicole Li, Johnny Lai, Eric Y. Wong, Kimberley Brown

908  **PROFILES OF HIV CARE DISRUPTIONS IN ZAMBIA: A LATENT CLASS ANALYSIS**
Aaloke Mody, Komakate Sikombe, Sheree Schwartz, Laura K. Beres, Ingrid Eshun-Wilson, Sandra Simbeza, Njeckwa Mukamba, Carolyn Bolton Moore, Izuokanji Sikazwe, Charles B. Holmes, Nancy Padian, Elvin Geng

909  **SURVIVAL OF PEOPLE LIVING WITH AIDS IN BRAZIL: BIAIDS-BRAZIL COHORT**
Mariza V. Tancredi, Carmen S. Domingues, Ione A. Guibu, Eliseu A. Waldman, Fabio A. Pires, Marco A. Gutierrez, Adele Benzaken, Gerson F. Pereira

910  **HIGH HIV PREVALENCE AND LOW ART COVERAGE AMONG AGYW WHO SELL SEX: A POOLED ANALYSIS**

911  **TIME TO UNDETECTABLE VIRAL LOAD ACHIEVEMENT AFTER ART START AND RISK OF MORTALITY**
Vincenzo Spagnuolo, Laura Galli, Alessandro Cozzi-Leprì, Giuseppe Lapadula, Andrea Antinori, Giancarlo Orofino, Nicoletta Bobbio, Maria Cristina Moioli, Andrea Calcagno, Andrea De Luca, Antonella D’Arminio Monforte, Antonella Castagna, for the ICONA Foundation Study Group

912  **CONTRIBUTION OF HIV DISEASE AND CARE STAGES TO HIV TRANSMISSION AMONG BALTIMORE MSM**
Romain Silhol, Marie-Claude Boily, Dobromir Dimitrov, Danièle German, Colin Flynn, Jason Farley, Marcy Gelman, James P. Hughes, Deborah J. Donnell, Adeola Adefuye, Robert H. Remien, Chris Beyrer, Gabriela Paz-Bailey, Cyprian Wejnert, Kate M. Mitchell

913  **CHANGING CONTEXTUAL FACTORS POST-HIV DIAGNOSIS PREDICT 5-YR MORTALITY IN SOUTH AFRICA**
Ingrid V. Bassett, Ai Xu, Janet Giddy, Laura M. Bogart, Andrew Boulle, Lucia Millham, Elena Losina, Robert A. Parker

914  **MORTALITY RATE AND ASSOCIATED RISK FACTORS AMONG HIV-INFECTED ADULTS ON ART IN KENYA**
Jacques Muthusi, Irene Mukui, Evelyne Ngugi, Tai Ho Chen, Kenneth Masamaro, Samuel M. Mwalili, Peter W. Young, Emily C. Zielinski-Gutierrez
915 POSTER SESSIONS

MORTALITY RATES AND CAUSES OF DEATH ACCORDING TO INCLUSION PERIOD IN HIV/HCV PATIENTS

Mathieu Chalouni, Dominique Salmon, Marc-Antoine Valantin, Firouze Bani-Sadr, Eric Rosenthal, Laure Esterle, Philippe Sogni, Linda Wittkop, for the ANRS C013 HEPAVIH study group

916 POSTER SESSIONS

LOW RATE OF SEX-SPECIFIC ANALYSES IN CROI PRESENTATIONS IN 2018: ROOM TO IMPROVE

Monica Gandhi, Laura M. Smeaton, Christina Vernon, Eileen P. Scully, Sara Gianella, Selvamuthu Poongulali, Anandi N. Sheth, Marije Van Schalkwyk, Karin L. Klingman, William R. Short, Valerie S. Opollo, Susan E. Cohn, Kimberly K. Scarsi, Rosie Mngqibisa, Elizabeth Connick

917 POSTER SESSIONS

DEPRESSION AND ANXIETY AS A BARRIER TO ART INITIATION IN KWAZULU-NATAL, SOUTH AFRICA

Michael Truong, Madhura Rane, Ann Vander Stoep, Paul K. Drain

918 POSTER SESSIONS

KNOWLEDGE OF HIV STATUS DECREASES DEPRESSIVE SYMPTOMS AMONG FEMALE SEX WORKERS

Katrina F. Ortblad, Daniel Kibuuka Museko, Michael M. Chanda, Thomson Ngabirano, Jennifer Velloza, Margaret McConnell, Catherine E. Oldenburg, Till Bärnighausen

919 POSTER SESSIONS

TREATED MENTAL DISORDERS IN PRIMARY AND TERTIARY HIV CARE PROGRAMS IN CAPE TOWN

Andreas D. Haas, Yann Ruffieux, Nicki Tiffin, Hans Prozesky, Catherine Orrell, Mpho Tiiali, Andrew Bouille, Mary-Ann Davies, Matthias Egger, for the IeDEA Southern Africa Collaboration

920 POSTER SESSIONS

DATING VIOLENCE AND HIV-ASSOCIATED OUTCOMES AMONG ADOLESCENT SEXUAL-MINORITY MALES

Christine Agnew-Brune, Susan Cha, Alexandra Balaji, Brian Mustanski, Michael E. Newcomb, Kathleen Brady, Sarah L. Braunstein, Cyprian Wejnert, for the NHBS-YMSM study group

921 POSTER SESSIONS

MULTILEVEL PREDICTORS OF SUICIDABILITY AMONG HIV+ SUBSTANCE USERS IN 11 US CITIES

Adam W. Carrico, Viviana Horigian, Rui Duan, Daniel Feaster, Lauren Gooden, Allan Rodriguez, James Sorensen, Tim Matheson, Susan Tross, Grant Colfax, David Metzger, Petra Jacobs, Carlos del Rio, Lisa Metsch

938 POSTER SESSIONS

IMPACT OF EARLY ART INITIATION ON PERFORMANCE OF CROSS-SECTIONAL INCIDENCE ASSAYS

Ethan B. Klock, Reinaldo Fernandez, Leigh Anne Eller, George Mwinnyaa, Josphat Kosgei, Hannah Kibuuka, Sorachai Nitayaphan, Richard D. Moore, Merlin L. Robb, Susan H. Eshleman, Oliver Laeyendecker

939 POSTER SESSIONS

POINT-OF-CARE RECENCY TEST TO MEASURE HIV TRANSMISSION IN KEY POPULATION IN GUATEMALA

Carlos Vargas, Sanny Northbrook, Ricardo Mendizabal-Burastero, Sandra Juárez, Amalia Giron-Callejas, Cesar Galindo-Arandi, Lucia Saravia, Salvador Soto, Nasim Farach
FIRST USE OF POINT-OF-CARE HIV RECENTY TESTS AS A SURVEILLANCE TOOL IN NICARAGUA
Sanny Northbrook, Carlos Vargas, Ricardo Mendizabal-Burastero, Jose Manuel Rodas Hernandez, Andrea A. Kim, Nasim Farach, Aleyda Solorzano, Luz Maria Romero, Bharat S. Parekh

PERFORMANCE COMPARISON OF THE MAXIM AND SEDIA LIMITING ANTIGEN AVIDITY ASSAYS
Joseph B. Sempa, Gary Murphy, Jake Hall, Sheila M. Keating, Dylan Hampton, Shelley Facente, Kara Marson, Christopher D. Pilcher, Neil Parkin, Michael P. Busch, Alex Welte, Eduard Grebe, for the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)

IMPACT OF HIV-1 SUBTYPE AND SEX ON SEDIA LIMITING ANTIGEN AVIDITY ASSAY PERFORMANCE
Eduard Grebe, Gary Murphy, Sheila M. Keating, Dylan Hampton, Michael P. Busch, Shelley Facente, Kara Marson, Christopher D. Pilcher, Andrew Longosz, Susan H. Eshleman, Thomas C. Quinn, Alex Welte, Neil Parkin, Oliver Laeyendecker, for the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)

ANTIBODY PROFILING IDENTIFIES NOVEL BIOMARKERS FOR DURATION OF HIV INFECTION
Oliver Laeyendecker, Kai Kammers, Athena Chen, Mariya V. Sivay, Brandon Sie, Tiezheng Yuan, Divya Mohan, Daniel Wansley, Tomasz Kula, Charles S. Morrison, Stephen Elledge, Ron Brookmeyer, Ingo Ruczinski, H. Benjamin Larman, Susan H. Eshleman

ESTIMATED PrEP ELIGIBILITY IN A NATIONAL SEXUAL NETWORK STUDY OF US MSM
Kevin M. Weiss, Pragati Prasad, Ramya Ramaraju, Emeli J. Anderson, Samuel Jenness

CHANGES IN HIV PrEP AWARENESS AND USE AMONG MEN WHO HAVE SEX WITH MEN, 2014 VS 2017
Teresa Finlayson, Susan Cha, Damian Denson, Lindsay Trujillo, Mingjing xia, Joseph Prejean, Cyprian Wejnert, for the NHBS Study Group

ASSESSING THE PrEP CONTINUUM IN THE SAN FRANCISCO BAY AREA: THE QUICKIE MOBILE SURVEY
Albert Y. Liu, Kenneth Coleman, Eric Vittinghoff, Caitlin Turner, Janie Vinson, Nicole Walker, Christina Quinonez, Edward M. Gardner, Henry F. Raymond, Susan P. Buchbinder, Marguerita Lightfoot, Susan Scheer, Sean Arayasirikul, Erin C. Wilson

INFLUENCE OF PrEP4LOVE CAMPAIGN ON PrEP UPTAKE AMONG YMSM IN CHICAGO
Gregory Phillips, Peter T. Lindeman, Anand B. Raman, Christina S. Hayford, Brian Mustanski

ASSOCIATION OF HIGHER RISK AND PrEP AWARENESS AMONG MSM IN BRAZIL, MEXICO, AND PERU
Poster Sessions

976 **PrEP-Related Barriers Among Men Who Have Sex With Men in Brazil, Mexico, & Peru**

977 **Determinants of Preexposure Prophylaxis Cascade Among Nigerian MSM**
Habib R. Omari, Nicaise Ndembali, Blessing Kayode, Ashley Shutt, Charlotte A. Gaydos, Julie Ake, Trevor A. Crowell, Stefan Baral, Rebecca G. Nowak, Man Charurat, for the For the TRUST/RV368 study Group

978 **Women’s PreEP Knowledge, Attitudes, Preferences and Experience in Chicago**
Lisa Hirschhorn, Rayna Brown, Eleanor E. Friedman, Cathy Christeller, George J. Greene, Alvie Bender, Alida Bouris, Laxmi Modali, Amy K. Johnson, Jim Pickett, Jessica Ridgway

979 **HIV Risk and Characteristics of Women Seeking PreEP in a US Demonstration Project**
Jill Blumenthal, Sheldon Morris, Sonia Jain, Feng He, Margaret R. Caplan, Eric Ellorin, Ryan M. Kofron, James F. Rooney, Gifty Ntim, Katya Calvo, Jamila Stockman, K. Rivet Amico, David J. Moore, Raphael J. Landovitz

980 **Concordance of HIV Risk Perception and Empiric Risk Score Among Pregnant Kenyan Women**
Laurén Gómez, John Kinuthia, Julia C. Dettinger, Jillian Pintye, Anjuli D. Wagner, Nancy M. Ngumbau, Ben O. Odhiambo, Mary M. Marwa, Salphine A. Wattoyi, Felix Abuna, Joshua Stern, Grace John-Stewart, Jared Baeten

981 **Low PreEP Awareness and Willingness Among Transgender Women in South Africa**
Tonia Poteat, Leigh Ann van der Merwe, Allani Coeote, Dee Adams, Mannat Malik, David B. Hanna

Poster P-T7 *Postexposure Prophylaxis*
Poster Hall - 4EF 2:30 PM - 4:00 PM

982 **Postexposure Prophylaxis and HIV Risk in Rwanda: Potential for Pep-to-PreEP Programs**
Sabin Nsanzimana, Remera Eric

983 **Are Routine Renal and Liver Labs Testing Among PEP Patients on TDF/FTC/DTV Necessary?**
Tarek Mikati, Addie Crawley, Demetre C. Daskalakis

984 **Postexposure Prophylaxis Noncompletion and Noncondom Use in France, 2004-2017**
Pierre Gantner, Clotilde Allavena, Claudine Duvivier, André Cabié, Jacques Reyes, Alain Makinson, Isabelle Ravaux, Laurent Cotte, David Rey, for the Dat’AIDS Study Group

985 **E/CF/TAF Single Tablet Regimen for HIV Postexposure Prophylaxis**
Pierre Gantner, Mojgan Hessamfar, Faouzi Souala, Nadia Valin, Anne Simon, Faiza Ajana, Emmanuelle Bouvet, Elisabeth Rouveix, Laurent Cotte, Firouze Bani-Sadr, Laurent Hustache-Mathieu, Marie-Gisele Lebrette, Patrice Muret, David Rey, for the E/C/F/TAF PEP Study Group
Poster P-T8 PrEP ADHERENCE AND PERSISTENCE
Poster Hall - 4EF 2:30 PM - 4:00 PM

986 HIV INFECTION AND FTC/TDF IN DRIED BLOOD SPOT: A POOLED ANALYSIS OF GLOBAL STUDIES
Li Tao, Scott McCallister, Lindsey Smith, Robertino Mera Giler, David Magnuson

987 PREDICTORS OF LONG-TERM HIV PrEP ADHERENCE AFTER TRIAL PARTICIPATION IN MSM
Martin Hoenigl, David J. Moore, Peter L. Anderson, Katya Calvo, Michael Dube, Eric Ellorin, Jill Blumenthal, Sheldon Morris, for the California Collaborative Treatment Group (CCTG) 601 Team

988 PrEP STIGMA PREDICTS PrEP UPTAKE AND ADHERENCE: RESULTS FROM THE RADAR COHORT STUDY
Brian Mustanski, Michael E. Newcomb, Daniel T. Ryan

989 LONGITUDINAL PREDICTORS OF PrEP DISCONTINUATION AMONG YMSM AND TRANSGENDER WOMEN
Michael E. Newcomb, Ethan Morgan, Brian Feinstein, Brian Mustanski

990 STOPPING HIV PREEXPOSURE PROPHYLAXIS: REASONS AND IMPLICATIONS
Uwe Koppe, Ulrich Marcus, Stefan Albrecht, Klaus Jansen, Heiko Jessen, Barbara Gunsenheimer-Bartmeyer, Viviane Bremer

991 FACTORS ASSOCIATED WITH REFUSING OR STOPPING PrEP AMONG AT-RISK MSM IN KENYA
Elizabeth Wahome, Grace Mwashigadi, Bernadette Kombo, Makobu Kimani, Elisabeth M. van der Elst, Khamisi Mohamed, Mark Brockman, Susan M. Graham, Eduard Sanders

992 HIGH PrEP USE IN AFRICAN MEN AND WOMEN CONTINUING PrEP IN PUBLIC-HEALTH HIV CLINICS

993 PERSISTENCE WITH PrEP USE IN AFRICAN ADOLESCENTS AND YOUNG WOMEN INITIATING PrEP
Kenneth K. Mugwanya, Jillian Pintye, John Kinuthia, Harrison Lagat, Felix Abuna, Emily R. Begnel, Juliana C. Dettinger, Grace John-Stewart, Jared Baeten, for the PrEP Implementation for Young Women and Adolescents Program Team

994 HIGH ADHERENCE AMONG YOUNG WOMEN IN CAPE TOWN IN THE FIRST 3 MONTHS AFTER PrEP START
Connie L. Celum, Katherine M. Gill, Jennifer F. Morton, Gabrielle Stein, Ariane van der Straten, Jared Baeten, Margaret McConnell, Memna Duyver, Eve Mendel, Keshani Naidoo, Laura Myers, Lubbe Wiesner, Linda-Gail Bekker

995 ADHERENCE 3 MONTHS AFTER PrEP INITIATION AMONG YOUNG AFRICAN WOMEN IN HPTN 082
996  SHORT-TERM RETENTION ON PREEXPOSURE PROPHYLAXIS IN DEMOCRATIC REPUBLIC OF THE CONGO
Halli S. Olsen, William J. Reidy, Nadine Mushimbele, Richted Tenda, Tania Tchissambou, Faustin Malele, Gaston Djomand, Trista Bingham, Jacob Dee, Elie Mukinda, Raimi Ewetola, Julie Franks

997  PREEXPOSURE PROPHYLAXIS: ACCEPTABILITY AND RETENTION IN SOUTH WESTERN UGANDA
Joseph Kagaayi, James Batte, Gertrude Nakigozi, Hadijja Nakawooya, Boniface Kigozi, Doreen Nabukala, Godfrey Kigozi, Helena Nordenstedt, Anna Mia Ekström, Susanne Strömahl, Larry W. Chang, Ronald H. Gray, Steven J. Reynolds, Maria Wawer, David Serwadda

Poster P-V1 ART INITIATION
Poster Hall - 4EF 2:30 PM - 4:00 PM

1016  “TREAT ALL” ADOPTION IMPROVES RAPID TREATMENT INITIATION IN 6 SUB-SAHARAN COUNTRIES
Olga Tymejczyk, Ellen Brazier, Constantin T. Yiannoutsos, Peter F. Rebeiro, Kara K. Wool-Kaloustian, Mary-Ann Davies, Elizabeth Zaniewski, Mark Urassa, Jean d’Amour Sinayobye, Nanina Anderegge, Grace Liu, Nathan Ford, Denis Nash, for the IeDEA Consortium

1017  OUTCOMES OF “TEST AND START” AT SCALE WITHIN HAITI’S NATIONAL ART PROGRAM
Nancy Puttkammer, Kesner Francois, Yrvel Desir, Gracia Desorges, Nadjy Joseph, Nathaelf Hypolite, Jean Guy Honore, Jean Solon Valles, Ermane Robin, Patrice Joseph

1018  SAME-DAY ART INITIATION IN THE SLATE TRIAL IN KENYA: PRELIMINARY RESULTS
Alana T. Brennan, Bruce Larson, Isaac Tsikhutsu, Margaret Bii, Matthew P. Fox, Willem D. Venter, Mhairi Maskew, Lungisile Vezi, Sydney Rosen

1019LB  WITHDRAWN/INTENTIONALLY UNASSIGNED

1020  IMPLEMENTING UTT IN AFRICAN CORRECTIONAL FACILITIES: A PROSPECTIVE COHORT STUDY
Michael Herce, Christopher Hoffmann, Katherine Fielding, Steph Topp, Harry Hausler, Helene Smith, Lucy Chimoyi, Candice Chetty-Makan, Rachek Mukora, Mpho Tlali, Abraham Olivier, Monde Muyoyeta, Stuart Reid, Salome Charalamous

1021  IMPROVEMENT IN TIME TO ART INITIATION REGARDLESS OF TB STATUS IN LATIN AMERICA
Bryan E. Shepherd, Serena Koenig, Ahra Kim, Cathy Jenkins, Pedro Cahn, Beatriz Grinsztejn, Marcelo Wolff, Denis Padgett, Juan Sierra-Madero, Eduardo Gotuzzo, Catherine McGowan, Jean William Pape, Timothy R. Sterling, for the The Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)

1022  UPTAKE OF ANTIRETROVIRAL THERAPY IN THE “TREAT ALL” ERA IN RIO DE JANEIRO, BRAZIL
Leila H. Chaissou, Juliana Domenico, Valeria Saraceni, Richard D. Moore, Jonathan Golub, Betina Durovni

1023  NARROWING THE GAP IN CD4 COUNT AT ENTRY INTO CARE AND AT ART INITIATION, 2005-2016
1024  PATIENT-REPORTED REASONS FOR DECLINING IMMEDIATE ART INITIATION IN LUSAKA, ZAMBIA
Jake Pry, Jenala Chipungu, Carolyn Bolton Moore, Jacob Mutale, Helene Smith, Theodora Savory, Michael Herce

1025  LB CASCADE TRIAL: 24 MONTH OUTCOMES AFTER SAME-DAY HOME-BASED ART INITIATION
Alain Amstutz, Isaac Ringeria, Thabo I. Lejone, Josephine Muhairwe, Jennifer A. Brown, Thomas Klimkait, Tracy R. Glass, Niklaus D. Labhardt

<table>
<thead>
<tr>
<th>Poster P-V4 VIRAL LOAD MONITORING AND VIRAL SUPPRESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster Hall - 4EF</td>
</tr>
<tr>
<td>2:30 PM - 4:00 PM</td>
</tr>
</tbody>
</table>

1045  VIRAL LOAD MONITORING AND FIRST-LINE FAILURE CASCADE OF CARE IN RURAL SOUTH AFRICA
Collins C. Iwuji, Maryam Shahmanesh, Olivier Koole, Kobotus Herbst, Deenan Pillay, Mark J. Siedner, Kathy Baisley

1046  MACHINE LEARNING APPLIED TO ELECTRONIC ADHERENCE DATA TO INFORM VIRAL LOAD MONITORING
Alejandra E. Benitez, Maya L. Petersen, Nicholas Musinguzi, David R. Bangsberg, Yap Boum, Bosco M. Bwana, Conrad Muzoora, Peter W. Hunt, Jeffrey N. Martin, Jessica E. Haberer

1047  PREDICTORS OF ART INITIATION AND VIRAL SUPPRESSION IN A LARGE COHORT IN UKRAINE
Kostyantyn Dumchev, Iulia Novak, Tetiana Saliuk

1048  SOCIAL NETWORKS AND TIE STRENGTH PREDICT OUTCOMES OF HIV+ YOUTH IN SEARCH TRIAL

1049  ASSOCIATION BETWEEN HIV CLINIC CASELOADS AND VIRAL LOAD SUPPRESSION IN NEW YORK CITY
Saiganesh Ravikumar, Erica D’Aquila, Muhammad Daud, Carly Skinner, Craig Hayes, Ellen Brazier, Tyeirra Seabrook, Erica Crittendon, Demetre C. Daskalakis, Bisrat Abraham

1050  VIRAL SUPPRESSION AMONG PEOPLE INITIATING HIV CARE: OUTCOMES FROM THE IENGAGE TRIAL

1051  INCREASES IN KNOWLEDGE OF HIV POSITIVE STATUS, ART, AND VIRAL SUPPRESSION IN BCPP
Refleletswe Lebelonyane, Pamela J. Bachanas, Mary Grace Alwano, William Abrams, Lisa Block, Gene Ussery, James A. Miller, Huisheng Wang, Lisa A. Mills, Tafireyi Marukutira, Faith Ussery, Shenaaz El Halabi, Michelle Roland, Kathleen Wirth, Janet Moore

1052  SUCCESSFUL VIRAL OUTCOMES AFTER IMPLEMENTING “TREAT ALL” IN SOUTH AFRICAN CLINICS
Jienchi Dorward, Yukteshwar Sookrahi, Kelly Gates, Nigel Garrett
1053 REACHING TOWARD 90-90-90 AMONGST CORRECTIONAL FACILITY INMATES IN ZAMBIA
Michael Herce, Christopher Hoffmann, Steph Topp, Harry Hauser, Helene Smith, Lucy Chimoyi, Candice Chetty-Makan, Rachek Mukora, Abraham Olivier, Monde Muyoyeta, Stewart Reid, Salome Charalambous, Katherine Fielding

1054 DIFFERENTIATED CARE PREFERENCES OF STABLE PATIENTS ON ART IN ZAMBIA
Ingrid Eshun-Wilson, Mpande Mumbwa-Mwenechanya, Hae-Young Kim, Arianna L. Zanolini, Chanda Mwamba, David Dowdy, Laura K. Beres, Monika Roy, Anjali Sharma, Steph Topp, Nancy Padian, Izukanji Sikazwe, Charles B. Holmes, Carolyn Bolton Moore, Elvin Geng

1055 DURABLE VIRAL SUPPRESSION AMONG PEOPLE WITH ACUTE AND NONACUTE HIV IN NORTH CAROLINA
Nicole Dzialowy Adams, Brad Wheeler, Anna Cope, Victoria L. Mobley, John Barnhart, Joann D. Kuruc, Cynthia L. Gay, Lindsey M. Filiatreau, Rhonda Ashby, Erika Samoff

1056 IMPLEMENTING U=U IN THE HIV CLINIC: CAN WE PREDICT HIV NONSUPPRESSION?
Fizza S. Gillani, Su Aung, Joseph Garland, Curt G. Beckwith

1057 FACTORS ASSOCIATED WITH LACK OF VIRAL SUPPRESSION IN THE YEAR AFTER HIV DIAGNOSIS
Bridget M. Whelan, Paul L. Hebert, Kym R. Ahrens, Susan E. Buskin, Matthew R. Golden, Julia C. Dombrowski

1058 THE IMPACT OF “CHURN” ON CUMULATIVE PLASMA HIV BURDEN WITHIN A POPULATION UNDER CARE
Michael John Gill, Hartmut B. Krentz

1059 RESUPPRESSION AFTER VIREMIA VERSUS VIROLOGIC FAILURE IN KHAYELITSHA, SOUTH AFRICA
Jonathan Euvrard, Amir Shroufi, Meg Osler, Katherine Hilderbrand, Laura Trivino Duran, Andrew Boule

1060 HIGH AWARENESS BUT UNCERTAIN BELIEF IN U=U AMONG PROVIDERS AND COUPLES IN KENYA

1061 RESUPPRESSION AFTER POINT-OF-CARE VIRAL LOAD TESTING TO GUIDE ADHERENCE COUNSELING
Giovanni Villa, Dorcas Owusu, Marilyn Azumah, Colette J. Smith, Adam Abdullahi, Dominic Awooa, Laila Sayeed, Apostolos Beloukas, David Chadwick, Richard Phillips, Anna Maria Geretti

Poster P-W2 MODELING THE IMPACT OF PREVENTION AND TREATMENT ON THE HIV EPIDEMIC
Poster Hall - 4EF 2:30 PM - 4:00 PM

1084 EPIDEMIC IMPACT OF SUSTAINED VIREMIA AMONG FEMALE SEX WORKERS IN SOUTHERN AFRICA
Sharmistha Mishra, Huiting Ma, Sheree Schwartz, Deliwe R. Phethu, Vijayandand Guddera, Nora West, Carly Comins, Harry Hauser, Stefan Baral, for the Siyamphambili Study Team
1085 ESTIMATING HIV INCIDENCE AMONG YOUNG WOMEN IN HPTN 082 USING BASELINE HIV RISK SCORES
James R. Moore, Deborah J. Donnell, Marie-Claude Boily, Kate M. Mitchell, Sinead Delany-Moretlwe, Connie L. Celum, Dobromir Dimitrov

1086 A MATHEMATICAL MODELING ANALYSIS OF COMBINATION HIV PREVENTION IN ANTENATAL CLINICS
Kimberly A. Powers, Kate Orroth, Nora E. Rosenberg, Lauren A. Graybill, Andrew Kumwenda, Tiwonge Mtande, Katie Mollan, Oliver Mweemba, Wilbroad Mutale, Benjamin H. Chi

1087 SCALE-UP OF ART AND VMMC EXPLAIN A TWO-FOLD DECLINE IN HIV INCIDENCE IN WESTERN KENYA
Anna Bershteyn, Adam N. Akullian, Daniel J. Klein, Britta Jewell, Kennedy Mutai, Samuel M. Mwalili

1088 SIMULATED VACCINE EFFICACY TRIALS TO ESTIMATE HIV INCIDENCE IN KEY POPULATIONS
Andrew M. Abaasa, Stephen Nash, Yunia Mayanja, Matt A. Price, Patricia E. Fast, Pontiano Kaleebu, Anatoli Kamali, Jim Todd

1089 THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030

1090 YOUTH-FOCUSED HIV TREATMENT-AS-PREVENTION YIELDS LARGE BENEFITS: A SIMULATION MODEL
John E. Mittler, James Murphy, Sarah E. Stansfield, Kathryn Peebles, Geoffrey S. Gottlieb, Neil Abernethy, Steven M. Goodreau, Joshua T. Herbeck

1091 WHO IS LEFT IN 10-10-10? IMPORTANCE OF REACHING KEY POPULATIONS WITH THE HIV CASCADE
Jesse Knight, Huiting Ma, Stefan Baral, Sosthenes Ketende, Oluwasolape M. Olawore, Amrita Rao, Carly Comins, Sheree Schwartz, Harry Hausler, Katherine Young, Mfezi Mcingana, Vijayanand Guddera, Sindy Matse, Zandile Mnisi, Sharmistha Mishra

1092 TasP COVERAGE MAY INCREASE WITHOUT SELECTING FOR MORE VIRULENT HIV: A MODELING STUDY
Sarah E. Stansfield, Joshua T. Herbeck, Geoffrey S. Gottlieb, Neil Abernethy, James Murphy, John E. Mittler, Steven M. Goodreau
POSTER SESSIONS, BY CATEGORY

All poster sessions will be held from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below). Posters should be displayed for the duration of the conference and are located in Hall 4 EF.

A. VIROLOGY
P-A1 EARLY EVENTS (Tuesday)
P-A2 VIRAL RESTRICTION (Tuesday)
P-A3 MECHANISTIC VIROLOGY (Wednesday)
P-A4 HOST-VIRUS INTERACTIONS (Wednesday)
P-A5 HIV NEF (Thursday)

B. PATHOGENESIS: HUMAN STUDIES AND ANIMAL MODELS
P-B1 HIV AND LYMPH NODES (Tuesday)
P-B2 INTO AND OUT OF THE GUT (Tuesday)
P-B3 IMMUNOPATHOGENESIS (Tuesday)
P-B4 HIV TRANSMISSION AND DISSEMINATION (Wednesday)
P-B5 HIV AND THE GUT MICROBIOME (Wednesday)
P-B6 HIV AND THE REPRODUCTIVE TRACT (Wednesday)
P-B7 LONG-TERM EFFECTS OF HIV AND ART (Thursday)
P-B8 HIV ELITE CONTROL (Thursday)

C. HIV-ASSOCIATED TUMOR VIRUSES AND AIDS-RELATED MALIGNANCIES
P-C1 AIDS MALIGNANCIES: KAPOSI SARCOMA AND KSHV (Tuesday)
P-C2 AIDS MALIGNANCIES: CERVICAL AND ANAL CANCER (Wednesday)
P-C3 AIDS MALIGNANCIES: EPIDEMIOLOGY, CANCER RISK, AND MORTALITY (Thursday)

D. HOST IMMUNE RESPONSES TO INFECTION, VACCINES, AND IMMUNOTHERAPY
P-D1 PRECLINICAL AND CLINICAL VACCINE TRIALS (Tuesday)
P-D2 NOVEL THERAPEUTIC INTERVENTIONS INCLUDING EARLY ART (Tuesday)
P-D3 STUDIES OF ANTIBODIES AND B CELLS (Wednesday)
P-D4 STUDIES OF NK AND T CELL FUNCTION (Thursday)

E. HIV RESERVOIRS, LATENCY, AND ALL CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY
P-E01 CHARACTERIZING HIV RESERVOIRS (Tuesday)
P-E02 STRUCTURE AND LOCATIONS OF PROVIRUSES ON ART (Tuesday)
P-E03 HIV RESERVOIR CELLS, PROVIRAL LANDSCAPE, AND REBOUND VIRUS (Tuesday)
P-E04 HIV CURATIVE APPROACHES: ANIMAL MODELS (Thursday)
P-E05 HIV CURATIVE APPROACHES: ANTIBODIES AND CAR-T CELL (Thursday)
P-E06 HIV CURATIVE APPROACHES: IN VITRO (Wednesday)
P-E07 HIV LATENCY REVERSAL (Thursday)
P-E08 MECHANISMS OF LATENCY (Wednesday)
P-E09 MECHANISMS OF PERSISTENCE (Thursday)
P-E10 INSIGHTS FROM ANALYTICAL TREATMENT INTERRUPTION (Wednesday)
P-E11 HUMAN STUDIES OF CURATIVE STRATEGIES AND ATI (Wednesday)

F. NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS
P-F1 HAND: BIOMARKERS, RISKS, PREVALENCE (Tuesday)
P-F2 NEUROPATHOGENESIS AND MODELING: HIV AND SIV (Wednesday)
P-F3 CNS DRUG TOXICITY: ART, HDAC, AND OTHERS (Wednesday)
P-F4 CNS RESERVOIRS, ESCAPE, AND IMMUNOLOGY (Thursday)
P-F5 NEUROIMAGING AND ASSOCIATED BIOMARKERS (Thursday)
G. CLINICAL PHARMACOLOGY
P-G1 OBJECTIVE ASSESSMENT OF ADHERENCE FOR PrEP AND ART (Tuesday)
P-G2 ARV AND ANTIHEPATITIS PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS (Wednesday)
P-G3 ARV PHARMACOLOGY IN COMPARTMENTS AND RESERVOIRS (Thursday)

H. ANTIRETROVIRAL THERAPY: PRE-CLINICAL DATA, RANDOMIZED TRIALS, EFFICACY AND EFFECTIVENESS STUDIES
P-H1 NOVEL ANTIRETROVIRAL AGENTS AND FORMULATIONS (Thursday)
P-H2 IT TAKES TWO BABY(?): TWO DRUG ART (Thursday)
P-H3 VIROLOGIC FAILURES: TO SECOND LINE AND BEYOND (Wednesday)
P-H4 SECONDARY ANALYSIS AND DESIGN ISSUES IN CLINICAL TRIALS AND OBSERVATION STUDIES (Wednesday)
P-H5 STRATEGIES: OLD AND NEW (Wednesday)
P-H6 WOMEN AND HIV: ARE OUTCOMES DIFFERENT? (Tuesday)
P-H7 ACUTE INFECTION AND HIV TRANSMISSION (Tuesday)

I. HIV DRUG RESISTANCE
P-I1 RESISTANCE SPREAD AND ITS IMPACT ON ART (Tuesday)
P-I2 PREVALENCE AND SPREAD OF RESISTANCE (Tuesday)
P-I3 NEW MECHANISMS OF RESISTANCE AND NEW DETECTION METHODS (Wednesday)
P-I4 ACTIVITY OF DRUGS AGAINST RESISTANT VIRUS (Wednesday)

J. HIV DIAGNOSTICS
P-J1 HIV DIAGNOSTICS: IT’S FOR THE VIRUS, STUPID (Thursday)

K. HEPATITIS VIRUSES AND LIVER COMPLICATIONS
P-K1 HCV THERAPEUTICS: REALITY TESTING (Tuesday)
P-K2 HCV THERAPEUTICS: MOVING FROM TREATING THE PERSON TO TREATING THE POPULATION (Tuesday)
P-K3 HCV TRANSMISSION: THE (MOLECULAR) WEBS WE WEAVE (Wednesday)
P-K4 HCV AND HIV: CANCER INFLAMMATION AND FIBROSIS (Wednesday)
P-K5 HIV AND HBV INFECTION (Thursday)
P-K6 HIV AND HBV: BAD (LIVER) BEDFELLOWS (Thursday)

L. AIDS-RELATED MALIGNANCIES HAS BEEN INTEGRATED INTO C. HIV-ASSOCIATED TUMOR VIRUSES AND AIDS-RELATED MALIGNANCIES

M. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-M1 NOVEL MEASURES AND DRIVERS OF INFLAMMATION AND VASCULAR FUNCTION (Tuesday)
P-M2 COAGULATION ABNORMALITIES IN HIV: WHAT’S THE CLOT GOT TO DO WITH IT? (Tuesday)
P-M3 BEYOND TRADITIONAL RISK FACTORS: MECHANISMS OF VASCULAR DISEASE IN HIV (Wednesday)
P-M4 ALL THINGS LIPIDS (Wednesday)
P-M5 ENDOTHELIAL DYSFUNCTIONS: THE VIRUS, ART, AND OTHER FACTORS (Wednesday)
P-M6 HEART FAILURE AND PULMONARY DISEASE (Thursday)
P-M7 CARDIOVASCULAR DISEASE: MORTALITY, RISK FACTORS, AND MANAGEMENT STRATEGIES (Thursday)
N. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-N1 WEIGHT GAIN DURING ART (Wednesday)
P-N2 INTEGRASE INHIBITORS: CARDIOMETABOLIC OUTCOMES (Wednesday)
P-N3 ADIPOSE TISSUE DENSITY AND BIOLOGY (Thursday)
P-N4 INSULIN RESISTANCE IN TREATED HIV (Tuesday)
P-N5 BONE DISEASE IN TREATED HIV (Tuesday)
P-N6 RENAL DISEASE IN TREATED HIV (Tuesday)
P-N7 BAD THINGS HAPPEN: HIV COMORBIDITIES (Thursday)
P-N8 FUNCTIONAL STATUS (Thursday)

O. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS
P-O1 CRYPTOCOCCAL MENINGITIS SCREENING, PREEMPTIVE THERAPY, AND OUTCOMES (Wednesday)
P-O2 WHAT'S APP WITH OTHER OIs? (Wednesday)
P-O3 NOVEL DIAGNOSTICS FOR LATENT AND ACTIVE TB (Wednesday)
P-O4 TB SCREENING AND PREVENTIVE THERAPY (Wednesday)
P-O5 THE INTERSECTION OF HIV AND TB (Wednesday)
P-O6 DRUG-RESISTANT TB (Wednesday)

P. MATERNAL AND FETAL HIV
P-P1 INTEGRASE INHIBITORS AND NEURAL TUBE DEFECTS (Tuesday)
P-P2 UNDERSTANDING ANTIRETROVIRAL EXPOSURE AND BIRTH OUTCOMES (Tuesday)
P-P3 PHARMACOKINETICS IN PREGNANCY AND POSTPARTUM (Thursday)
P-P4 MATERNAL VIRAL SUPPRESSION AND TREATMENT OUTCOMES (Thursday)
P-P5 DRILLING DOWN ON VERTICAL TRANSMISSION (Wednesday)
P-P6 PREVENTING HIV ACQUISITION IN PREGNANCY AND BREASTFEEDING (Wednesday)
P-P7 HIV TESTING OF INFANTS AND CHILDREN (Wednesday)

Q. PEDIATRICS AND ADOLESCENTS
P-Q1 BRAINS, BONE, AND GENOMES IN HIV-EXPOSED CHILDREN (Wednesday)
P-Q2 GROWING UP WITH HIV AND ARV EXPOSURES (Thursday)
P-Q3 EARLY INFANT TREATMENT (Wednesday)
P-Q4 RESPONSE TO ART IN CHILDREN AND YOUTH (Tuesday)
P-Q5 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH WITH HIV (Tuesday)
P-Q6 THE STATE OF THE MIND: GROWING UP WITH HIV (Thursday)
P-Q7 ANTIRETROVIRAL PHARMACOKINETICS, SAFETY, AND EFFICACY IN CHILDREN AND YOUTH (Thursday)

R. EPIDEMIOLOGY
P-R1 DESCRIPTIVE EPIDEMIOLOGY AND BEHAVIOR (Tuesday)
P-R2 HIV AND SEXUALLY TRANSMITTED INFECTIONS (Tuesday)
P-R3 PHYLGENETICS, MAPPING, AND OUTBREAKS (Wednesday)
P-R4 SUBSTANCE USE AND HIV (Wednesday)
P-R5 EPIDEMIOLOGY OF TREATMENT AND SURVIVAL (Thursday)
P-R6 MENTAL HEALTH AND HIV (Thursday)

S. TESTING
P-S1 HIV AND STI TESTING STRATEGIES (Tuesday)
P-S2 STRATEGIES FOR HIV TESTING PARTNERS AND KEY POPULATIONS (Tuesday)
P-S3 HIV TESTING IN MSM (Tuesday)
P-S4 RECENCY TESTING (Thursday)
T. PREVENTION INTERVENTIONS
P-T1 OUTCOMES AMONG PrEP USERS (Tuesday)
P-T2 RISK COMPENSATION, PrEP, AND NON-PrEP PREVENTION (Tuesday)
P-T3 PrEP ROLL-OUT AND DELIVERY (Wednesday)
P-T4 PrEP IN FITS AND STARTS (Wednesday)
P-T5 STIs IN PEOPLE AND MONKEYS USING PrEP (Wednesday)
P-T6 KNOWLEDGE AND UPTAKE OF PrEP (Thursday)
P-T7 POSTEXPOSURE PROPHYLAXIS (Thursday)
P-T8 PrEP ADHERENCE AND PERSISTENCE (Thursday)

U. CONTRACEPTION, SEXUALLY TRANSMITTED INFECTIONS, AND REPRODUCTIVE HEALTH
P-U1 HIV AND VAGINAL MICROBIOME (Tuesday)
P-U2 FOREVER YOUNG: STI AND HIV COINFECTION (Tuesday)
P-U3 SOMETHING’S MISSING; CONTRACEPTION AND HIV (Tuesday)
P-U4 THE MASKED MARVELS YOU DON’T WANT TO MEET: SYPHILIS AND LGV (Wednesday)

V. IMPLEMENTATION AND SCALE-UP OF TREATMENT AND CARE
P-V1 ART INITIATION (Thursday)
P-V2 ENGAGEMENT IN CARE (Tuesday)
P-V3 CASCADE OF CARE (Wednesday)
P-V4 VIRAL LOAD MONITORING AND VIRAL SUPPRESSION (Thursday)
P-V5 COMORBID CONDITIONS (Tuesday)

W. POPULATION AND COST MODELING
P-W1 MODELING AND MONEY (Wednesday)
P-W2 MODELING THE IMPACT OF PREVENTION AND TREATMENT ON THE HIV EPIDEMIC (Thursday)
INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that the authors have noted women or women’s issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the full Program for other presentations that may address this subject.

TUESDAY, MARCH 5, 2019

47  INCIDENT SYPHILIS RATES AND PREDICTORS IN US WOMEN WITH HIV, 2005-2016 (Oral Abstract Session O-05)

51  DOUBLE-DOSE LEVONORGESTREL IMPLANT DOES NOT FULLY OVERCOME INTERACTION WITH EFAVIRENZ (Oral Abstract Session O-05)

52  PHARMACOGENETICS WORSENS AN ADVERSE ANTIRETROVIRAL-HORMONAL CONTRACEPTIVE INTERACTION (Oral Abstract Session O-05)

269  KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS IN AN HIV-INFECTED COHORT, SOUTH AFRICA (Themed Discussion TD-01)

462  PLASMA EFV AND TFV VS DRIED BLOOD SPOT TFV-DP TO PREDICT VIRAL SUPPRESSION IN WOMEN (Themed Discussion TD-03)

518  IMPORTANT SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ART (Themed Discussion TD-04)

516  DEPRESSION IS A STRONGER PREDICTOR OF EXECUTIVE DYSFUNCTION IN HIV+ WOMEN THAN MEN (Themed Discussion TD-04)

519  TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS (Themed Discussion TD-04)

520  EFFECT OF ANTIRETROVIRAL THERAPY AND IMMUNE RECONSTITUTION ON VAGINAL MICROBIOME (Themed Discussion TD-04)

269  KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS IN AN HIV-INFECTED COHORT, SOUTH AFRICA (Poster Session P-C1)

345  RESIDENT MEMORY T CELLS ARE A CELLULAR RESERVOIR FOR HIV IN THE CERVICAL MUCOSA (Poster Session P-E03)

407  EARLY INFLAMMATORY PROFILES IN LONG-TERM VIRALLY SUPPRESSED WOMEN PREDICTS COGNITION (Poster Session P-F1)

408  LONGITUDINAL PHENOTYPING OF DECLARATIVE MEMORY AMONG WOMEN LIVING WITH HIV (Poster Session P-F1)

411  NEURON-DERIVED EXOSOMES IDENTIFY COGNITIVE IMPAIRMENT AND GENDER DIFFERENCES IN HIV (Poster Session P-F1)

424  IMPAIRED COGNITION PREDICTS FALLS AMONG HIV+ AND HIV-WOMEN (Poster Session P-F1)

462  PLASMA EFV AND TFV VS DRIED BLOOD SPOT TFV-DP TO PREDICT VIRAL SUPPRESSION IN WOMEN (Poster Session P-G1)

516  DEPRESSION IS A STRONGER PREDICTOR OF EXECUTIVE DYSFUNCTION IN HIV+ WOMEN THAN MEN (Poster Session P-H6)

518  IMPORTANT SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ART (Poster Session P-H6)
Index of Studies Related to Women

519  TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS (Poster Session P-H6)

520  EFFECT OF ANTIRETROVIRAL THERAPY AND IMMUNE RECONSTITUTION ON VAGINAL MICROBIOME (Poster Session P-H6)

586  DIVERSE OBSTETRICIAN HCV-SCREENING PRACTICES IN A LARGE REGIONAL HEALTH CARE SYSTEM (Poster Session P-K2)

589  THE COST-EFFECTIVENESS OF HCV SCREENING OF PREGNANT WOMEN IN THE UNITED STATES (Poster Session P-K2)

744  NO INCREASE IN BIRTH DEFECTS IN INFANTS EXPOSED TO INTEGRASE INHIBITORS AT CONCEPTION (Poster Session P-P1)

745  EVALUATION OF NEURAL-TUBE DEFECTS AFTER EXPOSURE TO Raltegravir DURING PREGNANCY (Poster Session P-P1)

746  REPORTS OF NEURAL TUBE DEFECTS FOR 8 ARTS, IN FDA, WHO, EMA, AND UK SAFETY DATABASES (Poster Session P-P1)

747  InSTI EXPOSURE AND NEURAL-TUBE DEFECTS: DATA FROM ANTIRETROVIRAL PREGNANCY REGISTRY (Poster Session P-P1)

748  UGANDAN CLINIC EXPERIENCE FOLLOWING POTENTIAL TERATOGENICITY ALERT FOR Dolutegravir (Poster Session P-P1)

749  SERUM FOLATE AND BIRTH OUTCOMES: DTG VS EFV TRIAL EVIDENCE IN SOUTH AFRICA (Poster Session P-P1)

750  FETAL BIOMETRY SIMILAR WITH Dolutegravir OR Efavirenz EXPOSURE (Poster Session P-P2)

752  ADVERSE BIRTH OUTCOMES AMONG PRENATALLY VS SEXUALLY HIV-INFECTED WOMEN IN BOTSWANA (Poster Session P-P2)

753  ADVERSE PREGNANCY OUTCOMES IN HIV-POSITIVE PREGNANT WOMEN ON ART IN KENYA (Poster Session P-P2)

754  TIMING OF MATERNAL ANTIRETROVIRAL THERAPY INITIATION AND STILLBIRTH IN MALAWI (Poster Session P-P2)

755  PRETERM BIRTH AMONG WOMEN WITH ULTRASOUND-BASED GESTATIONAL DATING IN PROMISE 1077BF (Poster Session P-P2)

756  Lopinavir (an HIV Protease Inhibitor) IMPAIRS UTERINE REMODELING DURING PREGNANCY (Poster Session P-P2)

831  RECENT HIV INFECTION SURVEILLANCE AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN MALAWI (Poster Session P-R1)

14  HPV VACCINE WITH LEEP DID NOT PREVENT RECURRENT CERVICAL HSIL IN HIV-INFECTED WOMEN (Oral Abstract Session O-01)

16  HIV IS ASSOCIATED WITH DECREASED BREAST CANCER SURVIVAL: A PROSPECTIVE COHORT STUDY (Oral Abstract Session O-01)

39  RANDOMIZED TRIAL OF Raltegravir-ART VS Efavirenz-ART WHEN INITIATED DURING PREGNANCY (Oral Abstract Session O-04)

40  RCT OF Dolutegravir VS Efavirenz-BASED THERAPY INITIATED IN LATE PREGNANCY: DOLPHIN-2 (Oral Abstract Session O-04)

41  MATERNAL HBV VIREMIA IS ASSOCIATED WITH ADVERSE INFANT OUTCOMES IN HIV/HBV WOMEN (Oral Abstract Session O-04)

854  ANTIBIOTIC USE AND VAGINAL DISCHARGE SYNDROME BY HIV STATUS IN PREGNANCY: BOTSWANA (Poster Session P-R2)

925  A NEW PREDICTION MODEL FOR CHLAMYDIA AND GONORRHEA SCREENING IN WOMEN WITH HIV (Poster Session P-S1)
926 SELF-TESTS FOR AT-HOME PARTNER TESTING ARE ACCEPTABLE & UTILIZED AMONG PREGNANT WOMEN (Poster Session P-S2)

928 OUTCOME AND COST OF 3 METHODS FOR INCREASING MALE PARTNER TESTING IN SOUTH AFRICA (Poster Session P-S2)

949 Y-CHROMOSOME DETECTION & CONDOMLESS SEX IN SEX WORKERS IN THE SENEGAL PrEP PROJECT (Poster Session P-T2)

952 SHIKAMANA INTERVENTION SIGNIFICANTLY REDUCES HIV INCIDENCE AMONG FSW IN TANZANIA (Poster Session P-T2)

998 IMPACT OF A CONTRACEPTIVE RING ON VAGINAL BACTERIA ASSOCIATED WITH HIV ACQUISITION (Poster Session P-U1)

999 DOES BV MODIFY THE EFFECT OF HORMONAL CONTRACEPTION ON HIV ACQUISITION? (Poster Session P-U1)

1000 CHANGES IN VAGINAL MICROBIOTA AMONG HIV-INFECTED AFRICAN WOMEN INITIATING DMPA (Poster Session P-U1)

1001 MENOPAUSE IMPACTS THE VAGINAL MICROBIOME AND IMMUNE MEDIATORS IN WOMEN WITH HIV (Poster Session P-U1)

1003 PREVALENCE AND DETERMINANTS OF STI IN HIV+ AND HIV-PREGNANT SOUTH AFRICAN WOMEN (Poster Session P-U2)

1006 INCIDENCE AND CORRELATES OF UNINTENDED PREGNANCY IN HIV-POSITIVE KENYAN SEX WORKERS (Poster Session P-U3)

1007 DRIVERS OF UNPLANNED PREGNANCY AND UNMET NEED FOR CONTRACEPTION IN SOUTH AFRICA (Poster Session P-U3)

1008 UPTAKE OF POSTPARTUM CONTRACEPTION IN BOTSWANA, A HIGH BURDEN HIV SETTING (Poster Session P-U3)

1009 IMPACT OF INTEGRATION OF FAMILY PLANNING INTO HIV TREATMENT PROGRAMS IN CAMEROON (Poster Session P-U3)

1010 PHARMACOKINETIC AND PHARMACOGENETIC ASSESSMENT OF ART AND CONTRACEPTIVE IMPLANTS (Poster Session P-U3)

1033 LONG-TERM OUTCOME IN HIV-1 INFECTED ADULTS WITH ADVANCED IMMUNODEFICIENCY (Poster Session P-V2)

1066 CASCADES TO EVALUATE THE CERVICAL CANCER SCREENING PROGRAM IN A ZIMBABWEAN ART CLINIC (Poster Session P-V5)

1068 POOR DIABETES CONTROL IN HIV+ AND HIV- WOMEN: OPPORTUNITIES FOR INTERVENTION (Poster Session P-V5)

1071 SYNDYNAMICS AND RETENTION IN CARE AMONG WOMEN LIVING WITH HIV IN RIO DE JANEIRO, BRAZIL (Poster Session P-V5)

WEDNESDAY, MARCH 6, 2019

77 IPT AND PREGNANCY OUTCOMES IN HIV-POSITIVE WOMEN, THE TSHEPISO COHORT (Oral Abstract Session O-07)

78 POTENTIAL CONCERN FOR TIMING OF DMPA INJECTION AMONG WOMEN TREATED FOR HIV AND TB (Oral Abstract Session O-07)

87 A PHASE 1 STUDY OF LEDIPASVIR/SOFOSBUVIR IN PREGNANT WOMEN WITH HEPATITIS C VIRUS (Oral Abstract Session O-08)

99 MODEL IMPACT ANALYSIS OF PrEP AND TasP IN FSW DEMONSTRATION PROJECT IN BENIN (Oral Abstract Session O-09)

672 INTEGRASE STRAND TRANSFER INHIBITORS ARE ASSOCIATED WITH WEIGHT GAIN IN WOMEN (Themed Discussion TD-08)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>673</td>
<td>THE IMPACT OF WEIGHT GAIN AND SEX ON IMMUNE ACTIVATION FOLLOWING INITIATION OF ART (Themed Discussion TD-08)</td>
</tr>
<tr>
<td>1084</td>
<td>EPIDEMIC IMPACT OF SUSTAINED VIREMIA AMONG FEMALE SEX WORKERS IN SOUTHERN AFRICA (Themed Discussion TD-11)</td>
</tr>
<tr>
<td>1085</td>
<td>ESTIMATING HIV INCIDENCE AMONG YOUNG WOMEN IN HPTN 082 USING BASELINE HIV RISK SCORES (Themed Discussion TD-11)</td>
</tr>
<tr>
<td>1086</td>
<td>A MATHEMATICAL MODELING ANALYSIS OF COMBINATION HIV PREVENTION IN ANTENATAL CLINICS (Themed Discussion TD-11)</td>
</tr>
<tr>
<td>234</td>
<td>THE MICROBIOME MAY MODIFY HIV INFECTION RISK ASSOCIATED WITH HORMONAL CONTRACEPTIVES (Poster Session P-B6)</td>
</tr>
<tr>
<td>235</td>
<td>ROLE OF FREM1 IN PRO-INFLAMMATORY RESPONSES DURING VAGINAL HIV/SIV INFECTION (Poster Session P-B6)</td>
</tr>
<tr>
<td>236</td>
<td>CERVICOVAGINAL MICROBIAL STRAINS ARE ASSOCIATED WITH DISTINCT IMMUNOPHENOTYPES (Poster Session P-B6)</td>
</tr>
<tr>
<td>237</td>
<td>GENITAL AND SYSTEMIC INFLAMMATION ASSOCIATED WITH FACTORS THAT MAY ALTER HIV RISK (Poster Session P-B6)</td>
</tr>
<tr>
<td>238</td>
<td>CHLAMYDIA AND CERVICOVAGINAL MICROBIOTA MODULATE GENITAL-TRACT CD4+ T-CELL SUBSETS (Poster Session P-B6)</td>
</tr>
<tr>
<td>278</td>
<td>HPV CLEARANCE AND REINFECTION IN 2 YEARS AFTER RANDOMIZATION TO CRYOTHERAPY OR LEEP (Poster Session P-C2)</td>
</tr>
<tr>
<td>279</td>
<td>HPV DNA TESTS FOR CERVICAL CANCER SCREENING OF HIV-INFECTED WOMEN (Poster Session P-C2)</td>
</tr>
<tr>
<td>280</td>
<td>RELATION OF CIN2 PROGRESSION WITH SERIAL CERVICOVAGINAL CYTOKINE/CHEMOKINE LEVELS (Poster Session P-C2)</td>
</tr>
<tr>
<td>283</td>
<td>PRIMARY HPV SCREENING IN WOMEN LIVING WITH HIV (Poster Session P-C2)</td>
</tr>
<tr>
<td>284</td>
<td>REDUCED COVERAGE OF HPV VACCINE TYPES IN CERVICAL PRECANCER IN HIV INFECTION (Poster Session P-C2)</td>
</tr>
<tr>
<td>306</td>
<td>HIGH-THROUGHPUT ASSAY TO ASSESS ADCC ACTIVITY AGAINST CLINICAL ISOLATES OF HIV-1 (Poster Session P-D3)</td>
</tr>
<tr>
<td>375</td>
<td>FORMATION OF THE REPLICATION-COMPETENT HIV-1 RESERVOIR COINCIDES WITH ART INITIATION (Poster Session P-E08)</td>
</tr>
<tr>
<td>430</td>
<td>DOLUTEGRAVIR ACCUMULATES IN THE FETAL BRAIN FOLLOWING IN UTERO EXPOSURE (Poster Session P-F2)</td>
</tr>
<tr>
<td>473</td>
<td>HORMONAL CONTRACEPTIVES DO NOT ALTER CABOTEGRAVIR PK IN HIV-UNINFECTED WOMEN HPTN 077 (Poster Session P-G2)</td>
</tr>
<tr>
<td>602</td>
<td>HIGH KYNURENINE:TRYPTOPHAN RATIO IS ASSOCIATED WITH LIVER FIBROSIS IN HIV INFECTION (Poster Session P-K4)</td>
</tr>
<tr>
<td>672</td>
<td>INTEGRASE STRAND TRANSFER INHIBITORS ARE ASSOCIATED WITH WEIGHT GAIN IN WOMEN (Poster Session P-N1)</td>
</tr>
<tr>
<td>673</td>
<td>THE IMPACT OF WEIGHT GAIN AND SEX ON IMMUNE ACTIVATION FOLLOWING INITIATION OF ART (Poster Session P-N1)</td>
</tr>
<tr>
<td>768</td>
<td>TOWARDS EMTCT IN ZIMBABWE: SERVICE UPTAKE AND IMPACT OF OPTION B+ ON MTCT, 2012-2018 (Poster Session P-P5)</td>
</tr>
<tr>
<td>769</td>
<td>HIV DRUG RESISTANCE AT PERINATAL TRANSMISSION AND ACCUMULATION DURING BREASTFEEDING (Poster Session P-P5)</td>
</tr>
<tr>
<td>770</td>
<td>GP41 ECTODOMAIN-SPECIFIC IGG IS ASSOCIATED WITH INCREASED VERTICAL HIV-1 TRANSMISSION (Poster Session P-P5)</td>
</tr>
</tbody>
</table>
771  EPITOPE TARGETS OF ADCC-MEDIATING ANTIBODIES AND THEIR RELATION TO MTCT OF HIV-1 (Poster Session P-P5)

773  INCIDENT HIV INFECTION AMONG PREGNANT WOMEN IN BOTSWANA (Poster Session P-P6)

774  HETEROGENEITY OF HIV RETESTING DURING PREGNANCY AND POSTPARTUM IN KENYA (Poster Session P-P6)

775  PRIMARY HIV PREVENTION IN PREGNANT AND LACTATING UGANDAN WOMEN: A RANDOMIZED TRIAL (Poster Session P-P6)

776  MODELING THE IMPACT OF PrEP FOR PREGNANT AND BREASTFEEDING WOMEN IN SOUTH AFRICA (Poster Session P-P6)

777  PREFERENCES FOR HOME VS CLINIC AND BLOOD VS SALIVA HIV RETESTING IN PREGNANCY (Poster Session P-P6)

778  CHALLENGES OF POTENTIALLY FALSE-POSITIVE HIV TESTS IN PREGNANT WOMEN IN THE PrEP ERA (Poster Session P-P6)

785  NEURODEVELOPMENT IN INFANTS OF WOMEN WITH PERINATALLY VS NONPERINATALLY ACQUIRED HIV (Poster Session P-Q1)

874  SPATIAL ANALYSIS TO IDENTIFY EMERGING HOT SPOTS OF MTCT IN ZIMBABWE, 2012-2018 (Poster Session P-R3)

958  PREFERENCES FOR PrEP DELIVERY AMONG FSW IN MALAWI USING A DISCRETE CHOICE EXPERIMENT (Poster Session P-T3)

961  POINT-OF-CARE CREATININE TESTING WITHIN A PROGRAMMATIC PrEP DELIVERY SETTING (Poster Session P-T4)

965  HIGH CURABLE STI PREVALENCE AND INCIDENCE AMONG YOUNG AFRICAN WOMEN IN HPTN 082 (Poster Session P-T5)

969  STI COINFECTIONS DO NOT REDUCE THE PROPHYLACTIC EFFICACY OF CAB LA IN MACAQUES (Poster Session P-T5)

1041  PRAISE MESSAGES TO INCREASE ART ADHERENCE AND RETENTION IN CARE FOR FSW IN ETHIOPIA (Poster Session P-V3)

1074  CONDOM USE AND PRICES IN TRANSACTIONAL SEX ENCOUNTERS AMONG HIGH-RISK WOMEN IN KENYA (Poster Session P-W1)

1077  COST-EFFECTIVENESS OF LONG-ACTING MULTIPURPOSE PREVENTION TECHNOLOGY IN SOUTH AFRICA (Poster Session P-W1)

1082  THE COST OF PrEP DELIVERY IN KENYAN ANTENATAL, POSTNATAL, AND FAMILY PLANNING CLINICS (Poster Session P-W1)

THURSDAY, MARCH 7, 2019

130  HIGH HIV VIRAL BURDEN PERSISTS IN CXCR3+ GCTFH DESPITE VERY EARLY ART INITIATION (Oral Abstract Session O-12)

961  POINT-OF-CARE CREATININE TESTING WITHIN A PROGRAMMATIC PrEP DELIVERY SETTING (Themed Discussion TD-14)

252  SEX DIFFERENCES IN CMV REPLICATION AND HIV PERSISTENCE DURING SUPPRESSIVE ART (Poster Session P-B7)

321  REGULATORY T CELLS IN HIV-INFECTED PREGNANT WOMEN (Poster Session P-D4)

322  THE IMPACT OF HIV EXPOSURE ON PLACENTAL PATHOLOGY AND TREG CELLS
Index of Studies Related to Women

(Poster Session P-D4)

478 DEPO-MEDROXYPROGESTERONE EFFECTS ON TENOFOVIR-DP AND LAMIVUDINE-TP IN CERVICAL TISSUE (Poster Session P-G3)

629 HEPATITIS B VIRUS DNA LEVEL CHANGES IN HBeAg+ PREGNANT WOMEN RECEIVING TDF FOR PMTCT (Poster Session P-K6)

663 SEX-SPECIFIC PATTERNS IN HIV-ASSOCIATED CARDIOVASCULAR MORTALITY IN NEW YORK CITY (Poster Session P-M7)

696 ALOPECIA AFTER SWITCH TO TENOFOVIR ALafenamide IN 5 AFRICAN AMERICAN WOMEN (Poster Session P-N7)

757 POPULATION PK OF DOLUTEGRAVIR IN PLASMA, CORD, AND BREASTMILK: RESULTS FROM DOLPHIN-1 (Poster Session P-P3)

758 DOLUTEGRAVIR PHARMACOKINETICS DURING PREGNANCY AND POSTPARTUM (Poster Session P-P3)

759 PREGNANCY ASSOCIATED WITH DECREASED SERUM ISONIAZID LEVELS IN WOMEN LIVING WITH HIV (Poster Session P-P3)

760 VIROLOGICAL RESPONSE OF RAL-BASED REGIMEN AMONG HIV-INFECTED PREGNANT WOMEN IN BRAZIL (Poster Session P-P4)

761 SEARCH INTERVENTION INCREASES VIRAL SUPPRESSION AMONG PREGNANT & POSTPARTUM WOMEN (Poster Session P-P4)

762 IDENTIFYING WOMEN LIVING WITH PERINATAL HIV INFECTION AT RISK OF POSTPARTUM VIREMIA (Poster Session P-P4)

763 LONG-TERM OUTCOMES OF AN INTEGRATED MATERNAL AND CHILD HIV CARE TRIAL IN SOUTH AFRICA (Poster Session P-P4)

764 EVALUATION OF GUIDELINES FOR VL MONITORING IN PREGNANCY & BREASTFEEDING: A SIMULATION (Poster Session P-P4)

765 MOBILITY AND THE 1-YEAR POSTPARTUM MATERNAL MORTALITY IN HIV-POSITIVE PREGNANT WOMEN (Poster Session P-P4)

766 TENOFOVIR HAIR LEVELS RISE OVER THE POSTPARTUM PERIOD AND HIGHLY PREDICT VIRAL LOADS (Poster Session P-P4)

767 POSTPARTUM DEPRESSIVE SYMPTOMS IN WOMEN LIVING WITH HIV IN BOTSWANA (Poster Session P-P4)

898 POVERTY STIGMA AND HIV TREATMENT OUTCOMES AMONG WOMEN LIVING WITH HIV IN THE US (Poster Session P-P5)

910 HIGH HIV PREVALENCE AND LOW ART COVERAGE AMONG AGYW WHO SELL SEX: A POOLED ANALYSIS (Poster Session P-P5)

916 LOW RATE OF SEX-SPECIFIC ANALYSES IN CROI PRESENTATIONS IN 2018: ROOM TO IMPROVE (Poster Session P-P5)

918 KNOWLEDGE OF HIV STATUS DECREASES DEPRESSIVE SYMPTOMS AMONG FEMALE SEX WORKERS (Poster Session P-P6)

978 WOMEN’S PrEP KNOWLEDGE, ATTITUDES, PREFERENCES AND EXPERIENCE IN CHICAGO (Poster Session P-T6)

979 HIV RISK AND CHARACTERISTICS OF WOMEN SEEKING PrEP IN A US DEMONSTRATION PROJECT (Poster Session P-T6)

980 CONCORDANCE OF HIV RISK PERCEPTION AND EMPIRIC RISK SCORE AMONG PREGNANT KENyan WOMEN (Poster Session P-T6)

995 ADHERENCE 3 MONTHS AFTER PrEP INITIATION AMONG YOUNG
AFRICAN WOMEN IN HPTN 082 (Poster Session P-T8)

997  PREEXPOSURE PROPHYLAXIS: ACCEPTABILITY AND RETENTION IN SOUTH WESTERN UGANDA (Poster Session P-T8)

1060  HIGH AWARENESS BUT UNCERTAIN BELIEF IN U=U AMONG PROVIDERS AND COUPLES IN KENYA (Poster Session P-V4)

1084  EPIDEMIC IMPACT OF SUSTAINED VIREMIA AMONG FEMALE SEX WORKERS IN SOUTHERN AFRICA (Poster Session P-W2)

1085  ESTIMATING HIV INCIDENCE AMONG YOUNG WOMEN IN HPTN 082 USING BASELINE HIV RISK SCORES (Poster Session P-W2)

1086  A MATHEMATICAL MODELING ANALYSIS OF COMBINATION HIV PREVENTION IN ANTENATAL CLINICS (Poster Session P-W2)

1091  WHO IS LEFT IN 10-10-10? IMPORTANCE OF REACHING KEY POPULATIONS WITH THE HIV CASCADE (Poster Session P-W2)
INDEX OF PRESENTING AUTHORS

The following index list presenting authors as of January 31, 2019. Changes to presenting authors after that date are not reflected. A complete list of all abstract authors can be found in the Abstract eBook on the CROI website.

-A-
Aamer, Hadega 380
Abaasa, Andrew M. 1088
Abrahams, Melissa-Rose 375
Abuogi, Lisa L. 753
Abutu, Andrew 1009
Achenbach, Chad J. 258, 285
Acosta, Riddhima 381
Bah, Katharine J. 305, 2005
Bahemuka, Michael J. 805
Balaji, Alexandra 848
Balagopal, Ashim 89
Balse, Michael J. 805
Banda, Riddhima 381
Bar, Katharine J. 305, 2005
Bares, Sara H. 673
Barlow-Mosha, Linda 743
Bartlett, Sofia 582
Bassett, Ingrid V. 913
Batra, Himanshu 364
Battalora, Linda A. 30
Baum, Marianna K. 617
Bebear, Cecile 966
Beck-Engeser, Gabriele B. 643
Beckwith, Curt G. 1056
Bedimo, Roger 648, 675
Bekker, Linda-Gail 994
Benitez, Alejandra E. 1046
Benito, Jose Miguel 571
Benson, Constance A. 2004
Berenguer, Juan 562, 687
Beres, Laura K. 1032
Bergs, Mary C. 1056
Bert, Paul 300
Bhattacharya, Debika 41
Bieniasz, Paul 2001
Bilinska, Julia 1005
Blackard, Jason T. 618, 623
Blair, Cherie 473
Bleth, Jose L. 1011
Blasi, Maria 226
Bloom, Seth M. 238
Blumenthal, Jill 979
Bolton, Valerie F. 377
Blumenthal, Melissa J. 268
Blumenthal, Jill 979
Boddi, Christabel Orera 905
Boerrink, Anna 460
Bose, Chitra 576, 627
Booth, Pauline 913
Bose, Arpana 913
Bosque, Alberto 379
Bosh, Karin A. 147
Bouvier, Claire 151
Bourgi, Kassem 670
Bourke, Claire D. 232
Bowers, Emily 647
Boyd, Ceejay 769
Bradshaw, Daniel 598
Brenchley, Jason 155
Brenner, Bluma 482
Brew, Bruce J. 454
Brites, Carlos 598
Brooks, Kristina M. 469, 477
Brown, Dananea 144
Brown, Lillian 1048
Brumme, Zubria 342
Bryson, Yvonne 796
Bugert, Marcus 200
Bullo, Manuela 513
Bunglawala, Fazila S. 827
Burlanapraditkun, Supranee 920, 1078
Butt, Adeel A. 88, 570
Burdo, Tricia H. 24
Burgerom, Adam 6, 234
Buseyne, Florence 215
Burdo, Tricia H. 24
CROI 2019

-B-
Back, David 120
Bade, Aditya N. 430
Baisely, Kathy 1027
Baker, Jason V. 36
Bakkour, Sonia 558
Balagopal, Ashwin 89
Balaji, Alexandra 848
Bale, Michael J. 805
Baranga, Riddhima 381
Bar, Katharine J. 305, 2005
Bares, Sara H. 673
Barlow-Mosha, Linda 743
Bartlett, Sofia 582
Bashouran, Adebobola T. 837
Basset, Ingrid V. 913
Batra, Himanshu 364
Battalora, Linda A. 30
Baum, Marianna K. 617
Bebear, Cecile 966
Beck-Engeser, Gabriele B. 643
Beckwith, Curt G. 1056
Bedimo, Roger 648, 675
Bekker, Linda-Gail 994
Benitez, Alejandra E. 1046
Benito, Jose Miguel 571
Benson, Constance A. 2004
Berenguer, Juan 562, 687
Beres, Laura K. 1032
Bergs, Mary C. 1056
Bert, Paul 300
Bhattacharya, Debika 41
Bieniasz, Paul 2001
Bilinska, Julia 1005
Blackard, Jason T. 618, 623
Blair, Cherie 473
Bleth, Jose L. 1011
Blasi, Maria 226
Bloom, Seth M. 238
Blumenthal, Jill 979
Bolton, Valerie F. 377
Blumenthal, Melissa J. 268
Blumenthal, Ruddy N. 63
Bocner, Jason 732
Bodo, Christabel Orera 905
Boerrink, Anna 460
Boescheke, Christoph 576, 627
Bollen, Pauline 758, 830
Boltz, Valerie F. 377
Bomse, Morgane 337
Borges, Alvaro H. 256
Borgelt, Alejandro 547
Bosh, Karin A. 147
Bosque, Alberto 379
Bosser, Claire 151
Bourgi, Kassem 670
Bourke, Claire D. 232
Bowman, Emily 647
Boyle, Ceejay 769
Bradshaw, Daniel 598
Brenchley, Jason 155
Brenner, Bluma 482
Brew, Bruce J. 454
Brites, Carlos 598
Brooks, Kristina M. 469, 477
Brown, Dananea 144
Brown, Lillian 1048
Brumme, Zubria 342
Bryson, Yvonne 796
Bugert, Marcus 200
Bullo, Manuela 513
Bunglawala, Fazila S. 827
Burlanapraditkun, Supranee 920, 1078
Burdo, Tricia H. 24
Burgerom, Adam 6, 234
Buseyne, Florence 215
Butt, Adeel A. 88, 570
Cali, Ray 920
Carr, Adam W. 921
Casazza, Joseph P. 183
Cassidy, Noah A. 1056
Castillo, Joseph L. 255, 274
Castillo-Mancilla, Jose R. 420
Cele, Refiole 1080
Celim, Connie L. 995
Cerianni, Cristina 716
Cerrone, Maddalena 628
Challion, Antoine 589, 877, 879
Chaixson, Lelia H. 1022
Chalouni, Mathieu 915
Chamie, Gabriel 896
Chan, Phillip 440
Chandrika, Rishi 621
Chandiwana, Nomathembu C. 749
Chandra, Jay 874
Chang, Kevin C. 455
Chang, Ming 556
Chapin-Bardalles, Johanna 968
Chappell, Catherine A. 87
Chapertier, Charlotte 491
Chasekwa, Bernard 791
Chaudhury, Omkar 316
Chen, Jun 726
Cheret, Antoine 299, 523
Chew, Glen M. 302
Chew, Kara W. 616
Chi, Benjamin H. 755
Chihota, Belinda V. 625, 1064
Chirinda, Witness 1007
Cholette, Francois 888
Chow, Felicia C. 128
Christ, Benedict 1030
Christ, Frauke 73
Clark, Eva 292
Clippman, Steven J. 593
Clutton, Genevieve T. 271
Coffey, Susa 515
Cohen, Jeffrey 56
Cohen, Tracy 1039, 1065
Coiras, Mayte 365
Colby, Donna M. 402
Colombo, Florent 385, 386
Cook, Ryan 230
Corley, Michael J. 410
Corrao, Giuseppe 752
Cowan, Matthew 318
Cowdery, Jonathan 670
Cox, Andrea L. 113

Poster Sessions
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Einkauf, Kevin</td>
<td>339</td>
</tr>
<tr>
<td>Egger, Matthias</td>
<td>150</td>
</tr>
<tr>
<td>Ebrahim, Ismaeel</td>
<td>81</td>
</tr>
<tr>
<td>Eaton, Ellen F.</td>
<td>953</td>
</tr>
<tr>
<td>Easterbrook, Philippa J.</td>
<td>588</td>
</tr>
<tr>
<td>D'Aquila, Erica</td>
<td>1049</td>
</tr>
<tr>
<td>Dziva Chikwari, Chido</td>
<td>782, 783</td>
</tr>
<tr>
<td>Dutta, Debashis</td>
<td>428</td>
</tr>
<tr>
<td>Dunn, Keith J.</td>
<td>907</td>
</tr>
<tr>
<td>Dunn, David</td>
<td>8, 937</td>
</tr>
<tr>
<td>Dumchev, Kostyantyn</td>
<td>1047</td>
</tr>
<tr>
<td>Driscoll, Connor</td>
<td>392</td>
</tr>
<tr>
<td>Drechsler, Henning J.</td>
<td>645</td>
</tr>
<tr>
<td>Dravid, N.</td>
<td>451</td>
</tr>
<tr>
<td>Driscoll, Brandon</td>
<td>452</td>
</tr>
<tr>
<td>Driscoll, Christia</td>
<td>86</td>
</tr>
<tr>
<td>Drovandi, Ria</td>
<td>880</td>
</tr>
<tr>
<td>Drolond, Kerri</td>
<td>881</td>
</tr>
<tr>
<td>Dooley, Kelly E.</td>
<td>80, 82</td>
</tr>
<tr>
<td>Dorsey, Kerri</td>
<td>881</td>
</tr>
<tr>
<td>Dorward, Jienchi</td>
<td>1052</td>
</tr>
<tr>
<td>Dorsh, Rupali</td>
<td>88</td>
</tr>
<tr>
<td>Dovel, Kathryn</td>
<td>93</td>
</tr>
<tr>
<td>Draper, Laura</td>
<td>118</td>
</tr>
<tr>
<td>Dominguez Rodriguez, Sara</td>
<td>44</td>
</tr>
<tr>
<td>Dooley, Pauline G.</td>
<td>182</td>
</tr>
<tr>
<td>Dooley, Eva</td>
<td>92</td>
</tr>
<tr>
<td>Dooley, Matthew</td>
<td>100</td>
</tr>
<tr>
<td>Dooley, Sarah</td>
<td>92</td>
</tr>
<tr>
<td>Dooley, Sharon</td>
<td>2003</td>
</tr>
<tr>
<td>Doss, Andrew</td>
<td>743</td>
</tr>
<tr>
<td>Dote, Kathleen</td>
<td>362</td>
</tr>
<tr>
<td>Duteja, Gaurav</td>
<td>1042</td>
</tr>
<tr>
<td>Dutillo, Ryan</td>
<td>450</td>
</tr>
<tr>
<td>Dumchev, Kostyantyn</td>
<td>1047</td>
</tr>
<tr>
<td>Dunn, David</td>
<td>8, 937</td>
</tr>
<tr>
<td>Dunn, Keith J.</td>
<td>907</td>
</tr>
<tr>
<td>Dutta, Debashis</td>
<td>428</td>
</tr>
<tr>
<td>Dvorsky, Samuel</td>
<td>78</td>
</tr>
<tr>
<td>Dvoncourt, Johnnie</td>
<td>96</td>
</tr>
<tr>
<td>Dvorak, Matthew</td>
<td>32</td>
</tr>
<tr>
<td>Dwyer, Kevin</td>
<td>98</td>
</tr>
<tr>
<td>Dykstra, Michael</td>
<td>90</td>
</tr>
<tr>
<td>Ehrlich, Scott</td>
<td>122</td>
</tr>
<tr>
<td>Eisenberg, Daniel</td>
<td>741</td>
</tr>
<tr>
<td>Ekblad, Marcus</td>
<td>919</td>
</tr>
<tr>
<td>Ekberg, Agnes</td>
<td>88</td>
</tr>
<tr>
<td>Eckert, Allison</td>
<td>685</td>
</tr>
<tr>
<td>Egger, Matthias</td>
<td>150</td>
</tr>
<tr>
<td>Eikhand, Kevin</td>
<td>339</td>
</tr>
<tr>
<td>El Kadi, Houda</td>
<td>1045</td>
</tr>
<tr>
<td>Elia, Evangelos</td>
<td>43</td>
</tr>
<tr>
<td>Elam, J.</td>
<td>919</td>
</tr>
<tr>
<td>Elzner, Todd</td>
<td>422</td>
</tr>
<tr>
<td>Ema, Mildard</td>
<td>88</td>
</tr>
<tr>
<td>Emmons, John</td>
<td>901</td>
</tr>
<tr>
<td>Emmons, John</td>
<td>901</td>
</tr>
<tr>
<td>Enz, Mark</td>
<td>94</td>
</tr>
<tr>
<td>Epperson, Nathaniel</td>
<td>323</td>
</tr>
<tr>
<td>Ericsson, Per</td>
<td>121</td>
</tr>
<tr>
<td>Erlandsson, Kristine M.</td>
<td>129, 702</td>
</tr>
<tr>
<td>Eshun-Wilson, Ingrid</td>
<td>1054</td>
</tr>
<tr>
<td>Estes, Jacob D.</td>
<td>4</td>
</tr>
<tr>
<td>Etta, Elizabeth M.</td>
<td>269</td>
</tr>
<tr>
<td>Eu, Qingming</td>
<td>1059</td>
</tr>
<tr>
<td>Evans, C.</td>
<td>790</td>
</tr>
<tr>
<td>Fahey, Carolyn A.</td>
<td>874</td>
</tr>
<tr>
<td>Falade-Nwulu, Oluwasemun</td>
<td>574, 575</td>
</tr>
<tr>
<td>Fanfair, Robin N.</td>
<td>1031</td>
</tr>
<tr>
<td>Farhadian, Shelli</td>
<td>126</td>
</tr>
<tr>
<td>Farja de Oliveira, Michiel</td>
<td>327, 452</td>
</tr>
<tr>
<td>Felber, Barbara K.</td>
<td>196</td>
</tr>
<tr>
<td>Fennell, Christina</td>
<td>752</td>
</tr>
<tr>
<td>Fenner, Lukas</td>
<td>725</td>
</tr>
<tr>
<td>Ferreira, Fernanda</td>
<td>373</td>
</tr>
<tr>
<td>Fierer, Daniel S.</td>
<td>86</td>
</tr>
<tr>
<td>Figueiroa, Maria L.</td>
<td>492</td>
</tr>
<tr>
<td>Fink, Asbjörg</td>
<td>638</td>
</tr>
<tr>
<td>Finlayson, Robert</td>
<td>577</td>
</tr>
<tr>
<td>Finlayson, Teresa</td>
<td>972</td>
</tr>
<tr>
<td>Finocchiaro Kessler, Sarah</td>
<td>779</td>
</tr>
<tr>
<td>Firnhaber, Cindy</td>
<td>14</td>
</tr>
<tr>
<td>Fishbein, Dawn</td>
<td>586</td>
</tr>
<tr>
<td>Fitzgerald, Kathryn</td>
<td>408</td>
</tr>
<tr>
<td>Fleming, Julia</td>
<td>497, 899</td>
</tr>
<tr>
<td>Fletcher, Courtney</td>
<td>103</td>
</tr>
<tr>
<td>Florence, Eric</td>
<td>389</td>
</tr>
<tr>
<td>Flynn, Jacob</td>
<td>202</td>
</tr>
<tr>
<td>Folkvord, Joy M.</td>
<td>197</td>
</tr>
<tr>
<td>Foote, Carrie</td>
<td>118</td>
</tr>
<tr>
<td>Fortuny, Claudia</td>
<td>789</td>
</tr>
<tr>
<td>Fourman, Lindsay T.</td>
<td>682, 795</td>
</tr>
<tr>
<td>Frange, Pierre P.</td>
<td>804, 828</td>
</tr>
<tr>
<td>Freeman, Tracey L.</td>
<td>187</td>
</tr>
<tr>
<td>Freiberg, Matthew</td>
<td>32</td>
</tr>
<tr>
<td>Fulcher, Jennifer A.</td>
<td>229, 884</td>
</tr>
<tr>
<td>Furin, Jennifer</td>
<td>115</td>
</tr>
<tr>
<td>Gaglardi, Roberta</td>
<td>693</td>
</tr>
<tr>
<td>Gaia, Michael</td>
<td>282</td>
</tr>
<tr>
<td>Galaviz, Karla I.</td>
<td>1068</td>
</tr>
<tr>
<td>Gallay, Philippe</td>
<td>371</td>
</tr>
<tr>
<td>Galloway, Denise</td>
<td>57</td>
</tr>
<tr>
<td>Gandhi, Malini M.</td>
<td>567</td>
</tr>
<tr>
<td>Gandhi, Monica</td>
<td>60, 464, 916</td>
</tr>
<tr>
<td>Gantner, Pierre</td>
<td>984, 985</td>
</tr>
<tr>
<td>Garber, David A.</td>
<td>100</td>
</tr>
<tr>
<td>Garcia Broncano, Pilar</td>
<td>43</td>
</tr>
<tr>
<td>Garcia-Mesa, Yoelvis</td>
<td>429</td>
</tr>
<tr>
<td>Garrett, Meghan E.</td>
<td>310</td>
</tr>
<tr>
<td>Garvey, Lucy J.</td>
<td>85</td>
</tr>
<tr>
<td>Gaseitsiwe, Simani</td>
<td>530</td>
</tr>
<tr>
<td>Gau, Aditya</td>
<td>46</td>
</tr>
<tr>
<td>Gaus, Kamunkhwala</td>
<td>759</td>
</tr>
<tr>
<td>Gavegnano, Christina</td>
<td>326</td>
</tr>
<tr>
<td>Geidelberg, Lily</td>
<td>99</td>
</tr>
<tr>
<td>Gelpi, Marco</td>
<td>676</td>
</tr>
<tr>
<td>Genberg, Becky L.</td>
<td>883</td>
</tr>
<tr>
<td>Geng, Elvin</td>
<td>901</td>
</tr>
<tr>
<td>Gersh, Jill K.</td>
<td>724</td>
</tr>
<tr>
<td>Gianella, Sara</td>
<td>252, 253, 392</td>
</tr>
<tr>
<td>Gill, Michael John</td>
<td>1058</td>
</tr>
<tr>
<td>Girardi, Enrico</td>
<td>730</td>
</tr>
<tr>
<td>Giron, Leila B.</td>
<td>124, 304</td>
</tr>
<tr>
<td>Gissiën, Magnus</td>
<td>436</td>
</tr>
<tr>
<td>Glenn, Jeffrey</td>
<td>2007</td>
</tr>
<tr>
<td>Godfrey, Catherine</td>
<td>518</td>
</tr>
<tr>
<td>Goff, Stephen P.</td>
<td>110</td>
</tr>
<tr>
<td>Golden, Matthew R.</td>
<td>891</td>
</tr>
<tr>
<td>Gómez, Laureen</td>
<td>980</td>
</tr>
<tr>
<td>Gordon, David E.</td>
<td>185</td>
</tr>
<tr>
<td>Goswami, Ria</td>
<td>800</td>
</tr>
<tr>
<td>Gottlieb, Geoffrey S.</td>
<td>949</td>
</tr>
<tr>
<td>Grau-Exposito, Judith</td>
<td>328</td>
</tr>
<tr>
<td>Grebe, Eduard</td>
<td>942</td>
</tr>
<tr>
<td>Grimwood, Ashraf</td>
<td>512</td>
</tr>
<tr>
<td>Grobler, Jay</td>
<td>481</td>
</tr>
<tr>
<td>Gruenewald, Anne-Lise</td>
<td>431</td>
</tr>
<tr>
<td>Grulich, Andrew E.</td>
<td>119</td>
</tr>
<tr>
<td>Guerri-Fernández, Robert C.</td>
<td>205, 634</td>
</tr>
<tr>
<td>Gupta, Amita</td>
<td>114</td>
</tr>
<tr>
<td>Gupta, Ravi D.</td>
<td>29</td>
</tr>
<tr>
<td>Guptil, Oluwaseun</td>
<td>958</td>
</tr>
<tr>
<td>Guthrie, Brandon</td>
<td>892</td>
</tr>
<tr>
<td>Guy, Rebecca J.</td>
<td>933, 935</td>
</tr>
<tr>
<td>Haaal, Richard</td>
<td>465</td>
</tr>
<tr>
<td>Haas, Andreas D.</td>
<td>919</td>
</tr>
<tr>
<td>Haas, David</td>
<td>52</td>
</tr>
<tr>
<td>Hachiya, Atsuko</td>
<td>74</td>
</tr>
<tr>
<td>Hackman, Jada</td>
<td>591</td>
</tr>
<tr>
<td>Halvas, Elias K.</td>
<td>23</td>
</tr>
<tr>
<td>Ham, Lillian</td>
<td>414</td>
</tr>
<tr>
<td>Hamze, Hasan</td>
<td>855</td>
</tr>
<tr>
<td>Han, Win Min</td>
<td>599, 808</td>
</tr>
<tr>
<td>Handoko, Ryan C.</td>
<td>450</td>
</tr>
<tr>
<td>Hanna, David B.</td>
<td>663, 981</td>
</tr>
<tr>
<td>Hannah, Hayley A.</td>
<td>721</td>
</tr>
<tr>
<td>Hansoti, Bhakti</td>
<td>1043</td>
</tr>
<tr>
<td>Harada, Shigeyoshi</td>
<td>182</td>
</tr>
<tr>
<td>Hate, Charles B.</td>
<td>104</td>
</tr>
<tr>
<td>Hata, Jason M.</td>
<td>349</td>
</tr>
<tr>
<td>Hauser, Anthony</td>
<td>525, 538</td>
</tr>
<tr>
<td>Hayes, Richard J.</td>
<td>92</td>
</tr>
<tr>
<td>Hayward, Matthew R.</td>
<td>236</td>
</tr>
<tr>
<td>Heffron, Anna S.</td>
<td>312</td>
</tr>
<tr>
<td>Herman, Michael O.</td>
<td>1020</td>
</tr>
<tr>
<td>Hermans, Linn</td>
<td>127</td>
</tr>
<tr>
<td>Hernandez, Diana</td>
<td>890</td>
</tr>
<tr>
<td>Hiebner, Bonnie</td>
<td>169, 347</td>
</tr>
<tr>
<td>Hightow-Weidman, Lisa</td>
<td>4221</td>
</tr>
<tr>
<td>Higashino, Tetsuji</td>
<td>749</td>
</tr>
<tr>
<td>Hijmans, Jamie</td>
<td>653, 654</td>
</tr>
<tr>
<td>Himeno, Masahiko</td>
<td>569</td>
</tr>
<tr>
<td>Hill, Andrew</td>
<td>739, 746</td>
</tr>
<tr>
<td>Hillier, Sharon L.</td>
<td>203</td>
</tr>
<tr>
<td>Hirsch-Moverman, Yael</td>
<td>79</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Mystakelis, Charalampos</td>
<td>923</td>
</tr>
<tr>
<td>Mwinnyaa, George</td>
<td></td>
</tr>
<tr>
<td>Mwanamsangu, Amasha</td>
<td></td>
</tr>
<tr>
<td>Murphy, Kerry</td>
<td>1001</td>
</tr>
<tr>
<td>Murnane, Pamela M.</td>
<td>766</td>
</tr>
<tr>
<td>Mupfumi, Lucy</td>
<td>733, 734</td>
</tr>
<tr>
<td>Munshi, Mohamed Husen</td>
<td>401</td>
</tr>
<tr>
<td>Medley, Amy M.</td>
<td>928</td>
</tr>
<tr>
<td>Mellors, John W.</td>
<td>117</td>
</tr>
<tr>
<td>melan, Valerie</td>
<td>307</td>
</tr>
<tr>
<td>Merchant, Nicolas</td>
<td>608</td>
</tr>
<tr>
<td>Mercurio, Vincenzo</td>
<td>217</td>
</tr>
<tr>
<td>Metcalfe, Pate, Kelly A.</td>
<td>212, 432</td>
</tr>
<tr>
<td>Metsch, Lisa R.</td>
<td>578</td>
</tr>
<tr>
<td>Meyer-Myklestad, Malin H.</td>
<td>206</td>
</tr>
<tr>
<td>Michel, Kate G.</td>
<td>72</td>
</tr>
<tr>
<td>Mikati, Tarek</td>
<td>962, 983</td>
</tr>
<tr>
<td>Mills, Lisa A.</td>
<td>839</td>
</tr>
<tr>
<td>Minichini, Carmine</td>
<td>564</td>
</tr>
<tr>
<td>Mintz, Carsten</td>
<td>170</td>
</tr>
<tr>
<td>Mukui, Irene</td>
<td>61, 824</td>
</tr>
<tr>
<td>Mugwanya, Kenneth K.</td>
<td>993</td>
</tr>
<tr>
<td>Mugavero, Michael J.</td>
<td>1050</td>
</tr>
<tr>
<td>Mudd, Joseph</td>
<td>210</td>
</tr>
<tr>
<td>Msukwa, Malango T.</td>
<td>754</td>
</tr>
<tr>
<td>Msafiri, Frank</td>
<td>555</td>
</tr>
<tr>
<td>Mpoza, Edward</td>
<td>708</td>
</tr>
<tr>
<td>Moyo, Sikhulile</td>
<td>836</td>
</tr>
<tr>
<td>Moisepe, Mosepele</td>
<td>677</td>
</tr>
<tr>
<td>Moore, James R.</td>
<td>1085</td>
</tr>
<tr>
<td>Moore, Penelope L.</td>
<td>201</td>
</tr>
<tr>
<td>Mora-Peris, Borja</td>
<td>443</td>
</tr>
<tr>
<td>Morales, Ayana</td>
<td>19</td>
</tr>
<tr>
<td>Morgan, Ethan</td>
<td>872</td>
</tr>
<tr>
<td>Moran-Lopez, Sara</td>
<td>397</td>
</tr>
<tr>
<td>Moselom, Ellen</td>
<td>794</td>
</tr>
<tr>
<td>Mosepele, Mosepele</td>
<td>677</td>
</tr>
<tr>
<td>Moyo, Sikhulile</td>
<td>836</td>
</tr>
<tr>
<td>Moyo, Sizulu</td>
<td>152</td>
</tr>
<tr>
<td>Mpoza, Edward</td>
<td>708</td>
</tr>
<tr>
<td>Msafiri, Frank</td>
<td>555</td>
</tr>
<tr>
<td>Musukwa, Malango T.</td>
<td>750</td>
</tr>
<tr>
<td>Mudd, Joseph</td>
<td>210</td>
</tr>
<tr>
<td>Mufu, Michael</td>
<td>217</td>
</tr>
<tr>
<td>Mugavero, Michael J.</td>
<td>72</td>
</tr>
<tr>
<td>Mupwanya, Kenneth K.</td>
<td>993</td>
</tr>
<tr>
<td>Mukui, Irene</td>
<td>61, 824</td>
</tr>
<tr>
<td>Munk, Carsten</td>
<td>19</td>
</tr>
<tr>
<td>Munoz-Moreno, Jose A.</td>
<td>438, 439</td>
</tr>
<tr>
<td>Munshi, Mohamed Husen</td>
<td>72</td>
</tr>
<tr>
<td>Mupfumi, Lucy</td>
<td>733, 734</td>
</tr>
<tr>
<td>Murnane, Pamela M.</td>
<td>766</td>
</tr>
<tr>
<td>Murphy, Kerry</td>
<td>1001</td>
</tr>
<tr>
<td>Mustanski, Brian</td>
<td>988</td>
</tr>
<tr>
<td>Mutembo, Simon</td>
<td>731</td>
</tr>
<tr>
<td>Mutthuis, Jacques</td>
<td>914, 1042</td>
</tr>
<tr>
<td>Mwanambakusungu, Amasha</td>
<td>H. 832</td>
</tr>
<tr>
<td>Mwinywa, George</td>
<td>923</td>
</tr>
<tr>
<td>Mystakelis, Charalampos</td>
<td>251</td>
</tr>
<tr>
<td>Naiman, Nicole</td>
<td>770, 771</td>
</tr>
<tr>
<td>Nance, Robin M.</td>
<td>665</td>
</tr>
<tr>
<td>Nanditha, Ni Gistu Ayu</td>
<td>1067</td>
</tr>
<tr>
<td>Nash, Denis</td>
<td>1016</td>
</tr>
<tr>
<td>Nayrac, Manon</td>
<td>203, 249</td>
</tr>
<tr>
<td>Ndhlou, Chiradizo E.</td>
<td>705</td>
</tr>
<tr>
<td>Ndhlou, zaza</td>
<td>130</td>
</tr>
<tr>
<td>Neesgaard, Bastian</td>
<td>504</td>
</tr>
<tr>
<td>Neff, Charles P.</td>
<td>214</td>
</tr>
<tr>
<td>Newcomb, Michael E.</td>
<td>989</td>
</tr>
<tr>
<td>Newton, Alicia</td>
<td>539</td>
</tr>
<tr>
<td>Ngo-Giang-Huong, Nicole</td>
<td>629</td>
</tr>
<tr>
<td>Nhure, kenneth</td>
<td>1060</td>
</tr>
<tr>
<td>Nguyen, Nadia</td>
<td>819</td>
</tr>
<tr>
<td>Nguyen, Son</td>
<td>134</td>
</tr>
<tr>
<td>Nichols, Brooke E.</td>
<td>1081</td>
</tr>
<tr>
<td>Nicol, Melanie</td>
<td>478</td>
</tr>
<tr>
<td>Nijhawan, Aniek E.</td>
<td>581</td>
</tr>
<tr>
<td>Noe, Sebastian</td>
<td>688</td>
</tr>
<tr>
<td>Noj-Lara, Erickson</td>
<td>930</td>
</tr>
<tr>
<td>Northbrook, Sanny</td>
<td>940</td>
</tr>
<tr>
<td>Noto, Alessandra</td>
<td>344</td>
</tr>
<tr>
<td>Novikova, Mariia</td>
<td>186</td>
</tr>
<tr>
<td>Novitsky, Vlad</td>
<td>875</td>
</tr>
<tr>
<td>Nsanzimana, Sabin</td>
<td>982</td>
</tr>
<tr>
<td>Ntozini, Robert</td>
<td>426</td>
</tr>
<tr>
<td>Ntwokolo, Nneka</td>
<td>117</td>
</tr>
<tr>
<td>O’Halloran, Jane A.</td>
<td>442, 680</td>
</tr>
<tr>
<td>Ofori, Vincent B.</td>
<td>976</td>
</tr>
<tr>
<td>Ogaz, Dana</td>
<td>48</td>
</tr>
<tr>
<td>Oh, Djin-Ye</td>
<td>76</td>
</tr>
<tr>
<td>Ohainle, Molly</td>
<td>69</td>
</tr>
<tr>
<td>Okabo, Stephen</td>
<td>934</td>
</tr>
<tr>
<td>Okoye, Afam</td>
<td>352</td>
</tr>
<tr>
<td>Okulicz, Jason</td>
<td>655</td>
</tr>
<tr>
<td>Okwuegbuna, Oluwakemi</td>
<td>426</td>
</tr>
<tr>
<td>Ollerton, Matthew T.</td>
<td>360</td>
</tr>
<tr>
<td>Olouch, Lynda M.</td>
<td>964</td>
</tr>
<tr>
<td>Omgane, Robert W.</td>
<td>235</td>
</tr>
<tr>
<td>Omar, Habib R.</td>
<td>977</td>
</tr>
<tr>
<td>Omuding, Abrahms</td>
<td>317</td>
</tr>
<tr>
<td>Onyango-Makumbi, Carolyn</td>
<td>792</td>
</tr>
<tr>
<td>Orkin, Chloe</td>
<td>140, 501</td>
</tr>
<tr>
<td>Ortblad, katrina F.</td>
<td>918, 948</td>
</tr>
<tr>
<td>Ortol, Alexandra</td>
<td>233</td>
</tr>
<tr>
<td>Osman, Nathan</td>
<td>816</td>
</tr>
<tr>
<td>Osma, Natalia</td>
<td>612</td>
</tr>
<tr>
<td>Oster, Alexandra M.</td>
<td>68</td>
</tr>
<tr>
<td>Overton, Edgar T.</td>
<td>35</td>
</tr>
<tr>
<td>Packman, Zoe</td>
<td>520</td>
</tr>
<tr>
<td>Paliarini, Mirko</td>
<td>132</td>
</tr>
<tr>
<td>Pakianathan, Mark R.</td>
<td>64</td>
</tr>
<tr>
<td>Pallada, Claudia</td>
<td>600</td>
</tr>
<tr>
<td>Palumbo, Philip R.</td>
<td>871</td>
</tr>
<tr>
<td>Parke-Ratsansi, Rosalind M.</td>
<td>1037</td>
</tr>
<tr>
<td>Patel, Eshan U.</td>
<td>96, 601</td>
</tr>
<tr>
<td>Patel, Payal</td>
<td>820</td>
</tr>
<tr>
<td>Pavi, Pascom</td>
<td>Ara R. 503, 760</td>
</tr>
<tr>
<td>Patro, sean</td>
<td>338</td>
</tr>
<tr>
<td>Pavalkis, George N.</td>
<td>355</td>
</tr>
<tr>
<td>Payne, Danielle</td>
<td>831</td>
</tr>
<tr>
<td>Pegu, Amarindra</td>
<td>28</td>
</tr>
<tr>
<td>Pei, Luxin</td>
<td>216</td>
</tr>
<tr>
<td>Peluso, Michael</td>
<td>125</td>
</tr>
<tr>
<td>Perazzo, Hugo</td>
<td>900</td>
</tr>
<tr>
<td>Permar, Sallie</td>
<td>676</td>
</tr>
<tr>
<td>Persaud, Deborah</td>
<td>799</td>
</tr>
<tr>
<td>Persico, Marcello</td>
<td>560</td>
</tr>
<tr>
<td>Persuk, Anne H.</td>
<td>922</td>
</tr>
<tr>
<td>Peters, Lars</td>
<td>565</td>
</tr>
<tr>
<td>Peters, Marion G.</td>
<td>9</td>
</tr>
<tr>
<td>Pettit, April</td>
<td>715</td>
</tr>
<tr>
<td>Pham, Phuong</td>
<td>540</td>
</tr>
<tr>
<td>Phanuphak, Praphan</td>
<td>137</td>
</tr>
<tr>
<td>Philippi, Carisella</td>
<td>457</td>
</tr>
<tr>
<td>Phillips, Gregory</td>
<td>974</td>
</tr>
<tr>
<td>Phillips, Tamsin K.</td>
<td>462, 763</td>
</tr>
<tr>
<td>Phipps, Warren</td>
<td>272</td>
</tr>
<tr>
<td>Piggott, Damani A.</td>
<td>418</td>
</tr>
<tr>
<td>Pillet, Marine</td>
<td>846</td>
</tr>
<tr>
<td>Pinzio, Claudia</td>
<td>228</td>
</tr>
<tr>
<td>Pino, Maria</td>
<td>133</td>
</tr>
<tr>
<td>Pintye, Jillian</td>
<td>926, 961</td>
</tr>
<tr>
<td>Pirone, Jason R.</td>
<td>475</td>
</tr>
<tr>
<td>Pischke, Sven</td>
<td>206</td>
</tr>
<tr>
<td>Planas, Delphine</td>
<td>301</td>
</tr>
<tr>
<td>Poizot-Martin, Isabelle</td>
<td>275</td>
</tr>
<tr>
<td>Pollock, Katrin</td>
<td>319</td>
</tr>
<tr>
<td>Poluektova, Larisa</td>
<td>217</td>
</tr>
<tr>
<td>Polvak, Christina</td>
<td>206</td>
</tr>
<tr>
<td>Poles, Evan</td>
<td>218</td>
</tr>
<tr>
<td>Powers, Kimberly A.</td>
<td>1036, 1086</td>
</tr>
<tr>
<td>Powis, Kathleen M.</td>
<td>787, 1008</td>
</tr>
<tr>
<td>Price, Jennifer</td>
<td>602</td>
</tr>
<tr>
<td>Price, Richard W.</td>
<td>391</td>
</tr>
<tr>
<td>Probert, William</td>
<td>833</td>
</tr>
<tr>
<td>Procter, Jessica</td>
<td>240</td>
</tr>
<tr>
<td>Promsote, Wanwisa</td>
<td>351</td>
</tr>
<tr>
<td>Protopopescu, Camelia</td>
<td>289</td>
</tr>
<tr>
<td>Pry, Jake</td>
<td>1024</td>
</tr>
<tr>
<td>Pujantell, Maria</td>
<td>171</td>
</tr>
<tr>
<td>Pulliam, Lynn</td>
<td>411</td>
</tr>
<tr>
<td>Puttkammer, Nancy</td>
<td>1017</td>
</tr>
<tr>
<td>Qu, Yang</td>
<td>413</td>
</tr>
<tr>
<td>Radix, Asa</td>
<td>162</td>
</tr>
<tr>
<td>Rahman, Kazi</td>
<td>172</td>
</tr>
<tr>
<td>Rajasingham, Radha</td>
<td>707</td>
</tr>
<tr>
<td>Rajol, Rajith Kumar Reddy</td>
<td>487</td>
</tr>
<tr>
<td>Rallion, Norma</td>
<td>265</td>
</tr>
<tr>
<td>Ram, Renée R.</td>
<td>370</td>
</tr>
<tr>
<td>Ramaswami, Ramya</td>
<td>172</td>
</tr>
<tr>
<td>Ramanchandani, Meena</td>
<td>1013</td>
</tr>
<tr>
<td>Ramendr, Rayoun</td>
<td>224</td>
</tr>
<tr>
<td>Reeves, R. Keith</td>
<td>156</td>
</tr>
<tr>
<td>Reidy, William J.</td>
<td>996</td>
</tr>
<tr>
<td>Reiss, Peter</td>
<td>636</td>
</tr>
<tr>
<td>Ren, Melody</td>
<td>1015</td>
</tr>
<tr>
<td>Ren, Yanqin</td>
<td>358, 362</td>
</tr>
<tr>
<td>Ribuado, Heather</td>
<td>7, 509</td>
</tr>
</tbody>
</table>
Index of Presenting Authors

Walusimbi, Simon  722
Walworth, Charles  543
Wandeler, Gilles  506
Wang, Li Yan  1083
Wang, Xiao Qian  613
Wang, Zhengyan  528
Wanjalla, Celestine  684
Warszawski, Joesiane  807
Waruru, Anthony  94, 1063
Waters, Laura  161
Webb, Nicholas E.  166
Weinberg, Adriana  259
Weinberger, Leor  109
Weiser, Sheri  898
Weiss, Kevin M.  971
Welch, Jennifer L.  241
Wen, Xiao Jun  729
Wertheim, Joel O.  856
Whelan, Bridget M.  1057
Whitney, Bridget M.  1000
Wirth, Kathleen  95
Womack, Julie A.  704
Wonderlich, Elizabeth R.  333
Wong, Lye-Yeng  660
Wu, Minjie  456
Wu, Vincent H.  341

-X-
Xiang, Jinhua  296

-Y-
Yager, Jenna  463
Yant, Stephen R.  480
Yin, Li  225
Yindom, Louis-Marie  810
Yu, Wendy  793
Yusuf, Ramsey  291

-Z-
Zachek, Christine M.  1071
Zale, Elizabeth A.  354
Zamar, David S.  838
Zanoni, Michelle  376
Zerbato, Jennifer M.  610
Zhai, Tracey D.  250
Zhang, Guoqing  1033
Zhang, YinFeng  534
Zielinski-Gutierrez, Emily C.  146
Zola, Courtney  659
Zoulim, Fabien  58
Zucker, Jason  1029
RECORD OF PARTICIPATION

(Full Name)

has participated in the live activity titled

2019 Conference on Retroviruses and Opportunistic Infections (CROI 2019)
March 4–7, 2019
Seattle, Washington, USA

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 17.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

If you are an MD, DO, or international equivalent, indicate the number of CME credits you claimed through the CROI website: _____ hours. Certificate Number: 2019CROI

(CROI 2019 Reference Number)

Richard A Koup, MD
CROI 2019 Chair
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Sharon L. Hillier, PhD
CROI 2019 Vice Chair
University of Pittsburgh, PA, USA

Elaine J. Abrams
CROI 2019 Vice Chair
ICAP at Columbia University, New York, NY, USA
4th Floor Meeting Rooms

Poster Hall
4EF

Cyber Cafe
4D

Registration
4C

4AB

6th Floor Meeting Rooms

6E
6C
6AB

618-620
615-617
611-612
613-614
606-609
604
603
602

4th FLOOR
Opening Session and Plenary Sessions .............. 4AB
Poster Hall .................................................. 4EF
Registration ............................................... 4C
Simultaneous Overflow ......................... 611-612
Cyber Cafe .................................................. 4D
New Mother's Room .................................. 416

5th FLOOR
Personal Considerations Room .......... 508

6th FLOOR
Oral Abstract, Themed Discussion, and Symposia Breakout Rooms .......... 6AB, 6C, 6E
606-609, 615-617

Speaker Ready Room ................................ 618-620
IAS–USA Office ............................................ 603